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Protocol Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with 
Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in 
Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Study phase: 3
Rationale: Although multiple agents are approved as monotherapies for the treatment of patients
with metastatic renal cell carcinoma (mRCC), the testing of combination therapies, in particular, 
treatment with immune-checkpoint inhibitors with tyrosine kinase inhibitors (TKIs) has not been 
fully explored. While single agent therapies have improved outcomes, ongoing drug resistance and 
disease progression demonstrate an urgent need to find more effective therapies for mRCC 
patients. The top priorities in treating RCC continue to be improving progression free survival 
(PFS) and overall survival (OS), management of toxicities, and a better understanding of 
biomarkers. The CA2099ER trial will include previously untreated participants with mRCC and 
uses 2 well-characterized immune checkpoint inhibitors (nivolumab and ipilimumab) in 
combination with cabozantinib, a known standard-of-care in previously treated mRCC 
participants. Nivolumab combined with cabozantinib or nivolumab and ipilimumab combined 
with cabozantinib may be an important step forward in evaluating combination regimens which 
could potentially optimize the management of previously untreated participants with mRCC. 
Study Population: Male and female participants ≥ 18 years or the age of majority with previously 
untreated, advanced or metastatic renal cell carcinoma (RCC).
The following list contains key eligibility criteria only. For full list of eligibility criteria please see 
Section 6.
Key Inclusion Criteria
 Histological confirmation of RCC with a clear-cell component, including participants who may 
also have sarcomatoid features
 Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American 
Joint Committee on Cancer [AJCC] Stage IV) RCC
 No prior systemic therapy for RCC with the following exception:
o One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such 
therapy did not include an agent that targets vascular endothelial growth factor (VEGF)
or VEGF receptors and if recurrence occurred at least 6 months after the last dose of 
adjuvant or neoadjuvant therapy
 Karnofsky Performance Status (KPS) grade  70%
 Measurable disease as per RECIST v1.1 per investigator
 Tumor tissue, preferably obtained within 3 months but no more than 12 months prior to 
enrollment, with an associated pathology report, must be received by the central laboratory 
during screening for determination of PD-L1 expression. In order to be randomized, a 






 Participants with favorable, intermediate, and poor risk categories will be eligible for the study. 
Participants must be categorized according to favorable versus intermediate versus poor risk 
status at registration as per International Metastatic RCC Database Consortium (IMDC) 
criteria.
 Negative pregnancy test and able to meet protocol-specified reproductive requirements
Key Exclusion Criteria
 Any active central nervous system (CNS) metastases. Participants with treated, stable CNS 
metastases for at least 3 months are eligible
 Any tumor invading the superior vena cava (SVC), other major blood vessels, or GI tract; any 
evidence of endotracheal or endobronchial tumor
 Prior systemic treatment with VEGF, MET, AXL, KIT or RET targeted therapy (including, 
but not limited to, sunitinib, pazopanib, axitinib, tivozanib, sorafenib, lenvatinib, bevacizumab,
and cabozantinib)
 Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or 
checkpoint pathways
 Any active, known or suspected autoimmune disease or any condition requiring systemic 
treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other 
immunosuppressive medications within 14 days of randomization
 Uncontrolled adrenal insufficiency
 Poorly controlled hypertension despite antihypertensive therapy
 History of unstable angina, myocardial infarction, symptomatic peripheral vascular disease, 
congestive heart failure (CHF, Class III or IV as defined by the New York Heart Association
[NYHA]), or cerebrovascular accident (CVA)
 Deep vein thrombosis (DVT) or pulmonary embolism (PE) unless adequately treated with low 
molecular weight heparin (LMWH)
 Any unstable cardiac arrhythmia; prolonged QTcF > 450 msec for males and > 470 msec for 
females
 Serious, non-healing wound or ulcer; evidence of active bleeding or bleeding susceptibility; 
history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel or 
gastric outlet obstruction 
 Concomitant strong CYP3A4 inducers or inhibitors within 14 days prior to randomization
 Ejection fraction ≤ 50% on screening echocardiogram or multigated acquisition scan (MUGA)








To compare progression-free survival (PFS) 
per blinded independent central review 
(BICR) of Arm A (doublet) with Arm C
(sunitinib) and of Arm B (triplet) with Arm 
C (sunitinib) in all intermediate/poor risk 
randomized participants. 
The primary objective specifies two comparisons: PFS per BICR of 
Arm A versus Arm C and of Arm B versus Arm C in all 
intermediate/poor risk randomized participants. PFS is defined as 
the time between the date of randomization and the first date of the 
documented progression, or death due to any cause, whichever 
occurs first. Participants who die without a reported progression 
will be considered to have progressed on the date of their death. 
Participants who did not progress or die will be censored on the date 
of their last evaluable tumor assessment. Participants who did not 
have any on study tumor assessments and did not die will be 
censored on their date of randomization. Participants who started 
anti-cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment prior 
to the initiation of first subsequent anti-cancer therapy.
Secondary
To compare progression-free survival (PFS) 
per BICR of Arm A (doublet) with Arm C 
(sunitinib) and of Arm B (triplet) with Arm 
C (sunitinib) in all randomized participants.
This secondary objective specifies two comparisons: PFS per BICR 
of Arm A versus Arm C and of Arm B versus Arm C in all 
randomized participants. The PFS will be defined similarly to the 
primary endpoint except that all randomized participants (any risk 
participants) will be used.
To compare overall survival (OS) of Arm A 
with Arm C and of Arm B with Arm C in 
all intermediate/poor risk randomized 
participants.
The secondary endpoint specifies two comparisons: OS of Arm A 
versus Arm C and of Arm B versus Arm C in all intermediate/poor 
risk randomized participants. OS is defined as the time between the 
date of randomization and the date of death due to any cause. A 
participant who has not died will be censored at the last known alive 
date.
To compare overall survival (OS) of Arm A 
with Arm C and of Arm B with Arm C in 
all randomized participants.
This secondary objective specifies two comparisons: OS of Arm A 
versus Arm C and of Arm B versus Arm C in all randomized 
participants. The OS will be defined similarly to the first 
secondary endpoint except that all randomized participants (any 
risk participants) will be used.
To evaluate the objective response rate 
(ORR) per BICR in all intermediate/poor 
risk randomized and all randomized 
participants.
This secondary objective is ORR per BICR in all intermediate/poor 
risk randomized participants and in all randomized participants (any 
risk participants). ORR is defined as the proportion of randomized 
participants who achieve a best response of complete response (CR) 
or partial response (PR) using the RECIST 1.1 criteria. Best overall 
response (BOR) is defined as the best response designation 
recorded between the date of randomization and the date of 
objectively documented progression per RECIST 1.1 or the date of 
subsequent therapy (including tumor-directed radiotherapy and 
tumor-directed surgery), whichever occurs first. For participants
without documented progression or subsequent therapy, all 
available response designations will contribute to the BOR 
assessment. Duration of response (DOR) is defined as the time 
between the date of first confirmed documented response (CR or 
PR) to the date of first documented tumor progression (per RECIST 






who neither progress nor die will be censored on the date of their 
last tumor assessment. Responders who started anti-cancer therapy 
without a prior reported progression will be censored on the date of 
their last evaluable tumor assessment prior to the initiation of first 
subsequent anti-cancer therapy. Time to response (TTR) is defined 
as the time from randomization to the date of the first confirmed 
documented response (CR or PR), as assessed by BICR. DOR and 
TTR will be evaluated for responders (CR or PR) only.
To assess overall safety and tolerability in 
all treated participants.
As measured by the incidence of adverse events (AEs), serious 
adverse events (SAEs), AEs leading to discontinuation, deaths, 
laboratory abnormalities and changes from baseline.
Overall Design: This is an open label, randomized trial of nivolumab combined with cabozantinib 
(doublet regimen) or nivolumab + ipilimumab combined with cabozantinib (triplet regimen) 
versus sunitinib in participants with previously untreated (first line) advanced or metastatic RCC. 
Participants will be randomized between 3 arms in a 1:1:1 ratio with approximately 810 
intermediate/poor risk participants (270 per arm) and 204 favorable risk participants (68 per arm). 
Participants will be stratified for randomization by IMDC prognostic score (0 [favorable risk] 
versus 1-2 [intermediate risk] versus 3-6 [poor risk]), PD-L1 tumor expression (≥ 1% versus < 1% 
or indeterminate), and region (US/Canada/Western Europe/Northern Europe versus rest of the 
world [ROW]).
The study design schematic is presented below.
Abbreviations: BICR= blinded independent central review; DMC= data monitoring committee; IMDC= International 





programmed death-ligand 1; PO= orally by mouth; Pts=participants; Q2W=every 2 weeks; Q3W=every 3 weeks; 
QD= once daily; RCC=renal cell carcinoma.
Number of Participants: Approximately 1353 participants will enroll in order to randomize 
1014 participants (338 per arm). This includes approximately 204 favorable risk randomized 
(68 per arm) and approximately 810 intermediate/poor risk randomized participants (270 per each 
arm). The number of randomized participants with favorable risk disease will be capped at 
approximately 204 participants.
Treatment Arms and Duration:
• Arm A (Doublet): Nivolumab 240 mg flat dose intravenously (IV) every 2 weeks (Q2W) + 
Cabozantinib 40 mg orally by mouth (PO) once daily (QD)
o Nivolumab treatment until disease progression or unacceptable toxicity with maximum
treatment of 2 years
o Cabozantinib treatment until disease progression or unacceptable toxicity
• Arm B (Triplet): Nivolumab 3mg/kg IV Q3W x 4 doses + Ipilimumab 1 mg/kg IV Q3W x 
4 doses + Cabozantinib 40 mg PO QD 
o Then, Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
o Nivolumab to be continued until disease progression or unacceptable toxicity with 
maximum treatment of 2 years from the start of first dose in Cycle 1
o Cabozantinib until disease progression or unacceptable toxicity
• Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off-treatment, per cycle. 
Cycles to be continued until progression or unacceptable toxicity
Refer to Section 7.1 Treatments Administered for additional details.
Study treatment: 





(Nivolumab) Solution for Injection
100 mg (10 mg/mL) IP
Ipilimumab Solution for Injection 200 mg (5 mg/mL) IP
Cabozantinib Tablet 20 mg IP






2. SCHEDULE OF ACTIVITIES





Register in Interactive Response Technology (IRT) system to obtain participant 
number.
Inclusion/Exclusion Criteria X Must be confirmed prior to randomization.
Medical History X
International Metastatic RCC Database 




(for stratification by PD-L1 tumor expression)
X
Tumor tissue (preferably obtained within 3 months but no more than 12 months 
prior to enrollment, with an associated pathology report) will be collected. 
Formalin-fixed paraffin-embedded (FFPE) block or 20 unstained slides: a 
minimum of 10 slides will be acceptable if tumor tissue is limited. See Section
9.8.2.
Central lab will determine PD-L1 tumor expression. Participants must have an 
evaluable PD-L1 result from the central lab in order to be randomized.
Safety Assessments
Full Physical Examination, Measurements, Vital 
Signs, and Performance Status
X
Height, weight, Karnofsky Performance Status (KPS) (Appendix 7), BP, HR,
RR, and temperature within 14 days prior to randomization.
Assessment of Signs and Symptoms X Within 14 days prior to randomization.
Review of Concomitant Medications X Within 14 days prior to randomization.
Serious Adverse Events Assessment X Serious Adverse Events from time of consent. See Section 9.2
Electrocardiogram (ECG) X
Within 28 days prior to randomization. Fridericia corrected QT (QTcF) 
required. If any time there is an increase in QTcF interval to an absolute value > 
500 msec, 2 additional ECGs must be performed each with intervals 
approximately 3 minutes apart.
Cardiac Ejection Fraction (via Echocardiogram or 
MUGA)









(includes blood and urine samples)
X
See Section 9.4.1 for additional details on tests required. To be completed 
locally at each site. Must be performed within 14 days prior to randomization.
• CBC w/differential
• PT/INR, PTT
• Chemistry panel (includes AST, ALT, total bilirubin, ALP, LDH, 
creatinine, BUN, glucose, albumin, Na, K, Cl, Ca (also corrected), P, Mg, 
amylase, lipase)
• Thyroid panel (includes TSH with free T3 and free T4)
• Hepatitis B/C (HBVsAg, HCV antibody or HCV RNA)
• HIV if mandated locally (sites in Germany, see Appendix 12)
• Urine protein and urine creatinine (for urine protocol/creatinine ratio
[UPCR]). If UPCR ≥ 1.0, obtain 24 hour urine protein.
Pregnancy Test X
WOCBP only. Serum or urine pregnancy test (minimum sensitivity 25 IU/L or 
equivalent units of HCG) to be done at screening visit and within 24 hours of 
first dose of study therapy.
Follicle Stimulating Hormone (FSH) X For women under the age of 55 years to confirm menopause as needed.
Efficacy Assessments
Baseline Tumor Assessments X
CT/MRI of the chest, abdomen, pelvis, brain, and all known sites of disease, 
performed within 28 days prior to randomization. 
All scans need to be submitted for blinded independent central review (BICR). 
See Section 9.1.
Abbreviations: For abbreviations on lab tests refer back to Section 9.4.1.
a Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the treating 





Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet
(CA2099ER) 
Procedure









Examination, Vital Signs, 
Performance Status
X X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status (KPS) 
(Appendix 7). Performance Status to be performed within 72 hours prior to 
dosing.
Assessment of Signs and 
Symptoms
X X
Adverse Events and Serious 
Adverse Events Assessment
X X
Record at each visit. Participants will be followed for drug-related toxicities until 
these toxicities resolve, return to baseline, or are deemed irreversible. All adverse 





Record at each visit.
Electrocardiogram (ECG) X X (See notes)
Fridericia corrected QT (OTcF) required. Only for Cycles 1, 4, 7, then every 6 
cycles (ie, Cycles 13, 19, 25, etc). If any time there is an increase in QTcF interval 
to an absolute value > 500 msec, 2 additional ECGs must be performed each with 
intervals approximately 3 minutes apart.
Laboratory Tests
(includes blood and urine 
samples)
X X (See notes)
See 9.4.1 for additional details on tests required. Laboratory tests do not need to be
repeated at C1D1 if performed within 14 days prior to first dose. After C1D1, 
within 72 hours prior to dosing:
 CBC w/differential at every cycle
 Chemistry panel at every cycle (includes AST, ALT, total bilirubin, ALP, 
LDH, creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg)
 Amylase and lipase to be done for Cycles, 1, 2, 4, 5, 7, and then every 3 
cycles (ie, Cycles 10, 13, 16, etc) 
 Thyroid panel (includes TSH with reflexive free T3 and free T4) for Cycles 1, 
2, 4, 5, 7, and then every 3 cycles (ie, Cycles 10, 13, 16, etc)
 Urine protein and urine creatinine (for UPCR, preferred) or urine dipstick for 





Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet
(CA2099ER) 
Procedure







Pregnancy Test X X
Within 24 hours prior to the initial administration of study drug, then every 4 
weeks 7 days. Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline 
should be performed Week 12 (± 7 days) 
following randomization. Use same 
imaging method as was used at baseline. 
Subsequent tumor assessments should 
occur at every 6 weeks (± 7 days) until 
Week 60, then every 12 weeks (± 14 
days) until radiographic progression, 
assessed by the investigator and 
confirmed by the BICR.
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
Tumor assessments should be performed at the specified time points regardless of 




PK blood samples X
X
(See notes)






For details on sampling time points see Table 9.5-1.
Exploratory Biomarker 
Assessments
Whole Blood (DNA) for 
Genotyping









Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet
(CA2099ER) 
Procedure




















Prior to dosing: At Cycles 1 and 4. See Sections 9.8.1 and 9.8.5
Tumor Tissue Sample
Every effort should be made to collect
fresh tumor tissue sample if available 
upon disease progression.
If a biopsy has been performed and tissue is available, participants are requested 
to submit fresh tumor tissue upon disease progression for biomarker research. 




Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X
Completed on Day 1 of each treatment cycle prior to any study-related 




Completed on Day 1 of each treatment cycle prior to any study-related 
procedures. See Section 9.1.4






Begins with call to Interactive Response Technology (IRT). Participants must 
have an evaluable PD-L1 result from the central lab in order to be randomized.
Administer Nivolumab and 
Cabozantinib
X X





Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
a





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER) 
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations

















Targeted Physical Examination, 
Vital Signs, Performance Status
X X X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status 
(KPS) (Appendix 7). Performance Status to be performed within 72 hours 
prior to dosing.
Assessment of Signs and 
Symptoms
X X X
Adverse Events and Serious 
Adverse Events Assessment
X X X
Record at each visit. Participants will be followed for drug-related toxicities 
until these toxicities resolve, return to baseline, or are deemed irreversible. 
All adverse events will be documented for a minimum of 100 days after last 
dose (Appendix 3).






Fridericia corrected QT (QTcF) required. Only Cycles 1, 3, 5, then every 6 
cycles (ie, Cycles 11, 17, 23, etc). If any time there is an increase in QTcF 
interval to an absolute value > 500 msec, 2 additional ECGs must be 
performed each with intervals approximately 3 minutes apart.
Laboratory Tests





See Section 9.4.1 for additional details on tests required. Laboratory tests
do not need to be repeated at C1D1 if performed within 14 days prior to first
dose. After C1D1, within 72 hours prior to dosing.
 CBC w/differential at every cycle
 Chemistry panel at every cycle (includes AST, ALT, total bilirubin, 
ALP, LDH, creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg)
 Amylase and lipase at every cycle until Cycle 5 then every 3 cycles (ie,
Cycles 8, 11, 14, etc)





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER) 
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations
















every cycle until Cycle 5, then every 3 cycles (ie, Cycles 8, 11, 14, etc)
 Urine protein and urine creatinine (for UPCR, preferred) or urine 
dipstick for protein at Cycles 1, 3, and 5, then every 3 cycles 
(ie, Cycles 8, 11, 14, etc)
Pregnancy Test X X X
Within 24 hours prior to the initial administration of study drug, then every
4 weeks days. Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline should 
be performed Week 12 (± 7 days) following 
randomization. Use same imaging method 
as was used at baseline.
Subsequent tumor assessments should occur 
at every 6 weeks (± 7 days) until Week 60, 
then every 12 weeks (± 14 days) until 
radiographic progression, assessed by the 
investigator and confirmed by the BICR. 
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
Tumor assessments should be performed at the specified time points 
regardless of dosing delays. See Section 9.1 for additional details.
Pharmacokinetic (PK) 
/Immunogenicity Assessments





For details on sampling timepoints see Table 9.5-2.












Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER) 
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations
















Whole Blood (DNA) for 
Genotyping








Prior to dosing. At Cycles 1, 2, and 3. See Sections 9.8.1 and 9.8.3.
Myeloid Derived Suppressor 
Cells 
X
Prior to dosing. At Cycle 1 only. See Section 9.8.4.





Prior to dosing. At Cycles 1 and 3 only. See Sections 9.8.1 and 9.8.5.
Tumor Tissue Sample
Every effort should be made to collect fresh 
tumor tissue sample if available upon 
disease progression.
If a biopsy has been performed and tissue is available, participants are 
requested to submit fresh tumor tissue upon disease progression for 
biomarker research. See Section 9.8.2.
Tissue submission is optional and biopsy is not required by protocol. 
Participant-Reported 
Outcomes
Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any study-related 
procedures. See Section 9.1.4.
EuroQoL group’s EQ-5D-3L 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any study-related 





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER) 
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations
















Health Care Resource Utilization X X X See Section 9.9.
Study Treatment
Randomize X
Begins with call to Interactive Response Technology (IRT). Participants 
must have an evaluable PD-L1 result from the central lab in order to be 
randomized.
Administer Nivolumab, 
Ipilimumab, and  Cabozantinib
X X
Cycles 1 to 4 are 3 week cycles. See Section 7.
Administer Nivolumab and  
Cabozantinib
X
Cycle 5 and subsequent cycles are 2 week cycles. See Section 7.
Dispense Study Treatment X X X See Section 7.
Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.































Examination, Vital Signs, 
Performance Status
X X X
Weight, BP, HR, RR, temperature, and Karnofsky 
Performance Status (KPS) (Appendix 7). Performance 
Status to be performed within 72 hours prior to dosing.
Assessment of Signs and 
Symptoms
X X X X X X
Adverse Events and Serious 
Adverse Events Assessment
X X X X X X
Record at each visit. Participants will be followed for drug-
related toxicities until these toxicities resolve, return to 
baseline, or are deemed irreversible. All adverse events 




X X X X X X
Record at each visit




Fridericia corrected QT (QTcF) required. Only Cycles 1, 2, 
and 3, then every 2 cycles (ie, Cycles 5, 7, 9, etc). If any 
time there is an increase in QTcF interval to an absolute 
value > 500 msec, 2 additional ECGs must be performed 
each with intervals approximately 3 minutes apart.
Laboratory Tests














See Section 9.4.1 for additional details on tests required.  
Laboratory tests do not need to be repeated at C1D1 if
performed within 14 days prior to first dose. After C1D1, 
within 72 hours prior to specified dosing day:
 CBC w/differential on Day 1 and Day 22 (+/- 3 days) 
of each cycle





























every cycle (includes AST, ALT, total bilirubin, ALP, 
LDH, creatinine, BUN, glucose, albumin, Na, K, Cl, 
Ca, P, Mg)
 Amylase and lipase on Day 1 and Day 22 (+/- 3 days) 
of Cycle 1 and 2, then on Day 1 of Cycle 3 and all 
subsequent cycles.
 Thyroid panel (includes TSH with reflexive free T3 
and free T4) on Day 1 and Day 22 (+/- 3 days) of 
Cycle 1 and 2, then on Day 1 of Cycle 3 and all 
subsequent cycles.
 Urine protein and urine creatinine (for UPCR, 
preferred) or urine dipstick for protein on Day 1 of 
every cycle
Pregnancy Test X X X X X X
Within 24 hours prior to the initial administration of study




First tumor assessment post-baseline should be performed Week 
12 (± 7 days) following randomization. Use same imaging 
method as was used at baseline. 
Subsequent tumor assessments should occur at every 6 weeks (± 
7 days) until Week 60, then every 12 weeks (± 14 days) until 
radiographic progression, assessed by the investigator and 
confirmed by the BICR.
CT/MRI of the chest, abdomen, pelvis, and all known sites 
of disease.
Tumor assessments should be performed at the specified 
































Whole Blood (DNA) for 
Genotyping
X Only prior to dose at Cycle 1. See Sections 9.8.1 and 9.8.6
Serum Biomarkers X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.3.
Plasma Biomarkers X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.3.
Myeloid Derived Suppressor 
Cells 
X Prior to dosing at Cycle 1 only. See Section 9.8.4.
Peripheral blood mononuclear 
cells (PBMCs)
X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.5.
Tumor Tissue Sample
Every effort should be made to collect fresh tumor tissue sample 
if available upon disease progression.
If a biopsy has been performed and tissue is available, 
participants are requested to submit fresh tumor tissue 
upon disease progression for biomarker research. See 
Section 9.8.2.




Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any 
study-related procedures. See Section 9.1.4.
EuroQoL group’s EQ-5D-3L 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any 





























Health Care Resource 
Utilization
X X X See Section 9.9.
Study Treatment
Randomize X
Begins with call to Interactive Response Technology 
(IRT). Participants must have an evaluable PD-L1 result 
from the central lab in order to be randomized.
Administer Sunitinib X X X X X X
Each cycle will be 6 weeks where sunitinib will be 
administered for 4 weeks, then participants will be off 
treatment for 2 weeks. See Section 7.
Dispense Study Treatment X X X See Section 7.
Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.


















Targeted Physical Examination, Vital 
Signs, Performance Status
X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status 
(KPS) (Appendix 7).
Assessment of Signs and Symptoms X
Adverse Events and Serious Adverse 
Events Assessment
X
Record at each visit. Participants will be followed for drug-related 
toxicities until these toxicities resolve, return to baseline, or are deemed 
irreversible. All adverse events will be documented for a minimum of 
100 days after last dose (Appendix 3).
Concomitant Medication Review X Record at each visit
Electrocardiogram (ECG) X
Fridericia corrected QT (QTcF) required. If any time there is an increase 
in QTcF interval to an absolute value > 500 msec, 2 additional ECGs 
must be performed each with intervals approximately 3 minutes apart.
Laboratory Tests
(includes blood and urine samples)
FU1 -yes
FU2 - if toxicities are 
present
See Section 9.4.1 for additional details on tests required.
 CBC w/differential, PT/INR, and PTT
 Chemistry panel (includes AST, ALT, total bilirubin, ALP, LDH, 
creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg, amylase, 
lipase)
 Thyroid panel (includes TSH with reflexive free T3 and free T4) 
 Urine protein and urine creatinine (for UPCR, preferred) or urine 
dipstick for protein
Pregnancy Test X Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline 
should be performed Week 12 (± 7 days) 
following randomization. Use same 
imaging method as was used at baseline. 
Participants who discontinue study treatment without radiographic 
progression, confirmed by BICR, will continue tumor assessments 
according to the protocol specified schedule, even if new anti-tumor 

















Subsequent tumor assessments should 
occur at every 6 weeks (± 7 days) until 
Week 60, then every 12 weeks (± 14 
days) until radiographic progression, 
assessed by the investigator and 
confirmed by the BICR.
progression has been assessed by the investigator and confirmed by 
BICR.
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
See Section 9.1.2 for additional details.
Survival Status X X
During safety follow up and every 3 months (clinic visit or by 
telephone) during survival phase. Include documentation of subsequent 
chemotherapy. See Section 8.1.5.
Pharmacokinetic (PK)/ 
Immunogenicity Assessments
PK blood samples 
X
(See notes)
Only for participants who were in Arm A (Nivolumab combined with 
cabozantinib, Doublet) or Arm B (Nivolumab and ipilimumab
combined with cabozantinib, Triplet). For details on sampling 




Only for participants who were in Arm A (Nivolumab combined with 
cabozantinib, Doublet) or Arm B (Nivolumab and ipilimumab
combined with cabozantinib, Triplet). For details on sampling 
timepoints see Table 9.5-1
Participant-Reported Outcomes
Functional Assessment of Cancer 








Health Care Resource Utilization X See Section 9.9.





a Participants must be followed for at least 100 days after last dose of study treatment. Follow-up visit #1 (FU1) should occur 30 days from the last dose (+/- 7) 
days or can be performed on the date of discontinuation if that date is greater than 42 days from last dose. Follow-up visit #2 (FU2) occurs approximately 100 
days (+/- 7 days) from last dose of study drug. Both Follow Up visits should be conducted in person.
b
Survival Follow-up visits to occur every 3 months from Follow-up Visit #2. Survival visits may be conducted in person or by telephone. BMS may request 
that survival data be collected on all treated participants outside of the 3 month specified window. At the time of this request, each participant will be 






Renal cell carcinoma (RCC) is the eighth most common cancer in the world with an increasing 
incidence.1 Globally, RCC occurs in more than 330,000 cases with approximately a third of the 
patients succumbing to their disease. More than 100,000 deaths occur annually, as a result of 
progression of metastatic disease. Despite the earlier detection of smaller kidney tumors, the rate 
of RCC-related mortality has increased suggesting that recurrence and advanced disease are 
responsible for mortality.2,3 With the rise in RCC incidence, as well as mortality and morbidity 
associated with advanced RCC, medical need in this population remains a priority. 
Over the last decade, an increased understanding of the biology of RCC has led to development 
of multiple agents that target specific growth pathways. The vascular endothelial growth factor 
(VEGF) pathway and targeted serine/threonine protein kinase therapies that block the 
mammalian target of rapamycin (mTOR) have been found to be important targets in RCC 
disease. Global health authorities (HAs) have approved multiple drugs targeting these pathways, 
including anti-VEGF agents, such as pazopanib, sorafenib, sunitinib, cabozantinib, and 
bevacizumab, and mTOR pathway inhibitors, such as temsirolimus and everolimus.4
Additionally, recent innovation of treating cancer with immunotherapies has also expanded 
treatment options. Nivolumab, an anti-PD-1 antibody, given as monotherapy or in combination 
with the anti-CTLA-4 antibody, ipilimumab, has demonstrated clinical activity in multiple tumor 
types, including RCC. 
To better understand treatment and patient outcomes, several academic groups have identified 
variables associated with survival and created prognostic models in mRCC. These risk models 
are commonly used for choosing therapies or selecting patients for treatment in clinical trials. 
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model 
stratifies patients into 3 prognostic groups, based on 6 adverse prognostic factors, into favorable 
(0 factors), intermediate (1-2 factors), and poor risk (3-6 factors) groups.5 The currently available 
first-line agents for mRCC, which target the VEGF pathway, have shown limited efficacy in the 
intermediate and poor risk populations, yielding median overall survival of less than 2 years. 
Cabozantinib and nivolumab both share category 1 NCCN guideline recommendations 
(ie, uniform consensus that the treatment is appropriate, based on high-level evidence) for the 
treatment of previously treated mRCC patients.6 Therefore, it is an appropriate next step to 
combine these agents and move them to the first-line setting in an attempt to improve clinical 
outcomes in patients with advanced RCC. This protocol CA2099ER will test the clinical activity 
of nivolumab combined with cabozantinib (doublet regimen) or nivolumab and ipilimumab
combined with cabozanitinib (triplet regimen). Given the different mechanisms of action of each 
of these agents, there is potential for distinct improvement in clinical efficacy.7  
3.1 Study Rationale
Agents that target the VEGF pathway prevent tumor growth by inhibiting angiogenesis. A recent 
clinical biomarker study has shown that anti-VEGF therapy also affects the RCC tumor immune 





had received prior bevacizumab or sunitinib were assessed for tumor immune cell infiltration. 
Samples from patients with prior anti-VEGF therapy demonstrated increased infiltration of 
regulatory T cells (Tregs) and enhanced tumor PD-L1 expression, both of which were negatively 
associated with patient survival.8 These effects suggest that the promotion of an immune 
suppressive tumor microenvironment may contribute to anti-VEGF therapy resistance and point 
to a rational strategy for combining anti-VEGF therapy with immunotherapies that target the PD-
1/PD-L1 pathway. Indeed, the phase 1 study CA209016 demonstrated the synergistic activity of 
such combinations in mRCC. This study included a cohort of 26 participants with mRCC (19 of 
whom were previously untreated) who received sunitinib in combination with nivolumab 5 
mg/kg Q3W. Using MSKCC risk criteria, 13 participants in this cohort had favorable risk 
disease, 12 had intermediate risk disease, and 1 had poor risk disease. After a minimum follow-
up of 22 months, the objective response rate (ORR) was 42.3%, median progression-free survival 
(PFS) was 12.3 months, and median overall survival (OS) was 36.8 months in this cohort.9
Similar efficacy results have been reported in other phase 1 studies which combine anti-VEGF 
agents with anti-PD-1 agents.10,11  
As described in Section 3.2, cabozantinib is a novel tyrosine kinase inhibitor that, in addition to 
VEGFR, targets additional tyrosine kinases that are implicated in the biology of mRCC, such as 
c-MET and AXL. In a randomized phase 3 trial in patients with advanced RCC that had 
progressed after anti-VEGFR therapy, cabozantinib was shown to improve PFS and OS 
compared to everolimus, leading to its regulatory approval. Subsequently, a randomized phase 2 
trial of cabozantinib vs sunitinib has demonstrated an improvement in ORR and PFS in 
intermediate- and poor-risk patients with previously untreated mRCC (see Section 3.2.1.5).
Cabozantinib has also been demonstrated to have effects on immune cells. In a study of 24 
subjects with advanced urothelial carcinoma, cabozantinib treatment resulted in a decrease in 
circulating Tregs and increased PD-1 expression on Tregs. Low Tregs at baseline were also 
predictive of improved response to cabozantinib and survival.12
Given the promising clinical activity of cabozantinib in previously untreated mRCC and its 
potential immune effects, combining cabozantinib with nivolumab (in a doublet regimen) is a 
rational strategy to optimize first-line therapy in mRCC. Based on both preclinical13 and clinical 
studies that demonstrate the activity of the nivolumab + ipilimumab combination
(Section 3.2.1.4), it is also rational to combine nivolumab and ipilimumab with cabozantinib (in 
a triplet regimen). An ongoing phase 1 study is evaluating both the doublet and triplet regimens 
in patients with refractory advanced urothelial cancer or other genitourinary tumors, including 
mRCC, and has defined dosing for both regimens that produces acceptable safety and tolerability
(Section 3.2.1.6). This 3-arm randomized phase 3 trial will determine if the combination doublet 
regimen (nivolumab combined with cabozantinib) and the combination triplet regimen 
(nivolumab and ipilimumab combined with cabozantinib) produce greater clinical benefit than 
sunitinib, a standard of care agent for patients with previously untreated mRCC. In addition, this 
trial will reveal the adverse event profiles, quality of life measures, as well as exploratory 






Treatment with nivolumab combined with cabozantinib (doublet regimen) or nivolumab and 
ipilimumab combined cabozantinib (triplet regimen) will demonstrate an improvement in PFS 
per BICR compared to sunitinib monotherapy in intermediate/poor risk participants with 
previously untreated mRCC.
3.2 Background
Cancer immunotherapy rests on the premise that tumors can be recognized as foreign rather than 
as self and can be effectively attacked by an activated immune system. An effective immune 
response in this setting is thought to rely on immune surveillance of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune response and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of traits that allow cancer cells to 
evade immunosurveillance and escape effective innate and adaptive immune responses.14,15,16
Current immunotherapy efforts attempt to break the apparent tolerance of the immune system to 
tumor cells and antigens by either introducing cancer antigens by therapeutic vaccination or by 
modulating regulatory checkpoints of the immune system. T-cell stimulation is a complex 
process involving the integration of numerous positive as well as negative co-stimulatory signals 
in addition to antigen recognition by the T-cell receptor (TCR).17 Collectively, these signals 
govern the balance between T-cell activation and tolerance. 
Programed death-1 (PD-1) is a member of the CD28 family of T-cell co-stimulatory receptors 
that also includes CD28, CTLA 4, ICOS, and BTLA.18 PD-1 signaling has been shown to inhibit 
CD-28-mediated upregulation of IL-2, IL-10, IL-13, interferon-γ (IFN-γ) and Bcl-xL. PD-1 
expression also been noted to inhibit T cell activation, and expansion of previously activated 
cells. Evidence for a negative regulatory role of PD-1 comes from studies of PD-1 deficient 
mice, which develop a variety of autoimmune phenotypes.19 These results suggest that PD-1 
blockade has the potential to activate anti-self T-cell responses, but these responses are variable 
and dependent upon various host genetic factors. Thus, PD-1 deficiency or inhibition is not 
accompanied by a universal loss of tolerance to self-antigens.
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affinity (EC50 0.39-2.62 nM), and 
inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (IC50 ± 1 nM). Nivolumab binds 
specifically to PD-1 and not to related members of the CD28 family such as CD28, ICOS, 
CTLA-4 and BTLA. Blockade of the PD-1 pathway by nivolumab results in a reproducible 
enhancement of both proliferation and IFN-γ release in the mixed lymphocyte reaction (MLR). 
Using a CMV re stimulation assay with human PBMC, the effect of nivolumab on antigen 
specific recall response indicates that nivolumab augmented IFN-γ secretion from CMV specific 
memory T cells in a dose-dependent manner versus isotype-matched control. In vivo blockade of 
PD-1 by a murine analog of nivolumab enhances the anti-tumor immune response and result in 






CTLA-4, an activation-induced T-cell surface molecule, is a member of the CD28:B7 
immunoglobulin superfamily that competes with CD28 for B7. CTLA-4 mediated signals are 
inhibitory and turn off T cell-dependent immune responses.21 Ipilimumab is a fully human 
monoclonal IgG1κ that binds to the CTLA-4 antigen expressed on a subset of T cells from 
human and nonhuman primates. The proposed mechanism of action for ipilimumab is 
interference of the interaction of CTLA-4 with B7 molecules on antigen presenting cells, with 
subsequent blockade of the inhibitory modulation of T-cell activation promoted by the CTLA 
4/B7 interaction.
Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, 
metastasis, and angiogenesis.22 The primary targets of cabozantinib implicated in mRCC are 
MET (c-MET), AXL and vascular endothelial growth factor receptor 2 (VEGFR2); additional 
targets identified in-vitro include RET, KIT, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and 
TIE-2. Both c-Met, AXL, and VEGFR2 are important mediators of tumor growth and tumor 
angiogenesis, and in vivo pharmacodynamic activity of cabozantinib against c-Met, and 
VEGFR2 has been demonstrated in both preclinical and clinical studies.23,24,25,26
In addition, preclinical and clinical observations have suggested that cabozantinib promotes an 
immunopermissive environment which might present an opportunity for synergistic effects from 
combination treatment with PD-1 checkpoint inhibitors. Specifically, treatment of tumor cells 
with cabozantinib in vitro led to increased tumor-cell expression of major histocompatibility 
complex (MHC) class 1 antigen and greater sensitivity of tumor cells to T-cell-mediated 
killing.27 In a mouse tumor model, cabozantinib treatment led to increased peripheral CD8+ T-
cell counts, decreased regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), 
and decreased Treg suppressor activity. Further, synergistic effects including increased CD8+ T-
cell infiltration and decreased infiltration by MDSCs and tumor-assisted macrophages (TAMs) 
were observed when a poxviral-based cancer vaccine was administered in addition to 
cabozantinib in the mouse tumor model. Reductions in immunosuppressive Treg lymphocytes 
following treatment with cabozantinib have also been observed in subjects with advanced 
refractory urothelial cancer.12 In a phase 2 study in metastatic triple-negative breast cancer, 
cabozantinib-treated subjects experienced a persistent increase in the fraction of circulating 
CD3+ T lymphocytes and a persistent decrease in the CD14+ monocytes possibly reflecting 
activation of systemic antitumor immunity.28
A detailed description of the chemistry, pharmacology, efficacy, and safety of nivolumab and 
ipilimumab in combination and cabozantinib is provided in the Nivolumab Investigator Brochure
(IB) and Cabozantinib IB, respectively.22,29,30
3.2.1 Indication Background
3.2.1.1 Sunitinib in Renal Cell Carcinoma
Sunitinib is a VEGF receptor TKI that is approved and recommended for the treatment of mRCC 
across prognostic groups.6,31 In a randomized phase 3 trial of sunitinib vs IFNin 





with poor risk per MSKCC criteria), PFS (by independent radiology review) was significantly 
improved in the sunitinib group compared to the IFNgroup (median PFS 11 vs 5 months, HR = 
0.42; p < 0.001). ORR was also greater in the sunitinib group (31% vs 6%). Median OS was 26.4 
months in the sunitinib group vs 21.8 months in the IFN group (HR = 0.82; p = 0.051).32 More 
recently, sunitinib was compared to pazopanib in treatment-naive subjects (including 27% 
favorable risk, 73% intermediate risk, and no poor risk) in the phase 3 COMPARZ study.33 In 
this non-inferiority study, sunitinib and pazopanib demonstrated similar median PFS (8.4 months
for pazopanib vs 9.5 months for sunitinib, HR = 1.05) and median OS (28.4 months for 
pazopanib vs 29.3 months for sunitinib, HR = 0.91, p = 0.28). The ORR of pazopanib and 
sunitinib was 31% and 24%, respectively. The most common ( 20% frequency) adverse 
reactions include fatigue, asthenia, fever, diarrhea, nausea, mucositis/stomatitis, vomiting, 
dyspepsia, abdominal pain, constipation, hypertension, peripheral edema, rash, hand-foot 
syndrome, skin discoloration, dry skin, hair color changes, altered taste, headache, back pain, 
arthralgia, extremity pain, cough, dyspnea, anorexia, and bleeding.34 Other important adverse 
reactions include hepatotoxicity, QT prolongation (including Torsades de Pointes), osteonecrosis 
of the jaw, tumor lysis syndrome, and thyroid dysfunction
3.2.1.2 Nivolumab Monotherapy in Renal Cell Carcinoma
Harnessing the immune system would be an attractive opportunity, together with efforts to find
cell surface markers that can be used to trace and target dormant renal-cell carcinoma cells.
Nivolumab monotherapy has been studied in participants with advanced RCC in several BMS-
sponsored studies (phases 1 through 3): MDX1106-03, CA209009, CA209010, and CA209025. 
MDX1106-03 was a phase 1 refractory solid tumor trial, which included 34 participants with 
previously-treated advanced RCC who received nivolumab at 1 mg/kg (n = 18) or 10 mg/kg (n = 
16) given every 2 weeks.25,35,36 Median progression-free survival (PFS) was 7.3 months. In both 
the 1 mg/kg and 10 mg/kg cohorts, approximately 30% of participants experienced an objective 
response with median duration of response of 12.9 months. Responses were generally rapid with 
a median time to response of 16 weeks. Notably, responses could occur after treatment cessation 
and persist off treatment. Median overall survival (mOS) was 22.4 months. These results were 
promising given that many of the participants were heavily pre-treated with 71% having had 2 or 
more lines of therapy. Treatment-related adverse events (AEs) of any grade were observed in 
85% of RCC participants, the most common being fatigue (41%), rash (27%), diarrhea (18%), 
and pruritus (18%). Grade 3-4 treatment-related AEs were observed in 18% of RCC participants. 
The spectrum, frequency, and severity of treatment-related AEs were similar in the RCC 
population compared to the overall study population and were similar across dose levels. 
In order to identify a potential dose-response relationship in RCC, a randomized phase 2 study 
(CA209010) was conducted in 168 participants with advanced RCC previously treated with an 
antiangiogenic therapy who received nivolumab at 0.3 mg (n = 60), 2 mg/kg (n = 24) or 10 
mg/kg (n=54) given every 3 weeks.37 No dose response relationship was found as measured by 
PFS, with median PFS of 2.7, 4.0, and 4.2 months for the 0.3, 2, and 10 mg/kg groups, 





respectively. Median time to achievement of an objective response was 2.8-3.0 months. The 
median duration of response was 22.3 months (4.8, NR) in the 10 mg/kg arm and not yet reached 
in the 2 lower dose cohorts. Median OS was at 18.2 to 25.5 months, with a minimum of follow-
up of 24 months. Fatigue was the most frequent toxicity (22-35%). No new toxicities were 
identified with 11% experiencing Grade 3-4 treatment-related AEs, none of which were due to 
pneumonitis. Treatment-related AEs led to discontinuation of study drug in 7% of participants. 
A parallel biomarker-focused trial, CA209009, using the same 3 nivolumab dose levels (03, 2, 
and 10 mg/kg every 3 weeks) was executed to explore predictors of response and identify 
mechanisms of resistance.38 This study included 67 participants with previously-treated, 
advanced RCC who were randomized to one of the 3 nivolumab dose groups and 24 participants 
with previously-untreated RCC who received nivolumab at 10 mg/kg every 3 weeks. The results 
mirrored the efficacy and toxicity profile of CA209010 with an overall ORR of 18% in 
previously-treated participants, and 13% in previously untreated participants and disease 
stabilization in another 32% of previously treated and untreated participants. At 24 weeks, 36% 
of participants were free from progression. Of 56 participants with evaluable pretreatment tumor 
samples, 18 (32%) had  5% PD-L1 tumor expression. ORR was 22% among those with  5% 
PD-L1 tumor expression versus 8% among those with < 5% PD-L1 tumor expression. 
Based on the clinical activity of nivolumab observed in these phase 1 and 2 studies, a large phase 
3 trial (CA209025) was conducted in 821 participants with advanced RCC previously treated 
with 1 or 2 antiangiogenic therapies who were randomized to receive nivolumab 3 mg/kg every 2 
weeks or everolimus 10 mg daily. A planned interim analysis, after a minimum of follow-up of 
14 months, demonstrated a statistically significant and clinically meaningful improvement in OS 
of nivolumab monotherapy vs everolimus (median OS, 25.0 months vs 19.6 months, 
respectively; HR 0.73 [98.5% CI, 0.57 to 0.93, P = 0.002). ORR was 25% for nivolumab vs 5% 
for everolimus. Additional efficacy results are presented in Table 3.2.1.2-1. Among 756 
participants with quantifiable PD-L1 tumor expression in pretreatment samples, 24% had 1% 
PD-L1 expression. Among participants with 1% PD-L1 expression, median OS was 21.8 
months in the nivolumab group and 18.8 months in the everolimus group (HR, 0.79; 95% CI, 
0.53 to 1.17). Among participants with <1% PD-L1 expression, the median OS was 27.4 months 
in the nivolumab group and 21.2 months in the everolimus group (HR, 0.77; 95% CI 0.60 to 
0.97). No new safety concerns were identified, and nivolumab monotherapy showed a favorable 
safety profile as compared to everolimus, evidenced by the lower rates of drug-related AEs (all 
grades, 79% vs 88%; Grade 3-4, 19%-37%, respectively) and drug-related AEs leading to 
discontinuation (all grades, 8% vs 13%, respectively) in the nivolumab group. These results were 





Table 3.2.1.2-1: Summary of Efficacy Results - All Randomized Subjects -
CA209025
Efficacy Parameters Nivolumab (N = 410) Everolimus (N = 411)
Primary Endpoint
Overall Survival
Events , n (%) 183/410 (44.6) 215/411 (52.3)
Stratified log-rank test P valuea,b 0.0018
HR (98.52% CI)c 0.73 (0.57, 0.93)
Median (95% CI), monthsd 25.00 (21.75, NR) 19.55 (17.64, 23.06)
Rate at 6 months (95% CI), %d 89.2 (85.7, 91.8) 81.2 (77.0, 84.7)
Rate at 12 months (95% CI), %d 76.0 (71.5, 79.9) 66.7 (61.8, 71.0)
Secondary Endpoints
Objective Response Rate per 
Investigator (CR + PR)e
N (%) 103 (25.1) 22 (5.4)
95% CIf (21.0, 29.6) (3.4, 8.0)
Odds ratio estimate (95%CI)g,h 5.98 (3.68, 9.72)
P Valuei < 0.0001
Duration of responsee
Ongoing responders, n/N (%) 49/103 (47.6) 10/22 (45.5)
Median (95% CI), monthsd 11.99 (7.85, 23.03) 11.99 (6.44, NR)
Min, Maxj 0.0, 27.6+ 0.0+, 22.2+
Progression-free survival
Events, n (%) 318 (77.6) 322 (78.3)
Stratified log-rank test p valuea 0.1135
HR (95% CI)c 0.88 (0.75, 1.03)
Median 95% CI) 4.60 (3.71, 5.39) 4.44 (3.71, 5.52)
a Log-rank test stratified by the MSKCC risk group (poor vs intermediate vs favorable), the number of prior 
antiangiogenic therapies in the advanced/metastatic setting (1 vs 2), and the region (W. Europe, US/Canada vs 
Rest of the World) as entered into the IVRS.
b Based on the 398 observed deaths and O’Brien-Fleming alpha spending function, the boundary for statistical 
significance requires the P value to be less than 0.0148.
c Stratified Cox proportional hazard model. Hazard ratio is nivolumab over everolimus. 





e The confirmed ORR was 88/410 (21.5%) in the nivolumab group and 16/411 (3.9%) in the everolimus group 
(stratified CMH test P value < 0.0001), with a median DOR of 23.03 months in the nivolumab group and 13.73 
months in the everolimus group.
f CR+PR, confidence interval based on the Clopper and Pearson method.
g Cochran-Mantel-Haenzel test stratified by the MSKCC risk group (poor vs intermediate vs favorable), the 
number of prior anti-angiogenic therapies in the advanced/metastatic setting (X vs 2) and the region (Western 
Europe vs US/Canada vs Rest of the World) as entered into the IVRS.
h Ratio of nivolumab over everolimus
i Two-sided p value from CMH test for the comparison of the odds ratio of nivolumab over everolimus.
j Symbol + indicated a censored value. 
3.2.1.3 Ipilimumab in Renal Cell Carcinoma
Ipilimumab monotherapy for the treatment of mRCC was studied in the phase 2 clinical trial 
MDX010-11.39 Two sequential cohorts were studied, each with a loading dose of 3 mg/kg 
followed by 3 doses of either 1 mg/kg (group 3-1; n = 21) or 3 mg/kg (group 3-3; n = 40). 
Participants with stable disease or partial or complete response were allowed additional 
treatment. In Group 3-1 (n = 21), 1 participant (5%) had a PR.26 In Group 3-3 (n = 40), 5 
participants (12.5%) had a PR. Among 14 treatment-naive participants in Group 3-3, 3 (21%) 
had a PR.
In the ipilimumab monotherapy phase 2 clinical trial MDX010-11, the major toxicities were 
colitis (all Grade 3 & 4; 14% in Group 3-1, 33% in Group3-3) and hypophysitis (1 Grade 3/4, 
1 Grade 1/2 in Group 3-3; none in Group 3-1). Most reported AEs were Grade 1/2 (57% in 
Group 3-1, 35% in Group 3-3) or Grade 3 (38% in Group 3-1, 48 % in Group 3-3).40 There were 
6 participants (15%) with Grade 4 AEs in Group 3-3. The most common treatment-related AEs 
in Group 3-1 (total 81%) and Group 3-3 (total 93%) were diarrhea (38% and 40%, respectively) 
and fatigue (33% and 38%, respectively). Most AEs were manageable with appropriate 
treatment, including high dose corticosteroids and hormone replacement. 
3.2.1.4 Nivolumab Plus Ipilimumab in Renal Cell Carcinoma
Promising safety and efficacy results were also observed with the combination of nivolumab and 
ipilimumab in the advanced RCC population in study CA209016,9 a phase 1 dose-escalation 
study of nivolumab in combination with VEGFR-TKIs or ipilimumab in participants with 
metastatic RCC. Treatment-experienced and -naive participants with metastatic RCC were 
randomized to receive nivolumab 3 mg/kg + ipilimumab 1 mg/kg (arm N3 + I1) or nivolumab 
1 mg/kg + ipilimumab 3 mg/kg (arm N1 + I3) IV Q3W for 4 doses then nivolumab 3 mg/kg IV 
Q2W until progression/toxicity. In Arm N1+I3, 25 out of 47 participants (53%) were treatment-
naive, and 61.7% were intermediate risk according to MSKCC criteria, and 4.3% were 
categorized as poor risk. In Arm N1 + I3, 21 of 47 participants (45%) were treatment-naive, and 
66.0% were in the intermediate risk category, and 6.4% were categorized as poor risk. The 
primary objective was to assess safety/tolerability; secondary objective was to assess antitumor 
activity. 
After a minimum of 22 months, the level of clinical activity, as measured by confirmed ORR, for 





observed in studies of either nivolumab monotherapy (Section 3.2.1.2) or ipilimumab 
monotherapy (Section 3.2.1.3) in metastatic RCC, including in the treatment-naive 
subpopulation. The dosing regimen including nivolumab 3 mg/kg combined with ipilimumab 1 
mg/kg (N3 + I1) was chosen for further clinical evaluation because it exhibited similar clinical 
activity to nivolumab 1 mg/kg combined with ipilimumab 3 mg/kg (N1 + I3) but had a more 
favorable safety profile.
Table 3.2.1.4-1: Antitumor Activity in All Participants (CA209016)9
N3 + I1 (n = 22)
Previously Treated
N3 + I1 (n = 25)
Treatment-Naive
N1 + I3 (n = 26)
Previously 
Treated
N1 + I 3 (n = 21)
Treatment-
naive








Median duration of 
response, weeks (range)




Ongoing responses, % 
(n/N)
4 ( 40.0) 4 ( 44.4) 2 ( 20.0)
NR (23.57, NA)
Best objective response, 
n (%)
Complete response 3 ( 13.6) 2 (8.0) 0 0
Partial response 7 ( 31.8) 7 (28.0) 10 ( 38.5) 9 (42.9)
Stable disease 6 ( 27.3) 13 (52.0) 11 ( 42.3) 6 (28.8)
Progressive disease 6 ( 27.3) 6 (27.3) 3 ( 11.5) 5 (23.8)
Unable to determine 0 0 2 (  7.7) 1 (4.8)
PFS
Median months (CI)
6.6 ( 1.41, 16.39) 8.3 ( 3.55, 19.29) 10.1 ( 5.42, 20.76)
8.5 ( 2.00, NA)
6-month PFS
Median months (CI)
54.5 ( 32.1,  72.4) 56.5 (34.3, 73.8) 65.4 ( 44.0,  80.3)
61.9 ( 38.1,  78.8)
Median OS NR ( 10.02, NA) NR (26.68, NA) 30.9 ( 25.99, NA) NR ( 17.45, NA)
Abbreviations: NR = Not Reached
Among the 91 participants treated with nivolumab + ipilimumab combination in CA209016 who 
provided evaluable baseline tumor samples, 37.4% had  1% PD-L1 tumor expression, and 
16.5% had 5% PD-L1 tumor expression. ORR was 47.1% among participants with 1% PD-L1 
expression and 36.8% among participants with < 1% PD-L1 expression. Among participants 
with 5% PD-L1 expression, ORR was 40.0%.9
Among all treated patients in the Arms N3 + I1 and N1 + N3, AEs were seen in 43/47 (91.5%) 
participants in the N3 + I1 arm and 45/47 (95.7%) participants in the N1 + I3 arm. In the N1 + I3 
arm, the most frequently reported drug-related AEs were fatigue (51.1%); rash, and pruritus 
(each 31.9%); nausea (27.7%); arthralgia (25.5%). In the N1 + I3 arm, the most frequently 
reported drug related AEs were fatigue (68.1%); diarrhea, and nausea (each 44.7%); pruritus 





(29.8%); hypothyroidism (27.7%); and rash (25.5%). In the N3 + I1 arm, the most frequently 
reported, Grade 3-4 drug-related AE was lipase increased (14.9%). In the N1 + I3 arm, the most 
frequently reported Grade 3-4 drug related AEs were lipase increased (27.7%); ALT increased 
(21.3%); diarrhea, and colitis (14.9%); AST increased (12.8%).9
Treatment-related AEs (including Grade 3-4), treatment-related AEs leading to discontinuation, 
and treatment-related SAEs all occurred more commonly in participants in the N1 + I3 arm than 
in the N3 + I1 arm (Table 3.2.1.4-2).29







Death, n (%) 16 ( 34.0) 18 ( 38.3)
Within 30 Days of Last Dose 0 1 (  2.1)
Within 100 Days of Last Dose 3 (  6.4) 4 (  8.5)
Due to Study Drug Toxicity 0 0
Any Grade Grade 3-4 Any Grade Grade 3-4
All-causality SAEs, n (%) 29 ( 61.7) 20 ( 42.6) 30 ( 63.8) 24 ( 51.0)
Drug-related SAEs, n (%) 11 ( 23.4) 9 ( 19.1) 16 ( 34.0) 16 ( 34.0)
All-causality AEs Leading to 
Discontinuation, n (%)
5 ( 10.6) 3 (  6.4) 15 (31.9) 11 ( 23.4)
Drug-related AEs Leading to 
Discontinuation, n (%)
5 ( 10.6) 3 (  6.4) 13 ( 27.7) 9 ( 19.1)
All-causality AEs, n (%) 47 (100.0) 33 ( 70.2) 47 (100.0) 34 ( 72.3)
Drug-related AEs, n (%) 43 ( 91.5) 18 ( 38.3) 45 ( 95.7) 29 ( 61.7)
All-causality Select AEs, 
within 30 Days of Last Dose, 
by Category, n (%)
Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 14 ( 29.8) 3 ( 6.4) 19 (40.4) 0
Gastrointestinal 16 ( 34.0) 3 ( 6.4) 25 (53.2) 12 ( 25.5)
Hepatic 11 ( 23.4) 3 ( 6.4) 15 (31.9) 8 ( 17.0)
Pulmonary 3 (  6.4) 0 5 (10.6) 0
Renal 11 ( 23.4) 2 (  4.3) 10 (21.3) 2 (  4.3)
Skin 29 ( 61.7) 1 (  2.1) 33 ( 70.2) 1 (  2.1)
Hypersensitivity/Infusion 
Reactions












Drug-related Select AEs, 
within 30 Days of Last Dose, 
by Category, n (%)
Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 13 ( 27.7) 2 (  4.3) 19  (40.4) 0
Gastrointestinal 12 ( 25.5) 2 (  4.3) 21 ( 44.7) 11 ( 23.4)
Hepatic 9 ( 19.1) 3 (  6.4) 13 ( 27.7) 8 ( 17.0)
Pulmonary 3 (  6.4) 0 5 ( 10.6) 0
Renal 9 ( 19.1) 2 (  4.3) 6 ( 12.8) 1 (  2.1)
Skin 23 ( 48.9) 0 28 ( 59.6) 1 (  2.1)
Hypersensitivity/Infusion 
Reactions
5 ( 10.6) 0 3 (  6.4) 0
All-causality Immune-




Any Grade Grade 3-4 Any Grade Grade 3-4
Diarrhea/Colitis 3 (  6.4) 2 (  4.3) 12 ( 25.5) 10 ( 21.3)
Hepatitis 5 ( 10.6) 2 (  4.3) 11 ( 23.4) 8 ( 17.0)
Pneumonitis 1 (  2.1) 0 5 ( 10.6) 0
Nephritis and Renal 
Dysfunction
2 (  4.3) 1 (  2.1) 1 (  2.1) 0
Rash 8 ( 17.0) 1 (  2.1) 9 ( 19.1) 1 (  2.1)
Hypersensitivity 0 0 0 0
Immune-Mediated 
Endocrine AEs Treated with 
or without Immune-
Modulating Medications
Any Grade Grade 3-4 Any Grade Grade 3-4
Adrenal Insufficiency 3 (  6.4) 1 (  2.1) 6 ( 12.8) 0
Hypophysitis 1 (  2.1) 1 (  2.1) 2 (  4.3) 0
Hypothyroidism/Thyroiditis 10 ( 21.3) 0 14 ( 29.8) 0
Hyperthyroidism 4 (  8.5) 1 (  2.1) 8 ( 17.0) 0
Diabetes Mellitus 0 0 0 0
MedDRA version 18.1; CTC version 4.0. All events are within 100 days of the last dose of study drug, unless 
otherwise indicated. Sources: Table S.6.2A (deaths), Table S.6.3A (all-causality SAEs), Table S.6.3B (drug-related 
SAEs), Table S.6.4B (all-causality AEs leading to discontinuation), Table S.6.4D (drug-related AEs leading to 
discontinuation), Table S.6.2 (all-causality AEs), Table S.6.3.1 (drug-related AEs), Table S.6.101 (all-causality 
select AEs), Table S.6.105 (all-causality endocrine select AEs), Table S.6.103 (drug-related select AEs), Table 
S.6.107 (drug-related endocrine select AEs), Table S.6.202 (all-causality IMAEs with exception of endocrine), and 
Table S.6.204 (all-causality endocrine IMAEs)
A large phase 3 trial, study CA209214, is currently ongoing to determine if nivolumab combined
with ipilimumab (N3+ I1 regimen) improves PFS, OS, and ORR vs sunitinib, in participants 





A detailed description of the chemistry, pharmacology, efficacy, and safety of nivolumab and 
ipilimumab in combination is provided in the Nivolumab Investigator Brochure and Product 
Label.29 Note that the nivolumab and ipilimumab combination is currently approved for 
unresectable or metastatic melanoma, using the N1 + I3 regimen.
3.2.1.5 Cabozantinib Monotherapy in Renal Cell Carcinoma
Cabozantinib is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2, 
and has been shown to reduce tumor growth, metastasis, and angiogenesis. Cabozantinib has 
been evaluated in both first-line and second-line settings in advanced and metastatic RCC.
In participants with advanced renal cell carcinoma (RCC) who progressed after previous VEGFR 
tyrosine-kinase inhibitor (VEGFR-TKI) treatment, the randomized phase 3 METEOR trial 
compared the efficacy and safety of cabozantinib monotherapy at a daily dose of 60 mg versus 
the mTOR inhibitor everolimus at a daily dose of 10 mg.41,42 In the trial, 658 participants were 
randomized to receive cabozantinib (n = 330) or everolimus (n = 328). After a minimum follow-
up of 11 months in the first 375 randomized subjects, the primary endpoint of PFS (by 
independent radiology review) was 7.4 months in the cabozantinib arm vs 3.8 months in the 
everolimus arm (HR 0.58 [95% CI 0.45 to 0.75, p<0.001). Using Memorial Sloan Kettering 
Cancer Center (MSKCC) criteria, subgroup analyses of risk groups demonstrated PFS benefit in 
participants with favorable risk (HR 0.54 [95% CI 0.37, 0.79]), intermediate risk (HR 0.56 [95% 
CI 0.37, 0.84]), and poor risk (HR 0.84 [95% CI 0.46, 1.53]). ORR was 17% in the cabozantinib 
arm vs 5% in the everolimus arm (p<0.001). An interim OS analysis at the time of this final PFS 
analysis demonstrated a trend toward longer OS (HR 0.67, p=0.005, with p≤0.0019 required for 
statistical significance). A subsequent OS analysis, performed after a median follow-up of 
approximately 19 months in all 658 randomized subjects, demonstrated a significant 
improvement in OS, with median OS of 21.4 months in the cabozantinib arm and 16.5 months in 
the everolimus arm (HR 0.66 [95% CI 0.53–0.83]; p = 0.00026). Subgroup analyses of OS 
according to MSKCC risk group were consistent with the results for the overall population. The 
most common grade 3 or 4 adverse events included hypertension (49 [15%] in the cabozantinib 
group vs 12 [4%] in the everolimus group), diarrhea (43 [13%] vs 7 [2%]), fatigue (36 [11%] vs 
24 [7%]), palmar-plantar erythrodysesthesia syndrome (27 [8%] vs 3 [1%]), anemia (19 [6%] vs 
53 [17%]), hyperglycemia (3 [1%] vs 16 [5%]), and hypomagnesemia (16 [5%] vs none). 
Serious adverse events grade  3 occurred in 130 (39%) participants in the cabozantinib group 
and in 129 (40%) in the everolimus group. One treatment-related death occurred in the 
cabozantinib group (death; not otherwise specified) and two occurred in the everolimus group (1 
aspergillus infection and 1 pneumonia aspiration).41,42
In treatment naive participants, cabozantinib was also evaluated in a randomized phase 2 
multicenter trial against sunitinib as first-line therapy in participants with advanced or metastatic 
RCC.43 Participants were required to have either intermediate or poor risk disease according to 
IMDC criteria and were randomized in 1:1 ratio to cabozantinib (n = 79) or sunitinib (n = 78). 
Investigator-assessed PFS was the primary endpoint. Compared with sunitinib, cabozantinib 





reduction in rate of progression or death (adjusted hazard ratio, 0.66; 95% CI, 0.46 to 0.95; one-
sided P = .012). ORR was 46% (95% CI, 34 to 57) for cabozantinib vs 18% (95% CI, 10 to 28) 
for sunitinib. Median OS was 30.3 months for cabozantinib vs 21.8 months for sunitinib 
(adjusted HR 0.80, 95% CI 0.50, 1.26). All-causality grade 3 or 4 adverse events were 67% for 
cabozantinib and 68% for sunitinib and included diarrhea (cabozantinib, 10% v sunitinib, 11%), 
fatigue (6% v 15%), hypertension (28% v 22%), palmar-plantar erythrodysesthesia (8% v 4%), 
and hematologic adverse events (3% v 22%). Treatment-related Grade 5 events occurred in 3 
participants in the cabozantinib arm (acute kidney injury, sepsis, and jejunal perforation) and 3 
participants in the sunitinib arm (sepsis, respiratory failure, and vascular disorders).
3.2.1.6 Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab
Combined with Cabozantinib
The ongoing phase 1 trial (NCT02496208) evaluating the safety and efficacy of nivolumab 
combined with cabozantinib (doublet regimen) and nivolumab and ipilimumab combined with 
cabozantinib (triplet regimen) in participants with refractory metastatic urothelial carcinoma 
(mUC) and other genitourinary tumors has reported interim results.44 The primary objective was 
to determine the dose limiting toxicity and recommended phase 2 dose of the doublet and triplet 
regimens.
At the time of an update in February 2017, 48 participants (enrolled from 22-Jul-2015 to 31-Dec-
2016) had been treated, including 19 with urothelial carcinoma; 9 with castration-resistance 
prostate cancer; 4 with urachal adenocarcinoma; 4 with germ cell tumor; 4 with penile cancer; 2 
with squamous cell carcinoma of the bladder/urethra; 2 with clear cell RCC; 2 with sarcomatoid 
RCC; 1 with trophoblastic tumor; and 1 with Sertoli cell tumor.44 Part 1 of the study was the 
dose escalation for the doublet regimen and enrolled first, followed by Part 2, which was the 
dose escalation for the triplet regimen (which dosed nivolumab and ipilimumab Q3W for the first 
4 doses, followed by nivolumab alone Q2W). Thirty participants were treated with the doublet, 
and 18 were treated with triplet. Both the doublet and triplet regimens were found to be safe and 
tolerable. The recommended phase 2 dose for the doublet was cabozantinib 40 mg/day + 
nivolumab 3 mg/kg. The recommended phase 2 dose for the triplet was cabozantinib 40 mg/day 
+ nivolumab 3 mg/kg + ipilimumab 1 mg/kg.
In the doublet arm, the most common treatment-related AEs of any grade were ALT increased 
(67%); fatigue (63%); diarrhea (60%); hypothyroidism (57%); ALT increased (50%); and 
anorexia (47%). The most common treatment-related Grade 3-4 AEs were neutropenia (17%); 
hypophosphatemia and lipase increase (13% each); hypertension (10%); fatigue, diarrhea, 
thrombocytopenia, and dehydration (7% each). One participant developed immune-mediated 
Grade 3 aseptic meningitis.
In the triplet arm, the most common treatment-related AEs of any grade were fatigue (72%); 
diarrhea and anorexia (61% each); ALT increased, hypophosphatemia, dysgeusia, and lipase 
increased (44% each). The most common treatment-related Grade 3-4 AEs were hypertension 
and hypophosphatemia (17% each); and fatigue, hyponatremia, nausea, and lipase increase (13% 





Among 43 participants who were evaluable for response, the ORR was 30%. The ORR was 38% 
among 26 evaluable participants treated with the doublet and 18% among 17 participants treated 
with the triplet. One of 2 participants with sarcomatoid RCC achieved a response. Neither of the 
2 participants with clear cell RCC were evaluable for response at the time of the analysis.
The doublet and triplet expansion cohorts are continuing to enroll participants with advanced 
urothelial carcinoma and RCC. Updated safety and efficacy results after additional enrollment 
and longer follow-up are awaited. 
3.3 Benefit/Risk Assessment
The currently available first-line agents for treatment of mRCC are associated with median OS of 
43.2 months in patients with favorable risk disease according to IMDC criteria.45 However, 
median OS is 22.5 months in those with intermediate risk disease and only 7.8 months in those 
with poor risk disease, indicating the higher unmet medical need in these intermediate and poor 
risk groups. Recently, cabozantinib demonstrated a significant improvement in investigator-
assessed PFS and ORR over standard-of-care sunitinib as first-line therapy in a randomized 
phase 2 study in participants with intermediate- or poor-risk mRCC. 
Based on their different mechanisms of action and the potential immune effects associated with 
anti-VEGF treatment, combining nivolumab with cabozantinib (doublet regimen) or nivolumab 
and ipilimumab combined with cabozantinib (triplet regimen) may produce synergistic clinical 
activity and provide improved benefit over standard of care sunitinib monotherapy in mRCC. As 
mentioned in Section 3.1, several phase 1 studies combining anti-PD-1 agents with anti-VEGF 
agents have demonstrated greater clinical activity than has been observed historically in trials of 
these agents given as monotherapy. Although additional risk may be involved with combination 
therapies, early safety results from the ongoing phase 1 combination study in refractory 
genitourinary cancers evaluating the safety and efficacy of nivolumab combined with 
cabozantinib (doublet regimen) and nivolumab and ipilimumab combined with cabozantinib 
(triplet regimen) suggest that safety profiles appear acceptable. Therefore, overall benefit/risk is 
acceptable for these doublet and triplet combinations compared to sunitinib in participants with 
intermediate/poor risk mRCC.
Although the relative benefit of cabozantinib vs sunitinib in participants with previously 
untreated, favorable risk mRCC was not evaluated in the CABOSUN study, subgroup analyses 
from the METEOR study suggest that the PFS and OS benefit of cabozantinib in favorable risk 
disease is similar to that in intermediate risk disease (see Section 3.2.1.4). Based on the 
preliminary efficacy results from the phase 1 combination study, which included participants 
with refractory genitourinary tumors, nivolumab combined with cabozantinib (doublet) or 
nivolumab and ipilimumab combined with cabozantinib (triplet) is anticipated to produce clinical 
activity that is greater than that observed with sunitinib monotherapy, even in favorable risk 
disease. Therefore, this study will also include participants with favorable risk disease, to 
comprise approximately 20% of the overall population.
Overall, the safety profile of nivolumab monotherapy as well as in combination with ipilimumab 





MTD reached at any dose tested up to 10 mg/kg. Most AEs were low-grade (Grade 1 to 2) with 
relatively few related high-grade (Grade 3 to 4) AEs. There was no pattern in the incidence, 
severity, or causality of AEs with respect to nivolumab dose level.
A pattern of immune-related adverse events has been defined, for which management algorithms 
have been developed; these are provided in Appendix 5 and within the Investigator Brochure.29
Most high-grade events were manageable with the use of corticosteroids or hormone replacement 
therapy (endocrinopathies) as instructed in these algorithms. 
More detailed information about the known and expected benefits and risks and reasonably 
anticipated adverse events (AEs) of nivolumab, ipilimumab, and cabozantinib may be found in 
their respective Investigator Brochures.22,29
4. OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objective Endpoint
Primary
To compare progression-free survival (PFS) 
per BICR of Arm A (doublet) with Arm C and 
of Arm B (triplet) with Arm C (sunitinib) in 
all intermediate/poor risk randomized 
participants. 
The primary objective specifies two comparisons: PFS per BICR 
of Arm A versus Arm C and of Arm B versus Arm C in all 
intermediate/poor risk randomized participants. PFS is defined as 
the time between the date of randomization and the first date of the 
documented progression, or death due to any cause, whichever 
occurs first. Participants who die without a reported progression 
will be considered to have progressed on the date of their death. 
Participants who did not progress or die will be censored on the 
date of their last evaluable tumor assessment. Participants who did 
not have any on study tumor assessments and did not die will be 
censored on their date of randomization. Participants who started 
anti-cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment prior 
to the initiation of first subsequent anti-cancer therapy.
Secondary
To compare progression-free survival (PFS) 
per BICR of Arm A with Arm C and of Arm 
B with Arm C in all randomized participants.
This secondary objective specifies two comparisons: PFS per 
BICR of Arm A versus Arm C and of Arm B versus Arm C in all 
randomized participants. The PFS will be defined similarly to the 
primary endpoint except that all randomized participants (any risk 
participants) will be used.
To compare overall survival (OS) of Arm A 
with Arm C and of Arm B with Arm C in all 
intermediate/poor risk randomized 
participants.
The secondary endpoint specifies two comparisons: OS of Arm A 
versus Arm C and of Arm B versus Arm C in all intermediate/poor 
risk randomized participants. OS is defined as the time between the 
date of randomization and the date of death due to any cause. A 
participant who has not died will be censored at the last known 
alive date.
To compare overall survival (OS) of Arm A 
with Arm C and of Arm B with Arm C in all 
randomized participants.
This secondary objective specifies two comparisons: OS of Arm A 
versus Arm C and of Arm B versus Arm C in all randomized 
participants. The OS will be defined similarly to the first secondary 





Table 4-1: Objectives and Endpoints
Objective Endpoint
participants) will be used.
To evaluate the objective response rate (ORR) 
per BICR in all intermediate/poor risk 
randomized and all randomized participants.
This secondary objective is ORR per BICR in all intermediate/poor 
risk randomized participants and in all randomized participants 
(any risk participants). ORR is defined as the proportion of 
randomized participants who achieve a best response of complete 
response (CR) or partial response (PR) using the RECIST 1.1 
criteria. Best overall response (BOR) is defined as the best 
response designation recorded between the date of randomization 
and the date of objectively documented progression per RECIST 
1.1 or the date of subsequent therapy (including tumor-directed 
radiotherapy and tumor-directed surgery), whichever occurs first. 
For participants without document progression or subsequent 
therapy, all available response designations will contribute to the 
BOR assessment. Duration of response (DOR) is defined as the 
time between the date of first confirmed documented response (CR 
or PR) to the date of first documented tumor progression (per 
RECIST 1.1) or death due to any cause, whichever occurs first. 
Participants who neither progress nor die will be censored on the 
date of their last tumor assessment. Responders who started anti-
cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment prior 
to the initiation of first subsequent anti-cancer therapy. Time to 
response (TTR) is defined as the time from randomization to the 
date of the first confirmed documented response (CR or PR), as 
assessed by BICR. DOR and TTR will be evaluated for responders 
(CR or PR) only.
To assess overall safety and tolerability in all 
treated participants.
As measured by the incidence of adverse events (AEs), serious 
adverse events (SAEs), AEs leading to discontinuation, deaths, 
laboratory abnormalities and changes from baseline.
Exploratory
To explore potential predictive biomarkers of 
clinical response to nivolumab, ipilimumab 
and cabozantinib combination. 
Analysis of tumor specimens and blood samples for proteins and 
genes involved in regulating immune response (eg, PD-1, PD-L1, 
PD-L2, CXCL10, MET). Other exploratory endpoints for 
biomarkers, pharmacogenomics, and immunogenicity are 
described in Section 9.8.
To evaluate health related quality of life 
(HRQoL).
Assessed by the NCCN Functional Assessment of Cancer Therapy-
Kidney Symptom Index (FKSI-19) and the EuroQoL Group’s EQ-
5D (3L version) is described in Section 9.9.
To characterize the pharmacokinetics of 
nivolumab, ipilimumab, and cabozantinib and 
explore exposure response relationships, if 
applicable.
Population PK parameters, exposure-response relationship between 
select PK measures of exposure and safety and efficacy endpoints, 
if applicable
To characterize the immunogenicity of 
nivolumab and ipilimumab.
Incidence of anti-nivolumab and anti-ipilimumab antibodies and 







This is an open label, randomized trial of nivolumab combined with cabozantinib (doublet 
regimen) or nivolumab + ipilimumab combined with cabozantinib (triplet regimen) versus 
sunitinib in participants with previously untreated (first line) advanced or metastatic RCC. 
Participants will be randomized between 3 arms in a 1:1:1 ratio with approximately 810 
intermediate/poor risk participants (270 per arm) and 204 favorable risk participants (68 per 
arm). Participants will be stratified at the time of randomization by IMDC prognostic score (0 
[favorable risk] versus 1-2 [intermediate risk] versus 3-6 [poor risk]), PD-L1 tumor expression (≥ 
1% versus < 1% or indeterminate), and region (US/Canada/Western Europe/Northern Europe 
versus rest of the world [ROW]).
The study design schematic is presented in Figure 5.1-1.
Figure 5.1-1: Study Design Schematic
Abbreviations: BICR= blinding independent central review; DMC= data monitoring committee; 
IMDC= International Metastatic Renal Cell Carcinoma Database Consortium; IV=intravenous; PD= progressive 
disease; D-L1= programmed death-ligand 1; PO= orally by mouth; Pts=patients/participants; Q2W=every 2 
weeks; Q3W=every 3 weeks; QD= once daily; RCC=renal cell carcinoma.
This study will consist of 3 stages: screening, treatment, and follow up phase.
Screening stage: Screening begins by establishing the participant’s initial eligibility and signing 
of the informed consent (ICF). Sufficient, recent tumor tissue, preferably obtained within 3 
months but no more than 12 months prior to enrollment, from a metastatic tumor lesion or from a
primary tumor lesion which has not been previously irradiated (formalin-fixed paraffin-





punch biopsy, excisional biopsy or surgical specimen) will be submitted to the central laboratory. 
Upon receipt of the tumor sample, the central lab will determine PD-L1 expression level by 
immunohistochemistry (IHC) testing (see Section 9.8.2). In order to be randomized in the 
Interactive Response Technology (IRT) system, a participant must be classified as PD-L1 
expression ≥ 1%, PD-L1 expression < 1%, or PD-L1 expression indeterminate. Sites will be 
informed when the submitted tumor sample is insufficient for PD-L1 testing by the central lab. 
Participants will be assessed for complete study eligibility prior to randomization as specified in 
Section 2. 
The Screening stage ends with either confirmation of full eligibility and randomization for the 
participant or with the confirmation that the participant is a screen failure. This study permits the 
re-enrollment of a participant that has discontinued the study as a pre-treatment failure prior to 
randomization. If re-enrolled, the participant must be re-consented. A new participant
identification number will be assigned by IRT at the time of re-enrollment. 
Treatment stage: The Treatment stage begins when the randomization call is made into the IRT. 
The participant is randomly assigned to 1 of the 3 treatment arms as noted in the study schematic 
above.
• Arm A (Doublet): Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
o Nivolumab to be continued until disease progression, unacceptable toxicity, or a 
maximum of 2 years from the first dose in Cycle 1
o Cabozantinib to be continued until disease progression or unacceptable toxicity
• Arm B (Triplet): Nivolumab 3mg/kg IV + Ipilimumab 1 mg/kg IV, both Q3W x 4 doses + 
Cabozantinib 40 mg PO QD 
o Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
o Nivolumab to be continued until disease progression, unacceptable toxicity, or a 
maximum of 2 years from the first dose in Cycle 1
o Cabozantinib to be continued until progression or unacceptable toxicity
• Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle. Cycles to 
be continued until progression or unacceptable toxicity
Study treatment must begin within 3 days of randomization. Participants in Arm A and Arm B 
will continue nivolumab until progression, unacceptable toxicity, withdrawal of consent, or a 
maximum of 2 years from the first dose in Cycle 1, whichever occurs first. Cabozantinib (Arm A 
and Arm B) may be continued until progression, unacceptable toxicity, or withdrawal of consent, 
whichever occurs first, and may extend beyond 2 years from the first dose in Cycle 1. See Table 
7.1-1 and Table 7.1-2 for the dosing schedule. Study drugs may be delayed for toxicity (See 
Section 7.4.1). Treatment may be continued beyond investigator-assessed progression if the 
investigator confirms that the participant meets the criteria specified in Section 8.1.4 and 
approval is granted by the BMS Medical Monitor.
A negative pregnancy test should be documented within 24 hours prior to the initial dose of the 





laboratory assessments should be drawn within 72 hours prior to dosing and will be assessed at 
the local laboratory.
Tumor assessments will occur in accordance with Section 2 and Section 9.1.2 until progression 
has been assessed by the investigator and confirmed by the blinded independent central review 
(BICR). Each site must submit scans on a rolling basis, preferably within 7 days of image 
acquisition, to a third-party vendor for BICR. If progression is assessed by the investigator, the 
site will inform the radiology vendor so that the BICR assessment of progression can be 
performed. The BICR assessment of progression will be completed, and the results provided to 
the site, within approximately 14 days, as specified in Section 9.1.2. 
PK and immunogenicity samples will be collected according to Table 9.5-1 and Table 9.5-2. 
Adverse event assessments should be documented at each clinic visit. 
Quality of Life will be assessed using the National Comprehensive Cancer Network (NCCN)
Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-19) and EuroQoL’s 
EQ-5D-3L. These questionnaires should be completed according to Section 2. 
The Treatment stage ends when the participant is discontinued from study therapy. 
Follow-up stage: The Follow-up stage begins when the decision to discontinue a participant from 
study therapy is made (no further treatment with study therapy). Participants will have 2 follow-
up visits (FU1 and FU2) for safety within approximately 100 days from the last dose of study 
therapy, and AEs will be followed until the toxicities resolve, return to baseline, or are deemed 
irreversible. The FKSI-19 and EQ-5D-3L will be completed as described in Section 2.
Participants who discontinued study treatment without BICR confirmed radiographic progression
will continue to have tumor assessments performed according to the frequency described in 
Sections 2 and 9.1.2, even if new anti-tumor therapy has been initiated. If progression is assessed 
by the investigator, the site will inform the radiology vendor, so that the BICR assessment of 
progression can be performed. Participants whose progression is not confirmed by the BICR will 
be required to continue tumor assessments (if clinically feasible) according to the protocol-
specified schedule or sooner if clinically indicated until BICR confirms progression on a 
subsequent tumor assessment (See Section 9.1.2.2 for additional details).
After the Follow-up 2 Visit, all participants will be followed for overall survival status every 
3 months (+/- 14 days) until death, withdrawal of consent, loss to follow-up, or end of study. 
Survival status can be ascertained in person or by telephone contact. If new anti-tumor therapy is 
initiated for either progression or a secondary malignancy at any time during this period, this and 
all other pertinent data obtained should be recorded on the appropriate Case Report Form (CRF). 
5.1.1 Data Monitoring Committee and Other External Committees
To provide independent oversight of safety, efficacy, and study conduct, a data monitoring 
committee (DMC) will be instituted. The DMC will meet regularly to ensure that participant
safety is carefully monitored, including a safety assessment after the first 75 participants are 
randomized across the 3 arms and are followed for at least 6 weeks. The DMC will convene 





continuation, modification, or discontinuation of the study based on observed toxicities. The 
DMC will also review the interim analysis results and inform BMS whether stopping criteria for 
superiority are met at that time. A separate DMC charter will describe the activities of this 
committee in more detail.
Blinded independent central review (BICR) will be utilized in this study for determination of
PFS and ORR endpoints. The BICR will review all available tumor assessment scans for all 
randomized participants. Details of BICR responsibilities and procedures will be specified in the 
BICR charter.
5.2 Number of Participants
Approximately 1353 participant will be enrolled in order to randomize approximately 
1014 participants (338 per arm). This includes approximately 204 favorable risk (per IMDC 
criteria) randomized participants (68 per arm) and approximately 810 intermediate/poor risk (per 
IMDC criteria) randomized participants (270 per each arm). The number of randomized 
participants with favorable risk disease will be capped at approximately 204 participants.
5.3 End of Study Definition
The start of the trial is defined as the first visit for the first participant screened. End of trial is 
defined as the last visit or scheduled procedure shown in the Schedule of Activities for the last 
participant. Study completion is defined as the final date on which data for the endpoint of 
overall survival was or is expected to be collected, if this is not the same.
5.4 Scientific Rationale for Study Design
Please refer to Section 3.1 for details of the rationale for evaluating the combination of 
nivolumab with cabozantinib (doublet regimen) or nivolumab and ipilimumab combined 
cabozantinib (triplet regimen) in this study. 
5.4.1 Rationale for Open-Label Design
The trial will have an open-label design with a blinded independent central review. Different 
dosing schedules and use of both IV infusions and oral medications across the 3 different arms 
make blinding the trial impractical. The complexity of including multiple visits for placebo 
infusions are burdensome for this participant population. Nivolumab and ipilimumab are 
associated with some toxicities that are also common to cabozantinib and sunitinib (eg, diarrhea, 
hepatotoxicity), and the management of these common toxicities are different for immuno-
oncology agents (eg, typically requiring steroids) vs TKIs (eg, typically requiring dose delay and 
reductions). Therefore, an open-label trial is preferable for participant safety as it allows the 
optimal management of toxicities.
5.4.2 Rationale for Choice of Primary Endpoint in Intermediate and Poor-Risk 
Participants
The primary endpoint to be evaluated is PFS per BICR in participants with intermediate or poor 
risk mRCC according to IMDC prognostic criteria. PFS has been an acceptable endpoint to 





pazopanib were approved based on an increase in PFS. While OS remains the “gold standard” 
for oncology trials, as more active agents gain approval in RCC, subsequent treatment with these 
agents confounds the effect of first-line treatment on OS. Therefore, PFS remains an important 
indicator of clinical benefit in first-line mRCC and has been chosen as the primary endpoint for 
this trial.
The primary efficacy analysis population is limited to intermediate and poor-risk participants, 
which comprises approximately 75% of the total treatment-naive mRCC population. The 
outcomes associated with standard of care first-line treatment for participants with intermediate 
and poor risk disease is suboptimal, and selecting these participants for the primary endpoint of 
the study will allow for potential meaningful differences in efficacy to be detected earlier than in
a broader population that includes favorable-risk participants. Nevertheless, this trial will also 
randomize approximately 204 favorable-risk participants in order to evaluate the clinical activity
and safety in participants across all risk groups (ie, all randomized population), which are 
included as secondary objectives. Based on results for favorable-risk subjects in the METEOR 
trial, efficacy would be expected in favorable-risk subjects in the current trial?
5.5 Justification for Dose
5.5.1 Dosing for Sunitinib Monotherapy in Arm C
Dosing for sunitinib monotherapy in Arm C uses the standard dosing schedule found in the 
sunitinib prescribing information.34
5.5.2 Dosing for Cabozantinib Doublet and Triplet Therapy in Arm A and 
Arm B
Dosing for nivolumab combined with cabozantinib (doublet regimen) or nivolumab and
ipilimumab combined with cabozantinib (triplet regimen) was determined based on a phase 1b/2 
trial (NCT02496208) conducted with the combination at NCI/NIH (see Section 3.2.1.5).
5.5.3 Dosing Rationale for Nivolumab 240 mg flat dose Q2W
A flat dose of nivolumab 240 mg every 2 weeks will be administered in Arm A and in the 
maintenance phase of Arm B in combination with cabozantinib. Nivolumab 3mg/kg once every 2 
weeks has been shown to be similar to 240 mg flat dose every 2 weeks, and is currently FDA 
approved, based on clinical data and modeling and simulation approaches using population PK 
(PPK) and exposure-response analyses of data from studies in multiple tumor types (melanoma, 
non-small-cell lung cancer [NSCLC], renal cell carcinoma [RCC]) and urothelial carcinoma 
where body weight normalized dosing (mg/kg) has been used.
PPK analyses have shown that the PK of nivolumab is linear with proportional exposure over a 
dose range of 0.1 to 10 mg/kg, and no differences in PK across ethnicities and tumor types were 
observed. Nivolumab clearance and volume of distribution were found to increase as the body 
weight increases, but less than proportionally with increasing weight, indicating that mg/kg 
dosing represents an over-adjustment for the effect of body weight on nivolumab PK. The PPK 
model developed using data from NSCLC participants was updated, using data from participants 





median (minimum to maximum) weight was 77 kg (35 to 160 kg) and thus, an approximately 
equivalent dose of 3 mg/kg for an 80 kg participant, nivolumab 240 mg Q2W was selected for 
future studies. To predict relevant summary exposures of nivolumab 240 mg Q2W, the PPK 
model was used to simulate nivolumab 3 mg/kg Q2W and 240 mg Q2W. In the simulations, the 
simulated participant populations consisted of 1000 participants per treatment arm randomly 
sampled from aforementioned pooled database of cancer participants. Because no differences in 
PK were noted across ethnicities and tumor types, these simulated melanoma, NSCLC and RCC 
data will be applicable to participants with other tumor types. The simulated measure of 
exposure of interest, time-averaged concentrations (Cavgss) for 240 mg Q2W were predicted to 
be similar for all participants in reference to 80 kg participants receiving 3 mg/kg Q2W.
Additionally, nivolumab is safe and well tolerated up to 10 mg/kg Q2W dose level. Adverse 
events have been consistent across tumor types following monotherapy and have not 
demonstrated clear dose-response or exposure-response relationships. Additionally, the 
simulated median and 95th prediction interval of nivolumab summary exposures across a wide 
body weight range (35 - 160 kg) are predicted to be maintained below the corresponding 
observed highest exposure experienced in nivolumab, ie, 95th percentile following nivolumab 10 
mg/kg Q2W from clinical study CA209003. Thus, while participants in the lower body weight 
ranges would have greater exposures than 80 kg participants, the exposures are predicted to be 
within the range of observed exposures at doses (up to 10 mg/kg Q2W) used in the nivolumab 
clinical program, and are not considered to put participants at increased risk. Additionally, for 
participants with greater body weights, the simulated ranges of exposures are also not expected 
to affect efficacy, because the exposures predicted following administration of a 240 mg Q2W 
are on the flat part of the exposure-response curves for previously investigated tumors, 
melanoma and NSCLC. Given the similarity of nivolumab PK across many tumor types, 
including RCC, and the similar exposures predicted following administration of 240 mg flat dose 
compared to 3 mg/kg, it was shown that the safety and efficacy profile of 240 mg nivolumab will 
be similar to that of 3 mg/kg nivolumab.
5.5.4 Rationale for Dosing Duration for Nivolumab
The optimal duration of immunotherapy is currently unknown. However, because 
immunotherapy engages the immune system to control the tumor, continuous treatment as is 
required with targeted agents or cytotoxic therapy may not be necessary. 
Accumulating evidence from different clinical trials in different tumor types with nivolumab or 
nivolumab combined to ipilimumab indicates that most of the responses are generally occurring 
early, with a median time to response of 2 to 4 months.46,47 A recent analysis in a melanoma 
study suggests the majority of participants who discontinue nivolumab and/or ipilimumab for 
toxicity maintain disease control in the absence of further treatment.48 Furthermore, a limited 
duration of ipilimumab including only 4 induction doses resulted in long term survival in 






For these reasons, in study CA2099ER, treatment with nivolumab or nivolumab with ipilimumab 
will be given for up to 24 months in the absence of disease progression or unacceptable toxicity. 
Participants who complete 24 months of nivolumab or nivolumab with ipilimumab and have 
subsequent disease progression may reinitiate nivolumab or nivolumab with ipilimumab at the 
same dose and schedule given previously on study and continue such treatment for up to 
1 additional year.
6. STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Participants must have signed and dated an IRB/IEC approved written informed consent 
form in accordance with regulatory and institutional guidelines. This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
participant care. 
b) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
and laboratory testing.
2) Type of Participant and Target Disease Characteristics
a) Histological confirmation of RCC with a clear-cell component, including participants 
who may also have sarcomatoid features
b) Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC 
Stage IV) RCC
c) No prior systemic therapy for RCC with the following exception:
i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such 
therapy did not include an agent that targets VEGF or VEGF receptors and if 
recurrence occurred at least 6 months after the last dose of adjuvant or 
neoadjuvant therapy.
d) Karnofsky Performance Status (KPS)  70% (See Appendix 7)
e) Measurable disease as per RECIST v1.1 per investigator. (See Appendix 8)
f) Either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue 
sections, preferably obtained within 3 months but no more than 12 months prior to 
enrollment, with an associated pathology report, must be submitted to the central 
laboratory during screening. Biopsy should be excisional, incisional or core needle. Fine 
needle aspiration is unacceptable for submission. In participants who received prior 
adjuvant or neoadjuvant therapy, the tumor sample must have been obtained after 
completion of adjuvant or neoadjuvant therapy. Upon receipt of the tumor sample, the 
central lab will determine PD-L1 expression level by IHC testing (see Section 9.8.2). In 
order to be randomized in the IRT system, a participant must be classified as PD-L1 
expression ≥ 1%, PD-L1 expression < 1%, or PD-L1 expression indeterminate. Sites will 
be informed when the submitted tumor sample is insufficient for PD-L1 testing by the 
central lab.
g) Participants with favorable, intermediate and poor risk categories will be eligible for the 





following prognostic factors as per International Metastatic RCC Database Consortium 
(IMDC) must be present: (See Appendix 6)
i) KPS equal to 70%
ii) Less than 1 year from initial diagnosis (including original localized disease if 
applicable) to randomization
iii) Hemoglobin < lower limit of normal (LLN)
iv) Corrected calcium concentration > 10 mg/dL
v) Absolute neutrophil count > ULN
vi) Platelet count > ULN
If none of the above factors are present, participants are only eligible for the favorable-
risk cohort. Approximately 204 favorable risk participants will be randomized. 
Enrollment of favorable risk participants may be closed earlier than enrollment for 
intermediate and poor risk participants.
3) Age and Reproductive Status
a) Males and Females, ages 18 or age of majority 
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 
hours prior to the start of study treatment
c) Women must not be breastfeeding
d) Women of childbearing potential (WOCBP) must agree to follow instructions for 
method(s) of contraception for the duration of study treatment and 5 months after the last 
dose of study treatment (ie, 30 days [duration of ovulatory cycle] plus the time required 
for the investigational drug to undergo approximately five half-lives).
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of study treatment and 7 months after the last 
dose of study treatment (ie, 90 days [duration of sperm turnover] plus the time required 
for the investigational drug to undergo approximately five half-lives).
f) Azoospermic males are exempt from contraceptive requirements. WOCBP who are 
continuously not heterosexually active are also exempt from contraceptive requirements, 
and still must undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP, and male participants who are sexually active with 
WOCBP, on the importance of pregnancy prevention and the implications of an unexpected 
pregnancy. Investigators shall advise on the use of highly effective methods of contraception 
(Appendix 4) which have a failure rate of < 1% when used consistently and correctly.
6.2 Exclusion Criteria
1) Medical Conditions
a) Any active CNS metastases. Participants with treated, stable CNS metastases for at least 
3 months are eligible as long as they meet the following criteria:
Treated CNS metastases are defined as having no ongoing requirement for corticosteroids 
for at least 2 weeks prior to randomization and no evidence of progression or hemorrhage 





clinical examination and brain imaging (MRI or CT). (Stable dose of anticonvulsants is 
allowed). Treatment for CNS metastases may include whole brain radiotherapy, 
radiosurgery (eg, RS, gamma knife, LINAC, or equivalent) or a combination as deemed 
appropriate by the treating physician. Participants with CNS metastases treated by 
neurosurgical resection or brain biopsy performed within 3 months prior to 
randomization are not eligible. Baseline imaging of the brain is required within 28 days 
prior to randomization.
b) Any active, known or suspected autoimmune disease. Participants with type I diabetes 
mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as 
vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not 
expected to recur in the absence of an external trigger are permitted to enroll.
c) Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg 
daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
d) Prior malignancy active within the previous 3 years except for locally curable cancers 
that have been apparently cured, such as basal or squamous cell skin cancer, superficial 
bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
e) Any tumor invading the SVC or other major blood vessels
f) Any tumor invading the GI tract or any evidence of endotracheal or endobronchial tumor 
within 30 days prior to randomization
g) Known history of positive test for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be 
performed at sites where mandated locally (sites in Germany, see Appendix 12).
h) Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis, 
aortic aneurysm, aortic dissection) that, in the investigator’s opinion, would increase the 
risk associated with study participation or study drug administration or interfere with the 
interpretation of safety results
i) History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel 
obstruction, or gastric outlet obstruction within the past 6 months prior to randomization
j) Impairment of gastrointestinal function or gastrointestinal disease that may significantly 
alter the absorption of cabozantinib or sunitinib (eg, malabsorptive disorder, ulcerative 
disease, uncontrolled nausea, vomiting, diarrhea, or small bowel resection)
k) Serious, non-healing wound or ulcer within 30 days prior to randomization
l) Evidence of active bleeding or bleeding susceptibility; or medically significant 
hemorrhage within prior 3 months prior to randomization
m) Uncontrolled adrenal insufficiency
n) History of cerebrovascular accident (CVA) including transient ischemic attack within the 
past 6 months prior to randomization
o) History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within past 6 
months prior to randomization unless stable, asymptomatic, and treated with low 
molecular weight heparin (LMWH) for at least 6 weeks prior to randomization





q) Prolongation of the Fridericia corrected QT (QTcF) interval defined as > 450 msec for 
males and > 470 msec for females, where QTcF = QT / 3√RR with triplicate 
measurements
r) Poorly controlled hypertension (defined as systolic blood pressure (SBP) of > 150 mmHg 
or diastolic blood pressure (DBP) of > 90 mmHg), despite antihypertensive therapy
s) History of any of the following cardiovascular conditions within 6 months of 
randomization: cardiac angioplasty or stenting, myocardial infarction, unstable angina, 
coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, class III 
or IV congestive heart failure (CHF), as defined by the New York Heart Association
(NYHA)
t) Any radiologic or clinical evidence of pancreatitis within 30 days prior to randomization
u) Inability to swallow oral medications
2) Prior/Concomitant Therapy
a) Prior treatment with VEGF, MET, AXL, KIT, or RET targeted therapy (including, but 
not limited to, sunitinib, pazopanib, axitinib, tivozanib, sorafenib, lenvatinib, 
bevacizumab, and cabozantinib).
b) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or 
checkpoint pathways.
c) Concomitant strong CYP3A4 inducers or inhibitors within 14 days prior to 
randomization. Please refer to Appendix 9 for a list of common strong CYP3A4 inducers 
and inhibitors.
d) Concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or 
warfarin-related agents, thrombin or Factor Xa inhibitors. Aspirin (up to 325 mg/day) and 
prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted.
e) Major surgery (eg, nephrectomy) less than 6 weeks prior to randomization 
f) Any of the following prior radiotherapy procedures:
i) Radiotherapy to the thoracic cavity or abdomen within 4 weeks prior to 
randomization
ii) Radiotherapy to bone lesions within 2 weeks prior to randomization
iii) Radiotherapy to any other site within 4 weeks prior to randomization
NOTE: In all cases, there must be complete recovery and no ongoing complications from 
prior radiotherapy.
3) Physical and Laboratory Test Findings
a) Ejection fraction  50% on screening echocardiogram or MUGA
b) WBC < 2000/μL
c) Neutrophils < 1500/μL
d) Platelets < 100 x 103/μL
e) Hemoglobin < 9.0 g/dL (support with transfusion is acceptable)






g) AST/ALT > 3.0 x ULN
h) Total bilirubin > 1.5 x ULN (except participants with Gilbert Syndrome who must have a 
total bilirubin level of < 3.0 x ULN)
i) Urine protein/creatinine ratio (UPCR) ≥ 1.0, unless 24-hour urine protein is < 1.0 g
j) INR > 1.2
k) Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of 
virus, eg, hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody 
(anti-HCV) positive (except if HCV-RNA negative)
4) Allergies and Adverse Drug Reaction
a) History of allergy or hypersensitivity to study drug components
b) No history of severe hypersensitivity to a monoclonal antibody
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to 
continue as a participant. Strict conditions apply and Bristol-Myers Squibb approval is 
required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or 
physical (eg, infectious disease) illness
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
6.3.1 Meals and Dietary Restrictions
For participants in Arms A and B, cabozantinib should not be taken with grapefruit/grapefruit 
juice or Seville oranges.
For participants in Arm C, sunitinib should not be taken with grapefruit/grapefruit juice.
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomized. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants, to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from 
regulatory authorities. Minimal information includes date of consent, demography, screen failure 
details, eligibility criteria, and any serious AEs.
6.4.1 Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment of a participant that has 
discontinued the study as a pre-treatment failure (ie, participant has not been randomized / has 





Retesting of laboratory parameters and/or other assessments within any single Screening or 
Lead-in period will be permitted (in addition to any parameters that require a confirmatory 
value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participant’s most current, clinical state.
Laboratory parameters and/or assessments that are included in Table 2-1 Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participants. Consultation 
with the BMS Medical Monitor may be needed to identify whether repeat testing of any 
particular parameter is clinically relevant.
7. TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
randomization or treatment allocation.
Study treatment includes both Investigational [Medicinal] Product (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
Other medications used as support or escape medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be 





Table 7-1: Study treatments for CA2099ER
Product Description / 










100 mg (10 mg/mL) IP Open Label
Vial
(multiple vials per carton)
Store at 2° - 8 °C. Protect 
from light and freezing
Ipilimumab Solution for
Injection
200 mg (5mg/mL) IP Open Label
Vial
(multiple vials per carton)
Store at 2° - 8 °C. Protect 
from light and freezing
Cabozantinib
Tablet
20 mg IP Open Label Tablets in a bottle
Refer to storage 




12.5 mg IP Open Label
Capsules in various 
packaging configurations
Refer to storage 
conditions on container 
label/package insert
*May be labeled as “BMS-936558-01” or “Nivolumab”
** Sunitinib may be obtained by the investigational sites in certain countries as local commercial product (which may be available as a different potency/package 
size than listed above) if local regulations allow and agreed to by BMS.
Premedications or medications used to treat infusion-related reactions should be sourced by the investigative sites if available and
permitted by local regulations. Solutions used as diluent (ie, 0.9% Sodium Chloride Injection or 5% Dextrose Injection) should also be






The selection and timing of dose for each participant is presented in Table 7.1-1 and the dosing 
scheduled by cycle is presented in Table 7.1-2.
Table 7.1-1: Selection and Timing of Dose
Arm Study 
Treatment
Dosage level(s) and 
Formulation




Nivolumab 240 mg IV Every 2 weeks IV
Cabozantinib 40 mg (20 mg tablets) Once daily (QD) PO
B
(Triplet)
Nivolumab 3 mg/kg IV for 4 doses
then 240 mg IV
Every 3 weeks (Q3W) for 4 doses 
then every 2 weeks (Q2W)
IV
Ipilimumab 1 mg/kg IV for 4 doses Every 3 weeks (Q3W) for 4 doses IV
Cabozantinib 40 mg (20 mg tablets) Once daily (QD) PO
C Sunitinib 50 mg (12.5 mg capsules) Every 3 weeks (Q3W) for 4 doses 
then every 2 weeks (Q2W)
IV
Abbreviations: IV=intravenous; PO= by mouth
Table 7.1-2: Dosing Schedule for CA2099ER
Arm Cycle 1 Cycle 2 Cycle 3 Cycle 4






(each cycle = 2 weeks)
Nivolumab 




40 mg PO QD
Nivolumab 




40 mg PO QD
Nivolumab 240 




40 mg PO QD
Nivolumab 




40 mg PO QD
Nivolumab 









(Cycle 1 to 4 = 3 
weeks, 
Cycle 5 and subsequent 
cyces = 2 weeks)
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab




40 mg PO QD
Arm C
Sunitinib
(each cycle = 6 weeks, 
treatment for 4 weeks 
then 2 weeks off each 
cycle)
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks





Participants should begin study treatment within 3 calendar days of randomization. 
For Arm A, participants should receive nivolumab at a dose of 240 mg as an approximately 
30 minute infusion on Day 1 of each treatment cycle until progression, unacceptable toxicity, 
withdrawal of consent, completion of 24 months of treatment (from the first dose on Cycle 1), or
the end of the study, whichever occurs first. The first cabozantinib dose should be given in the 
evening on Day 1, Cycle 1 (after the Cycle 1 nivolumab dose).
For Arm B, when nivolumab and ipilimumab are to be administered on the same day, nivolumab 
is to be administered first. Nivolumab infusion (approximately 30 minutes) must be promptly 
followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion. 
The second infusion will always be the ipilimumab study drug (approximately 30 minutes
infusion) and will start after the infusion line has been flushed, filters changed and participant 
has been observed to ensure no infusion reaction has occurred. The time in between infusions is 
expected to be approximately 30 minutes (from the end of the nivolumab infusion to the start of 
the ipilimumab infusion) but may be more or less depending on the situation. The first 
cabozantinib dose should be given in the evening on Day 1, Cycle 1 (after the Cycle 1 nivolumab 
and ipilimumab doses).
Starting with Cycle 5 in Arm B, participants should receive nivolumab at a dose of 240 mg as a 
30 minute infusion on Day 1 of each treatment cycle until progression, unacceptable toxicity, 
withdrawal of consent, completion of 24 months of treatment (from the first dose on Cycle 1), or 
the end of the study, whichever occurs first.
Dosing calculations for nivolumab and ipilimumab should be based on the body weight assessed 
at baseline. It is not necessary to re-calculate subsequent doses if the participant weight is within 
10% of the weight used to calculate the previous dose. All doses should be rounded up or to the 
nearest milligram per institutional standard.
There will be no dose escalations or reductions of nivolumab or ipilimumab allowed. Participants 
may be dosed with nivolumab no less than 12 days from the previous dose during q2w cycles. 
Participants may be dosed with nivolumab and ipilimumab no less than 19 days from the 
previous dose during q3w cycles (ie, Cycles 1-4 in Arm B). Participants in Arm B may be dosed
with the first nivolumab maintenance dose (Cycle 5) no less than 19 days from the previous 
nivolumab and ipilimumab doses. Premedications are not recommended for the first dose of 
nivolumab or ipilimumab. 
Participants should be carefully monitored for infusion reactions during nivolumab and/or 
ipilimumab administration. If an acute infusion reaction is noted, participants should be managed 
according to Section 7.4.4.
Doses of nivolumab and/or ipilimumab may be interrupted, delayed, or discontinued depending 
on how well the participant tolerates the treatment. Dosing visits are not skipped, only delayed.
The only exception is Cycle 4 in Arm B, which may be skipped (omitted) only for the reasons 






Nivolumab Injection, 100 mg/10 mL (10 mg/mL) and 40 mg/mL (10 mg/mL) Nivolumab 
injection is to be administered as an IV infusion through a 0.2-micron to 1.2-micron pore size, 
low-protein binding in-line filter at the protocol-specified doses. It is not to be administered as an 
IV push or bolus injection. Please refer to the Investigational Brochure/pharmacy manual for 
further details regarding storage, preparation and administration. Care must be taken to assure 
sterility of the prepared solution as the product does not contain any antimicrobial preservative or 
bacteriostatic agent. 
7.1.2 Ipilimumab
For details regarding ipilimumab storage, preparation, and administration, please refer to the 
instructions in the ipilimumab IB and/or pharmacy manual.
Separate infusion bags and filters should be used when administering nivolumab and ipilimumab 
on the same day.
Care must be taken to assure sterility of the prepared solutions, since the drug product does not 
contain any antimicrobial preservatives or bacteriostatic agents.  
7.1.3 Cabozantinib
Cabozantinib is taken orally on an empty stomach, preferably at bed time. Participants should 
fast (with the exception of water) for at least 2 hours before until 1 hour after each dose of 
cabozantinib. Cabozantinib tablets should not be crushed or chewed. Cabozantinib should not be 
taken with grapefruit/grapefruit juice or Seville oranges. Missed doses of cabozantinib should 
not be taken within 12 hours of the next dose.
Dispense cabozantinib tablets in their original containers.
7.1.4 Sunitinib
Sunitinib is taken orally without regard to meals. Participants are to avoid grapefruit/grapefruit 
juice while on treatment with sunitinib.
7.2 Method of Treatment Assignment
All participants will be centrally randomized using an Interactive Response Technology (IRT). 
Before the study is initiated, each user will receive log in information and directions on how to 
access the IRT. Specific instructions for using IRT will be provided to the investigational site in 
a separate document. 
The investigator or designee will register the participant for enrollment by following the 
enrollment procedures established by BMS. 
Once enrolled in IRT, enrolled participants that have met all eligibility criteria, including 
determination of PD-L1 expression in the tumor sample submitted to and evaluated by the 
central laboratory, will be ready to be randomized through the IRT prior to the start of study 
treatment administration for each participant. The site will record the treatment assignment on 





Study treatment will be dispensed at the study visits as listed in Schedule of Activities 
(Section 2). 
7.3 Blinding
Not applicable as this is an open-label study; however, the specific treatment to be taken by a 
participant will be assigned using an Interactive Response Technology (IRT). 
Treatment assignments will be released to the bioanalytical laboratory in order to minimize 
unnecessary analysis of samples.
BICR will remain blinded to treatment assignment.
7.4 Dosage Modification 
In Arm A and Arm B, the assessment of causality for any AE should be performed
independently for each study drug in the combination regimen.
In the doublet treatment arm (Arm A), cabozantinib and nivolumab will be administered at Cycle 
1. After Cycle 1, modifications in cabozantinib dosing (delay, reduction/escalation, and 
discontinuation) may occur as outlined in Section 7.4.1, Section 7.4.2, and Section 8. After Cycle 
1, nivolumab may be modified as outlined in Section 7.4.1, Section 7.4.2, and Section 8.
In the triplet treatment arm (Arm B), cabozantinib, nivolumab, and ipilimumab will be 
administered at Cycle 1. After Cycle 1, modifications in cabozantinib dosing (delay, 
reduction/escalation, and discontinuation) may occur as outlined in Section 7.4.1, Section 7.4.2, 
and Section 8. After Cycle 1, nivolumab or ipilimumab may be modified as outlined in 
Section 7.4.1, Section 7.4.2, and Section 8.
In Arm C, sunitinib will be administered at Cycle 1. After Cycle 1, modifications in sunitinib 
dosing (delay, reduction/escalation, and discontinuation) may occur as outlined in Section 7.4.1, 
Section 7.4.2, and Section 8.
7.4.1 Dose Delay Criteria 
Dose delay criteria for management of adverse events during nivolumab, ipilimumab, 
cabozantinib, or sunitinib treatment are outlined in this section. 
Dosing of nivolumab (in Arm A) or nivolumab and ipilimumab (in Arm B) may be delayed 
without delay of cabozantinib dosing if toxicity is felt to be related to only nivolumab (Arm A) 
or nivolumab and ipilimumab (Arm B) and not related to cabozantinib. Conversely, dosing of 
cabozantinib may be delayed without delay of nivolumab dosing (in Arm A) or nivolumab and 
ipilimumab dosing (in Arm B) if toxicity is felt to be related to only cabozantinib and not related 
to nivolumab (Arm A) or nivolumab and ipilimumab (Arm B). However, if toxicity is considered 
related to all study drugs or if the investigator is unable to determine which study drug is the 
cause of the AE, then all study drugs in the combination should be delayed.
Participants who require dose delay should be re-evaluated weekly or more frequently if 





7.4.1.1 Dose Delay Criteria for Nivolumab and Ipilimumab
In Arm A, nivolumab administration should be delayed, and in Arm B, both nivolumab and 
ipilimumab administration should be delayed, for any of the following:
 Any Grade  2 non-skin, drug-related adverse event, with the exception of fatigue
 Grade 2 drug-related creatinine, AST, ALT, and/or total bilirubin abnormalities
 Any Grade 3 skin, drug-related adverse event
 Any Grade 3 drug-related laboratory abnormality, with the following exceptions:
o Grade 3 lymphopenia does not require dose delay
o Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatitis do not require a dose delay. 
o Grade ≥ 3 AST, ALT or total bilirubin will require dose discontinuation
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
During Cycles 1-4 in Arm B, both nivolumab and ipilimumab must be delayed at the same time.
Immuno-oncology agents, such as nivolumab and ipilimumab, are associated with AEs that 
differ in severity and duration than AEs caused by other therapeutic classes. Early recognition 
and management of AEs associated with immuno-oncology agents may mitigate severe toxicity. 
Management Algorithms have been developed to assist investigators in assessing and managing 








The management algorithms recommended for use in CA2099ER are included in Appendix 5.
7.4.1.2 Dose Delay Criteria for Cabozantinib
Cabozantinib dosing should be delayed for the following: 
 Urine protein/creatinine ratio (UPCR) ≥ 2.0 or urine dipstick protein ≥ 3+ or urine protein ≥. 
2.0 g / 24 hours. Obtain 24 hour urine protein prior to next dosing visit.
 Grade 3 prolonged QTc interval (ie, QTcF interval > 500 msec on at least 2 out of 3 separate 
ECGs performed at least 3 minutes apart)
 Any Grade 2 or 3 drug-related venous thrombosis requiring anticoagulation, with the 
following exception:
o Any recurrent or worsening venous thromboembolic event after restarting 
cabozantinib will require discontinuation
 Any other Grade 2 drug-related adverse event that persists or worsens despite supportive care 





o Any Grade 2 drug-related hemorrhage requires dose delay
o Grade ≥ 2 arterial thromboembolic events, including cerebrovascular ischemia, 
cardiac ischemia/infarction, peripheral or visceral arterial ischemia, require 
discontinuation
 Sustained Grade 3 drug-related hypertension (systolic BP  160 mm Hg or diastolic BP 
100 mm Hg). NOTE: Stopping or reducing the dose of cabozantinib is expected to cause a 
decrease in BP. The treating physician should monitor the participant for hypotension and 
adjust the number and dose of antihypertensive medications accordingly.
 Any other Grade 3 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
o Grade  3 drug-related hemorrhage requires discontinuation (Section 8.1.2).
o Drug-related AST or ALT > 8 x ULN requires discontinuation (Section 8.1.2).
o Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN, consistent with 
potential drug-induced liver injury (see Section 9.2.7), requires discontinuation 
(Section 8.1.2)
o Grade 3 drug-related amylase or lipase abnormalities that are not associated with 
symptoms or clinical manifestations of pancreatitis do not require dose delay. In such 
cases, more frequent monitoring (eg, weekly) of amylase and lipase is recommended. 
If amylase or lipase worsen to Grade 4 severity or the participant develops symptoms 
or clinical manifestations of pancreatitis, dosing should be delayed.
 Grade 4 drug-related amylase or lipase abnormalities require dose delay. Participants should 
be monitored for development of symptoms or clinical manifestations of pancreatitis.
 Grade 4 drug-related electrolyte abnormalities require dose delay. Electrolyte correction with 
supplementation/appropriate management should be promptly initiated.
 Grade 4 drug-related neutropenia, lymphopenia, leukopenia, anemia, or thrombocytopenia
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying cabozantinib dosing
 For participants scheduled for major surgery, including dental surgery which may impact 
bone healing, cabozantinib dosing should be delayed at least 28 days prior to scheduled 
surgery. The treating physician should use clinical judgment with regard to the risks and 
benefits of the planned surgical procedure if it is not possible to delay cabozantinib dosing 
for 28 days prior to the procedure. A delay of cabozantinib dosing of 5 to 7 days is 
recommended for healing for minor surgery.
As a general approach, all AEs related to cabozantinib should be managed with supportive care 
when possible at the earliest signs of toxicity. Calcium, magnesium, potassium, and phosphorus 





cabozantinib IB, Appendix 10, and Appendix 11 for additional information regarding dose 
modifications and AE management.22
7.4.1.3 Dose Delay Criteria for Sunitinib
Sunitinib dose delays should be based on instructions in the approved product label and should 
be considered for any severe or intolerable drug-related adverse events.
Within a cycle, missed doses of sunitinib should be skipped. Participants should never be dosed 
during the 2-week off period of each 6-week cycle, even if treatment delays occurred earlier in 
the cycle and therapy is ready to be resumed. If treatment is delayed past the end of the 6-week 
cycle, the start of the next cycle should be delayed until treatment with sunitinib resumes.
Prior to resuming therapy after a dose delay, refer to Section 7.4.2 for dose reduction 
recommendations and Section 8 for discontinuation criteria.
For this protocol, sunitinib dosing should be delayed for any of the following:
 Urine protein/creatinine ratio (UPCR) ≥ 2.0 or urine dipstick protein ≥ 3+ or urine protein 
≥ 2.0 g / 24 hours. Obtain 24 hour urine protein prior to next dosing visit.
 Grade 3 prolonged QTc interval (ie, QTcF interval > 500 msec on at least 2 out of 3 separate 
ECGs performed at least 3 minutes apart)
 Any Grade 2 or 3 drug-related venous thrombosis requiring anticoagulation, with the 
following exception:
o Any recurrent or worsening venous thromboembolic event after restarting sunitinib 
will require discontinuation
 Any other Grade 2 drug-related adverse event that persists or worsens despite supportive care 
management, with the following exception:
o Any Grade 2 drug-related hemorrhage requires dose delay
o Grade ≥ 2 arterial thromboembolic events, including cerebrovascular ischemia, 
cardiac ischemia/infarction, peripheral or visceral arterial ischemia, require 
discontinuation
 Grade 3 drug-related hypertension (systolic BP  160 mm Hg or diastolic BP  100 mm Hg). 
NOTE: Stopping or reducing the dose of sunitinib is expected to cause a decrease in BP. The 
treating physician should monitor the participant for hypotension and adjust the number and 
dose of antihypertensive medications accordingly.
 Any other Grade 3 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
o Grade  3 drug-related hemorrhage requires discontinuation (Section 8.1.2).
o Drug-related AST or ALT > 8 x ULN requires discontinuation (Section 8.1.2).
o Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN, consistent with 






o Grade 3 drug-related amylase or lipase abnormalities that are not associated with 
symptoms or clinical manifestations of pancreatitis do not require dose delay. In such 
cases, more frequent monitoring (eg, weekly) of amylase and lipase is recommended. 
If amylase or lipase worsen to Grade 4 severity or the participant develops symptoms 
or clinical manifestations of pancreatitis, dosing should be delayed.
 Grade 4 drug-related amylase or lipase abnormalities require dose delay. Participants should 
be monitored for development of symptoms or clinical manifestations of pancreatitis.
 Grade 4 drug-related electrolyte abnormalities require dose delay. Electrolyte correction with 
supplementation/appropriate management should be promptly initiated.
 Grade 4 drug-related neutropenia, lymphopenia, leukopenia, anemia, or thrombocytopenia
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying cabozantinib dosing
 For participants scheduled for major surgery, including dental surgery which may impact 
bone healing, sunitinib dosing should be delayed at least 28 days prior to scheduled surgery. 
The treating physician should use clinical judgment with regard to the risks and benefits of 
the planned surgical procedure if it is not possible to delay sunitinib dosing for 28 days prior 
to the procedure. A delay of sunitinib dosing of 5 to 7 days is recommended for healing for 
minor surgery.
As a general approach, all AEs related to sunitinib should be managed with supportive care when 
possible at the earliest signs of toxicity. Calcium, magnesium, potassium, and phosphorus should 
be kept above the lower limits of the laboratory normal values. Please refer to the sunitinib 
approved product label and Appendix 10 for additional information regarding AE management.
7.4.2 Dose Reductions and Escalations
Dose reductions are permitted for cabozantinib and sunitinib but not for nivolumab and 
ipilimumab (see Table 7.4.2-1). 














0 (starting dose) 40 mg daily 50 mg daily 3mg/kg 1 mg/kg 240 mg
-1 20 mg daily 37.5 mg daily - - -
-2 20 mg every other day 25 mg daily - - -
7.4.2.1 Dose Reduction and Escalation for Nivolumab and Ipilimumab





7.4.2.2 Dose Reduction and Escalation for Cabozantinib
Dose reductions and dose escalations for adverse event management are allowed for 
cabozantinib (Table 7.4.2-1). Cabozantinib doses will not be re-escalated once reduced, unless a 
concomitant strong CYP3A4 inducer is started (see below). The only exception is participants 
who continue on cabozantinib alone after discontinuation of nivolumab alone (Arm A) or 
discontinuation of both nivolumab and ipilimumab (Arm B) who may re-escalate one dose level 
if the prior dose reduction was due to a toxicity felt by the investigator to have been mainly 
related to nivolumab and/or ipilimumab.
After toxicity requiring a dose delay has improved and meets the criteria to resume dosing 
(Section 7.4.3.2), participants who were receiving cabozantinib 40 mg daily prior to the delay 
will resume cabozantinib at 20 mg daily. Participants who were receiving cabozantinib 20 mg 
daily prior to the delay and require another dose delay will resume cabozantinib at 20 mg every 
other day. If more than 2 dose reductions are necessary (ie, reduction to less than 20 mg every 
other day), cabozantinib must be permanently discontinued (Section 8.1.2). 
Participants who required a dose delay due to Grade 3 hypertension, which improved with 
antihypertensive medications, or any Grade 2 or 3 drug-related adverse event or asymptomatic 
laboratory abnormality that improved to Grade ≤ 1 within 7 days with supportive medical care 
may resume cabozantinib at the same dose or a reduced dose, at the discretion of the investigator.
Participants with Grade 3 drug-related lipase or amylase abnormalities that are not associated 
with symptoms or clinical manifestations of pancreatitis may reduce cabozantinib by one dose 
level, without delaying dosing, at the discretion of the investigator.
In Participants Who Start Taking a Concomitant Strong CYP3A4 Inhibitor: Reduce the 
daily cabozantinib dose by 20 mg (for example, from 40 mg to 20 mg daily). Resume the dose 
that was used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the 
strong inhibitor (see Prescribing Information for cabozantinib).
In Participants Who Start Taking a Concomitant Strong CYP3A4 Inducer: Increase the 
daily cabozantinib dose by 20 mg (eg, from 40 mg to 60 mg daily) as tolerated. Resume the dose 
that was used prior to initiating the CYP3A4 inducer 2 to 3 days after discontinuation of the 
strong inducer. In this study, the daily dose of cabozantinib should not exceed 60 mg (see 
Prescribing Information for cabozantinib).
7.4.2.3 Dose Reduction and Escalation for Sunitinib
Sunitinib Dose Reductions are permitted as per the approved product label for safety reasons or 
when a concomitant strong CYP3A4 inhibitor is needed (Appendix 9). Selection of an alternative 
concomitant medication with minimal or no enzyme inhibition potential is recommended 
whenever possible. 
After toxicity requiring a dose delay has improved and meets the criteria to resume dosing 
(Section 7.4.3.3), participants should resume sunitinib at one dose level reduction. Dose 





more than 2 dose reductions are necessary (ie, reduction to less than 25 mg daily), the participant
must be permanently discontinued (Section 8.1.3).
Participants who required a dose delay due to Grade 3 hypertension, which improved with 
antihypertensive medications, or any Grade 2 or 3 drug-related adverse event or asymptomatic 
laboratory abnormality that improved to Grade ≤ 1 within 7 days with supportive medical care 
may resume sunitinib at the same dose or a reduced dose, at the discretion of the investigator.
At the time a dose reduction is considered, also refer to Section 7.4.2.3 for dose delay
recommendations and Section 8.1.3 for discontinuation criteria.
Sunitinib Dose Escalations are permitted as per the approved product label when a concomitant 
CYP3A4 inducer is needed (Appendix 9). Selection of an alternative concomitant medication 
with minimal or no enzyme induction potential is recommended whenever possible. 
7.4.3 Criteria to Resume Treatment
7.4.3.1 Criteria to Resume Nivolumab and Ipilimumab Treatment
Delayed doses of nivolumab and/or ipilimumab should be administered as soon as the participant 
meets criteria to resume treatment. If a dose has been delayed, the participant should not wait 
until the next scheduled dosing date.
Participants may resume treatment with study drug when the drug-related AE(s) resolve to 
Grade  1 or baseline value, with the following exceptions:
 Participants may resume treatment in the presence of Grade 2 fatigue. 
 Participants who have not experienced a Grade 3 drug-related skin AE may resume treatment 
in the presence of Grade 2 skin toxicity. 
 For participants with Grade 2 AST, ALT, and/or total bilirubin abnormalities, dosing may 
resume when laboratory values return to baseline and management with corticosteroids, if 
needed, has been completed.
 Participants with combined Grade 2 AST/ALT AND total bilirubin values meeting 
discontinuation parameters (Section 8.1.1) should have treatment permanently discontinued.
 Drug-related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline before 
treatment is resumed. Participants with persistent Grade 1 pneumonitis after completion of a 
steroid taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by the BMS Medical Monitor or designee.
 Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment.
 If treatment is delayed > 6 weeks, the participant must be permanently discontinued from 
study therapy, except as specified in Section 8.1.1.
For Arm B participants who delay nivolumab and ipilimumab dosing after Cycle 1 or 2, both 
nivolumab and ipilimumab must be resumed on the same day when the criteria to resume 
treatment are met. 
For Arm B participants who delay nivolumab and ipilimumab dosing after Cycle 3 due to any





treatment with systemic corticosteroids, it is acceptable to omit Cycle 4 if the investigator feels 
that ipilimumab was the main cause of the toxicity requiring dose delay. In this situation, when 
the participant meets criteria to resume nivolumab, the participant may proceed to Cycle 5 and 
begin nivolumab monotherapy maintenance.
7.4.3.2 Criteria to Resume Cabozantinib Treatment
Participants may resume treatment with cabozantinib when the drug-related AE(s) resolve to 
Grade  1 or baseline value, with the following exceptions:
 Participants may resume dosing in the presence of Grade 2 fatigue
 Participants who delayed dosing due to prolonged QTcF may resume dosing at one reduced 
dose level once QTcF returns to ≤ 500 msec
 Participants who delayed dosing due to UPCR ≥ 2.0 or urine dipstick protein ≥ 3+ may 
resume dosing at one dose level reduction when 24 hour urine protein < 2.0 g
 Participants who delayed dosing due to Grade 3 hypertension may resume dosing at the same 
dose or at one dose level reduction, at the discretion of the investigator, when hypertension 
has improved to Grade  2
 Participants who delayed dosing due to Grade 4 lipase or amylase abnormalities may resume 
dosing upon resolution to Grade  2
 Participants who delayed dosing due to major surgery should not resume cabozantinib until 
complete wound healing has taken place. Following cabozantinib resumption, participants 
should be monitored for wound dehiscence, wound infections, and other signs of impaired 
wound healing.
 If treatment is delayed > 6 weeks for any reason, the participant must be permanently 
discontinued from study therapy, except in cases where permission to resume treatment is 
granted by the BMS Medical Monitor or designee.
7.4.3.3 Criteria to Resume Sunitinib Treatment
Within a cycle, missed doses of sunitinib should be skipped and not replaced. Participants should 
never be dosed during the 2-week off period of each 6-week cycle, even if treatment delays 
occurred earlier in the cycle and therapy is ready to be resumed. If treatment is delayed past the 
end of the 6-week cycle, the start of the next cycle should be delayed until treatment with 
sunitinib resumes.
Participants may resume treatment with sunitinib when the drug-related AE(s) resolve to 
Grade  1 or baseline value, with the following exceptions:
 Participants may resume dosing in the presence of Grade 2 fatigue
 Participants who delayed dosing due to prolonged QTcF may resume dosing at one reduced 
dose level once QTcF returns to ≤ 500 msec
 Participants who delayed dosing due to UPCR ≥ 2.0 or urine dipstick protein ≥ 3+ may 
resume dosing at one dose level reduction when 24 hour urine protein < 2.0 g
 Participants who delayed dosing due to Grade 3 hypertension may resume dosing at the same 
dose or at one dose level reduction, at the discretion of the investigator, when hypertension 





 Participants who delayed dosing due to Grade 4 lipase or amylase abnormalities may resume 
dosing upon resolution to Grade  2
 If treatment is delayed > 6 weeks for any reason, the participant must be permanently 
discontinued from study therapy, except in cases where permission to resume treatment is 
granted by the BMS Medical Monitor or designee.
7.4.4 Treatment of Nivolumab- or Ipilimumab-Related Infusion Reactions
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, they 
are unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if 
such a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, 
pruritus, arthralgias, hypotension, hypertension, bronchospasm, or other allergic-like reactions. 
Regardless of whether or not the event is attributed to the study drugs, all Grade 3 or 4 infusion 
reactions should be reported within 24 hours to the study BMS Medical Monitor or designee and 
reported as an SAE if it meets the criteria, given the blinded nature of the study. Infusion 
reactions should be graded according to NCI CTCAE (Version 4) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reaction; infusion interruption not indicated; intervention not 
indicated):
 Remain at bedside and monitor participant until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg at least 30 minutes before 
additional study drug administrations.
For Grade 2 symptoms: (moderate reaction required therapy or infusion interruption but responds 
promptly to symptomatic treatment (eg, antihistamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for 
 24 hours):
 Stop the study drug infusion, begin an IV infusion of normal saline, and treat the participant 
with diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 
1000 mg; remain at bedside and monitor participant until resolution of symptoms. 
Corticosteroid and/or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor participant closely. If symptoms 
recur, then no further study dug will be administered at that visit.
 For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg 
should be administered at least 30 minutes before study drug infusions. If necessary, 
corticosteroids (up to 25 mg of hydrocortisone or equivalent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prolonged [ie, not rapidly responsive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms 





impairment, pulmonary infiltrates). Grade 4: Life-threatening; pressor or ventilatory support 
indicated):
 Immediately discontinue infusion of study drug. Begin an IV infusion of normal saline and 
treat the participant as follows: Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Participant should be monitored 
until the Investigator is comfortable that the symptoms will not recur. Study drug will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor participant until recovery of the 
symptoms.
In case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study Participants. The investigational product must be dispensed only from official study sites 
by authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment
should not be dispensed and contact BMS immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
 Further guidance and information for final disposition of unused study treatment are provided 
in Appendix 2.
7.5.1 Retained Samples for Bioavailability / Bioequivalence
Not applicable.
7.6 Treatment Compliance
Study treatment compliance will be periodically monitored by drug accountability (including 
review of dosing diary cards, as applicable). Drug accountability should be reviewed by the site 
study staff at each visit to confirm treatment compliance. Sites should discuss discrepancies with 






7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unless utilized to treat a drug related 
adverse event):
• Immunosuppressive agents
• Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.3)
• Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy, extensive, non-palliative radiation therapy, or standard or investigational 
agents)
Supportive care for disease-related symptoms may be offered to all participants on the trial.
7.7.2 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization are excluded. Inhaled or topical steroids, and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
7.7.2.1 Restrictions and Precautions for Cabozantinib
Cabozantinib is a substrate of CYP3A4. In Arm A and Arm B participants, co-administration of 
cabozantinib with medications that are strong inhibitors/inducers of CYP3A4 should be avoided. 
Cabozantinib is highly protein bound (99.9%) to human plasma proteins. Concomitant 
medications that are highly protein bound (eg, diazepam, furosemide, dicloxacillin, propanolol) 
should be used with caution. Because warfarin is a highly protein bound drug with a low 
therapeutic index, administration of warfarin should be avoided in participants receiving 
cabozantinib in Arms A and B. 
Cabozantinib has been associated with a mild prolongation of the QTc interval. Caution should 
be used when treating participants on cabozantinib in Arms A and B with other drugs associated 
with QTc prolongation. Additional QTc monitoring is suggested for participants who are treated 
concomitantly with QTc prolonging drugs.
Low-dose aspirin for cardioprotection (as per local applicable guidelines) and low-dose low 
molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of 
LMWH is allowed in participants without known brain metastases who are on a stable dose of 
LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically 
significant hemorrhagic complications from the anticoagulation regimen or the tumor.
While on study, invasive dental procedures (eg, extractions, dental implants) should be avoided 
and conservative dental therapy, such as endodontic therapy (root canal treatment) would be 






7.7.2.2 Restrictions and Precautions for Sunitinib
Sunitinib is metabolized by CYP3A4. Arm C participants who initiate CYP3A4 
inhibitors/inducers after randomization should follow sunitinib dose modification instructions.
Sunitinib has been shown to prolong the QTc interval. Concomitant treatment with dysrhythmic 
drugs (ie, terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, haloperidol, 
risperidone, and indapamide) is not recommended.
Medications taken within 4 weeks prior to study drug administration must be recorded on the 
CRF.
7.7.2.3 Imaging Restriction and Precautions
It is the local imaging facility’s responsibility to determine, based on participant attributes 
(eg, allergy history, diabetic history and renal status), the appropriate imaging modality and 
contrast regimen for each participant. Imaging contraindications and contrast risks should be 
considered in this assessment. Participants with renal insufficiency should be assessed as to 
whether or not they should receive contrast and if so, what type and dose of contrast is 
appropriate. Specific to MRI, participants with severe renal insufficiency (ie, estimated 
glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) are at increased risk of nephrogenic 
systemic fibrosis. MRI contrast should not be given to this participant population. In addition, 
participants are contraindicated from MRI if they have tattoos, metallic implants, pacemakers, 
etc.
The ultimate decision to perform MRI in an individual participant in this study rests with the site 
radiologist, the investigator and the standard set by the local Ethics Committee.
7.7.3 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg 
daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for 
prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions 
(eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.
Concomitant medications are recorded at baseline and throughout the treatment phase of the 
study in the appropriate section of the CRF. All medications (prescriptions or over the counter 
medications) continued at the start of the study or started during the study and different from the 
study drug must be documented in the concomitant therapy section of the CRF.
7.8 Treatment After the End of the Study
At the conclusion of the study, participants who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study treatment for the maximum treatment duration specified 
in protocol Section 7.1. Study treatment will be provided via an extension of the study, a rollover 
study requiring approval by responsible health authority and ethics committee or through another 





BMS reserves the right to terminate access to BMS supplied study treatment if any of the 
following occur: a) the study is terminated due to safety concerns; b) the development of the
nivolumab, ipilimumab, cabozantinib, or sunitinib is terminated for other reasons, including but 
not limited to lack of efficacy and/or not meeting the study objectives; c) the participant can 
obtain medication from a government sponsored or private health program. In all cases BMS will 
follow local regulations.
8. DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Participants MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:
 Participant’s request to stop study treatment. Participants who request to discontinue study 
treatment will remain in the study and must continue to be followed for protocol specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant 
to provide this information
 Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the 
best interest of the participant
 Termination of the study by Bristol-Myers Squibb (BMS)
 Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness
 Criteria listed in 8.1.1
 Disease progression of RCC or occurrence of a secondary malignancy which requires 
systemic therapy for treatment
Refer to the Schedule of Activities for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations that can be completed.
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the study treatment will be permanently 
discontinued in an appropriate manner (eg, dose tapering if necessary for participant safety). 
Please call the BMS Medical Monitor within 24 hours of awareness of the pregnancy. If the 
investigator determines a possible favorable benefit/risk ratio that warrants continuation of study 
treatment, a discussion between the investigator and the BMS Medical Monitor/designee must 
occur.
All participants who discontinue study treatment should comply with protocol specified follow-
up procedures as outlined in Section 2. The only exception to this requirement is when a 
participant withdraws consent for all study procedures including post-treatment study follow-up 
or loses the ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the 





If study treatment is discontinued prior to the participant’s completion of the study, the reason 
for the discontinuation must be documented in the participant’s medical records and entered on 
the appropriate case report form (CRF) page.
8.1.1 Nivolumab and Ipilimumab Dose Discontinuation (Arms A and B)
The assessment for discontinuation of nivolumab, ipilimumab, and cabozantinib should be made 
separately for each study drug. Although there is overlap among the discontinuation criteria, if 
discontinuation criteria are met for one study drug but not the other(s), it may be acceptable to 
continue treatment with the study drug(s) that are not felt to be related the toxicity, as specified 
below. If the investigator considers the toxicity to be related to all study drugs or is unable to 
determine which of the study drug(s) in Arm A or Arm B are the cause of toxicity, then all study 
drugs in the treatment regimen should be discontinued, and the recommendations for 
management of toxicity related to all study drugs should be promptly initiated.
Nivolumab and/or ipilimumab treatment should be permanently discontinued for any of the
following:
 Any Grade 2 drug-related uveitis, eye pain or blurred vision that does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-treatment period OR requires 
systemic treatment 
 Any Grade 3 non-skin, drug-related adverse event lasting > 7 days, or recurs with the 
following exceptions for laboratory abnormalities, diarrhea, colitis, neurologic toxicity, drug-
related uveitis, pneumonitis, bronchospasm, hypersensitivity reactions, infusion reactions, 
and endocrinopathies:
o Grade 3 drug-related diarrhea, colitis, neurologic toxicity, uveitis, pneumonitis, 
bronchospasm, hypersensitivity reaction, or infusion reaction of any duration requires 
discontinuation. NOTE: The diagnosis of colitis should be supported by findings on 
colonoscopy whenever possible.
o Grade 3 drug-related endocrinopathies, adequately controlled with only physiologic 
hormone replacement do not require discontinuation. Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement.
o Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
 Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding 
requires discontinuation
 Any drug-related liver function test (LFT) abnormality that meets the following 
criteria require discontinuation:
 Grade ≥ 3 drug-related AST, ALT or Total Bilirubin requires 
discontinuation*





* In most cases of Grade 3 AST or ALT elevation, study drug(s) will be 
permanently discontinued. If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study drug(s), a discussion 
between the investigator and the BMS Medical Monitor/designee must occur.
 Any Grade 4 drug-related adverse event or laboratory abnormality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the following events which do not 
require discontinuation:
o Grade 4 neutropenia ≤ 7 days
o Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 
hours of their onset
o Grade 4 drug-related endocrinopathy adverse events, such as, hyper- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately controlled with physiologic 
hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, 
respectively, may not require discontinuation after discussion with and approval from the 
BMS Medical Monitor or designee.
 Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires 
discontinuation, with the following exceptions:
o Dosing delays to allow for prolonged steroid tapers to manage drug-related adverse 
events are allowed. 
o Dosing delays lasting > 6 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS Medical Monitor or designee. 
Prior to re-initiating treatment in a participant with a dosing delay lasting > 6 weeks, the BMS 
Medical Monitor or designee must be consulted. Tumor assessments should continue as per 
protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory studies 
should also continue every 6 weeks or more frequently if clinically indicated during such dosing 
delays.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued 
nivolumab dosing.
Participants in Arm B who meet any of the discontinuation criteria above prior to Cycle 3 must 
discontinue both nivolumab and ipilimumab and may not receive nivolumab monotherapy 
maintenance. 
Participants in Arm B who meet any of the discontinuation criteria above after Cycle 3 or Cycle 





monotherapy maintenance if the toxicity is felt to be related mainly to ipilimumab, only after 
discussion with and approval by the BMS Medical Monitor or designee.
8.1.2 Cabozantinib Dose Discontinuation
Permanently discontinue cabozantinib for participants with any of the following:
 Any requirement for more than 2 cabozantinib dose reductions (ie, reduction to less than 20 
mg every other day)
 Any Grade  2 drug-related arterial thromboembolic events, including cerebrovascular 
ischemia, cardiac ischemia/infarction, peripheral or visceral arterial ischemia
 Any Grade ≥ 3 drug-related hemorrhage
 Grade 4 hypertension or persistent Grade 3 hypertension despite optimal medical 
management and cabozantinib dose reduction
 Drug-related reversible posterior leukoencephalopathy syndrome
 Development of drug-related fistula or GI perforation
 Drug-related nephrotic syndrome
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
requires discontinuation:
o AST or ALT > 8 x ULN.
o Concurrent AST or ALT > 3 x ULN and total bilirubin >2 x ULN, consistent with 
potential drug-induced liver injury (see Section 9.2.7).
 Any Grade 4 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
o Grade 4 neutropenia  7 days
o Grade 4 lymphopenia or leukopenia
o Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis
o Isolated Grade 4 electrolyte abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 
hours of their onset
 Any dosing interruption lasting > 6 weeks unless the BMS Medical Monitor or designee is 
consulted and agrees with the rationale for resuming therapy after a delay > 6 weeks. Note 
that tumor assessments should continue as per protocol even if dosing is interrupted.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 






8.1.3 Sunitinib Dose Discontinuation
Treatment with sunitinib should be permanently discontinued for any of the following:
 Any requirement for more than 2 sunitinib dose reductions (ie, reduction to less than 25 mg 
daily)
 Any Grade drug-related arterial thrombosis.
 Grade  drug-related hemorrhage or recurrent Grade 3 drug-related hemorrhage after dose 
reduction.
 Grade 4 drug-related symptomatic venous thrombosis.
 Grade 4 drug-related cardiac toxicity.
 Grade 4 hypertension or persistent Grade 3 hypertension despite optimal medical 
management and sunitinib dose reduction
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
requires discontinuation:
o AST or ALT > 8 x ULN.
o Concurrent AST or ALT > 3 x ULN and total bilirubin >2 x ULN, consistent with 
potential drug-induced liver injury (see Section 9.2.7).
 Any other Grade 4 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
o Grade 4 neutropenia  7 days
o Grade 4 lymphopenia or leukopenia
o Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis
o Isolated Grade 4 electrolyte abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 
hours of their onset
 Any dosing interruption lasting > 6 weeks unless the BMS Medical Monitor or designee is 
consulted and agrees with the rationale for resuming therapy after a delay > 6 weeks. Note 
that tumor assessments should continue as per protocol even if dosing is interrupted.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued sunitinib 
dosing.
8.1.4 Treatment Beyond Disease Progression
Accumulating evidence indicates a minority of participants treated with immunotherapy or 
anti-angiogenic therapy may derive clinical benefit despite initial evidence of PD.20,50,51
Participants, regardless of study arm, will be permitted to continue treatment beyond initial 
RECIST 1.1 defined PD, assessed by the investigator, as long as they meet the following criteria:
 Investigator-assessed clinical benefit





 Stable performance status
 Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (eg, CNS metastases)
 Participant provides written informed consent prior to receiving additional treatment with the 
study drug regimen. All other elements of the main consent including description of 
reasonably foreseeable risks or discomforts, or other alternative treatment options will still 
apply.
A radiographic assessment/ scan should be performed within 6 weeks of initial investigator-
assessed progression to determine whether there has been a decrease in the tumor size or 
continued PD. The assessment of clinical benefit should be balanced by clinical judgment as to 
whether the participant is clinically deteriorating and unlikely to receive any benefit from 
continued treatment with nivolumab.
If the investigator feels that the participant continues to achieve clinical benefit by continuing
treatment, the participant should remain on the trial and continue to receive monitoring according 
to the Schedule of Activities Schedule in Section 2.
For the participants who continue study therapy beyond progression, further progression is 
defined as an additional 10% increase in tumor burden with a minimum 5 mm absolute increase 
from time of initial PD. This includes an increase in the sum of diameters of all target lesions 
and/ or the diameters of new measurable lesions compared to the time of initial PD. It is 
recommended that study treatment should be discontinued permanently upon documentation of 
further progression.
New lesions are considered measureable at the time of initial progression if the longest diameter 
is at least 10 mm (except for pathological lymph nodes which must have a short axis of at least15 
mm). Any new lesion considered non-measureable at the time of initial progression may become 
measureable and therefore included in the tumor burden if the longest diameter increases to at 
least 10 mm (except for pathological lymph nodes which must have a short axis of at least 15 
mm). In situations where the relative increase in total tumor burden by 10% is solely due to 
inclusion of new lesions which become measurable, these new lesions must demonstrate an 
absolute increase of at least 5 mm.
8.1.5 Post-Study Treatment Follow-up
In this study, overall survival is a key endpoint of the study. Post-study treatment follow-up is of 
critical importance and is essential to preserving participant safety and the integrity of the study. 
Participants who discontinue study treatment must continue to be followed for collection of 
outcome and/or survival follow-up data as required and in line with Section 5 until death or the 
conclusion of the study.
BMS may request that survival data be collected on all treated/randomized participants outside 
of the protocol defined window (See Section 2). At the time of this request, each participant will 
be contacted to determine their survival status unless the participant has withdrawn consent for 





8.2 Discontinuation from the Study
Participants who request to discontinue study treatment will remain in the study and must 
continue to be followed for protocol specified follow-up procedures. The only exception to this 
is when a participant specifically withdraws consent for any further contact with him/her or 
persons previously authorized by participant to provide this information. 
 Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
 The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study treatment only 
or also from study procedures and/or post treatment study follow-up, and entered on the 
appropriate CRF page.
 In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
 If the participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.3 Lost to Follow-Up
 All reasonable efforts must be made to locate participants to determine and report their 
ongoing status. This includes follow-up with persons authorized by the participant.
 Lost to follow-up is defined by the inability to reach the participant after a minimum of three
documented phone calls, faxes, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in the participant’s medical 
records.
 If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
 If investigator’s use of third-party representative to assist in the follow-up portion of the 
study has been included in the participant’s informed consent, then the investigator may use a 
Sponsor retained third-party representative to assist site staff with obtaining participant’s 
contact information or other public vital status data necessary to complete the follow-up 
portion of the study. 
 The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.
 If after all attempts, the participant remains lost to follow-up, then the last known alive date 
as determined by the investigator should be reported and documented in the participant’s 
medical records.
9. STUDY ASSESSMENTS AND PROCEDURES
 Study procedures and timing are summarized in the Schedule of Activities. 
 Protocol waivers or exemptions are not allowed.
 All immediate safety concerns must be discussed with the Sponsor immediately upon






 Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.
 All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria before randomization. The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
 Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of informed consent may be utilized for screening or 
baseline purposes provided the procedure meets the protocol-defined criteria and has been 
performed within the timeframe defined in the Schedule of Activities.
Additional measures, including non-study required laboratory tests, should be performed as 
clinically indicated or to comply with local regulations. Laboratory toxicities (eg, suspected drug 
induced liver enzyme evaluations) will be monitored during the follow-up phase via on site/local 
labs until all study drug related toxicities resolve, return to baseline, or are deemed irreversible.
If a participant shows pulmonary-related signs (hypoxia, fever) or symptoms (eg, dyspnea, 
cough, fever) consistent with possible pulmonary adverse events, the participant should be 
immediately evaluated to rule out pulmonary toxicity, according to the suspected pulmonary 
toxicity management algorithm in the BMS-936558 (nivolumab) Investigator Brochure.
Some of the assessments referred to in this section may not be captured as data in the eCRF. 
They are intended to be used as safety monitoring by the treating physician. Additional testing or 
assessments may be performed as clinically necessary or where required by institutional or local 
regulations.
9.1 Efficacy Assessments
Study evaluations will take place in accordance with the Schedule of Activities in Section 2.
Images will be submitted to an imaging core lab. Sites should be trained prior to scanning the 
first study participant. Image acquisition guidelines and submission process will be outlined in 
the CA2099ER Imaging Manual to be provided by the core lab. 
9.1.1 Methods of Measurements
The following imaging assessments should be performed at pre-specified intervals: CT of the 
chest, CT or MRI of the abdomen, pelvis, and other known sites of disease.
 CT scans should be acquired with slice thickness of 5 mm or less with no intervening gap 
(continuous) 
 Should a participant have a contraindication for CT IV contrast, a non-contrast CT of the 
chest and a contrast enhanced MRI of the abdomen and pelvis and other sites of disease may 
be obtained. MRIs should be acquired with slice thickness of 5 mm or less with no gap 
(continuous).
 Every attempt should be made to image each participant using an identical acquisition 
protocol on the same scanner for all imaging time points
 PET alone will not be considered for the disease assessment. Complementary CT and/or MRI 





Note: Use of CT component of a PET/CT scanner: Combined modality scanning, such as 
with FDG-PET/CT, is increasingly used in clinical care and is a modality/technology that is 
in rapid evolution; therefore, the recommendations outlined here may change rather quickly 
with time. At present, low-dose or attenuation correction CT portions of a combined FDG-
PET/CT are of limited use in anatomically-based efficacy assessments, and it is, therefore, 
suggested that they should not be substituted for dedicated diagnostic contrast enhanced CT 
scans for anatomically-based RECIST (Appendix 8) measurements. However, if a site can 
document that the CT performed as part of a FDG-PET/CT is of identical diagnostic quality 
to a diagnostic CT (with IV and oral contrast), then the CT portion of the FDG-PET/CT can 
be used for RECIST 1.1 measurements. Note, however, that the FDG-PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially 
performed. 
9.1.2 Imaging and Clinical Assessment 
Images will be submitted to an imaging core lab. Sites should be trained prior to scanning the 
first study participant. Image acquisition guidelines and submission process will be outlined in 
the CA2099ER Imaging Manual to be provided by the core lab. 
Baseline imaging, including CT/MRI of the chest, abdomen, pelvis, and all known sites of 
disease performed within 28 days prior to randomization, should be submitted to the imaging 
core lab. Baseline brain MRI (preferred) or CT scan should also be performed within 28 days 
prior to randomization and submitted to the imaging core lab. Participants who are found to have 
untreated brain metastases on the baseline brain scan may not be randomized.
9.1.2.1 Investigator Assessment of Progression
The same method of assessment used at Screening should be used for on-study time points. Brain 
MRI or CT scans during on-study time points and the follow-up phase are only required in
participants with a history of CNS metastases prior to randomization or if clinically indicated for 
new signs or symptoms that suggest new or worsening CNS metastases. 
Post-baseline tumor assessments will be performed at the time points described below until 
progression assessed by the investigator and confirmed by BICR, death, or withdrawal from the 
study, whichever occurs first. 
 First tumor assessment post-baseline should be performed at Week 12 (± 7 days) following 
randomization. Use same imaging method as was used at screening/baseline. 
 Subsequent tumor assessments should occur at every 6 weeks until Week 60. Allowable 
window for assessments is ± 7 days until Week 60. After Week 60, tumor assessments 
should occur every 12 weeks (± 14 days) until radiographic progression, assessed by the 
investigator and confirmed by the BICR. 
 Additional imaging of potential disease sites should be performed whenever disease 
progression or a secondary malignancy is suspected. In participants with no history of brain 





clinically indicated. Bone imaging during on-study treatment and follow-up periods should 
be obtained if clinically indicated.
 Tumor assessments are to continue for all randomized participants according to the protocol 
schedule until radiographic progression has been assessed by the investigator and confirmed 
by the BICR, regardless of whether study drug dosing is delayed, reduced, or discontinued.
The investigator (in consultation with the local radiologist as needed) will complete tumor 
assessments using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria on all 
imaging time points specified in the protocol. Any additional imaging that may demonstrate 
tumor response or progression, including scans performed at unscheduled time points and/or at 
an outside institution, should also be collected for the investigator to complete RECIST 1.1 
tumor assessments on these images and to submit them for BICR review.
All study treatment decisions will be based on the investigator’s assessment of tumor images and 
not on the BICR assessment.
9.1.2.2 BICR Assessment of Progression
Sites should submit all scans to a BICR on a rolling basis, preferably within 7 days of scan 
acquisition, throughout the duration of the study. BICR will review scans on a rolling basis and 
remain blinded to treatment arm and investigator assessment of submitted scans. When 
progression per RECIST 1.1 criteria is assessed by the investigator, the site will inform the
imaging core lab, so that the BICR assessment of progression can be performed. The BICR 
review will be completed and the results provided to the site within approximately 14 days of 
receipt of the scans, provided there are no pending imaging queries to the site. 
Participants whose progression is not confirmed by the BICR will be required to continue tumor 
assessments (if clinically feasible) according to the protocol-specified schedule or sooner if
clinically indicated until the BICR confirms progression on a subsequent tumor assessment. 
Also, if participants discontinue treatment without radiographic progression, tumor assessments 
will continue according to the protocol specified schedule, as noted in Section 2, until 
progression has been confirmed by BICR.
All study treatment decisions will be based on the investigator’s assessment of tumor images and 
not on the BICR assessment. The BICR assessment of progression is only relevant for 
determining when tumor assessments for a given participant are no longer required to be 
submitted to the imaging vendor.
9.1.3 Imaging Restriction and Precautions
Table 9.1.3-1 provides a summary of the alternative methods, acceptable per protocol, in the 
event of contraindications for use of IV and oral contrast, and or/MRI. 
Table 9.1.3-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions





Table 9.1.3-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions
Anatomic Region Preferred Method Alternative Methods
Chest, abdomen, 
and pelvis
Note: Scan must 
cover lung apices to 
diaphragm, 
diaphragm through 
entire liver, and to 
below the pubic 
symphysis
CT with IV contrast
For chest:
 CT without contrast can be used only if the participant has a 
clinical contraindication for iodine-based IV contrast (eg,
hypersensitivity, renal insufficiency)
For abdomen and pelvis:
 MRI with gadolinium-based IV contrast is the first alternative 
method if the participant has a clinical contraindication for 
iodine-based IV contrast
 CT without contrast can be used as the second alternative 
method only if the participant has a clinical contraindication 
for both contrast-enhanced CT and MRI.
Brain MRI with IV contrast
 CT with IV contrast is the first alternative method if IV 
gadolinium is clinically contraindicated. 
 MRI without contrast can be used as a second alternative 
method if a participant has clinical contraindications for 
both contrast-enhanced CT and MRI
Bone Bone scintigraphy PET (18F-fluoride NaF or FDG) and 99m Technetium SPECT
Notes:
1. CT scans must be performed with slices thickness of  5 mm are required. The reconstruction interval should be 
equal to slice thickness to avoid gap. 
2. The same modality for a given anatomical coverage and the same scanning procedure (most importantly: 
reconstruction slice thickness, anatomic coverage, use of IV contrast) should be consistent between baseline and 
all subsequent follow-up scanning. If possible, the same scanner or an equivalent scanners should be used 
throughout the study. 
3. For abdomen and pelvis CT scans, oral contrast is recommended as per institutional standards. 
4. MRI should include T1 and T2-weighted sequences with T1-weighted at both pre- and post-contrast. 
5. If bone scan shows hotspots indicative of metastases, further investigation with X-ray, CT, or MRI is warranted. 
6. All scans generated should be exportable in electronic format (DICOM) to enable secure and rapid electronic 
transmission to the designated central imaging laboratory. 
The use of gadolinium-based contrast agents in participants with acute or chronic renal 
insufficiency, with a glomerular filtration rate (GFR) less than 30 mL per minute per 1.73m2 or 
with any acute renal failure caused by hepatorenal syndrome or perioperative liver 
transplantation, is not recommended. 
If gadolinium is contraindicated, proceed without contrast but reason for not using contrast must 
be documented. 
9.1.4 Outcomes Research Assessments 
Participant-reported outcomes will be captured through the use of 2 validated self-reported 
questionnaires: the National Comprehensive Cancer Network (NCCN) Functional Assessment of 





The NCCN FKSI-19 is a 19-item scale that measures tumor specific HrQoL in kidney cancer 
participants. The FKSI-19 uses 5 Likert-type response categories that range from “not at all” to 
“very much.” Participants are asked to circle the response category that best characterizes their 
response over the last 7 days on 19 items that include symptoms such as lack of energy, fatigue, 
appetite, coughing, shortness of breath, pain, nausea, and ability to work. 
General health status will be measured using the EQ-5D-3L. The EQ-5D-3L is a standardized 
instrument for use as a measure of self-reported general health status. The EQ-5D-3L comprises 
5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety) and a visual 
analog rating scale (VAS). The utility data generated from EQ-5D-3L is recommended for and 
commonly used in cost effectiveness analysis. 
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or the study, or that caused the 
participant to discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3
Immune-mediated adverse events (IMAEs, imAEs) are AEs consistent with an immune-
mediated mechanism or immune-mediated component for which non-inflammatory etiologies 
(eg, infection or tumor progression) have been ruled out. IMAEs can include events with an 
alternate etiology which were exacerbated by the induction of autoimmunity. Information 
supporting the assessment will be collected on the participant’s case report form.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information should begin at initiation of study treatment until 
[the follow-up contact], at the timepoints specified in the Schedule of Activities (Section 2). 
Nonserious AE information should also be collected from the start of a placebo lead-in period or 
other observational period intended to establish a baseline status for the participants.
Sections 5.6.1 and 5.6.2 in the Investigator Brochures (IBs) for Nivolumab29 and Ipilimumab30
represent the Reference Safety Information (also Appendix K in the IB for cabozantinib22) to 
determine expectedness of serious adverse events for expedited reporting. Following the 
participant’s written consent to participate in the study, all SAEs, whether related or not related 
to study drug, must be collected, including those thought to be associated with protocol-specified 
procedures.
All SAEs must be collected that occur during the screening period and within 100 days of the 





study drug, SAEs should be collected for 30 days from the date of randomization. If applicable, 
SAEs must be collected that relate to any later protocol-specified procedure (eg, a follow-up skin 
biopsy).
The investigator must report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure.
 Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the appropriate section of the eCRF section.
 All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3. 
 The investigator will submit any updated SAE data to the sponsor within 24 hours of this 
being available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the 
study treatment or study participation, the investigator must promptly notify the sponsor.
The method of evaluating, and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a participant. (In order to prevent reporting bias, participants
should not be questioned regarding the specific occurrence of one or more AEs.)
9.2.3 Follow-up of AEs and SAEs
 Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section Appendix 3).
 Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate.
 All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities that are reported/identified during the course of the study.
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in 
Section 9.2 will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3).
Further information on follow-up procedures is given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
 Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 





 An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the Investigator Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
Sponsor or designee will be reporting adverse events to regulatory authorities and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and 
FDA Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR (Suspected, 
Unexpected Serious Adverse Reaction) is a subset of SAEs and will be reported to the 
appropriate regulatory authorities and investigators following local and global guidelines and 
requirements.
All SAEs must be collected that occur during the screening period and within 100 days of the 
last dose of study treatment. For participants randomized/assigned to treatment and never treated 
with study drug, SAEs should be collected for 30 days from the date of randomization.
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subsequently discovered that a participant is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5 half-lives after product administration, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance 
Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE 
reporting procedures described in Appendix 3.
In most cases, the study treatment will be permanently discontinued in an appropriate manner 
(eg, dose tapering if necessary for participant safety). Please call the BMS Medical Monitor 
within 24 hours of awareness of the pregnancy.
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
participant.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collect any pregnancy surveillance 
information from the female partner, the female partner must sign an informed consent form for 
disclosure of this information. Information on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.





 Any laboratory test result abnormality that required the participant to have study treatment
discontinued or interrupted
 Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by 
the reporting investigator (eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section 9.2 and Appendix 3 for 
reporting details).
Potential drug induced liver injury is defined as: 
 AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
 Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
 No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, 
electrocardiogram, x-ray filming, any other potential safety assessment required or not required 
by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported 
accordingly.
9.3 Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as SAEs (see Section 9.2).
9.4 Safety
Planned time points for all safety assessments are listed in the Schedule of Activities.
9.4.1 Clinical Safety Laboratory Assessments










Prothrombin time (PT)/ International normalized ratio (INR)























Urine protein/creatinine ratio (UPCR)
Serology
Serum for hepatitis C antibody, HCV RNA, hepatitis B surface antigen (screening only).
HIV, if mandated locally. (Sites in Germany, see Appendix 12)
Other Analyses
Thyroid stimulating hormone (TSH) with free thyroxine (fT3) and free triiodothyronine (fT4)
(screening only); TSH with reflexive fT3 and fT4 during study and follow up
Pregnancy test (WOCBP only: screening and during study)
Follicle stimulating hormone (FSH) (screening only for women under 55 years old to confirm 
menopause as needed)
9.4.2 Imaging Safety Assessment
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment. 
9.5 Pharmacokinetics and Immunogenicity
Samples for nivolumab, ipilimumab, and cabozantinib PK and nivolumab and ipilimumab 
immunogenicity assessments will be collected for participants in Arm A (doublet) receiving 
nivolumab combined with cabozantinib and in Arm B (triplet) receiving nivolumab and 
ipilimumab combined with cabozantinib as described in Table 9.5-1 and Table 9.5-2, 
respectively. Treatment assignments will be released to the bioanalytical laboratory in order to 
minimize unnecessary analysis of samples. All timepoints for nivolumab/ipilimumab sampling 
are relative to the start of study drug administration for nivolumab in Arms A and B. All 
timepoints for cabozantinib PK sampling are relative to the start of study drug administration for 
nivolumab in Arms A and B and should be drawn approximately at least 8 hours after the 





All on-treatment timepoints are intended to align with days on which study drug is administered. 
If it is known that a dose is going to be delayed, then the predose sample for 
nivolumab/ipilimumab and cabozantinib, if appropriate, should be collected just prior to the 
delayed dose. However, if a predose sample for nivolumab/ipilimumab is collected but the dose 
is subsequently delayed, an additional predose sample should not be collected. Further details of 
sample collection, processing, and shipment will be provided in the laboratory/procedure
manual.
Blood samples should be drawn from a site other than the infusion site (ie, contralateral arm) on 
days of infusion. If the infusion was interrupted, the interruption details will also be documented 
on the CRF. Further details of pharmacokinetic sample collection and processing will be 
provided to the site in the laboratory/procedure manual.
Samples collected from participants for immunogenicity analyses of nivolumab and/or 
ipilimumab will be evaluated for the development of Anti-Drug Antibody (ADA) for nivolumab 
and/or ipilimumab by validated immunoassays. Samples may also be analyzed for neutralizing 
ADA response to nivolumab and/or ipilimumab. 
Serum concentration analyses for nivolumab and/or ipilimumab will be performed by validated 
immunoassay bioanalytical method(s) for nivolumab and ipilimumab. Plasma concentration 
analyses for cabozantinib will be performed by validated liquid chromatography tandem-mass 
spectrometry (LC-MS-MS).
In addition, selected serum samples may be analyzed by an exploratory method that measures 
nivolumab and ipilimumab, or detect anti-drug antibodies for technology exploration purposes; 
exploratory results will not be reported. The corresponding serum samples designated for either 
PK, immunogenicity or biomarker assessments may also be used for any of those analyses, if 
required (eg, insufficient sample volume to complete testing or to follow up on suspected





Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule for Arm A (Doublet)
Study Day
a









Blood Sample for 
Nivolumab for Arm A
Immunogenicity 
Blood Sample for 
Nivolumab for Arm A
Pharmacokinetic 








C3/D1 Predose nivo 00:00 X
e
C4/D1 Predose nivo 00:00 X X X
e
C7/D1 Predose nivo 00:00 X X Xe
C15/D1 Predose nivo 00:00 X X
C23/D1 Predose nivo 00:00 X X
Every 16 weeks from 
C23 to 2 years
Predose nivo 00:00 X X
Follow-up Samples -
Approximately 30 and 
100 days from the 
discontinuation of 
study drug
NA NA X X
Abbreviations: C=cycle; D=day; EOI=end of infusion; NA=not applicable; nivo=nivolumab
a If a participant discontinues study drug treatment during the sampling period, they will move to sampling at the follow-up visits.
b Predose: All predose samples for nivolumab should be taken prior to the start of nivolumab infusion.  
c Though cabozantinib will be dosed in the evening on Day 1 of Cycle 1, the cabozantinib predose sample on Day 1 can be drawn at the same time nivolumab 
predose sample is drawn.
d EOI-nivo : End of Infusion samples for nivolumab should be collected immediately (preferably within 2-5 minutes) prior to the end of infusion. If the end of 
infusion is delayed, the collection of the EOI samples should be delayed accordingly. EOI samples may not be collected from the same IV access as drug was 





e Cabozantinib is preferably dosed at bedtime. A PK sample for cabozantinib will be drawn at the same time when predose PK samples for nivolumab are drawn 





Table 9.5-2: Pharmacokinetic (PK) and Immunogenicity Sampling Schedule for Arm B (Triplet)
Study Day
a
(C1 to C4 Cycles 
= 3 weeks then C5 

































b 00:00 X X X X X
c
C1/D1 EOI-ipi
d 01:30 X X
C2/D1 Predose nivo 00:00 X
e
C3/D1 Predose nivo 00:00 X X X X X
e
C5/D1 Predose nivo 00:00 X X X X Xe
C13/D1 Predose nivo 00:00 X X
C21/D1 Predose nivo 00:00 X X
Every 16 weeks 
from C21 to 2 
years
Predose nivo 00:00 X X
Follow-up Samples 
- Approximately 30 
and 100 days from 
the discontinuation 
of study drug
NA NA X X X X
Abbreviations: C=cycle; D=day; EOI=end of infusion; ipi=ipilimumab; NA=not applicable; nivo=nivolumab
a If a participant discontinues study drug treatment during the sampling period, they will move to sampling at the follow-up visits.
b Predose: All predose samples for nivolumab and/or ipilimumab should be taken prior to the start of nivolumab infusion.
c Though cabozantinib will be dosed in the evening on Day 1 of Cycle 1, the cabozantinib predose sample on Day 1 can be drawn at the same time nivolumab 





d EOI-ipi: The end of infusion (EOI) samples for both nivolumab and ipilimumab should be collected immediately (preferably within 2-5 minutes) prior to the 
end of ipilimumab infusion. If the end of infusion is delayed, the collection of the EOI samples should be delayed accordingly. EOI samples may not be 
collected from the same IV access as drug was administered, refer to the laboratory manual for additional instructions.
e
Cabozantinib is preferably dosed at bedtime. A PK sample for cabozantinib should be drawn at the same time when predose PK samples for nivolumab and 






Refer to Section 9.8.
9.7 Pharmacogenomics
Refer to Section 9.8.6.
9.8 Biomarkers
9.8.1 Additional Research Collection
This protocol will include residual sample storage for additional research (AR).
For All US sites:
Additional research is required for all study participants.
• If the IRB/ethics committees and site agree to the mandatory additional research retention 
and/or collection, then the study participant must agree to the mandatory additional 
research as a requirement for inclusion in the study.
For non-US Sites
Additional research is optional for all study participants, except where retention and/or collection 
is prohibited by local laws or regulations, ethics committees, or institutional requirements. 
This collection for additional research is intended to expand the translational R&D capability at 
Bristol-Myers Squibb, and will support as yet undefined research aims that will advance our 
understanding of disease and options for treatment. It may also be used to support health 
authority requests for analysis, and advancement of pharmacodiagnostic development to better 
target drugs to the right participants.  This may also include genetic/genomic exploration aimed 
at exploring disease pathways, progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for additional research will be vetted through a diverse 
committee of the study sponsor’s senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scientific research activities.
 Residual whole blood (DNA), serum, plasma, PBMCs, tumor tissue from whole blood 
(DNA), serum biomarkers, plasma biomarkers, PBMCs, tumor biopsy collections (see Table
9.8.1-1) will also be retained for additional research purposes
Samples kept for future research will be stored at the BMS Biorepository in Hopewell, NJ, USA 
or an independent, BMS-approved storage vendor.
 The manager of these samples will ensure they are properly used throughout their usable life 
and will destroy the samples at the end of the scheduled storage period, no longer than fifteen 
(15) years after the end of the study or the maximum allowed by applicable law.
 Transfers of samples by research sponsor to third parties will be participant to the recipient’s 





Samples will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held by the Investigator at the clinical site, so there is no direct ability for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing will be provided to the site in the procedure 
manual.
Table 9.8.1-1: Residual Sample Retention for Additional Research Schedule
Sample Type Timepoints for which residual samples will be retained






Sufficient tumor tissue specimens, preferably collected within 3 months but no more than 12 
months prior to enrollment with an associated pathology report, will be required in the form of a 
formalin-fixed paraffin-embedded block or 20 unstained slides. A minimum of 10 slides will be 
acceptable if tumor tissue is limited. In these situations, it is recommended to consult with the 
protocol team to discuss the specifics of the case. In addition, it is recommended, although 
optional, for tumor tissue samples to be collected upon progression. These samples may be used 
for the assessment of markers implicated in resistance.
The tumor tissue samples may be used to assess putative predictive biomarkers of nivolumab,
ipilimumab, and cabozantinib efficacy and/or to better characterize the tumor-immune 
microenvironment. Baseline tumor tissue samples will be evaluated for PD-L1 by IHC during 
screening by the central lab pathologist, who will determine the number of tumor cells with 
membranous staining among a minimum of 100 evaluable tumor cells. Participants will be 
stratified at randomization as either PD-L1 expression ≥ 1% versus PD-L1 expression < 1% or 
indeterminate (ie, sample contains at least 100 evaluable tumor cells but membrane scoring is 
hampered by high cytoplasmic staining). 
Various other markers with potential predictive value for the treatment of RCC with nivolumab, 
ipilimumab and other immunotherapies are currently under investigation and may be assessed in 
this study. These tumor tissue biomarkers include, but are not limited to PD-L1, PD-1, PD-L2, 
TILs or subpopulations of TILs and a Th1 immune mRNA expression signature. Evaluation of 
MET, AXL, and other markers may be performed by IHC or other methods. Tumor samples may 
also be used to further characterize the tumor-immune microenvironment, including but not 
limited to other T cell checkpoint receptors and ligands (eg, Lag-3, Tim-3), and intratumoral 
immune cell subsets, including T-regulatory cells, myeloid derived suppressor cells, 





investigate the effect of nivolumab, ipilimumab, and cabozantinib on the expression of 
potentially relevant predictive and/or prognostic RCC biomarkers. Both the baseline tumor 
sample and the sample collected upon progression may be retrospectively assessed for the 
expression of other immune related genes, RNAs and/or proteins, or for the presence of immune 
cell populations using a variety of methodologies inclusive of, but not limited to IHC, RNA 
Scope, qRT-PCR, RNA seq, genetic mutation detection (including whole exome sequencing) and 
fluorescent in-situ hybridization (FISH).
9.8.3 Exploratory Serum and Plasma Biomarkers
Blood samples for exploratory serum and plasma biomarker analyses will be drawn at the 
specified time points. Serum and plasma samples may be assessed by ELISA, seromics, 
microRNA profiling, circulating tumor DNA measurements, metabolomics and/or other relevant 
multiplex-based protein assay methods for immune or RCC-related factors that will predict for 
clinical benefit or correlate with treatment-related adverse events. Potential serum and plasma-
based biomarkers to potentially b investigated include, but are not limited to levels of soluble 
PD-L1, anti-tumor antibodies, cytokines, chemokines, inflammatory factors, angiogenic 
biomarkers (eg, VEGF-A, soluble VEGF2) NKG2D ligands (eg, soluble MICA), circulating 
tumor DNA, and microRNAs (such as, but not limited to, miR-513 and miR19b).  
9.8.4 Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are an immune cell population capable of 
suppressing T cell activation and proliferation. MDSCs will be measured at baseline to assess 
associations with outcome. 
9.8.5 PBMC for Flow Cytometry
Exploratory flow cytometry analysis will be used to assess baseline and on-treatment alterations 
in the composition/ activation status of cell subsets. Lymphocyte subsets to be assayed may 
include, but are not limited to, CD4+ and CD8+ subsets (activated, effector/memory, regulatory) 
and populations of those cells as defined by the expression of activation, exhaustion or signaling 
markers.
9.8.6 Whole Blood for Genotyping
Whole blood samples for exploratory pharmacogenetic assessment will be collected from all 
participants. Genomic DNA will be extracted and subsequently assessed for SNPs and other 
genetic variations in candidate genes that may predispose participants to clinical benefit or 
adverse events (unless restricted by local requirements). Such genes include, but are not limited 
to, PD-1, PD-L1, PD-L2 and CTLA-4. Additional use of these data may include correlative 
analyses aimed at identifying genotypic associations with clinically relevant biomarkers 
identified by other methodologies described in this section (including whole exome sequencing).
Genomic DNA from whole blood will be collected and may be used as a comparator for subjects 







9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Economics parameters will be 
evaluated in this study as noted in Section 2.
Medical resource utilization and health economics data, associated with medical encounters, will 
be collected in the CRF by the investigator and study-site personnel for all participants 
throughout the study. Protocol-mandated procedures, tests, and encounters are excluded. 
The data collected may be used to conduct exploratory economic analyses and will include:
 Number and duration of medical care encounters, including surgeries, and other selected 
procedures (inpatient and outpatient)
 Duration of hospitalization (total days length of stay, including duration by wards; eg,
intensive care unit)
 Number and character of diagnostic and therapeutic tests and procedures
 Outpatient medical encounters and treatments (including physician or emergency room visits, 
tests and procedures, and medications)].
10. STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
The sample size of this study accounts for the primary endpoint of progression-free survival 
(PFS) per BICR in the intermediate/poor risk randomized participants. The primary objective 
specifies two comparisons: PFS per BICR of Arm A (doublet) versus Arm C (sunitinib) and of 
Arm B (triplet) versus Arm C (sunitinib). This study is not powered for the comparison of Arm 
A versus Arm B. The sample size and the timing of the analyses are driven by Arm A versus 
Arm C comparison in intermediate/poor risk randomized participants. Assuming a 25% screen 
failure rate, it is expected that approximately 1353 any risk participants will need to be enrolled 
in order to randomize 1014 any risk participants (338 per arm) in a 1:1:1 ratio. This includes at 
most 273 favorable risk participants (91 per arm) enrolled to randomize 204 favorable risk 
participants in a 1:1:1 ratio. The rest of the enrolled participants will provide approximately 810 
intermediate/poor risk randomized participants (270 per each arm).
The overall alpha for this study is 0.05 (two-sided). This is split with 0.0245 (two-sided) for each 
of two comparisons to evaluate PFS after penalizing 0.001 (two-sided) to evaluate ORR since it 
is planned to have an early assessment of ORR. PFS will be evaluated on approximately 810 
intermediate/poor risk randomized participants (270 per each arm) for treatment effect at an 
alpha of 0.0245 (two-sided, penalized 0.0005 from each 0.025 allocation), with at least 90% 
power. No interim analysis of PFS is planned. OS will be evaluated for treatment effect at an 
alpha level of 0.0245 (two-sided) with 75% power, accounting for an interim analyses to assess 
efficacy at the time of the final PFS analysis. ORR will be analyzed on a descriptive basis and 
will occupy an administrative adjustment of alpha of 0.001 (0.0005 per pairwise comparison).





The primary endpoint of PFS per BICR of Arm A versus Arm C and of Arm B versus Arm C 
analyses conducted on approximately 810 intermediate/poor risk randomized participants (270 
per each arm) will be triggered by approximately 336 events in Arm A and Arm C (or 
approximately 456 events in all three arms). The 336 PFS events provide at least 90% power to 
detect a hazard ratio (HR) of 0.68 for PFS of Arm A versus Arm C or a HR of 0.56 for PFS of 
Arm B versus Arm C with a type I error of 0.0245 (two-sided) for each test for a total of 0.049. 
The HR of 0.68 corresponds to a 48% increase in the median PFS, assuming a median PFS of 
11.8 months for Arm A and 8 months for Arm C. Similarly, the HR of 0.56 corresponds to a 
79% increase in the median PFS, assuming a median PFS of 14.3 months for Arm B and 8 
months for Arm C. It is projected that an observed hazard ratio of 0.782 or less, which 
corresponds to a 2.2 month or greater improvement in median PFS (8 versus 10.2 months), 
would result in a statistically significant improvement in PFS for the Arm A versus Arm C 
comparison. Similarly, an observed hazard ratio of 0.691 or less, which corresponds to a 3.6 
month or greater improvement in median PFS (8 versus 11.6 months), would result in a 
statistically significant improvement in PFS for the Arm B versus Arm C comparison. An 
efficacy comparison of between Arm A and Arm B is not an objective of this study, and this 
study is not powered for such a comparison. Based on the above assumptions, the presumed PFS 
HR of 0.83 between Arm A and Arm B can be detected with at most 39% power with the 
specified study design.
For assessing the secondary objectives of this study, a hierarchical testing procedure will be used 
so that the overall type I error rate is preserved at 0.05. For both Arm A versus Arm C and Arm 
B versus Arm C comparisons, the key secondary objectives within each pairwise comparison 
will be tested in the following hierarchical order only if PFS is significant for that pair:
• PFS per BICR assessment among all randomized participants
• OS among intermediate/poor risk randomized participants
• OS among all randomized participants
Sample Size Computation for Secondary OS Endpoint
The secondary objective of OS in intermediate/poor risk participants specifies two comparisons: 
OS of Arm A versus Arm C and of Arm B versus Arm C. Among the 810 intermediate/poor risk 
randomized participants (270 per each arm), approximately 295 events (ie, deaths) in Arm A and 
Arm C (or approximately 414 in all three arms) with an interim analysis at the time of the PFS 
analysis (when approximately 65% of total OS events have occurred, ie, 192 events in Arms A 
and C, or approximately 270 in all three arms) provides at least 75% power to detect a HR of 
0.71 for OS of Arm A and Arm C and at least 75% power to detect a HR of 0.65 for OS of Arm 
B vs Arm C with an overall type 1 error of 0.0245 (two-sided) for each test. The HR of 0.71 
corresponds to a 41% increase in the median OS, assuming a median OS of 31 months for Arm 
A and 22 months for Arm C. Similarly, the HR of 0.65 corresponds to a 55% increase in the 
median OS, assuming a median OS of 34 months for Arm B and 22 months for Arm C. 
The stopping boundaries at interim and final OS analyses will be derived based on the actual 





295 observed events in Arm A and Arm C at the interim and final analyses, the respective 
stopping boundaries would be α=0.005 (two-sided) and α=0.023 (two-sided). Similarly, with 122 
and 187 observed events in Arm B and Arm C at the interim and final analyses, the respective 
stopping boundaries would be α=0.005 (two-sided) and α=0.023 (two-sided). However, Arm B 
will have more events than presumed for these calculations at the time of the PFS and final OS 
analysis since the timing of the analysis is triggered by the Arm A versus Arm C comparison.
Assuming a constant accrual rate (an average rate of 60 participants /month), the accrual will 
take approximately 17 months. The final PFS analysis is expected to occur approximately 22 
months from FPFV, at which time the interim analysis of OS will also be conducted. The final 
OS analysis is expected to occur approximately 34 months from FPFV. Table 10.1-1
summarizes the results of these calculations.
Table 10.1-1: Summary of sample size parameters and schedule of analyses
Primary/Secondary 
Endpoints
PFS (Primary) OS (Secondary)a
Primary analysis population Intermediate/poor risk participants (IMDC score  1)




Comparison (Arm vs Arm) A vs C B vs C A vs C B vs C
Alpha
0.0245 2-sided 0.0245 2-sided
0.0245 2-sided (0.005 
at IA, 0.023 at FA)
0.0245 2-sided (0.005 
at IA, 0.023 at FA)
Hypothesized Median Control 
vs exp (months) 
8 vs 11.8 8 vs 14.3 22 vs 31 22 vs 34
Hypothesized Hazard ratio 0.68 0.56 0.71 0.65
Critical Hazard ratio (Observed 
hazard ratio at which a 
statistically significant 
difference would be observed) / 
Difference in median (months) 
Corresponding to a minimal 
clinically significant effect size 
(FA)b
0.782 / 2.2 0.691 / 3.6 0.767 / 6.7 0.717 / 8.7
Critical HR at interim analysis-
1(IA) / difference in medians
N/A 0.665 / 11.1 0.6 / 14.7
Target number of event for IA 
(percentage of target events)
N/A 270 (65%) (192 in A vs C)
Timing of IA from FPFV 
(months)
N/A 22
Accrual Duration (months) 17 17







Table 10.1-1: Summary of sample size parameters and schedule of analyses
Primary/Secondary 
Endpoints
PFS (Primary) OS (Secondary)a
Sample size 810 810
Target number of events (Event 
Goal)
456 (336 in A vs C) 414 (295 in A vs C)
a OS analyses is subject to significance in hierarchical testing strategy for each pairwise comparison.
b The difference in median (months) only applies if the control group median is exactly as hypothesized.
Sample Size Computation for Secondary ORR Endpoint
One of the secondary objectives of the study is to evaluate the ORR per BICR in intermediate 
and poor-risk participants. The primary analysis of ORR in the intermediate and poor-risk 
randomized participants will be performed at the time prior to the final PFS analysis when the 
first 420 participants (140 per arm) will have an approximate 9 months minimum follow-up from 
7 months of enrollment. Nine months of minimum follow-up allows for 3 months for responses 
to occur and an additional 6 months follow-up thereafter intended for sufficient follow-up for 
ORR, adequate safety follow-up as well as duration of response in this population.
The maximum width of the exact two-sided 95% confidence interval (CI) is approximately 17% 
when the ORR is expected to be in the 20% to 50% range. Table 10.1-2 summarizes the 95% 
exact CI when observed ORRs are 20% to 50%, respectively.
Table 10.1-2: 95% Exact CI when Observed ORRs are 20% to 50%
Observed ORR 95% Exact CI
20% (13.7% - 27.6%)
25% (18.1% - 33.0%)
30% (22.6% - 38.3%)
35% (27.1% - 43.5%)
40% (31.8% - 48.6%)
45% (36.6% - 53.6%)
50% (41.4% - 58.6%)
For example if at least 42 responders are observed among the 140 nivolumab and ipilimumab 
combination intermediate/poor risk randomized participants (ie, ORR ≥ 30%) then the lower 
bound of the 95% CI is above 22.6%. 
10.2 Populations for Analyses
All analyses will be performed using the treatment arm as randomized (intent to treat), with the 
exception of dosing and safety, for which the treatment arm as received will be used. For 





Table 10.2-1: Populations for Analyses
Population Description
All Enrolled Participants All participants who sign informed consent and were registered into the IRT.
All Intermediate/Poor Risk 
Randomized Participants
All randomized participants with baseline IMDC score ≥ 1 at the time 
randomization who were randomized to any treatment group. This is the primary 
efficacy analysis population. 
ORR Intermediate/Poor Risk 
Randomized Participants
The first 420 randomized participants with baseline IMDC score ≥ 1 at the time 
randomization who were randomized to any treatment group. The analysis of 
ORR in the intermediate and poor-risk randomized participants will be 
performed for this population.
All Randomized Participants 
(any risk participants)
All participants who were randomized to any treatment group. Analysis of 
demography, protocol deviations, baseline characteristics, secondary efficacy 
analyses, and outcome research analysis will be performed for this population.
All Treated Participants All participants who received at least one dose of any study medication. This is 
the primary population for exposure and safety analyses.
Pharmacokinetic Participants All participants with available data from randomized participants dosed with 
nivolumab, ipilimumab, or cabozantinib.
Immunogenicity Participants All participants with available data from randomized participants dosed with 
nivolumab or ipilimumab.
Biomarker Participants All participants with available biomarker data from randomized participants.
10.3 Statistical Analyses
The statistical analysis plan will be developed and finalized before database lock and will 
describe the selection of participants to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data. Below is a summary of planned statistical 
analyses of the primary and secondary endpoints.
10.3.1 Efficacy Analyses
Table 10.3.1-1: Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary The primary objective specifies two comparisons: PFS per BICR of Arm A (doublet) versus 
Arm C (single agent) and Arm B (triplet) versus Arm C (single agent), in all 
intermediate/poor risk randomized participants. 
PFS is defined as the time between the date of randomization and the first date of the 
documented progression, or death due to any cause, whichever occurs first. Participants who 
die without a reported progression will be considered to have progressed on the date of their 
death. Participants who did not progress or die will be censored on the date of their last 
evaluable tumor assessment. Participants who did not have any on study tumor assessments 
and did not die will be censored on their date of randomization. Participants who started anti-
cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery) without a 
prior reported progression will be censored on the date of their last evaluable tumor 
assessment prior to the initiation of first subsequent anti-cancer therapy.
The primary formal comparisons of PFS will be conducted using a two-sided 0.0245 
stratified log-rank test for each comparison, with IMDC scores, PD-L1 tumor expression, and 





Table 10.3.1-1: Efficacy Analyses
Endpoint Statistical Analysis Methods
randomized participants. 
Median PFS will be estimated via the Kaplan-Meier product limit method. Two-sided 95% 
CI for the median PFS will be computed for each randomized arm. 
Kaplan-Meier plots of PFS will be presented. Hazard ratios (HR) and corresponding two-
sided 97.55% confidence intervals (CI) will be estimated using a Cox proportional hazards 
model, with treatment arm as a single covariate, stratified by the stratification factors, 
corresponding to the comparison of PFS. 
The totality of PFS results will be presented in a single graphical display that includes 
Kaplan-Meier curves for all treatment arms, the log-rank p-values for the formal 
comparisons, the HRs and corresponding CIs, and the median PFS estimates and 
corresponding CIs. 
The following supportive analyses of PFS will also be conducted:
A stratified multivariate Cox regression model will be used in order to estimate the treatment 
effect after adjustment for possible imbalances in known or potential prognostic factors. The 
covariates included in this model will be specified in the statistical analysis plan.
PFS using an un-stratified log rank test. The hazard ratio associated with treatment will be 
presented along with the associated two-sided 97.55% CIs.
PFS accounting for missing tumor assessment prior to PFS event (progression or death). This 
analysis will be performed only if at least 10% of events have missing prior tumor 
assessment. It will apply the following restriction to the primary definition: If the elapsed 
time between the PFS event and the last assessment immediately prior to the event is two or 
more missed visits (more than 12 weeks - 10 days), the participant’s PFS will be censored at 
his/her last tumor assessment prior to the PFS event.
Secondary The first secondary objective specifies two comparisons: PFS per BICR of Arm A versus 
Arm C and Arm B versus Arm C, in all randomized participants. PFS will be defined 
similarly to the primary endpoint except that all randomized participants will be used.
At the time of the primary endpoint analysis, the first secondary endpoint will be summarized 
using the same methods as described above for the primary endpoint analysis.
The second secondary endpoint of this specifies two comparisons: OS of Arm A versus Arm 
C and of Arm B versus Arm C in all intermediate/poor risk randomized participants. OS is 
defined as the time between the date of randomization and the date of death due to any cause. 
A participant who has not died will be censored at the last known alive date.
At the time of the primary endpoint analysis, there will be an interim analysis of OS, and 
final analysis of OS is planned to occur 34 months of FPFV. OS will be compared between 
the treatment arms using a two sided, 0.0245 level log-rank test, stratified using IMDC 
scores, PD-L1 tumor expression, and region at screening as stratification factors among all 
randomized participants. A similar analysis as in PFS will be conducted for OS. Hazard ratios 
(HR) and corresponding two-sided 97.55% confidence intervals (CI) will be estimated using 
a Cox proportional hazards model, with treatment arm as a single covariate, stratified by the 
stratification factors, corresponding to the comparison of OS.
The third secondary endpoint of this specifies two comparisons: OS of Arm A versus Arm C 
and of Arm B versus Arm C in all randomized participants. OS is defined as the time 
between the date of randomization and the date of death due to any cause. A participant who 
has not died will be censored at the last known alive date.
As in the second secondary endpoint, the third secondary endpoint will be summarized at the 
time of the primary endpoint analysis using the same methods as described above for the first 
secondary endpoint analysis.





Table 10.3.1-1: Efficacy Analyses
Endpoint Statistical Analysis Methods
intermediate/poor risk randomized participants and all randomized participants. ORR is 
defined as the proportion of randomized participants who achieve a best response of complete 
response (CR) or partial response (PR) using the RECIST 1.1 criteria. Best overall response 
(BOR) is defined as the best response designation recorded between the date of 
randomization and the date of objectively documented progression per RECIST 1.1 or the 
date of subsequent therapy (including tumor-directed radiotherapy and tumor-directed 
surgery), whichever occurs first. For participants without document progression or 
subsequent therapy, all available response designations will contribute to the BOR 
assessment. Duration of response (DOR) is defined as the time between the date of first 
confirmed documented response (CR or PR) to the date of first documented tumor 
progression (per RECIST 1.1) or death due to any cause, whichever occurs first. Participants 
who neither progress nor die will be censored on the date of their last tumor assessment. 
Responders who started anti-cancer therapy without a prior reported progression will be
censored on the date of their last evaluable tumor assessment prior to the initiation of first 
subsequent anti-cancer therapy. TTR is defined as the time from randomization to the date of 
the first confirmed documented response (CR or PR), as assessed by BICR. DOR and TTR 
will be evaluated for responders (CR or PR) only.
Tumor assessments are scheduled to be performed at Week 12 following randomization, 
every 6 weeks for the first 12 months and then every 12 weeks until progression.
ORR will be analyzed at the time prior to the final PFS analysis when the first 420 
participants (140 per arm) will have an approximate 9 months minimum follow-up from 7 
months of enrollment. ORRs and corresponding 95% exact CIs will be calculated using the 
Clopper Pearson method within each treatment arms. A two sided 95% CI for difference of 
response rate between Arm A and Arm C arms will also be computed. Similarly, a two sided 
95% CI for difference of response rate between Arm B and Arm C arms will also be 
computed. BOR will be tabulated for each treatment group. An estimate of the response rate 
and an associated exact two-sided 95% CI (Clopper and Pearson) will be presented, by 
treatment group. Sensitivity analysis based on investigator-determined ORR may also be 
performed. DOR and TTR will also be evaluated.
Exploratory Will be described in the statistical analysis plan finalized before database lock.
10.3.2 Safety Analyses
The safety analysis will be performed in all treated participants.
Table 10.3.2-1: Safety Analyses
Endpoint Statistical Analysis Methods
Primary The primary endpoint is related to efficacy and there are no primary safety endpoints.
Secondary Safety will be analyzed at the time of the primary endpoint analysis. Descriptive statistics of 
safety will be presented using the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 by treatment arm. All AEs, drug-related 
AEs, SAEs and drug-related SAEs, imAEs, and select AEs will be tabulated using the worst 
grade per NCI CTCAE version 4.0 criteria by system organ class and preferred term. On-
study lab parameters including hematology, coagulation, chemistry, liver function and renal 
function will be summarized using worse grade per NCI CTCAE version 4.0 criteria.





10.3.3 Other Analyses 
Pharmacokinetic, pharmacodynamic, and biomarker exploratory analyses will be described in the 
statistical analysis plan finalized before database lock. The population pharmacokinetics analysis 
and pharmacodynamic analyses will be presented separately from the main clinical study report. 
Immunogenicity may be reported for ADA positive status (such as persistent positive, other 
positive, only last sample positive, baseline positive) and ADA negative status, relative to 
baseline. In addition, presence of neutralizing antibody may be reported, if applicable. Effect of 
immunogenicity on safety/efficacy and biomarkers and PK may be explored.
10.3.4 Interim Analyses 
An interim analysis of ORR will be performed at the time prior to the final PFS analysis when 
the first 420 participants (140 per arm) will have an approximate 9 months minimum follow-up 
from 7 months of enrollment. Nine months of minimum follow-up allows for 3 months for 
responses to occur and an additional 6 months follow-up thereafter intended for sufficient 
follow-up for ORR, adequate safety follow-up as well as duration of response in this population.
An interim analysis of OS is planned at the time of final PFS analysis and it is expected after 
observing 192 deaths (approximately 65% of the targeted OS events, or 270 in all three arms) 
have been observed among intermediate/poor risk participants based on above accrual rate and 
the exponential distribution in each arm. These formal comparisons of OS will allow for early 
stopping for superiority, and the boundaries for declaring superiority will be derived based on the 
actual number of deaths using Lan-DeMets spending function with O’Brien and Fleming type of 
boundary in EAST version 6. If this interim analysis is performed exactly at 192 deaths, the 
boundary in terms of statistical significance for declaring superiority would be 0.005 (HR=0.665 
with 11.1 months improvement in median OS for the Arm A versus Arm C comparison (22 
versus 33.1 months) and HR=0.6 with 14.7 months improvement in median OS for the Arm B 
versus Arm C comparison (22 versus 36.7 months)). The boundary for declaring superiority in 
terms of statistical significance for the final analysis after 294 events (or approximately 414 in all 
three arms) would be 0.023 (HR=0.767 with 6.7 months improvement in median OS for the Arm 
A versus Arm C comparison (22 versus 28.7 months) and HR=0.717 with 8.7 months 
improvement in median OS for the Arm B versus Arm C comparison (22 versus 30.7 months)). 
More details are summarized in Table 10.1-1. An independent statistician external to BMS will 
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APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
AE adverse event
ACLS advanced cardiac life support
AHA alpha hydroxy acid
AI accumulation index
AIDS acquired immunodeficiency syndrome
AJCC American Joint Committee on Cancer
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANOVA analysis of variance
APC antigen-presenting cell
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration-time curve
AUC(INF) area under the concentration-time curve from time zero extrapolated to 
infinite time
AUC(0-T) area under the concentration-time curve from time zero to the time of the 
last quantifiable concentration
AUC(TAU) area under the concentration-time curve in one dosing interval
A-V atrioventricular
AXL member of the TAM (Tyro-3, Axl, Mer) receptor tyrosine kinases (RTK) 
subfamily
-HCG beta-human chorionic gonadotrophin
Bcl-xL anti-apoptotic member of the B-cell lymphoma 2 (BCL-2) protein family
BICR blinded independent central review
BID, bid bis in die, twice daily
BLQ below limit of quantification 







BOR best overall response
BP blood pressure
BTLA B and T lymphocyte attenuator
BUN blood urea nitrogen
C Celsius
C cycle
C12 concentration at 12 hours
C24 concentration at 24 hours
Ca, Ca++ calcium
Cavg average concentration
Cavgss average concentration at steady state
CBC complete blood count
CD cluster of differentiation
CD3, CD8, CD14, 
CD28
cluster of differentiation 3, 8, 14, 28
CD137 member of the tumor necrosis factor (TNF) receptor family. Alternative 
names are TNF receptor superfamily member 9 (TNFRSF9), 4-1BB and 
induced by lymphocyte activation (ILA)
Cexpected-tau expected concentration in a dosing interval
CFR Code of Federal Regulations 




CLT total body clearance
CLT/F (or CLT) apparent total body clearance
CLT/F/fu or 
CLT/fu
Apparent clearance of free drug or clearance of free if (if IV)
cm centimeter






c-MET tyrosine-protein kinase mesenchymal-epithelial transition (MET) or 
hepatocyte growth factor receptor, is a protein that in humans is encoded 
by the MET gene
CMH Cochran-Mantel-Haenzel
Cmin, CMIN minimum observed concentration
CMV cytomegalovirus
CNS central nervous system
CONSORT Consolidated standards of reporting trials
CR complete response
CRC Clinical Research Center
CRF Case Report Form, paper or electronic
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 cytotoxic T lymphocyte antigen-4
Ctrough Trough observed plasma concentration




DBP diastolic blood pressure
D/C discontinue
DILI drug induced liver injury
dL deciliter
DMC data monitoring committee
DNA deoxyribonucleic acid
DOR duration of response
DSM IV Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
DVT deep vein thrombosis
EA extent of absorption







eCRF Electronic Case Report Form
EDC Electronic Data Capture
EEG electroencephalogram
e.g., eg exempli gratia (for example)
eGFR estimated glomerular filtration rate
ELISA enzyme-linked immunosorbent assay
EOI end of infusion
EQ-5D-3L EuroQoL Group’s instrument to measure general health status
ESR Expedited Safety Report
F bioavailability
FA final analysis 
FDA Food and Drug Administration
FDG-PET fludeoxyglucose- positron emission tomography
FFPE formalin-fixed, paraffin-embedded
FISH fluorescent in-situ hybridization
FKSI-19 Functional Assessment of Cancer Therapy - Kidney Symptom Index
FLT-3 Fms-related tyrosine kinase 3
FSH follicle stimulating hormone




GCP Good Clinical Practice
GGT gamma-glutamyl transferase




HBsAg hepatitis B surface antigen






hCG, HCG human chorionic gonadotropin
HCO3
- bicarbonate
HCV hepatitis C virus
HFS hand foot syndrome
HIV Human Immunodeficiency Virus
HR heart rate, hazard ratio
HrQoL health-related quality of life
HRT hormone replacement therapy
ICD International Classification of Diseases
IC50 half maximal inhibitory concentration
ICH International Conference on Harmonisation 
ICOS inducible co-stimulator
i.e., ie id est (that is)







IMAEs, imAEs immune-mediated adverse events
IMDC International Metastatic Renal Cell Carcinoma Database Consortium
IMP investigational medicinal products
IND Investigational New Drug Exemption
INR international normalized ratio
IP investigational product
ipi ipilimumab
iRAEs immune-related adverse events
IRB Institutional Review Board






IRT Interactive Response Technology
IU International Unit
IV intravenous
K slope of the terminal phase of the log concentration-time curve
K3EDTA potassium ethylenediaminetetraacetic acid
K, K+ potassium
kg kilogram
KIT platelet-derived growth factor receptors (PDGFRs)
KPS Karnofsky Performance Status
L liter
LAM Lactation amenorrhea method
LC liquid chromatography
LC-MS-MS liquid chromatography tandem-mass spectrometry
LDH lactate dehydrogenase
LFT liver function test
LINAC linear accelerator 
LLN lower limit of normal
LMWH low molecular weight heparin
ln natural logarithm
MDSCs myeloid-derived suppressor cells
MER proto-oncogene tyrosine-protein kinase MER is an enzyme that in 
humans is encoded by the MERTK gene
MET mesenchymal-epithelial transition factor, a tyrosine kinase receptor
mg milligram
Mg, Mg++ magnesium
MHC major histocompatibility complex
min minute
mL milliliter
MLR mixed lymphocyte reaction






mOS median overall survival
mRCC metastatic renal cell carcinoma
MRI magnetic resonance imaging
MS mass spectrometry
MSKCC Memorial Sloan Kettering Cancer Center
MTD maximum tolerated dose
mTOR mammalian target of rapamycin
mUC metastatic urothelial carcinoma
MUGA multigated acquisition scan
mWHO modified World Health Organization
g microgram
N number of subjects or observations
N/A, NA not applicable
Na, Na+ sodium
NaF Sodium fluoride
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
NE not evaulable
ng nanogram
NIMP non-investigational medicinal products 
nivo nivolumab
NK natural killer
NKG2D encoded by KLRK1 gene which is located in the NK-gene complex 
(NKC)
NR not reached
NSAID nonsteroidal anti-inflammatory drug
NSCLC non-small cell lung cancer








PCR polyermase chain reaction
PD progressive disease, disease progression
PD pharmacodynamics
PD-1 programmed death-1
PD-L1 programmed death-ligand 1
PE pulmonary embolism
PET positron emission tomography
PFS progression-free survival
PK pharmacokinetics
PO per os (by mouth route of administration)
PR partial response
PT prothrombin time
PTT partial thromboplastin time
Q2W, Q3W every 2 weeks, every 3 weeks
QC quality control
QD, qd quaque die, once daily
qRT-PCR quantitative real time polyermase chain reaction
QTcF Fridericia corrected QT
R2 coefficient of determination
RBC red blood cell
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
RET proto-oncogene encodes a receptor tyrosine kinase for members of the 
glial cell line-derived neurotrophic factor family of extracellular 
signalling molecules
RNA ribonucleic acid
ROS1 proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans 
is encoded by the ROS1 gene








RTK receptor tyrosine kinases
SAE serious adverse event
SBP systolic blood pressure
SCC squamous cell carcinoma
SD standard deviation, stable disease
SNP single-nucleotide polymorphism
SOP Standard Operating Procedures
Subj subject




TAO Trial Access Online, the BMS implementation of an EDC capability
TCR T-cell receptor
T-HALF Half life
TID, tid ter in die, three times a day
TIE-2 tunica interna endothelial cell kinase 2
TIL tumour-infiltrating lymphocyte,
TKIs tyrosine kinase inhibitors
Tmax, TMAX time of maximum observed concentration
Tregs regulatory T cells
TRKB tropomyosin receptor kinase B (TrkB), also known as tyrosine receptor 
kinase B
TSH thyroid stimulating hormone
TTR time to response
TYRO3 tyrosine-protein kinase receptor TYRO3 is an enzyme that in humans is 
encoded by the TYRO3 gene
ULN upper limit of normal
UPCR urine protein to creatinine ratio
UV ultraviolet






VEGF vascular endothelial growth factor
VEGFR2 vascular endothelial growth factor receptor 2
Vss/F (or Vss) apparent volume of distribution at steady state
Vz volume of distribution of terminal phase (if IV and if multi-exponential 
decline)
W washout
WBC white blood cell
WHO World Health Organization
wks weeks
WOCBP women of childbearing potential
WNOCBP women not of childbearing potential






APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS
The term ‘Participant’ is used in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‘Subject’ used in the eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
 Good Clinical Practice (GCP), 
 as defined by the International Council on Harmonisation (ICH)
 in accordance with the ethical principles underlying European Union Directive 2001/20/EC
 United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) 
 applicable local requirements.
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will receive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A serious
breach is a breach of the conditions and principles of GCP in connection with the study or the 
protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity 
of the subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant recruitment materials (eg,
advertisements), and any other written information to be provided to subjects. The investigator or 
BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling 
information to be provided to subjects and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 





COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation or change will be submitted, as 
soon as possible to:
 IRB/IEC for 
 Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the participant volunteers to participate. 
Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample
informed consent form which will include all elements required by ICH, GCP and applicable
regulatory requirements. The sample informed consent form will adhere to the ethical principles 






 Provide a copy of the consent form and written information about the study in the language 
in which the participant is most proficient prior to clinical study participation. The language 
must be non-technical and easily understood. 
 Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details of the study.
 Obtain an informed consent signed and personally dated by the participant or the 
participant's legally acceptable representative and by the person who conducted the 
informed consent discussion. 
 Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent 
form and any other information to be provided to the subjects, prior to the beginning of the 
study, and after any revisions are completed for new information.
If informed consent is initially given by a participant’s legally acceptable representative or legal 
guardian, and the participant subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a person designated by the investigator, 
should fully inform the participant or the participant's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to participant records. 
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The participant
must also be informed about the nature of the study to the extent compatible with his or her 
understanding, and should this participant become capable, he or she should personally sign and 
date the consent form as soon as possible. The explicit wish of a participant who is unable to give 
his or her written consent, but who is capable of forming an opinion and assessing information to 
refuse participation in, or to be withdrawn from, the clinical study at any time should be considered 
by the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 





electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.
If Then
Supplied by BMS (or its vendors): Records or logs must comply with applicable 
regulations and guidelines and should include:
 amount received and placed in storage area
 amount currently in storage area
 label identification number or batch number
 amount dispensed to and returned by each 
participant, including unique participant identifiers
 amount transferred to another area/site for 
dispensing or storage
 nonstudy disposition (eg, lost, wasted) 
 amount destroyed at study site, if applicable
 amount returned to BMS
 retain samples for bioavailability/bioequivalence, 
if applicable 
 dates and initials of person responsible for 
Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
Sourced by site, and not supplied by 
BMS or its vendors (examples include 
IP sourced from the sites stock or 
commercial supply, or a specialty 
pharmacy)
The investigator or designee accepts responsibility for 
documenting traceability and study drug integrity in 
accordance with requirements applicable under law and 






These records should include:
 label identification number or batch number 
 amount dispensed to and returned by each 
participant, including unique participant identifiers
 dates and initials of person responsible for 
Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillance form, respectively.  If 
electronic SAE form is not available, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by study-specific CRF completion guidelines provided by 
Sponsor or designee. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task For electronic CRFs, review and approval/signature is completed electronically through the 
BMS electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the BMS electronic data capture tool using the unique user 







Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of study records.
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents:
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee.
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vendor or sourced by the investigator) 
such as partially used study treatment containers, vials and syringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including 
its vendors
Any unused study treatments supplied by BMS 
can only be destroyed after being inspected 
and reconciled by the responsible Study 
Monitor unless study treatments containers 
must be immediately destroyed as required for 







If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or commercial supply, or a specialty 
pharmacy)
It is the investigator’s or designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
 On-site disposal practices must not expose humans to risks from the drug.
 On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
 Written procedures for on-site disposal are available and followed. The procedures must 
be filed with the site’s SOPs and a copy provided to BMS upon request.
 Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. 
The method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor must be documented.
 Accountability and disposal records are complete, up-to-date, and available for the Monitor 
to review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non- study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
 National Coordinating Investigator 





 Participant recruitment (eg, among the top quartile of enrollers)
 Involvement in trial design
 Regional representation (eg, among top quartile of enrollers from a specified region or 
country)
 Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing [Study site or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 





APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation participant administered study drug and 
that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study drug, whether or not 






Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 
o a visit to the emergency room or other hospital department < 24 hours, that does 
not result in admission (unless considered an important medical or life-
threatening event)
o elective surgery, planned prior to signing consent
o admissions as per protocol for a planned medical/surgical procedure
o routine health assessment requiring admission for baseline/trending of health 
status (e.g., routine colonoscopy)
o medical/surgical admission other than to remedy ill health and planned prior to 
entry into the study. Appropriate documentation is required in these cases
o admission encountered for another life circumstance that carries no bearing on 
health status and requires no medical/surgical intervention (e.g., lack of housing, 
economic inadequacy, caregiver respite, family circumstances, administrative 
reason)
o admission for administration of anticancer therapy in the absence of any other 
SAEs (applies to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug induced liver injury (DILI) is also considered an important 





Suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
treatment is an SAE. 
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See Section 9.2.5
for reporting pregnancies).
Any component of a study endpoint that is considered related to study therapy should be reported 
as SAE (e.g., death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
The causal relationship to study drug is determined by a physician and should be used to 
assess all adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug 
administration and the AE.
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE. 
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. (Note: 
Follow-up SAE reports must include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study drug or if new 
information becomes available, the SAE report must be updated and submitted within 24 
hours to BMS (or designee) using the same procedure used for transmitting the initial SAE 
report.





REPORTING OF SAES TO SPONSOR OR DESIGNEE
 SAEs, whether related or not related to study drug, and pregnancies must be 
reported to BMS (or designee) within 24 hours of awareness of the event.
 SAEs must be recorded on the SAE Report Form; pregnancies on a Pregnancy 
Surveillance Form (electronic or paper forms).
 The preferred method for SAE data reporting collection is through the eCRF.
 The paper SAE/pregnancy surveillance forms are only intended as a back-up option 
when the eCRF system is not functioning.
o In this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission 
is the required method for reporting. In the event the electronic system is unavailable for 
transmission, paper forms must be used and submitted immediately. When paper forms are 
used, the original paper forms are to remain on site.






APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
 Premenarchal
 Premenopausal female with 1 of the following:
 Documented hysterectomy
 Documented bilateral salpingectomy
 Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
 Postmenopausal female
 A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 45 
years in the absence of other biological or physiological causes. In addition, females under 
the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 
mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 5 months after the end of study 
treatment. 
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
 Combined (estrogen- and progestogen-containing) hormonal contraception associated with 








 Progestogen-only hormonal contraception associated with inhibition of ovulationb 
 oral 
 injectable 
Highly Effective Methods That Are User Independent
 Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation b
 Hormonal methods of contraception including oral contraceptive pills containing a 
combination of estrogen and progesterone, vaginal ring, injectables, implants and 
intrauterine hormone-releasing system (IUS)c
 Intrauterine device (IUD)c
 Bilateral tubal occlusion
 Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
 Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
 It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
 WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
 Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abstinence 
NOTES: 
a
Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study medications will not alter hormonal exposures such that contraception would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods 
of contraception should be utilized. 
c Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Unacceptable Methods of Contraception






 Diaphragm with spermicide
 Cervical cap with spermicide
 Vaginal Sponge with spermicide
 Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
 Periodic abstinence (calendar, symptothermal, post-ovulation methods)
 Withdrawal (coitus interruptus).
 Spermicide only
 Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
 Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.
 Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study treatment.
 Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 7 months after the end of 
treatment in the male participant.
 Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 7 months after the end of study treatment.
 Refrain from donating sperm for the duration of the study treatment and until 7 months after 
the end of study treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 






































APPENDIX 6 INTERNATIONAL METASTATIC RCC DATABASE 




Time from initial diagnosis (including original localized disease if applicable) to treatment < 1 year
Laboratory 
Hemoglobin < LLN
Corrected calcium > 10 mg/dL
Absolute neutrophil count > ULN
Platelet count > ULN
Note: The corrected calcium criterion was adapted from to Heng et al, 2009 to account for local laboratories that may 
not provide an ULN for corrected calcium.
Abbreviations: KPS= Karnofsky Performance Status; LLN = Lower limit of normal; ULN = Upper limit of normal
Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 - serum albumin [g/dL]), where 
4.0 represents the average albumin level in g/dL.
Corrected calcium (mmol/L) = measured total Ca (mmol/L) + 0.02 (40 - serum albumin [g/L]), 
where 40 represents the average albumin level in g/L
Risk Group Based on Number of Adverse Prognostic Factors




Reference: Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal 
cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. 





APPENDIX 7 PERFORMANCE STATUS SCORES
STATUS SCALES STATUS
KARNOFSKY ZUBROD-ECOG-WHO
Normal, no complaints 100 0 Normal activity
Able to carry on normal 
activities Minor signs or 
symptoms of disease
90 0 Symptoms, but fully 
ambulatory
Normal activity with effort 80 1
Cares for self. Unable to 
carry on normal activity or 
to do active work
70 1 Symptomatic, but in bed 
< 50% of the day.
Requires occasional 
assistance, but able to care 
for most of his needs
60 2
Requires considerable 
assistance and frequent 
medical care
50 2 Needs to be in bed 
> 50% of the day, but 
not bedridden





though death non imminent
30 3 Unable to get out of bed











APPENDIX 8 RADIOLOGIC EVALUATION CRITERIA IN SOLID TUMOURS 
VERSION 1.1 (RECIST CRITERIA 1.1)
1 ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE 
DISEASE
Subjects must have measureable disease to be eligible for this study.
To assess objective response or future progression, it is necessary to estimate the overall tumor
burden at baseline and use this as a comparator for subsequent measurements. Measurable disease 
is defined by the presence of at least 1 measurable tumor lesion. When computed tomography (CT)
scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness.
At baseline, tumor lesions/lymph nodes will be categorized measurable or nonmeasurable, which 
are discussed below.
1.1 Measurable Lesions
Measurable lesions must be accurately measured in at least 1 dimension (longest diameter in the 
plane of the measurement to be recorded) with a minimum size of:
 10 mm by CT/magnetic resonance imaging (MRI) scan - (CT/MRI scan slice thickness no 
greater than 5 mm)
 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured 
with calipers should be recorded as nonmeasurable)
 20 mm by chest x-ray
 Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be  15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis 
will be measured and followed.
1.2 Non-measurable Lesions
 All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph 
nodes with  10 to < 15 mm short axis), as well as truly non-measurable lesions
 Lesions considered truly nonmeasurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
and abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques.
1.3 Special Considerations Regarding Lesion Measurability
1.3.1 Bone Lesions
 Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques to measure bone lesions. However, these techniques can be used 
to confirm the presence or disappearance of bone lesions. 
 Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components that 





measurable lesions if the soft tissue component meets the definition of measurability described 
above.
 Blastic bone lesions are nonmeasurable.
1.3.2 Cystic Lesions
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor nonmeasurable) since they are, by 
definition, simple cysts. 
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions 
if they meet the definition of measurability described above. However, if non-cystic lesions 
are present in the same subject, these are preferred for selection as target lesions.
1.3.3 Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable, unless there has been demonstrated progression in 
the lesion. Measurable lesions may be in an irradiated field as long as there is documented 
progression, and the lesion(s) can be reproducibly measured.
1.4 Specifications by Methods of Measurements
1.4.1 Measurement of Lesions
All measurements should be recorded in metric notation (mm). All baseline evaluations should be 
performed as close as possible to the treatment start and never more than 30 days before the 
beginning of the treatment.
1.4.2 Method of Assessment
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation should 
always be done rather than clinical examination, unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.
1.4.2.1 CT/MRI Scan
CT/MRI is the best currently available and reproducible method to measure lesions selected for 
response assessment. Measurability of lesions on CT/MRI scan is based on the assumption that 
CT/MRI slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, 
the minimum size for a measurable lesion should be twice the slice thickness.
1.4.2.2 Chest X-ray
Chest CT is preferred over chest X-ray, particularly when progression is an important endpoint,
since CT is more sensitive than X-ray in identifying new lesions. However, lesions on chest X-ray 
may be considered measurable if they are clearly defined and surrounded by aerated lung.
1.4.2.3 Clinical Lesions 
Clinical lesions will only be considered measurable when they are superficial and  10 mm 





photography including a ruler to estimate the size of the lesion is suggested. As previously noted, 
when lesions can be evaluated by both clinical examination and imaging, imaging evaluation 
should be undertaken since it is more objective and may also be reviewed at the end of the study.
1.4.2.4 Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement. If new lesions are identified by ultrasound in the course of the study, confirmation 
by CT or MRI is advised. 
1.4.2.5 Endoscopy, Laparoscopy
The utilization of these techniques for objective tumor evaluation is not advised.
1.4.2.6 Tumor Markers 
Tumor markers alone cannot be used to assess objective tumor response.
2 BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’
LESIONS
2.1 Target Lesions
When more than 1 measurable lesion is present at baseline, all lesions up to a maximum of 
5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline.
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, and should lend themselves to reproducible repeated
measurements.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted below, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.
2.1.1 Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes, which are defined as 
measurable and may be identified as target lesions, must meet the criterion of a short axis of 
 15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. Nodes 
that have a short axis < 10 mm are considered nonpathological and should not be recorded or 
followed.
2.2 Non-target Lesions
All other lesions (or sites of disease), including pathological lymph nodes, should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required, and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases, ‘unequivocal





organ as a single item on the case record form (e.g., ‘multiple enlarged pelvic lymph nodes’ or 
‘multiple liver metastases’).
3 TUMOR RESPONSE EVALUATION 
3.1 Evaluation of Target Lesions
 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to < 10 mm.
 Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions,
taking as reference the baseline sum diameters.
 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also 
considered progression).
 Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum on study.
3.1.1 Special Notes on the Assessment of Target Lesions
3.1.1.1 Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes, which are defined as 
measurable and may be identified as target lesions, must meet the criterion of a short axis of  15 
mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. Nodes 
that have a short axis <10 mm are considered nonpathological and should not be recorded or 
followed.
3.1.1.2 Target Lesions That Become ‘Too Small to Measure’
All lesions (nodal and nonnodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm). If the radiologist is 
able to provide an actual measurement, that should be recorded even if it is below 5 mm.
However, when such a lesion becomes difficult to assign an exact measure to then:
 If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement 
should be recorded as 0 mm.
 If the lesion is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned (Note: In case of a lymph node believed to be present and 
faintly seen but too small to measure, a default value of 5 mm should be assigned in this 
circumstance as well). This default value is derived from the 5 mm CT slice thickness (but 
should not be changed with varying CT slice thickness).
3.1.1.3 Target Lesions that Split or Coalesce on Treatment
 When non-nodal lesions fragment, the longest diameters of the fragmented portions should be 





 As lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this instance should 
be the maximal longest diameter for the ‘coalesced lesion’
3.2 Evaluation of Non-target Lesions
While some non-target lesions may actually be measurable, they need not be measured and instead 
should be assessed only qualitatively at the time points specified in the protocol. 
 CR: Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size 
(< 10 mm short axis).
 PD: Unequivocal progression of existing non-target lesions. (Note: The appearance of 1 or 
more new lesions is also considered progression).
 NonCR/NonPD: Persistence of 1 or more non-target lesion(s).
3.2.1 Special Notes on Assessment of Non-target Lesions
The concept of progression of non-target disease requires additional explanation as discussed 
below.
3.2.1.1 When the Subject Also has Measurable Disease
 To achieve unequivocal progression on the basis of the non-target disease, there must be an 
overall level of substantial worsening in non-target disease, such that even in presence of SD 
or PR in target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy.
 A modest ‘increase’ in the size of 1 or more non-target lesions is usually not sufficient to 
quality for unequivocal progression status.
3.2.1.2 When the Subject has Only Non-measurable Disease
 To achieve unequivocal progression on the basis of the non-target disease, there must be an 
overall level of substantial worsening, such that the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.
 A modest increase in the size of 1 or more non-target lesions is usually not sufficient to qualify 
for unequivocal progression status.
 Because worsening in non-target disease cannot be easily quantified (by definition, if all 
lesions are nonmeasurable), a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease, ie, an increase in tumor burden representing an 
additional 73% increase in volume (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as ‘sufficient to require a change in therapy’.







Tumor markers will not be used to assess objective tumor responses.
3.3 New Lesions
The appearance of new malignant lesions denotes disease progression. The finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, change in 
imaging modality, or findings thought to represent something other than tumor (for example, some 
new bone lesions may be simply healing or flare of preexisting lesions). This is particularly 
important when the subject’s baseline lesions show PR or CR. For example, necrosis of a liver 
lesion may be reported on a CT scan report as a new cystic lesion, which it is not.
A lesion identified on a follow-up study in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate disease progression. An example of this is the subject
who has visceral disease at baseline and while on study, has a CT or MRI brain scan ordered that
reveals metastases. The subject’s brain metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely 
a new lesion, then progression should be declared using the date of the initial scan.
4 RESPONSE CRITERIA
4.1 Time Point Response
A response assessment should occur at each time point specified in the protocol.
For subjects who have measurable disease at baseline, Table 1 provides a summary of the overall 
response status calculation at each time point.
Table 1: Subjects with Target (+/– Non-target) Disease
Target Lesions Non-target Lesions New Lesions Overall Response
CR CR No CR
CR NonCR/nonPD No PR
CR Not evaluated No PR
PR




NonPD or not all 
evaluated
No SD
Not all evaluated NonPD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 





4.1.1 Missing Assessments and Not Evaluable Designation
When no imaging/measurement is done at a particular time point, the subject is not evaluable 
(NE) at that time point. If only a subset of lesion measurements are made at an assessment, the 
case is also considered NE at that time point, unless a convincing argument can be made that the 
contribution of the individual missing lesion(s) would not have changed the assigned time point 
response.
4.2 Best Overall Response: All Time Points
The best overall response is determined once all the data for the subject is known. It is the best 
response recorded from the start of the study treatment to the date of radiographic progression per 
RECIST 1.1 or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy 
and tumor-directed surgery), whichever occurs first, taking into account any requirement for 
confirmation. The subject’s best overall response assignment will depend on the findings of both 
target and non-target disease and will also take into consideration the appearance of new lesions.
Complete or partial responses may be claimed only if the criteria for each are met at a subsequent 
time point of ≥ 4 weeks later. In this circumstance, the best overall response can be interpreted as 
specified in Table 2. 
When SD is believed to be best response, it must meet the protocol specified minimum time from 
baseline. In this protocol, measurements must have met the SD criteria at least once after study 
entry at a minimum interval of 6 weeks from randomization in order for SD to be the best response.
Table 2: Best Overall Response When Confirmation of CR and PR is 
Required
Overall Response Overall Response Best Overall Response
First Time Point Subsequent Time Point
CR CR CR
CR PR SD, PD, or PRa
CR SD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR PD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR NE
SD provided minimum criteria for 





SD provided minimum criteria for 
SD duration met, otherwise, PD
PR NE
SD provided minimum criteria for 





Table 2: Best Overall Response When Confirmation of CR and PR is 
Required
Overall Response Overall Response Best Overall Response
NE NE NE
a Abbreviations: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 
NE = not evaluable.
If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the subject had PR, not CR at the 
first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
4.2.1 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tumor measurements 
must be confirmed by consecutive repeat assessments that should be performed no less than 28 
days after the criteria for response are first met. For this study, the next scheduled tumor assessment 
can meet this requirement.
4.3 Duration of Response
4.3.1 Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that progressive disease is objectively 
documented (taking as reference for PD the smallest measurements recorded on study), subsequent 
anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery) is 
initiated, or the participant dies, whichever occurs first.
The duration of overall complete response is measured from the time measurement criteria are first 
met for CR until the first date that progressive disease is objectively documented, subsequent anti-
cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery) is initiated, or 
the participant dies, whichever occurs first.
4.3.2 Duration of Stable Disease  
If SD is the best overall response, the duration of SD is measured from the date of randomization
until the criteria for progression are met, taking as reference the smallest sum on study (if the 
baseline sum is the smallest, this is the reference for calculation of PD), subsequent anti-cancer 
therapy (including tumor-directed radiotherapy and tumor-directed surgery) is initiated, or the 
participant dies, whichever occurs first..
Reference: Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised 





APPENDIX 9 INDUCERS AND INHIBITORS OF CYP3A4






















Notes: The above list is not exhaustive. Please refer to the drug interaction tables at the link below for lists of 
substrates, inducers, and inhibitors of selected CYP450 isozyme pathways. 
(Http://medicine.iupui.edu/clinpharm/ddis/table.aspx).
Grapefruit, grapefruit juice and other foods that are known to inhibit CYP3A4 activity should be avoided during 
treatment.  






APPENDIX 10 SUPPORTIVE CARE GUIDELINES FOR THE MANAGEMENT OF 
HAND FOOT SYNDROME (HFS)
Supportive Care Guidelines for the Management of Hand Foot Syndrome (HFS)
Management of HFS can begin before any symptoms occur. Several prophylactic measures may 
be taken to prevent or reduce the severity of HFS. Before therapy with begins, a full-body skin 
exam should be performed, with a special emphasis on hyperkeratotic areas on palms and soles 
and any deformities. Patients can receive a pedicure, using properly sterilized utensils, to remove 
any preexisting hyperkeratotic areas or calluses that may predispose them to developing HFSR. 
Patients should be advised to reduce the exposure of their hands and feet to hot water, either 
through dishwashing or hot baths and showers, because this is believed to exacerbate symptoms, 
and patients frequently report symptomatic relief with cold water.
Before initiating treatment:
 Check condition of hands and feet
 Suggest a manicure/pedicure, when indicated
 Recommend pumice stone use for callus or ‘rough spot’ removal
During treatment:
 Avoid pressure points
 Avoid items that rub, pinch, or create friction
 Apply non-urea based skin-hydrating creams liberally
 Keratolytic creams: Use sparingly and only to affected (hyperkeratotic) areas.
Urea-based creams:
 Salicylic acid 6%
 Alpha hydroxy acid (AHA) based creams
 Concentrations of approximately 5-8% provide gentle chemical exfoliation
 Apply liberally two times each day
Topical analgesics like lidocaine 2% should be considered for pain control
Topical corticosteroids like clobetasol 0.05% should be considered for patients with grade 2 or 3 
hand-foot skin reaction. Avoid systemic steroids.
Cushions:
 Protect tender areas
 Use socks/gloves to cover moisturizing creams
 Wear well-padded footwear
 Use insole cushions or inserts (e.g., silicon, gel)





APPENDIX 11 SUPPORTIVE CARE GUIDELINES FOR THE MANAGEMENT OF 
DIARRHEA FOR CABOZANTINIB
Participants should be instructed to notify their physician immediately at the first signs of poorly 
formed or loose stool or an increased frequency of bowel movements. Guidelines for the 
evaluation and management of diarrhea are shown in Table 1. 
Administration of antidiarrheal/antimotility agents is recommended at the first sign of diarrhea as 
initial management. Some participants may require concomitant treatment with more than 1 
antidiarrheal agent. When therapy with antidiarrheal agent does not control diarrhea to tolerable 
levels, cabozantinib should be temporarily interrupted or dose reduced. When the diarrhea is 
controlled, retreatment with cabozantinib may be acceptable per investigator decision. 
In addition, general supportive measures should be implemented such as continuous oral isotonic 
hydration, correction of fluid and electrolyte abnormalities, small frequent meals, and stopping 
lactose-containing products, high-fat meals, and alcohol.
Recurrent or prolonged diarrhea can be associated with anal or perianal skin erosions which 
increase the risk for anal abscesses, fistulas, or proctitis. Good hygiene should be emphasized. 
Regular examinations of the perianal region should be performed wherever diarrhea has occurred 






Table 1: Guidelines for Management of Treatment-Emergent Diarrhea for 
Cabozantinib
Status Management
Tolerable Grade 1-2 
(duration < 48 h)
 Continue with study treatment and consider dose reduction
 Initiate treatment with an antidiarrheal agent (e.g., loperamide 4 mg followed by 2 mg 
after each episode of diarrhea [maximum: 16 mg loperamide daily])
 Dietary modifications (e.g., small lactose-free meals, bananas and rice)
 Intake of isotonic fluids 1-1.5 L/day)
 Re-assess after 24 hours:
- Diarrhea resolving to baseline bowel habits: gradually add solid foods and 
discontinue or decrease antidiarrheal treatment after 12 h diarrhea-free interval
- Diarrhea not resolving: Continue/resume antidiarrheal treatment
Intolerable Grade 2, 
Grade 2 > 48h, or ≥ 
Grade 3
 Interrupt study treatment
 Ask participant to attend clinic
 Rule out infection (e.g., stool sample for culture)
- Administer antibiotics as needed, (e.g., if fever or Grade 3-4 neutropenia persists > 
24 h)
 Administer fluids 1-1.5L/day orally or IV, as appropriate for hydration or to correct 
electrolyte abnormalities
 For Grade 3-4 or complicated lower grade diarrhea consider hospitalization and IV 
hydration
 Re-assess after 24 hour
 Diarrhea resolving to baseline bowel habits or Grade ≤ 1: 
- Consider restarting study treatment at reduced dose
 Diarrhea not resolving:
- Start and or continue antidiarrheal treatment (e.g., loperamide 4 mg followed by 2 
mg after each episode of diarrhea [maximum 16 mg loperamide per day





APPENDIX 12 COUNTRY SPECIFIC REQUIREMENTS
1 COUNTRY SPECIFIC REQUIREMENTS
1.1 Germany
Original language Country-specific language
Section 2 Schedule of Activities, Table 2-1, 
Screening Procedural Outline,  Laboratory Tests
Add “HIV” to the list of laboratory tests
Section 6.2 Exclusion
Criteria, Exclusion criterion 1 g)
“Known history of testing positive for human
immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS)”to be
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this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, e.g., a Contract Research 
Organization (CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a copy 
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DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised Protocol 02 03-May-2019 Major Changes:
 Revised protocol 02 adjusts the timing of the PFS and 
OS interim analyses with modified hypothesized OS 
hazard ratio (HR). The number of randomized 
participants is increased. 
 The interim analysis for ORR is removed, resulting in 
revised overall alpha for PFS and OS endpoints.
 No change in eligibility or study procedure. 
 Clinical data for nivolumuab + ipilimumab in renal cell 
carcinoma (RCC) has been updated. 
Other changes include more detail on PRO measures and 
updates to align with BMS standards for the nivolumab 
program.
Administrative Letter 02 08-Feb-2018 Clarification to the sites on the implementation of 
CA2099ER Global Revised Protocol 01 which stopped
further randomization into Arm B, and the timing of  IRB 
approval and impact on randomization. Protocol text was 
not changed.
Revised Protocol 01 18-Dec-2017 Primary revisions: (i) To stop enrollment into Arm B 
(nivolumab, ipilimumab and cabozantinib triplet) and (ii) to 
include favorable risk participants (capped at 25%) in the 
primary data analysis.  
Secondary items include: (i) to add a Data Monitoring 
Committee review after 30 participants are treated for 6 
weeks, (ii) to adjust, clarify and add exclusion criteria, (iii) 
to add treatment restrictions, (iv) to clarify criteria 
associated with hemorrhage with regard to resuming 
treatment, (v) to specify an additional precaution when 
sunitinib dosing is resumed, and (vi) to apply newly 
updated Sponsor standards for nivolumab clinical protocols.
Tertiary items include (i) incorporation of Administrative 
Letter 01 and (ii) correction of typographical and 
grammatical errors.
Administrative Letter 01 20-Jul-2017 To notify of a change of Medical Monitor and Study 
Director. To correct typographical errors and resolve 
inconsistencies found in the original protocol.




OVERALL RATIONALE FOR REVISED PROTOCOL 02:
Given that both the CheckMate-2141 and KeyNote-4262 studies have shown clinically and 
statistically significant improvements in overall survival (OS) of immunotherapy-containing 
combinations compared with single agent sunitinib in first-line clear cell metastatic RCC with OS 
hazard ratio (HR)=0.63 and 0.53, respectively, the CA209-9ER statistical analysis plan is being 
updated to improve OS assessment. To be more consistent with emerging data, the hypothesized 
OS HR is being updated to a more clinically meaningful 0.70 and the power to detect a difference 
in OS is being increased, with less required overall clinical follow-up time. The statistical plan is 
updated to reflect increased overall enrollment and accrual period. There has been no change to 
the study endpoints although the interim analysis for ORR is being removed with the 
corresponding 0.001 alpha reallocated to the primary PFS analysis. Patient-reported outcome 
measures and analyses are updated for clarity. Additional changes reflect alignment of the protocol 
with BMS standards for the nivolumab program.
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 02
Section Number & 
Title
Description of Change Brief Rationale
Synopsis, Exclusion 
Criteria
6.2 Exclusion Criteria (2h)
Added exclusion for live/attenuated vaccine Reflects the new required 
standard language for BMS 
nivolumab studies
Synopsis, Objectives and 
Endpoints
Table 4.1 Objectives and 
Endpoints
Table 10.3.1-1 Efficacy 
Analyses
Added text to statistical analysis description of 
PFS
Clarified that those participants 
who had subsequent therapy 
before death will be censored
Synopsis, Overall Design
5.1 Overall Design
The total number of randomized participants is 
changed from approximately 580 to 638 
participants (from 290 to 319 per arm for Arm 
A and C) and from 434 to 478 for 
intermediate/poor risk participants
The enrollment target is updated 
for further improvement of OS 
power
Synopsis, Number of 
Participants
5.2 Number of Participants
The total number of participants enrolled is 
changed from 774 to 850 as well as the number 
of randomized participants per arm A and C
See Overall Rationale above
Table 4-1 Objectives and 
Endpoints
Added row in exploratory analyses for 
assessment of PFS-2 
To assess the effect of the study 
treatment beyond first 
progression
5.1.1 Data Monitoring 
Committee and Other 
External Committees




Deleted text and table on ORR endpoint
Deleted first paragraph in 10.3.4
The interim analysis for ORR is 
being removed





SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 02
Section Number & 
Title
Description of Change Brief Rationale
6.2 Exclusion Criteria (5a)
8.1 Discontinuation from 
Study Treatment
Added “only in countries where local 
regulations permit”
Provides clarification
7.7.1 Prohibited and/or 
Restricted Treatments




Created new subsections and revised and added
text for FKSI-19 and EQ-5D-3L
To provide more detail on the 
properties of the PRO measures
10.1 Sample Size 
Determination
Table 10.1-1 Summary of 
Sample Size Parameters 
and Schedule of Analyses
Table 10.3.1-1 Efficacy 
Analyses
10.3.4. Interim Analyses
Removed early assessment of ORR, so overall 
alpha for PFS and OS endpoints is revised from 
0.049 to 0.05
Accrual duration (and accruals per months) are
updated from 15 months to 19 months 
Added requirements for minimal follow-up 
time of all randomized participant and minimal 
numbers of events required for final PFS and 
the 2 interim OS analyses
Revised OS hypothesized HR assumption from 
0.76 to 0.70. The overall power for OS is 
therefore increased to 80%
Accordingly, the accruals, the number of 
events, HRs, the timing of analyses, the power 
for PFS and OS are updated in the 
correspondent sections and table 10.3.1-1
Deleted first paragraph of 10.3.4
The hypothesized HR for OS is 
updated based on emerging 
evidence of OS benefits 
observed in immunotherapy 
containing combinations. The 
power for OS as the key 
secondary endpoint is increased




Thresholds Values for 
Change Scores Judged to 
be Important to Patients
Added new subsection and table To provide more detail on 
analyses to be performed and the 
clinically meaningful scores to 
be used
Appendix 2 Study 
Governance Consideration
Slightly modified definition of “serious 
breach”; provided additional criteria for the 
CSR Signatory Investigator; added publication 
policy
Reflects the new required 
standard language for BMS 
nivolumab studies
Appendix 4 Women of 
Childbearing Potential 
Definitions and Methods of 
Contraception
Revised section on Highly Effective Methods 
That Are User Independent
Reflects the new required 
standard language for BMS 
nivolumab studies
1Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-
Cell Carcinoma. N Engl J Med 2018;378(14):1277-1290.
2
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell
Carcinoma. N Engl J Med 2019;380:1116-1127.
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Protocol Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with 
Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic 
Renal Cell Carcinoma
Study phase: 3
Rationale: Although multiple agents are approved as monotherapies for the treatment of patients
with metastatic renal cell carcinoma (mRCC), the testing of combination therapies, in particular, 
treatment with immune-checkpoint inhibitors in combination with tyrosine kinase inhibitors 
(TKIs) has not been fully explored. While single agent therapies have improved outcomes, ongoing 
drug resistance and disease progression demonstrate an urgent need to find more effective 
therapies for mRCC patients. The top priorities in treating RCC continue to be improving
progression free survival (PFS) and overall survival (OS), management of toxicities, and a better 
understanding of biomarkers. The CA2099ER trial will include previously untreated participants 
with mRCC and uses the well-characterized immune checkpoint inhibitor nivolumab in 
combination with cabozantinib, a known standard-of-care in previously treated mRCC 
participants. Nivolumab combined with cabozantinib may be an important step forward in 
evaluating combination regimens which could potentially optimize the management of previously 
untreated participants with mRCC. 
Study Population: Male and female participants ≥ 18 years or the age of majority with previously 
untreated, advanced or metastatic renal cell carcinoma (RCC).
The following list contains key eligibility criteria only. For full list of eligibility criteria please see 
Section 6.
Key Inclusion Criteria
 Histological confirmation of RCC with a clear-cell component, including participants who may 
also have sarcomatoid features
 Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American 
Joint Committee on Cancer [AJCC] Stage IV) RCC
 No prior systemic therapy for RCC with the following exception:
o One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such 
therapy did not include an agent that targets vascular endothelial growth factor (VEGF)
or VEGF receptors and if recurrence occurred at least 6 months after the last dose of 
adjuvant or neoadjuvant therapy
 Karnofsky Performance Status (KPS) grade  70%
 Measurable disease as per RECIST v1.1 per investigator
 Tumor tissue, preferably obtained within 3 months but no more than 12 months prior to 
enrollment, with an associated pathology report, must be received by the central laboratory 
during screening for determination of PD-L1 expression. In order to be randomized, a 
participant must be classified as PD-L1 expression ≥ 1%, PD-L1 expression < 1%, or PD-L1 
expression indeterminate. 





 Participants with favorable, intermediate, and poor risk categories will be eligible for the study. 
Participants must be categorized according to favorable versus intermediate versus poor risk 
status at registration as per International Metastatic RCC Database Consortium (IMDC) 
criteria.
 Negative pregnancy test and able to meet protocol-specified reproductive requirements
Key Exclusion Criteria
 Any active central nervous system (CNS) metastases. Participants with treated, stable CNS 
metastases for at least 1 month are eligible
 Any tumor invading the superior vena cava (SVC), other major blood vessels, or GI tract; any 
evidence of endotracheal or endobronchial tumor
 Prior systemic treatment with VEGF, MET, AXL, KIT or RET targeted therapy (including, 
but not limited to, sunitinib, pazopanib, axitinib, tivozanib, sorafenib, lenvatinib, bevacizumab,
and cabozantinib)
 Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or 
checkpoint pathways
 Any active, known or suspected autoimmune disease or any condition requiring systemic 
treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other 
immunosuppressive medications within 14 days of randomization
 Uncontrolled adrenal insufficiency
 Poorly controlled hypertension despite antihypertensive therapy
 History of unstable angina, myocardial infarction, symptomatic peripheral vascular disease, 
congestive heart failure (CHF, Class III or IV as defined by the New York Heart Association
[NYHA]), or cerebrovascular accident (CVA)
 Deep vein thrombosis (DVT) or pulmonary embolism (PE) unless adequately treated with low 
molecular weight heparin (LMWH)
 Any unstable cardiac arrhythmia; prolonged QTcF > 450 msec for males and > 470 msec for 
females
 Serious, non-healing wound or ulcer; evidence of active bleeding or bleeding susceptibility; 
history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel or 
gastric outlet obstruction 
 Concomitant strong CYP3A4 inducers or inhibitors within 14 days prior to randomization
 Ejection fraction ≤ 50% on screening echocardiogram or multigated acquisition scan (MUGA)
 Major surgery less than 6 weeks, nephrectomy less than 4 weeks, prior to randomization,  with 
complete wound healing and no ongoing post-operative complications.
 Participants who have received a live/attenuated vaccine within 30 days of first treatment.








To compare progression-free survival (PFS) 
per blinded independent central review 
(BICR) of nivolumab plus cabozantinib 
(Arm A, doublet) with sunitinib (Arm C) in 
all randomized participants. 
The primary endpoint of this study is to compare the PFS per BICR 
of Arm A versus Arm C in all randomized participants. PFS is 
defined as the time between the date of randomization and the first 
date of the documented progression, or death due to any cause, 
whichever occurs first. Participants who die without a reported 
progression (and die without start of subsequent anti-cancer 
therapy) will be considered to have progressed on the date of their 
death. Participants who did not progress or die will be censored on 
the date of their last evaluable tumor assessment on or prior to 
initiation of subsequent anti-cancer therapy. Participants who did 
not have any on study tumor assessments and did not die will be 
censored on their date of randomization. Participants who started 
anti-cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment on or
prior to the initiation of first subsequent anti-cancer therapy.
Secondary
To compare overall survival (OS) of Arm A 
with Arm C in all randomized participants.
The first secondary endpoint is to compare the OS of Arm A versus 
Arm C in all randomized participants. OS is defined as the time 
between the date of randomization and the date of death due to any 
cause. A participant who has not died will be censored at the last 
known alive date.
To evaluate the objective response rate 
(ORR) per BICR in all randomized 
participants.
The second secondary endpoint is to describe ORR per BICR in all 
randomized participants. ORR is defined as the proportion of 
randomized participants who achieve a best response of complete 
response (CR) or partial response (PR) using the RECIST 1.1 
criteria. Best overall response (BOR) is defined as the best response 
designation recorded between the date of randomization and the 
date of objectively documented progression per RECIST 1.1 or the 
date of subsequent therapy (including tumor-directed radiotherapy 
and tumor-directed surgery), whichever occurs first. For 
participants without documented progression or subsequent 
therapy, all available response designations will contribute to the 
BOR assessment. Duration of response (DOR) is defined as the time 
between the date of first confirmed documented response (CR or 
PR) to the date of first documented tumor progression (per RECIST 
1.1) or death due to any cause, whichever occurs first. Participants 
who neither progress nor die will be censored on the date of their 
last tumor assessment. Responders who started anti-cancer therapy 
without a prior reported progression will be censored on the date of 
their last evaluable tumor assessment prior to the initiation of first 
subsequent anti-cancer therapy. Time to response (TTR) is defined 
as the time from randomization to the date of the first confirmed 
documented response (CR or PR), as assessed by BICR. DOR and 
TTR will be evaluated for responders (CR or PR) only.
To assess overall safety and tolerability in 
all treated participants.
As measured by the incidence of adverse events (AEs), serious 
adverse events (SAEs), AEs leading to discontinuation, deaths, 
laboratory abnormalities and changes from baseline.






CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
This is an open label, randomized trial of nivolumab combined with cabozantinib (doublet 
regimen) versus sunitinib in participants with previously untreated (first line) advanced or 
metastatic RCC. Participants will be randomized between Arm A and Arm C in a 1:1 ratio with 
approximately 638 participants (319 per Arms A and C, respectively), and capped at 25% 
favorable risk participants. Participants will be stratified for randomization by IMDC prognostic 
score (0 [favorable risk] versus 1-2 [intermediate risk] versus 3-6 [poor risk]), PD-L1 tumor 
expression (≥ 1% versus < 1% or indeterminate), and region (US/Canada/Western
Europe/Northern Europe versus rest of the world [ROW]).
The study design schematic is presented below.
Abbreviations: DMC= data monitoring committee; IMDC= International Metastatic Renal Cell Carcinoma 
Database Consortium; IV=intravenous;; PD-L1= programmed death-ligand 1; PO= orally by mouth; 
Pts=participants; Q2W=every 2 weeks; Q3W=every 3 weeks; QD= once daily; RCC=renal cell carcinoma.
Arm B is shown in the design schematic because after implementation of Revised Protocol 01, there will be patients 
on Arm B treatment from the original protocol version 08 Mar 2017.





Number of Participants: Approximately 850 participants will enroll in order to randomize 
638 participants into Arms A and C (319 per Arm A and per Arm C) capped at 25% favorable risk
participants.
Treatment Arms and Duration:
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
• Arm A (Doublet): Nivolumab 240 mg flat dose intravenously (IV) every 2 weeks (Q2W) + 
Cabozantinib 40 mg orally by mouth (PO) once daily (QD)
o Nivolumab treatment until disease progression or unacceptable toxicity with maximum
treatment of 2 years
o Cabozantinib treatment until disease progression or unacceptable toxicity
• Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off-treatment, per cycle. 
Cycles to be continued until progression or unacceptable toxicity 
Note - Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into 
Arm B. Participants previously randomized to Arm B continue with Arm B treatment and continue 
with Arm B clinical planned events, per protocol.
o Arm B (Triplet): Nivolumab 3mg/kg IV Q3W x 4 doses + Ipilimumab 1 mg/kg IV
Q3W x 4 doses + Cabozantinib 40 mg PO QD 
 Then, Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
 Nivolumab to be continued until disease progression or unacceptable toxicity 
with maximum treatment of 2 years from the start of first dose in Cycle 1
 Cabozantinib until disease progression or unacceptable toxicity
Refer to Section 7.1 Treatments Administered for additional details.











(Nivolumab) Solution for Injection
100 mg (10 mg/mL) IP
Ipilimumab Solution for Injection* 200 mg (5 mg/mL) IP
Cabozantinib Tablet 20 mg IP
Sunitinib Malate Capsule 12.5 mg IP
Abbreviation: IP=investigational product
*Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants 
previously randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, 
per protocol.





2 SCHEDULE OF ACTIVITIES





Register in Interactive Response Technology (IRT) system to obtain participant 
number. The participant should sign the Informed consent prior to any study 
related assessment is performed.
Inclusion/Exclusion Criteria X Must be confirmed prior to randomization.
Medical History X
International Metastatic RCC Database 




(for stratification by PD-L1 tumor expression)
X
Tumor tissue (preferably obtained within 3 months but no more than 12 months 
prior to enrollment, with an associated pathology report) will be collected. 
Formalin-fixed paraffin-embedded (FFPE) block or 20 unstained slides: a 
minimum of 10 slides will be acceptable if tumor tissue is limited. See Section 
9.8.2.
Central lab will determine PD-L1 tumor expression. Participants must have an 
evaluable PD-L1 result from the central lab in order to be randomized.
Safety Assessments
Full Physical Examination, Measurements, Vital 
Signs, and Performance Status
X
Height, weight, Karnofsky Performance Status (KPS) (Appendix 7), BP, HR,
RR, and temperature within 14 days prior to randomization.
Assessment of Signs and Symptoms X Within 14 days prior to randomization.
Review of Concomitant Medications X Within 14 days prior to randomization.
Serious Adverse Events Assessment X Serious Adverse Events from time of consent. See Section 9.2
Electrocardiogram (ECG) X
Within 28 days prior to randomization. Fridericia corrected QT (QTcF) 
required. If any time there is an increase in QTcF interval to an absolute value > 
500 msec, 2 additional ECGs must be performed each with intervals 
approximately 3 minutes apart.





Table 2-1: Screening Procedural Outline (CA2099ER)
Procedure Screening Visit
a Notes
Cardiac Ejection Fraction (via Echocardiogram or 
MUGA)
X Within 28 days prior to randomization.
Laboratory Tests
(includes blood and urine samples)
X
See Section 9.4.1 for additional details on tests required. To be completed 
locally at each site. Must be performed within 14 days prior to randomization.
• CBC w/differential
• PT/INR, PTT
• Chemistry panel (includes AST, ALT, total bilirubin, ALP, LDH, 
creatinine, BUN, glucose, albumin, Na, K, Cl, Ca (also corrected), P, Mg, 
amylase, lipase)
• Thyroid panel (includes TSH with free T3 and free T4)
• Hepatitis B/C (HBVsAg, HCV antibody or HCV RNA)
• HIV if mandated locally (sites in Germany, see Appendix 12)
• Urine protein and urine creatinine (for urine protein/creatinine ratio
[UPCR]). If UPCR ≥ 1.0, obtain 24 hour urine protein.
Pregnancy Test X
WOCBP only. Serum or urine pregnancy test (minimum sensitivity 25 IU/L or 
equivalent units of HCG) to be done at screening visit and within 24 hours of 
first dose of study therapy.
Follicle Stimulating Hormone (FSH) X For women under the age of 55 years to confirm menopause as needed.
Efficacy Assessments
Baseline Tumor Assessments X
CT/MRI of the chest, abdomen, pelvis, brain, and all known sites of disease, 
performed within 28 days prior to randomization. 
All scans need to be submitted for blinded independent central review (BICR). 
See Section 9.1.
Abbreviations: For abbreviations on lab tests refer back to Section 9.4.1.
a Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.





Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet  
(CA2099ER) 
Procedure









Examination, Vital Signs, 
Performance Status
X X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status (KPS) 
(Appendix 7). Performance Status to be performed within 72 hours prior to 
dosing.
Assessment of Signs and 
Symptoms
X X
Adverse Events and Serious 
Adverse Events Assessment
X X
Record at each visit. Participants will be followed for drug-related toxicities until 
these toxicities resolve, return to baseline, or are deemed irreversible. All adverse 





Record at each visit.
Electrocardiogram (ECG) X X (See notes)
Fridericia corrected QT (OTcF) required. Only for Cycles 1, 4, 7, then every 6 
cycles (ie, Cycles 13, 19, 25, etc). If any time there is an increase in QTcF interval 
to an absolute value > 500 msec, 2 additional ECGs must be performed each with 
intervals approximately 3 minutes apart.
Laboratory Tests
(includes blood and urine 
samples)
X X (See notes)
See 9.4.1 for additional details on tests required. Laboratory tests do not need to be
repeated at C1D1 if performed within 14 days prior to first dose. After C1D1, 
within 72 hours prior to dosing:
 CBC w/differential at every cycle
 Chemistry panel at every cycle (includes AST, ALT, total bilirubin, ALP, 
LDH, creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg)
 Amylase and lipase to be done for Cycles, 1, 2, 4, 5, 7, and then every 3 
cycles (ie, Cycles 10, 13, 16, etc) 
 Thyroid panel (includes TSH with reflexive free T3 and free T4) for Cycles 1, 
2, 4, 5, 7, and then every 3 cycles (ie, Cycles 10, 13, 16, etc)
 Urine protein and urine creatinine (for UPCR, preferred) or urine dipstick for 
protein every 3 cycles (ie, Cycles 1, 4, 7, 10, etc). 





Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet  
(CA2099ER) 
Procedure







Pregnancy Test X X
Within 24 hours prior to the initial administration of study drug, then every 4 
weeks 7 days. Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline 
should be performed Week 12 (± 7 days) 
following randomization. Use same 
imaging method as was used at baseline. 
Subsequent tumor assessments should 
occur at every 6 weeks (± 7 days) until 
Week 60, then every 12 weeks (± 14 
days) until radiographic progression, 
assessed by the investigator and 
confirmed by the BICR.
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
Tumor assessments should be performed at the specified time points regardless of 
dosing delays. See Section 9.1 for additional details.
Treatment Beyond Progression
A radiographic assessment/ scan should be performed within 6 weeks of initial 
investigator-assessed progression. Refer to Section 8.1.4 for tumor assessment 




PK blood samples X
X
(See notes)






For details on sampling time points see Table 9.5-1.
Exploratory Biomarker 
Assessments
Whole Blood (DNA) for 
Genotyping




Prior to dosing. At Cycles 1, 2, and 4. See Sections 9.8.1 and 9.8.3.





Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet  
(CA2099ER) 
Procedure




















Prior to dosing: At Cycles 1 and 4. See Sections 9.8.1 and 9.8.5
Tumor Tissue Sample
Every effort should be made to collect 
fresh tumor tissue sample if available 
upon disease progression.
If a biopsy has been performed and tissue is available, participants are requested 
to submit fresh tumor tissue upon disease progression for biomarker research. 
Tissue submission is optional and biopsy is not required by protocol. See 
Section 9.8.2.
Treatment Beyond Progression
A radiographic assessment/ scan should be performed within 6 weeks of initial 
investigator-assessed progression. Refer to Section 8.1.4 for tumor assessment 
associated with Treatment beyond progression.
Participant-Reported 
Outcomes
Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X
Completed on Day 1 of each treatment cycle prior to any study-related 




Completed on Day 1 of each treatment cycle prior to any study-related 
procedures. See Section 9.1.4










Table 2-2: On Treatment Procedural Outline for Arm A Nivolumab Combined with Cabozantinib, Doublet  
(CA2099ER) 
Procedure








Begins with call to Interactive Response Technology (IRT). Participants must 
have an evaluable PD-L1 result from the central lab in order to be randomized.
Administer Nivolumab and 
Cabozantinib
X X
See Section 7. Dispense study treatment as appropriate.
Day 1 Treatment must begin within 3 days (72 hours ) of Randomization)
Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
a If a dose is delayed, the procedures scheduled for that same timepoint should also be delayed to coincide with when that timepoint’s dosing actually occurs.





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously 
randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations

















Targeted Physical Examination, 
Vital Signs, Performance Status
X X X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status 
(KPS) (Appendix 7). Performance Status to be performed within 72 hours 
prior to dosing.
Assessment of Signs and 
Symptoms
X X X
Adverse Events and Serious 
Adverse Events Assessment
X X X
Record at each visit. Participants will be followed for drug-related toxicities 
until these toxicities resolve, return to baseline, or are deemed irreversible. 
All adverse events will be documented for a minimum of 100 days after last 
dose (Appendix 3).






Fridericia corrected QT (QTcF) required. Only Cycles 1, 3, 5, then every 6 
cycles (ie, Cycles 11, 17, 23, etc). If any time there is an increase in QTcF 
interval to an absolute value > 500 msec, 2 additional ECGs must be 
performed each with intervals approximately 3 minutes apart.
Laboratory Tests





See Section 9.4.1 for additional details on tests required. Laboratory tests
do not need to be repeated at C1D1 if performed within 14 days prior to first
dose. After C1D1, within 72 hours prior to dosing.
 CBC w/differential at every cycle





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously 
randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations
















 Chemistry panel at every cycle (includes AST, ALT, total bilirubin, 
ALP, LDH, creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg)
 Amylase and lipase at every cycle until Cycle 5 then every 3 cycles (ie,
Cycles 8, 11, 14, etc)
 Thyroid panel (includes TSH with reflexive free T3 and free T4) at 
every cycle until Cycle 5, then every 3 cycles (ie, Cycles 8, 11, 14, etc)
 Urine protein and urine creatinine (for UPCR, preferred) or urine 
dipstick for protein at Cycles 1, 3, and 5, then every 3 cycles 
(ie, Cycles 8, 11, 14, etc)
Pregnancy Test X X X
Within 24 hours prior to the initial administration of study drug, then every
4 weeks days. Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline should 
be performed Week 12 (± 7 days) following 
randomization. Use same imaging method 
as was used at baseline.
Subsequent tumor assessments should occur 
at every 6 weeks (± 7 days) until Week 60, 
then every 12 weeks (± 14 days) until 
radiographic progression, assessed by the 
investigator and confirmed by the BICR. 
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
Tumor assessments should be performed at the specified time points 
regardless of dosing delays. See Section 9.1 for additional details.
Treatment Beyond Progression
A radiographic assessment/ scan should be performed within 6 weeks of 
initial investigator-assessed progression. Refer to Section 8.1.4 for tumor 
assessment associated with Treatment beyond progression.





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously 
randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations























For details on sampling timepoints see Table 9.5-2.





For details on sampling timepoints see Table 9.5-2.
Exploratory Biomarker 
Assessments
Whole Blood (DNA) for 
Genotyping








Prior to dosing. At Cycles 1, 2, and 3. See Sections 9.8.1 and 9.8.3.
Myeloid Derived Suppressor 
Cells 
X
Prior to dosing. At Cycle 1 only. See Section 9.8.4.





Prior to dosing. At Cycles 1 and 3 only. See Sections 9.8.1 and 9.8.5.





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously 
randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations

















Every effort should be made to collect fresh 
tumor tissue sample if available upon 
disease progression.
If a biopsy has been performed and tissue is available, participants are 
requested to submit fresh tumor tissue upon disease progression for 
biomarker research. See Section 9.8.2.
Tissue submission is optional and biopsy is not required by protocol. 
Treatment Beyond Progression
A radiographic assessment/ scan should be performed within 6 weeks of 
initial investigator-assessed progression. Refer to Section 8.1.4 for tumor 
assessment associated with Treatment beyond progression.
Participant-Reported 
Outcomes
Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any study-related 
procedures. See Section 9.1.4.
EuroQoL group’s EQ-5D-3L 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any study-related 
procedures. See Section 9.1.4.
Health Care Resource Utilization X X X See Section 9.9.
Study Treatment





Table 2-3: On Treatment Procedural Outline for Arm B Nivolumab and Ipilimumab Combined with 
Cabozantinib, Triplet (CA2099ER)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously 
randomized to Arm B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
Procedure
Part 1 Part 2
Notes
(Please note differences in cycle durations

















Begins with call to Interactive Response Technology (IRT). Participants 
must have an evaluable PD-L1 result from the central lab in order to be 
randomized.
Implementation of CA2099ER Global Revised Protocol 01 stops further 
randomization into Arm B. Participants previously randomized to Arm B 
(Triplet) continue with Arm B treatment and continue with Arm B 
clinically planned events, per protocol.
Administer Nivolumab, 
Ipilimumab, and  Cabozantinib
X X
Cycles 1 to 4 are 3 week cycles. See Section 7.
Implementation of CA2099ER Global Revised Protocol 01 stops further 
randomization into Arm B. Participants previously randomized to Arm B 
(Triplet) continue with Arm B treatment and continue with Arm B 
clinically planned events, per protocol.
Administer Nivolumab and  
Cabozantinib
X
Day 1 Treatment must begin within 3 days (72 hours ) of Randomization)
Cycle 5 and subsequent cycles are 2 week cycles. See Section 7.
Dispense Study Treatment X X X See Section 7.
Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
a
If a dose is delayed, the procedures scheduled for that same timepoint should also be delayed to coincide with when that timepoint’s dosing actually occurs.
































Examination, Vital Signs, 
Performance Status
X X X
Weight, BP, HR, RR, temperature, and Karnofsky 
Performance Status (KPS) (Appendix 7). Performance 
Status to be performed within 72 hours prior to dosing.
Assessment of Signs and 
Symptoms
X X X X X X
Adverse Events and Serious 
Adverse Events Assessment
X X X X X X
Record at each visit. Participants will be followed for 
drug-related toxicities until these toxicities resolve, return 
to baseline, or are deemed irreversible. All adverse events 




X X X X X X
Record at each visit




Fridericia corrected QT (QTcF) required. Only Cycles 1, 
2, and 3, then every 2 cycles (ie, Cycles 5, 7, 9, etc). If 
any time there is an increase in QTcF interval to an 
absolute value > 500 msec, 2 additional ECGs must be 
performed each with intervals approximately 3 minutes 
apart.
Laboratory Tests














See Section 9.4.1 for additional details on tests required.  
Laboratory tests do not need to be repeated at C1D1 if
performed within 14 days prior to first dose. After C1D1, 
within 72 hours prior to specified dosing day:
 CBC w/differential on Day 1 and Day 22 (+/- 3 days) 
of each cycle






























 Chemistry panel on Day 1 and Day 22 (+/- 3 days) of 
every cycle (includes AST, ALT, total bilirubin, 
ALP, LDH, creatinine, BUN, glucose, albumin, Na, 
K, Cl, Ca, P, Mg)
 Amylase and lipase on Day 1 and Day 22 (+/- 3 days) 
of Cycle 1 and 2, then on Day 1 of Cycle 3 and all 
subsequent cycles.
 Thyroid panel (includes TSH with reflexive free T3 
and free T4) on Day 1 and Day 22 (+/- 3 days) of 
Cycle 1 and 2, then on Day 1 of Cycle 3 and all 
subsequent cycles.
 Urine protein and urine creatinine (for UPCR, 
preferred) or urine dipstick for protein on Day 1 of 
every cycle
Pregnancy Test X X X X X X
Within 24 hours prior to the initial administration of study




First tumor assessment post-baseline should be performed 
Week 12 (± 7 days) following randomization. Use same 
imaging method as was used at baseline. 
Subsequent tumor assessments should occur at every 6 weeks 
(± 7 days) until Week 60, then every 12 weeks (± 14 days) until 
radiographic progression, assessed by the investigator and 
confirmed by the BICR.
CT/MRI of the chest, abdomen, pelvis, and all known 
sites of disease.
Tumor assessments should be performed at the specified 
time points regardless of dosing delays. See Section 9.1
for additional details.
Treatment Beyond Progression
A radiographic assessment/ scan should be performed 
within 6 weeks of initial investigator-assessed 






























progression. Refer to Section 8.1.4 for tumor assessment
associated with Treatment beyond progression.
Exploratory Biomarker 
Assessments
Whole Blood (DNA) for 
Genotyping
X Only prior to dose at Cycle 1. See Sections 9.8.1 and 9.8.6
Serum Biomarkers X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.3.
Plasma Biomarkers X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.3.
Myeloid Derived Suppressor 
Cells 
X Prior to dosing at Cycle 1 only. See Section 9.8.4.
Peripheral blood mononuclear 
cells (PBMCs)
X X
Prior to dosing. At Cycles 1 and 2. See Sections 9.8.1 and 
9.8.5.
Tumor Tissue Sample
Every effort should be made to collect fresh tumor tissue 
sample if available upon disease progression.
If a biopsy has been performed and tissue is available, 
participants are requested to submit fresh tumor tissue 
upon disease progression for biomarker research. See 
Section 9.8.2.
Tissue submission is optional and biopsy is not required 
by protocol.
Treatment Beyond Progression
A radiographic assessment/ scan should be performed 
within 6 weeks of initial investigator-assessed 
progression. Refer to Section 8.1.4 for tumor assessment 
associated with Treatment beyond progression.
































Functional Assessment of 
Cancer Therapy - Kidney 
Symptom Index (FKSI-19) 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any 
study-related procedures. See Section 9.1.4.
EuroQoL group’s EQ-5D-3L 
Questionnaire
X X X
Completed on Day 1 of each treatment cycle prior to any 
study-related procedures. See Section 9.1.4.
Health Care Resource 
Utilization
X X X See Section 9.9.
Study Treatment
Randomize X
Begins with call to Interactive Response Technology 
(IRT). Participants must have an evaluable PD-L1 result 
from the central lab in order to be randomized.
Administer Sunitinib X X X X X X
Day 1 Treatment must begin within 3 days (72 hours ) of 
Randomization)
Each cycle will be 6 weeks where sunitinib will be 
administered for 4 weeks, then participants will be off 
treatment for 2 weeks. See Section 7.
Dispense Study Treatment X X X See Section 7.
Abbreviations: C=cycle; D=day; wks= weeks. For abbreviations on lab tests refer back to Section 9.4.1.
Notes: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the 
treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
a If a dose is delayed, the procedures scheduled for that same timepoint should also be delayed to coincide with when that timepoint’s dosing actually occurs.


















Targeted Physical Examination, Vital 
Signs, Performance Status
X
Weight, BP, HR, RR, temperature, and Karnofsky Performance Status 
(KPS) (Appendix 7).
Assessment of Signs and Symptoms X
Adverse Events and Serious Adverse 
Events Assessment
X
Record at each visit. Participants will be followed for drug-related 
toxicities until these toxicities resolve, return to baseline, or are deemed 
irreversible. All adverse events will be documented for a minimum of 
100 days after last dose (Appendix 3).
Concomitant Medication Review X Record at each visit
Electrocardiogram (ECG) X
Fridericia corrected QT (QTcF) required. If any time there is an increase 
in QTcF interval to an absolute value > 500 msec, 2 additional ECGs 
must be performed each with intervals approximately 3 minutes apart.
Laboratory Tests
(includes blood and urine samples)
FU1 -yes
FU2 - if toxicities are 
present
See Section 9.4.1 for additional details on tests required.
 CBC w/differential, PT/INR, and PTT
 Chemistry panel (includes AST, ALT, total bilirubin, ALP, LDH, 
creatinine, BUN, glucose, albumin, Na, K, Cl, Ca, P, Mg, amylase, 
lipase)
 Thyroid panel (includes TSH with reflexive free T3 and free T4) 
 Urine protein and urine creatinine (for UPCR, preferred) or urine 
dipstick for protein
Pregnancy Test X Serum or Urine. WOCBP only.
Efficacy Assessments
Tumor Assessments
First tumor assessment post-baseline 
should be performed Week 12 (± 7 days) 
following randomization. Use same 
imaging method as was used at baseline. 
Participants who discontinue study treatment without radiographic 
progression, confirmed by BICR, will continue tumor assessments 
according to the protocol specified schedule, even if new anti-tumor 
therapy has been initiated in the Follow-Up phase, until radiographic

















Subsequent tumor assessments should 
occur at every 6 weeks (± 7 days) until 
Week 60, then every 12 weeks (± 14 
days) until radiographic progression, 
assessed by the investigator and 
confirmed by the BICR.
progression has been assessed by the investigator and confirmed by 
BICR.
CT/MRI of the chest, abdomen, pelvis, and all known sites of disease.
See Section 9.1.2 for additional details.
Survival Status X X
During safety follow up and every 3 months (clinic visit or by 
telephone) during survival phase. Include documentation of subsequent 
chemotherapy. See Section 8.1.5.
Pharmacokinetic (PK)/ 
Immunogenicity Assessments
PK blood samples 
X
(See notes)
Only for participants who were in Arm A (Nivolumab combined with 
cabozantinib, Doublet) or Arm B (Nivolumab and ipilimumab
combined with cabozantinib, Triplet). For details on sampling 




Only for participants who were in Arm A (Nivolumab combined with 
cabozantinib, Doublet) or Arm B (Nivolumab and ipilimumab
combined with cabozantinib, Triplet). For details on sampling 
timepoints see Table 9.5-1
Participant-Reported Outcomes
Functional Assessment of Cancer 








Health Care Resource Utilization X See Section 9.9.
Abbreviations: C=cycle; wks= weeks; FU= follow up. For abbreviations on lab tests, see Section 9.4.1.





a Participants must be followed for at least 100 days after last dose of study treatment. Follow-up visit #1 (FU1) should occur 30 days from the last dose (+/- 7) 
days or can be performed on the date of discontinuation if that date is greater than 42 days from last dose. Follow-up visit #2 (FU2) occurs approximately 100 
days (+/- 7 days) from last dose of study drug. Both Follow Up visits should be conducted in person.
b
Survival Follow-up visits to occur every 3 months from Follow-up Visit #2. Survival visits may be conducted in person or by telephone. BMS may request that 
survival data be collected on all treated participants outside of the 3 month specified window. At the time of this request, each participant will be contacted to 
determine their survival status unless the participant has withdrawn consent for all contact.






Renal cell carcinoma (RCC) is the eighth most common cancer in the world with an increasing 
incidence.1 Globally, RCC occurs in more than 330,000 cases with approximately a third of the 
patients succumbing to their disease. More than 100,000 deaths occur annually, as a result of 
progression of metastatic disease. Despite the earlier detection of smaller kidney tumors, the rate 
of RCC-related mortality has increased suggesting that recurrence and advanced disease are 
responsible for mortality.2,3 With the rise in RCC incidence, as well as mortality and morbidity 
associated with advanced RCC, medical need in this population remains a priority. 
Over the last decade, an increased understanding of the biology of RCC has led to development of 
multiple agents that target specific growth pathways. The vascular endothelial growth factor 
(VEGF) pathway and targeted serine/threonine protein kinase therapies that block the mammalian 
target of rapamycin (mTOR) have been found to be important targets in RCC disease. Global 
health authorities (HAs) have approved multiple drugs targeting these pathways, including anti-
VEGF agents, such as pazopanib, sorafenib, sunitinib, cabozantinib, and bevacizumab, and mTOR 
pathway inhibitors, such as temsirolimus and everolimus.4 Additionally, recent innovation of 
treating cancer with immunotherapies has also expanded treatment options. Nivolumab, an anti-
PD-1 antibody, given as monotherapy or in combination with the anti-CTLA-4 antibody, 
ipilimumab, has demonstrated clinical activity in multiple tumor types, including RCC. 
To better understand treatment and patient outcomes, several academic groups have identified 
variables associated with survival and created prognostic models in mRCC. These risk models are 
commonly used for choosing therapies or selecting patients for treatment in clinical trials. The 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model stratifies 
patients into 3 prognostic groups, based on 6 adverse prognostic factors, into favorable (0 factors), 
intermediate (1-2 factors), and poor risk (3-6 factors) groups.5 The currently available first-line 
agents for mRCC, which target the VEGF pathway, have shown limited efficacy in the 
intermediate and poor risk populations, yielding median overall survival of approximately 2 years
or less. 
Cabozantinib and nivolumab both share category 1 NCCN guideline recommendations 
(ie, uniform consensus that the treatment is appropriate, based on high-level evidence) for the 
treatment of previously treated mRCC patients.6 Therefore, it is an appropriate next step to 
combine these agents and move them to the first-line setting in an attempt to improve clinical 
outcomes in patients with advanced RCC. This protocol CA2099ER will test the clinical activity 
of nivolumab combined with cabozantinib (doublet regimen). Given the different mechanisms of 
action of each of these agents, there is potential for distinct improvement in clinical efficacy.7  
3.1 Study Rationale
Agents that target the VEGF pathway prevent tumor growth by inhibiting angiogenesis. A recent 
clinical biomarker study has shown that anti-VEGF therapy also affects the RCC tumor immune 
microenvironment. In this study, RCC tumor tissue from treatment-naive patients and those who 
had received prior bevacizumab or sunitinib were assessed for tumor immune cell infiltration. 





Samples from patients with prior anti-VEGF therapy demonstrated increased infiltration of 
regulatory T cells (Tregs) and enhanced tumor PD-L1 expression, both of which were negatively 
associated with patient survival.8 These effects suggest that the promotion of an immune 
suppressive tumor microenvironment may contribute to anti-VEGF therapy resistance and point 
to a rational strategy for combining anti-VEGF therapy with immunotherapies that target the PD-
1/PD-L1 pathway. Indeed, the phase 1 study CA209016 demonstrated the synergistic activity of 
such combinations in mRCC. This study included a cohort of 26 participants with mRCC (19 of 
whom were previously untreated) who received sunitinib in combination with nivolumab 5 mg/kg 
Q3W. Using MSKCC risk criteria, 13 participants in this cohort had favorable risk disease, 12 had 
intermediate risk disease, and 1 had poor risk disease. After a minimum follow-up of 22 months, 
the objective response rate (ORR) was 42.3%, median progression-free survival (PFS) was 12.3 
months, and median overall survival (OS) was 36.8 months in this cohort.9 Similar efficacy results 
have been reported in other phase 1 studies which combine anti-VEGF agents with anti-PD-1 
agents.10,11  
As described in Section 3.2, cabozantinib is a novel tyrosine kinase inhibitor that, in addition to 
VEGFR, targets additional tyrosine kinases that are implicated in the biology of mRCC, such as 
c-MET and AXL. In a randomized phase 3 trial in patients with advanced RCC that had progressed 
after anti-VEGFR therapy, cabozantinib was shown to improve PFS and OS compared to 
everolimus, leading to its regulatory approval. Subsequently, a randomized phase 2 trial of 
cabozantinib vs sunitinib has demonstrated an improvement in ORR and PFS in intermediate- and 
poor-risk patients with previously untreated mRCC (see Section 3.2.1.4).
Cabozantinib has also been demonstrated to have effects on immune cells. In a study of 24 subjects 
with advanced urothelial carcinoma, cabozantinib treatment resulted in a decrease in circulating 
Tregs and increased PD-1 expression on Tregs. Low Tregs at baseline were also predictive of 
improved response to cabozantinib and survival.12
Given the promising clinical activity of cabozantinib in previously untreated mRCC and its 
potential immune effects, combining cabozantinib with nivolumab (in a doublet regimen) is a 
rational strategy to optimize first-line therapy in mRCC. An ongoing phase 1 study is evaluating 
both the doublet and triplet (nivolumab plus ipilimumab plus cabozantinib) regimens in patients 
with refractory advanced urothelial cancer or other genitourinary tumors, including mRCC, and 
has defined dosing for both regimens that produces acceptable safety and tolerability (Section 
3.2.1.5). This 2-arm randomized phase 3 trial will determine if the combination doublet regimen
(nivolumab combined with cabozantinib) produces greater clinical benefit than sunitinib, a 
standard of care agent for patients with previously untreated mRCC. In addition, this trial will 
reveal the adverse event profiles, quality of life measures, as well as exploratory biomarkers 
associated with these different first-line treatment regimens.
3.1.1 Research Hypothesis
Treatment with nivolumab combined with cabozantinib (doublet regimen) will demonstrate an 
improvement in PFS per BICR compared to sunitinib monotherapy in participants with previously 
untreated mRCC.






Cancer immunotherapy rests on the premise that tumors can be recognized as foreign rather than 
as self and can be effectively attacked by an activated immune system. An effective immune 
response in this setting is thought to rely on immune surveillance of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune response and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of traits that allow cancer cells to 
evade immunosurveillance and escape effective innate and adaptive immune responses.13,14,15
Current immunotherapy efforts attempt to break the apparent tolerance of the immune system to 
tumor cells and antigens by either introducing cancer antigens by therapeutic vaccination or by 
modulating regulatory checkpoints of the immune system. T-cell stimulation is a complex process 
involving the integration of numerous positive as well as negative co-stimulatory signals in 
addition to antigen recognition by the T-cell receptor (TCR).16 Collectively, these signals govern 
the balance between T-cell activation and tolerance. 
Programed death-1 (PD-1) is a member of the CD28 family of T-cell co-stimulatory receptors that 
also includes CD28, CTLA 4, ICOS, and BTLA.17 PD-1 signaling has been shown to inhibit CD-
28-mediated upregulation of IL-2, IL-10, IL-13, interferon-γ (IFN-γ) and Bcl-xL. PD-1 expression 
also been noted to inhibit T cell activation, and expansion of previously activated cells. Evidence 
for a negative regulatory role of PD-1 comes from studies of PD-1 deficient mice, which develop 
a variety of autoimmune phenotypes.18 These results suggest that PD-1 blockade has the potential 
to activate anti-self T-cell responses, but these responses are variable and dependent upon various 
host genetic factors. Thus, PD-1 deficiency or inhibition is not accompanied by a universal loss of 
tolerance to self-antigens.
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affinity (EC50 0.39-2.62 nM), and 
inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (IC50 ± 1 nM). Nivolumab binds 
specifically to PD-1 and not to related members of the CD28 family such as CD28, ICOS, CTLA-
4 and BTLA. Blockade of the PD-1 pathway by nivolumab results in a reproducible enhancement 
of both proliferation and IFN-γ release in the mixed lymphocyte reaction (MLR). Using a 
cytomegalovirus (CMV) re stimulation assay with human peripheral blood mononuclear cells 
(PBMC), the effect of nivolumab on antigen specific recall response indicates that nivolumab 
augmented IFN-γ secretion from CMV specific memory T cells in a dose-dependent manner versus 
isotype-matched control. In vivo blockade of PD-1 by a murine analog of nivolumab enhances the 
anti-tumor immune response and result in tumor rejection in several immunocompetent mouse 
tumor models (MC38, SA1/N, and PAN02).19
CTLA-4, an activation-induced T-cell surface molecule, is a member of the CD28:B7 
immunoglobulin superfamily that competes with CD28 for B7. CTLA-4 mediated signals are 
inhibitory and turn off T cell-dependent immune responses.20 Ipilimumab is a fully human 
monoclonal IgG1κ that binds to the CTLA-4 antigen expressed on a subset of T cells from human 
and nonhuman primates. The proposed mechanism of action for ipilimumab is interference of the 





interaction of CTLA-4 with B7 molecules on antigen presenting cells, with subsequent blockade 
of the inhibitory modulation of T-cell activation promoted by the CTLA 4/B7 interaction.
Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, 
metastasis, and angiogenesis.21 The primary targets of cabozantinib implicated in mRCC are MET 
(c-MET), AXL and vascular endothelial growth factor receptor 2 (VEGFR2); additional targets 
identified in-vitro include RET, KIT, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. Both 
c-Met, AXL, and VEGFR2 are important mediators of tumor growth and tumor angiogenesis, and 
in vivo pharmacodynamic activity of cabozantinib against c-Met, and VEGFR2 has been 
demonstrated in both preclinical and clinical studies.22,23,24,25
In addition, preclinical and clinical observations have suggested that cabozantinib promotes an 
immunopermissive environment which might present an opportunity for synergistic effects from 
combination treatment with PD-1 checkpoint inhibitors. Specifically, treatment of tumor cells with 
cabozantinib in vitro led to increased tumor-cell expression of major histocompatibility complex 
(MHC) class 1 antigen and greater sensitivity of tumor cells to T-cell-mediated killing.26 In a 
mouse tumor model, cabozantinib treatment led to increased peripheral CD8+ T-cell counts, 
decreased regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and 
decreased Treg suppressor activity. Further, synergistic effects including increased CD8+ T-cell 
infiltration and decreased infiltration by MDSCs and tumor-assisted macrophages (TAMs) were 
observed when a poxviral-based cancer vaccine was administered in addition to cabozantinib in 
the mouse tumor model. Reductions in immunosuppressive Treg lymphocytes following treatment 
with cabozantinib have also been observed in subjects with advanced refractory urothelial 
cancer.12 In a phase 2 study in metastatic triple-negative breast cancer, cabozantinib-treated 
subjects experienced a persistent increase in the fraction of circulating CD3+ T lymphocytes and 
a persistent decrease in the CD14+ monocytes possibly reflecting activation of systemic antitumor 
immunity.27
A detailed description of the chemistry, pharmacology, efficacy, and safety of nivolumab and 
ipilimumab in combination and cabozantinib is provided in the Nivolumab Investigator Brochure
(IB) and Cabozantinib IB, respectively.21,28,29
3.2.1 Indication Background
3.2.1.1 Sunitinib in Renal Cell Carcinoma
Sunitinib is a VEGF receptor TKI that is approved and recommended for the treatment of mRCC 
across prognostic groups.6,30 In a randomized phase 3 trial of sunitinib vs IFNin treatment-naive 
subjects (including 36% with favorable risk, 57% with intermediate risk, and 7% with poor risk 
per MSKCC criteria), PFS (by independent radiology review) was significantly improved in the 
sunitinib group compared to the IFNgroup (median PFS 11 vs 5 months, hazard ratio [HR] = 
0.42; p < 0.001). ORR was also greater in the sunitinib group (31% vs 6%). Median OS was 26.4 
months in the sunitinib group vs 21.8 months in the IFN group (HR = 0.82; p = 0.051).31 More 
recently, sunitinib was compared to pazopanib in treatment-naive subjects (including 27% 
favorable risk, 73% intermediate risk, and no poor risk) in the phase 3 COMPARZ study.32 In this 





non-inferiority study, sunitinib and pazopanib demonstrated similar median PFS (8.4 months for 
pazopanib vs 9.5 months for sunitinib, HR = 1.05) and median OS (28.4 months for pazopanib vs 
29.3 months for sunitinib, HR = 0.91, p = 0.28). The ORR of pazopanib and sunitinib was 31% 
and 24%, respectively. The most common ( 20% frequency) adverse reactions include fatigue, 
asthenia, fever, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspepsia, abdominal pain, 
constipation, hypertension, peripheral edema, rash, hand-foot syndrome, skin discoloration, dry 
skin, hair color changes, altered taste, headache, back pain, arthralgia, extremity pain, cough, 
dyspnea, anorexia, and bleeding.33 Other important adverse reactions include hepatotoxicity, QT 
prolongation (including Torsades de Pointes), osteonecrosis of the jaw, tumor lysis syndrome, and 
thyroid dysfunction
3.2.1.2 Nivolumab Monotherapy in Renal Cell Carcinoma
Harnessing the immune system would be an attractiveopportunity, together witheffortsto find cell
surface markers that can be used to trace and target dormant renal-cell carcinoma cells. Nivolumab 
monotherapy has been studied in participants with advanced RCC in several BMS-sponsored 
studies (phases 1 through 3): MDX1106-03, CA209009, CA209010, and CA209025. MDX1106-
03 was a phase 1 refractory solid tumor trial, which included 34 participants with previously-
treated advanced RCC who received nivolumab at 1 mg/kg (n = 18) or 10 mg/kg (n = 16) given 
every 2 weeks.24,34,35 Median progression-free survival (PFS) was 7.3 months. In both the 1 mg/kg 
and 10 mg/kg cohorts, approximately 30% of participants experienced an objective response with 
median duration of response of 12.9 months. Responses were generally rapid with a median time 
to response of 16 weeks. Notably, responses could occur after treatment cessation and persist off 
treatment. Median overall survival (mOS) was 22.4 months. These results were promising given 
that many of the participants were heavily pre-treated with 71% having had 2 or more lines of 
therapy. Treatment-related adverse events (AEs) of any grade were observed in 85% of RCC 
participants, the most common being fatigue (41%), rash (27%), diarrhea (18%), and pruritus 
(18%). Grade 3-4 treatment-related AEs were observed in 18% of RCC participants. The spectrum, 
frequency, and severity of treatment-related AEs were similar in the RCC population compared to 
the overall study population and were similar across dose levels. 
In order to identify a potential dose-response relationship in RCC, a randomized phase 2 study 
(CA209010) was conducted in 168 participants with advanced RCC previously treated with an 
antiangiogenic therapy who received nivolumab at 0.3 mg (n = 60), 2 mg/kg (n = 24) or 10 mg/kg 
(n=54) given every 3 weeks.36 No dose response relationship was found as measured by PFS, with 
median PFS of 2.7, 4.0, and 4.2 months for the 0.3, 2, and 10 mg/kg groups, respectively (P = 0.9). 
ORR was 20%, 22%, and 20% in the 0.3, 2, and 10 mg/kg groups, respectively. Median time to 
achievement of an objective response was 2.8-3.0 months. The median duration of response was 
22.3 months (4.8, NR) in the 10 mg/kg arm and not yet reached in the 2 lower dose cohorts. Median 
OS was at 18.2 to 25.5 months, with a minimum of follow-up of 24 months. Fatigue was the most 
frequent toxicity (22-35%). No new toxicities were identified with 11% experiencing Grade 3-4 
treatment-related AEs, none of which were due to pneumonitis. Treatment-related AEs led to 
discontinuation of study drug in 7% of participants. 





A parallel biomarker-focused trial, CA209009, using the same 3 nivolumab dose levels (03, 2, and 
10 mg/kg every 3 weeks) was executed to explore predictors of response and identify mechanisms 
of resistance.37 This study included 67 participants with previously-treated, advanced RCC who 
were randomized to one of the 3 nivolumab dose groups and 24 participants with 
previously-untreated RCC who received nivolumab at 10 mg/kg every 3 weeks. The results 
mirrored the efficacy and toxicity profile of CA209010 with an overall ORR of 18% in previously-
treated participants, and 13% in previously untreated participants and disease stabilization in 
another 32% of previously treated and untreated participants. At 24 weeks, 36% of participants 
were free from progression. Of 56 participants with evaluable pretreatment tumor samples, 18 
(32%) had  5% PD-L1 tumor expression. ORR was 22% among those with  5% PD-L1 tumor 
expression versus 8% among those with < 5% PD-L1 tumor expression. 
Based on the clinical activity of nivolumab observed in these phase 1 and 2 studies, a large phase 
3 trial (CA209025) was conducted in 821 participants with advanced RCC previously treated with 
1 or 2 antiangiogenic therapies who were randomized to receive nivolumab 3 mg/kg every 2 weeks 
or everolimus 10 mg daily. A planned interim analysis, after a minimum of follow-up of 
14 months, demonstrated a statistically significant and clinically meaningful improvement in OS 
of nivolumab monotherapy vs everolimus (median OS, 25.0 months vs 19.6 months, respectively; 
HR 0.73 [98.5% CI, 0.57 to 0.93, P = 0.002). ORR was 25% for nivolumab vs 5% for everolimus. 
Additional efficacy results are presented in Table 3.2.1.2-1. Among 756 participants with 
quantifiable PD-L1 tumor expression in pretreatment samples, 24% had 1% PD-L1 expression. 
Among participants with 1% PD-L1 expression, median OS was 21.8 months in the nivolumab 
group and 18.8 months in the everolimus group (HR, 0.79; 95% CI, 0.53 to 1.17). Among 
participants with <1% PD-L1 expression, the median OS was 27.4 months in the nivolumab group 
and 21.2 months in the everolimus group (HR, 0.77; 95% CI 0.60 to 0.97). No new safety concerns 
were identified, and nivolumab monotherapy showed a favorable safety profile as compared to 
everolimus, evidenced by the lower rates of drug-related AEs (all grades, 79% vs 88%; Grade 3-
4, 19%-37%, respectively) and drug-related AEs leading to discontinuation (all grades, 8% vs 
13%, respectively) in the nivolumab group. These results were the basis for regulatory approval of 
nivolumab monotherapy in advanced RCC.
Table 3.2.1.2-1: Summary of Efficacy Results - All Randomized Subjects -
CA209025
Efficacy Parameters Nivolumab (N = 410) Everolimus (N = 411)
Primary Endpoint
Overall Survival
Events , n (%) 183/410 (44.6) 215/411 (52.3)
Stratified log-rank test P valuea,b 0.0018
HR (98.52% CI)
c 0.73 (0.57, 0.93)
Median (95% CI), monthsd 25.00 (21.75, NR) 19.55 (17.64, 23.06)





Table 3.2.1.2-1: Summary of Efficacy Results - All Randomized Subjects -
CA209025
Efficacy Parameters Nivolumab (N = 410) Everolimus (N = 411)
Rate at 6 months (95% CI), %d 89.2 (85.7, 91.8) 81.2 (77.0, 84.7)
Rate at 12 months (95% CI), %d 76.0 (71.5, 79.9) 66.7 (61.8, 71.0)
Secondary Endpoints
Objective Response Rate per 
Investigator (CR + PR)e
N (%) 103 (25.1) 22 (5.4)
95% CIf (21.0, 29.6) (3.4, 8.0)
Odds ratio estimate (95%CI)g,h 5.98 (3.68, 9.72)
P Valuei < 0.0001
Duration of responsee
Ongoing responders, n/N (%) 49/103 (47.6) 10/22 (45.5)
Median (95% CI), monthsd 11.99 (7.85, 23.03) 11.99 (6.44, NR)
Min, Maxj 0.0, 27.6+ 0.0+, 22.2+
Progression-free survival
Events, n (%) 318 (77.6) 322 (78.3)
Stratified log-rank test p valuea 0.1135
HR (95% CI)c 0.88 (0.75, 1.03)
Median 95% CI) 4.60 (3.71, 5.39) 4.44 (3.71, 5.52)
a Log-rank test stratified by the MSKCC risk group (poor vs intermediate vs favorable), the number of prior 
antiangiogenic therapies in the advanced/metastatic setting (1 vs 2), and the region (W. Europe, US/Canada vs Rest 
of the World) as entered into the IVRS.
b Based on the 398 observed deaths and O’Brien-Fleming alpha spending function, the boundary for statistical 
significance requires the P value to be less than 0.0148.
c Stratified Cox proportional hazard model. Hazard ratio is nivolumab over everolimus. 
d Based on Kaplan-Meier Estimates. 
e The confirmed ORR was 88/410 (21.5%) in the nivolumab group and 16/411 (3.9%) in the everolimus group 
(stratified CMH test P value < 0.0001), with a median DOR of 23.03 months in the nivolumab group and 13.73 
months in the everolimus group.
f CR+PR, confidence interval based on the Clopper and Pearson method.
g Cochran-Mantel-Haenzel test stratified by the MSKCC risk group (poor vs intermediate vs favorable), the number 
of prior anti-angiogenic therapies in the advanced/metastatic setting (X vs 2) and the region (Western Europe vs 
US/Canada vs Rest of the World) as entered into the IVRS.
h Ratio of nivolumab over everolimus
i Two-sided p value from CMH test for the comparison of the odds ratio of nivolumab over everolimus.
j Symbol + indicated a censored value.





3.2.1.3 Nivolumab Plus Ipilimumab in Renal Cell Carcinoma
Promising safety and efficacy results were also observed with the combination of nivolumab and 
ipilimumab in the advanced RCC population in study CA209016,9 a phase 1 dose-escalation study 
of nivolumab in combination with VEGFR-TKIs or ipilimumab in participants with metastatic 
RCC. Treatment-experienced and -naive participants with metastatic RCC were randomized to 
receive nivolumab 3 mg/kg + ipilimumab 1 mg/kg (arm N3 + I1) or nivolumab 1 mg/kg + 
ipilimumab 3 mg/kg (arm N1 + I3) IV Q3W for 4 doses then nivolumab 3 mg/kg IV Q2W until 
progression/toxicity. In Arm N1+I3, 25 out of 47 participants (53%) were treatment-naive, and
61.7% were intermediate risk according to MSKCC criteria, and 4.3% were categorized as poor 
risk. In Arm N1 + I3, 21 of 47 participants (45%) were treatment-naive, and 66.0% were in the 
intermediate risk category, and 6.4% were categorized as poor risk. The primary objective was to 
assess safety/tolerability; secondary objective was to assess antitumor activity. 
After a minimum of 22 months, the level of clinical activity, as measured by confirmed ORR, for 
the combination of nivolumab and ipilimumab in CA209016 was substantially greater than that 
observed in studies of either nivolumab monotherapy (Section 3.2.1.2) in metastatic RCC, 
including in the treatment-naive subpopulation. The dosing regimen including nivolumab 3 mg/kg 
combined with ipilimumab 1 mg/kg (N3 + I1) was chosen for further clinical evaluation because 
it exhibited similar clinical activity to nivolumab 1 mg/kg combined with ipilimumab 3 mg/kg (N1 
+ I3) but had a more favorable safety profile.
Table 3.2.1.3-1: Antitumor Activity in All Participants (CA209016)9
N3 + I1 (n = 22)
Previously Treated
N3 + I1 (n = 25)
Treatment-Naive
N1 + I3 (n = 26)
Previously 
Treated
N1 + I 3 (n = 21)
Treatment-
naive








Median duration of 
response, weeks (range)




Ongoing responses, % 
(n/N)
4 ( 40.0) 4 ( 44.4) 2 ( 20.0)
NR (23.57, NA)
Best objective response, 
n (%)
Complete response 3 ( 13.6) 2 (8.0) 0 0
Partial response 7 ( 31.8) 7 (28.0) 10 ( 38.5) 9 (42.9)
Stable disease 6 ( 27.3) 13 (52.0) 11 ( 42.3) 6 (28.8)
Progressive disease 6 ( 27.3) 6 (27.3) 3 ( 11.5) 5 (23.8)
Unable to determine 0 0 2 (  7.7) 1 (4.8)
PFS
Median months (CI)
6.6 ( 1.41, 16.39) 8.3 ( 3.55, 19.29) 10.1 ( 5.42, 20.76)
8.5 ( 2.00, NA)
6-month PFS
Median months (CI)
54.5 ( 32.1,  72.4) 56.5 (34.3, 73.8) 65.4 ( 44.0,  80.3)
61.9 ( 38.1,  78.8)





Table 3.2.1.3-1: Antitumor Activity in All Participants (CA209016)9
N3 + I1 (n = 22)
Previously Treated
N3 + I1 (n = 25)
Treatment-Naive
N1 + I3 (n = 26)
Previously 
Treated
N1 + I 3 (n = 21)
Treatment-
naive
Median OS NR ( 10.02, NA) NR (26.68, NA) 30.9 ( 25.99, NA) NR ( 17.45, NA)
Abbreviations: NR = Not Reached
Among the 91 participants treated with nivolumab + ipilimumab combination in CA209016 who 
provided evaluable baseline tumor samples, 37.4% had  1% PD-L1 tumor expression, and 16.5% 
had 5% PD-L1 tumor expression. ORR was 47.1% among participants with 1% PD-L1 
expression and 36.8% among participants with < 1% PD-L1 expression. Among participants with 
5% PD-L1 expression, ORR was 40.0%.9
Among all treated patients in the Arms N3 + I1 and N1 + N3, AEs were seen in 43/47 (91.5%) 
participants in the N3 + I1 arm and 45/47 (95.7%) participants in the N1 + I3 arm. In the N1 + I3 
arm, the most frequently reported drug-related AEs were fatigue (51.1%); rash, and pruritus (each 
31.9%); nausea (27.7%); arthralgia (25.5%). In the N1 + I3 arm, the most frequently reported drug
related AEs were fatigue (68.1%); diarrhea, and nausea (each 44.7%); pruritus (36.2%); lipase 
increased (34%); AST increased (31.9%); ALT increased, and decreased appetite (29.8%); 
hypothyroidism (27.7%); and rash (25.5%). In the N3 + I1 arm, the most frequently reported, 
Grade 3-4 drug-related AE was lipase increased (14.9%). In the N1 + I3 arm, the most frequently 
reported Grade 3-4 drug related AEs were lipase increased (27.7%); ALT increased (21.3%); 
diarrhea, and colitis (14.9%); AST increased (12.8%).9
Treatment-related AEs (including Grade 3-4), treatment-related AEs leading to discontinuation, 
and treatment-related SAEs all occurred more commonly in participants in the N1 + I3 arm than 
in the N3 + I1 arm (Table 3.2.1.3-2).28







Death, n (%) 16 ( 34.0) 18 ( 38.3)
Within 30 Days of Last Dose 0 1 (  2.1)
Within 100 Days of Last 
Dose
3 (  6.4) 4 (  8.5)
Due to Study Drug Toxicity 0 0
Any Grade Grade 3-4 Any Grade Grade 3-4
All-causality SAEs, n (%) 29 ( 61.7) 20 ( 42.6) 30 ( 63.8) 24 ( 51.0)
Drug-related SAEs, n (%) 11 ( 23.4) 9 ( 19.1) 16 ( 34.0) 16 ( 34.0)












All-causality AEs Leading to 
Discontinuation, n (%)
5 ( 10.6) 3 (  6.4) 15 (31.9) 11 ( 23.4)
Drug-related AEs Leading to 
Discontinuation, n (%)
5 ( 10.6) 3 (  6.4) 13 ( 27.7) 9 ( 19.1)
All-causality AEs, n (%) 47 (100.0) 33 ( 70.2) 47 (100.0) 34 ( 72.3)
Drug-related AEs, n (%) 43 ( 91.5) 18 ( 38.3) 45 ( 95.7) 29 ( 61.7)
All-causality Select AEs, 
within 30 Days of Last Dose, 
by Category, n (%)
Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 14 ( 29.8) 3 ( 6.4) 19 (40.4) 0
Gastrointestinal 16 ( 34.0) 3 ( 6.4) 25 (53.2) 12 ( 25.5)
Hepatic 11 ( 23.4) 3 ( 6.4) 15 (31.9) 8 ( 17.0)
Pulmonary 3 (  6.4) 0 5 (10.6) 0
Renal 11 ( 23.4) 2 (  4.3) 10 (21.3) 2 (  4.3)
Skin 29 ( 61.7) 1 (  2.1) 33 ( 70.2) 1 (  2.1)
Hypersensitivity/Infusion 
Reactions
5 ( 10.6) 0 3 (  6.4) 0
Drug-related Select AEs, 
within 30 Days of Last Dose, 
by Category, n (%)
Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 13 ( 27.7) 2 (  4.3) 19  (40.4) 0
Gastrointestinal 12 ( 25.5) 2 (  4.3) 21 ( 44.7) 11 ( 23.4)
Hepatic 9 ( 19.1) 3 (  6.4) 13 ( 27.7) 8 ( 17.0)
Pulmonary 3 (  6.4) 0 5 ( 10.6) 0
Renal 9 ( 19.1) 2 (  4.3) 6 ( 12.8) 1 (  2.1)
Skin 23 ( 48.9) 0 28 ( 59.6) 1 (  2.1)
Hypersensitivity/Infusion 
Reactions
5 ( 10.6) 0 3 (  6.4) 0
All-causality Immune-




Any Grade Grade 3-4 Any Grade Grade 3-4
Diarrhea/Colitis 3 (  6.4) 2 (  4.3) 12 ( 25.5) 10 ( 21.3)
Hepatitis 5 ( 10.6) 2 (  4.3) 11 ( 23.4) 8 ( 17.0)
Pneumonitis 1 (  2.1) 0 5 ( 10.6) 0
Nephritis and Renal 
Dysfunction
2 (  4.3) 1 (  2.1) 1 (  2.1) 0












Rash 8 ( 17.0) 1 (  2.1) 9 ( 19.1) 1 (  2.1)
Hypersensitivity 0 0 0 0
Immune-Mediated 
Endocrine AEs Treated 
with or without Immune-
Modulating Medications
Any Grade Grade 3-4 Any Grade Grade 3-4
Adrenal Insufficiency 3 (  6.4) 1 (  2.1) 6 ( 12.8) 0
Hypophysitis 1 (  2.1) 1 (  2.1) 2 (  4.3) 0
Hypothyroidism/Thyroiditis 10 ( 21.3) 0 14 ( 29.8) 0
Hyperthyroidism 4 (  8.5) 1 (  2.1) 8 ( 17.0) 0
Diabetes Mellitus 0 0 0 0
MedDRA version 18.1; CTC version 4.0. All events are within 100 days of the last dose of study drug, unless otherwise 
indicated. Sources: Table S.6.2A (deaths), Table S.6.3A (all-causality SAEs), Table S.6.3B (drug-related SAEs), 
Table S.6.4B (all-causality AEs leading to discontinuation), Table S.6.4D (drug-related AEs leading to 
discontinuation), Table S.6.2 (all-causality AEs), Table S.6.3.1 (drug-related AEs), Table S.6.101 (all-causality select 
AEs), Table S.6.105 (all-causality endocrine select AEs), Table S.6.103 (drug-related select AEs), Table S.6.107 
(drug-related endocrine select AEs), Table S.6.202 (all-causality IMAEs with exception of endocrine), and Table 
S.6.204 (all-causality endocrine IMAEs)
A large phase 3 trial, study CA209214, is currently ongoing to determine if nivolumab combined
with ipilimumab (N3+ I1 regimen) improves PFS, OS, and ORR vs sunitinib, in participants with 
previously untreated, advanced or metastatic RCC.
A detailed description of the chemistry, pharmacology, efficacy, and safety of nivolumab and 
ipilimumab in combination is provided in the Nivolumab Investigator Brochure and Product 
Label.28 Note that the nivolumab and ipilimumab combination is currently approved for 
unresectable or metastatic melanoma, using the N1 + I3 regimen.
3.2.1.4 Cabozantinib Monotherapy in Renal Cell Carcinoma
Cabozantinib is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2, and 
has been shown to reduce tumor growth, metastasis, and angiogenesis. Cabozantinib has been 
evaluated in both first-line and second-line settings in advanced and metastatic RCC.
In participants with advanced renal cell carcinoma (RCC) who progressed after previous VEGFR 
tyrosine-kinase inhibitor (VEGFR-TKI) treatment, the randomized phase 3 METEOR trial 
compared the efficacy and safety of cabozantinib monotherapy at a daily dose of 60 mg versus the 
mTOR inhibitor everolimus at a daily dose of 10 mg.38,39 In the trial, 658 participants were 
randomized to receive cabozantinib (n = 330) or everolimus (n = 328). After a minimum follow-
up of 11 months in the first 375 randomized subjects, the primary endpoint of PFS (by independent 
radiology review) was 7.4 months in the cabozantinib arm vs 3.8 months in the everolimus arm 
(HR 0.58 [95% CI 0.45 to 0.75, p<0.001). Using Memorial Sloan Kettering Cancer Center 
(MSKCC) criteria, subgroup analyses of risk groups demonstrated PFS benefit in participants with 





favorable risk (HR 0.54 [95% CI 0.37, 0.79]), intermediate risk (HR 0.56 [95% CI 0.37, 0.84]), 
and poor risk (HR 0.84 [95% CI 0.46, 1.53]). ORR was 17% in the cabozantinib arm vs 5% in the 
everolimus arm (p<0.001). An interim OS analysis at the time of this final PFS analysis 
demonstrated a trend toward longer OS (HR 0.67, p=0.005, with p≤0.0019 required for statistical 
significance). A subsequent OS analysis, performed after a median follow-up of approximately 19 
months in all 658 randomized subjects, demonstrated a significant improvement in OS, with 
median OS of 21.4 months in the cabozantinib arm and 16.5 months in the everolimus arm (HR 
0.66 [95% CI 0.53–0.83]; p = 0.00026). Subgroup analyses of OS according to MSKCC risk group 
were consistent with the results for the overall population. The most common grade 3 or 4 adverse 
events included hypertension (49 [15%] in the cabozantinib group vs 12 [4%] in the everolimus 
group), diarrhea (43 [13%] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar 
erythrodysesthesia syndrome (27 [8%] vs 3 [1%]), anemia (19 [6%] vs 53 [17%]), hyperglycemia 
(3 [1%] vs 16 [5%]), and hypomagnesemia (16 [5%] vs none). Serious adverse events grade  3 
occurred in 130 (39%) participants in the cabozantinib group and in 129 (40%) in the everolimus 
group. One treatment-related death occurred in the cabozantinib group (death; not otherwise 
specified) and two occurred in the everolimus group (1 aspergillus infection and 1 pneumonia 
aspiration).38,39
In treatment naive participants, cabozantinib was also evaluated in a randomized phase 2 
multicenter trial against sunitinib as first-line therapy in participants with advanced or metastatic 
RCC.40 Participants were required to have either intermediate or poor risk disease according to 
IMDC criteria and were randomized in 1:1 ratio to cabozantinib (n = 79) or sunitinib (n = 78). 
Investigator-assessed PFS was the primary endpoint. Compared with sunitinib, cabozantinib 
treatment significantly increased median PFS (8.2 v 5.6 months) and was associated with a 34% 
reduction in rate of progression or death (adjusted hazard ratio, 0.66; 95% CI, 0.46 to 0.95; one-
sided P = .012). ORR was 46% (95% CI, 34 to 57) for cabozantinib vs 18% (95% CI, 10 to 28) for 
sunitinib. Median OS was 30.3 months for cabozantinib vs 21.8 months for sunitinib (adjusted HR 
0.80, 95% CI 0.50, 1.26). All-causality grade 3 or 4 adverse events were 67% for cabozantinib and 
68% for sunitinib and included diarrhea (cabozantinib, 10% v sunitinib, 11%), fatigue (6% v 15%), 
hypertension (28% v 22%), palmar-plantar erythrodysesthesia (8% v 4%), and hematologic 
adverse events (3% v 22%). Treatment-related Grade 5 events occurred in 3 participants in the 
cabozantinib arm (acute kidney injury, sepsis, and jejunal perforation) and 3 participants in the 
sunitinib arm (sepsis, respiratory failure, and vascular disorders).
3.2.1.5 Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab
Combined with Cabozantinib
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
The ongoing phase 1 trial (NCT02496208) evaluating the safety and efficacy of nivolumab 
combined with cabozantinib (doublet regimen) and nivolumab and ipilimumab combined with 





cabozantinib (triplet regimen) in participants with refractory metastatic urothelial carcinoma 
(mUC) and other genitourinary tumors has reported interim results.41 The primary objective was 
to determine the dose limiting toxicity and recommended phase 2 dose of the doublet and triplet 
regimens.
At the time of an update in February 2017, 48 participants (enrolled from 22-Jul-2015 to 31-Dec-
2016) had been treated, including 19 with urothelial carcinoma; 9 with castration-resistance 
prostate cancer; 4 with urachal adenocarcinoma; 4 with germ cell tumor; 4 with penile cancer; 2 
with squamous cell carcinoma of the bladder/urethra; 2 with clear cell RCC; 2 with sarcomatoid 
RCC; 1 with trophoblastic tumor; and 1 with Sertoli cell tumor.41 Part 1 of the study was the dose 
escalation for the doublet regimen and enrolled first, followed by Part 2, which was the dose 
escalation for the triplet regimen (which dosed nivolumab and ipilimumab Q3W for the first 4 
doses, followed by nivolumab alone Q2W). Thirty participants were treated with the doublet, and 
18 were treated with triplet. Both the doublet and triplet regimens were found to be safe and 
tolerable. The recommended phase 2 dose for the doublet was cabozantinib 40 mg/day + 
nivolumab 3 mg/kg. The recommended phase 2 dose for the triplet was cabozantinib 40 mg/day + 
nivolumab 3 mg/kg + ipilimumab 1 mg/kg.
In the doublet arm, the most common treatment-related AEs of any grade were ALT increased 
(67%); fatigue (63%); diarrhea (60%); hypothyroidism (57%); ALT increased (50%); and anorexia 
(47%). The most common treatment-related Grade 3-4 AEs were neutropenia (17%); 
hypophosphatemia and lipase increase (13% each); hypertension (10%); fatigue, diarrhea, 
thrombocytopenia, and dehydration (7% each). One participant developed immune-mediated 
Grade 3 aseptic meningitis.
In the triplet arm, the most common treatment-related AEs of any grade were fatigue (72%); 
diarrhea and anorexia (61% each); ALT increased, hypophosphatemia, dysgeusia, and lipase 
increased (44% each). The most common treatment-related Grade 3-4 AEs were hypertension and 
hypophosphatemia (17% each); and fatigue, hyponatremia, nausea, and lipase increase (13% 
each). One participant developed immune-mediated Grade 3 colitis.
Among 43 participants who were evaluable for response, the ORR was 30%. The ORR was 38% 
among 26 evaluable participants treated with the doublet and 18% among 17 participants treated 
with the triplet. One of 2 participants with sarcomatoid RCC achieved a response. Neither of the 
2 participants with clear cell RCC were evaluable for response at the time of the analysis.
The doublet and triplet expansion cohorts are continuing to enroll participants with advanced 
urothelial carcinoma and RCC. Updated safety and efficacy results after additional enrollment and 
longer follow-up are awaited. 
3.3 Benefit/Risk Assessment
The currently available first-line agents for treatment of mRCC are associated with median OS of 
43.2 months in patients with favorable risk disease (which accounts for approximate 25% of all 
untreated mRCC), 22.5 months in those with intermediate risk disease and only 7.8 months in 
those with poor risk disease according to IMDC criteria.42 Recently, cabozantinib demonstrated a 





significant improvement in investigator-assessed PFS and ORR over standard-of-care sunitinib as 
first-line therapy in a randomized phase 2 study in participants with intermediate- or poor-risk 
mRCC. Nivolumab plus ipilimumab showed a significant improvement in OS in participants with 
intermediate and poor risk mRCC, compared with sunitinib.  At this moment, sunitinib is still one 
of the treatment options for first-line mRCC in all risk groups.  Further improvement of efficacy 
and safety in all risk groups using a combination of agents with synergistic mechanisms of action 
is highly desirable. 43
Based on their different mechanisms of action and the potential immune effects associated with 
anti-VEGF treatment, combining nivolumab with cabozantinib (doublet regimen) may produce 
synergistic clinical activity and provide improved benefit over standard of care sunitinib 
monotherapy in mRCC. As mentioned in Section 3.1, several phase 1 studies combining anti-PD-1 
agents with anti-VEGF agents have demonstrated greater clinical activity than has been observed 
historically in trials of these agents given as monotherapy. Although additional risk may be 
involved with combination therapies, early safety results from the ongoing phase 1 combination 
study in refractory genitourinary cancers evaluating the safety and efficacy of nivolumab 
combined with cabozantinib (doublet regimen) suggest that safety profiles appear acceptable. 
Therefore, overall benefit/risk is acceptable for doublet combination compared to sunitinib in 
participants with mRCC in all risk groups.
Although the relative benefit of cabozantinib vs sunitinib in participants with previously untreated, 
favorable risk mRCC was not evaluated in the CABOSUN study, subgroup analyses from the 
METEOR study suggest that the PFS and OS benefit of cabozantinib in favorable risk disease is 
similar to that in intermediate risk disease (see Section 3.2.1.3). Based on the preliminary efficacy 
results from the phase 1 combination study, which included participants with refractory 
genitourinary tumors, nivolumab combined with cabozantinib (doublet) is anticipated to produce 
clinical activity that is greater than that observed with sunitinib monotherapy, even in favorable 
risk disease. Therefore, this study will also include participants with favorable risk disease, to 
comprise approximately 25% of the overall population.
Overall, the safety profile of nivolumab monotherapy is manageable and generally consistent 
across completed and ongoing clinical trials with no MTD reached at any dose tested up to 10 
mg/kg. Most AEs were low-grade (Grade 1 to 2) with relatively few related high-grade (Grade 3 
to 4) AEs. There was no pattern in the incidence, severity, or causality of AEs with respect to 
nivolumab dose level.
A pattern of immune-related adverse events has been defined, for which management algorithms 
have been developed; these are provided in Appendix 5 and within the Investigator Brochure.28
Most high-grade events were manageable with the use of corticosteroids or hormone replacement 
therapy (endocrinopathies) as instructed in these algorithms. 
More detailed information about the known and expected benefits and risks and reasonably 
anticipated adverse events (AEs) of nivolumab and cabozantinib may be found in their respective 
Investigator Brochures.21,28





4 OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objective Endpoint
Primary
To compare progression-free survival (PFS) 
per BICR of nivolumab combined with 
cabozantinib (Arm A: doublet) with sunitinib
(Arm C) in all randomized participants. 
The primary endpoint of this study is to compare PFS per BICR of 
Arm A versus Arm C in all randomized participants. PFS is 
defined as the time between the date of randomization and the first 
date of the documented progression, or death due to any cause, 
whichever occurs first. Participants who die without a reported 
progression (and die without start of subsequent anti-cancer
therapy) will be considered to have progressed on the date of their 
death. Participants who did not progress or die will be censored on 
the date of their last evaluable tumor assessment on or prior to 
initiation of subsequent anti-cancer therapy. Participants who did 
not have any on study tumor assessments and did not die will be 
censored on their date of randomization. Participants who started 
anti-cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment on or
prior to the initiation of first subsequent anti-cancer therapy.
Secondary
To compare overall survival (OS) of Arm A 
with Arm C in all randomized participants.
The first secondary endpoint is to compare OS of Arm A versus 
Arm C in all randomized participants. OS is defined as the time 
between the date of randomization and the date of death due to any 
cause. A participant who has not died will be censored at the last 
known alive date.
To evaluate the objective response rate 
(ORR) per BICR in all randomized 
participants.
The second secondary endpoint is to describe ORR per BICR in 
all randomized participants. ORR is defined as the proportion of 
randomized participants who achieve a best response of complete 
response (CR) or partial response (PR) using the RECIST 1.1 
criteria. Best overall response (BOR) is defined as the best 
response designation recorded between the date of randomization 
and the date of objectively documented progression per RECIST 
1.1 or the date of subsequent therapy (including tumor-directed 
radiotherapy and tumor-directed surgery), whichever occurs first. 
For participants without document progression or subsequent 
therapy, all available response designations will contribute to the 
BOR assessment. Duration of response (DOR) is defined as the 
time between the date of first confirmed documented response (CR 
or PR) to the date of first documented tumor progression (per 
RECIST 1.1) or death due to any cause, whichever occurs first. 
Participants who neither progress nor die will be censored on the 
date of their last tumor assessment. Responders who started anti-
cancer therapy without a prior reported progression will be 
censored on the date of their last evaluable tumor assessment prior 
to the initiation of first subsequent anti-cancer therapy. Time to 
response (TTR) is defined as the time from randomization to the 
date of the first confirmed documented response (CR or PR), as 
assessed by BICR. DOR and TTR will be evaluated for responders 
(CR or PR) only.





Table 4-1: Objectives and Endpoints
Objective Endpoint
To assess overall safety and tolerability in all 
treated participants.
As measured by the incidence of adverse events (AEs), serious 
adverse events (SAEs), AEs leading to discontinuation, deaths, 
laboratory abnormalities and changes from baseline.
Exploratory
To explore potential predictive biomarkers of 
clinical response to nivolumab and 
cabozantinib combination. 
Analysis of tumor specimens and blood samples for proteins and 
genes involved in regulating immune response (eg, PD-1, PD-L1, 
PD-L2, CXCL10, MET). Other exploratory endpoints for 
biomarkers, pharmacogenomics, and immunogenicity are 
described in Section 9.8.
To evaluate health related quality of life 
(HRQoL).
Assessed by the NCCN Functional Assessment of Cancer 
Therapy- Kidney Symptom Index (FKSI-19) and the EuroQoL 
Group’s EQ-5D (3L version) is described in Section 9.1.4.
To characterize the pharmacokinetics of 
nivolumab and cabozantinib and explore 
exposure response relationships, if 
applicable.
Population PK parameters, exposure-response relationship 
between select PK measures of exposure and safety and efficacy 
endpoints, if applicable
To characterize the immunogenicity of 
nivolumab
Incidence of anti-nivolumab antibodies and their potential 
relationship with safety and efficacy endpoints
To assess PFS after next line of treatment 
(PFS-2) in each arm
PFS-2 is defined as the time from randomization to the date of
investigator-defined documented second objective disease
progression after second-line therapy or death due to any cause, 
whichever comes first. Clinical deterioration will not be 
considered as progression. A subject who neither progresses nor 
dies will be censored on the date of his/her last adequate tumor 
assessment or last follow-up for progression/subsequent therapy.
A subject who does not have any post-baseline tumor 
assessments and who has not died will be censored on the date at
which he/she was randomized.
5 STUDY DESIGN
5.1 Overall Design
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
This is an open label, randomized trial of nivolumab combined with cabozantinib (doublet 
regimen) versus sunitinib in participants with previously untreated (first line) advanced or 
metastatic RCC. Participants will be randomized between Arm A and Arm C in a 1:1 ratio with 
approximately 638 participants (319 per arm) capped at approximate 25% to represent the normal 
frequency of favorable risk group in mRCC. The rest of the randomized participants will provide 
approximately 478 intermediate/poor risk randomized participants (239 per arm). Participants will 
be stratified at the time of randomization by IMDC prognostic score (0 [favorable risk] versus 1-





2 [intermediate risk] versus 3-6 [poor risk]), PD-L1 tumor expression (≥ 1% versus < 1% or 
indeterminate), and region (US/Canada/Western Europe/Northern Europe versus rest of the world 
[ROW]). 
The study design schematic is presented in Figure 5.1-1.
Figure 5.1-1: Study Design Schematic
Abbreviations: DMC= data monitoring committee; IMDC= International Metastatic Renal Cell Carcinoma Database 
Consortium; IV=intravenous; PD-L1= programmed death-ligand 1; PO= orally by mouth; Pts=patients/participants; 
Q2W=every 2 weeks; Q3W=every 3 weeks; QD= once daily; RCC=renal cell carcinoma.
Arm B is shown in the design schematic because after implementation of Revised Protocol 01, there will be be patients 
on treatment from the original protocol version 08 Mar 2017.
This study will consist of 3 stages: screening, treatment, and follow up phase.
Screening stage: Screening begins by establishing the participant’s initial eligibility and signing of 
the informed consent (ICF). Sufficient, recent tumor tissue, preferably obtained within 3 months
but no more than 12 months prior to enrollment, from a metastatic tumor lesion or from a primary 
tumor lesion which has not been previously irradiated (formalin-fixed paraffin-embedded block or 
20 unstained slides: a minimum of 10 slides, obtained from core biopsy, punch biopsy, excisional 
biopsy or surgical specimen) will be submitted to the central laboratory. Upon receipt of the tumor 
sample, the central lab will determine PD-L1 expression level by immunohistochemistry (IHC) 
testing (see Section 9.8.2). In order to be randomized in the Interactive Response Technology 
(IRT) system, a participant must be classified as PD-L1 expression ≥ 1%, PD-L1 expression < 1%, 





or PD-L1 expression indeterminate. Sites will be informed when the submitted tumor sample is 
insufficient for PD-L1 testing by the central lab. 
Participants will be assessed for complete study eligibility prior to randomization as specified in 
Section 2. 
The Screening stage ends with either confirmation of full eligibility and randomization for the 
participant or with the confirmation that the participant is a screen failure. This study permits the 
re-enrollment of a participant that has discontinued the study as a pre-treatment failure prior to 
randomization. If re-enrolled, the participant must be re-consented. A new participant
identification number will be assigned by IRT at the time of re-enrollment. 
Treatment stage: 
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
The Treatment stage begins when the randomization call is made into the IRT. The participant is 
randomly assigned to 1 of the 2 treatment arms as noted in the study schematic above.
• Arm A (Doublet): Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
o Nivolumab to be continued until disease progression or unacceptable toxicity with 
maximum treatment of 2 years from the first dose in Cycle 1
o Cabozantinib to be continued until disease progression or unacceptable toxicity
• Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle. Cycles to be 
continued until progression or unacceptable toxicity
• Note - Randomization to Arm B stops with implementation of approved CA2099ER Global 
Revised Protocol 01. Treatment B (below) continues only for participants randomized to Arm 
B prior to implementation of Global Revised Protocol 01 
o Arm B (Triplet): Nivolumab 3mg/kg IV + Ipilimumab 1 mg/kg IV, both Q3W x 4 doses 
+ Cabozantinib 40 mg PO QD 
 Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
 Nivolumab to be continued until disease progression, unacceptable toxicity, or 
a maximum of 2 years from the first dose in Cycle 1
 Cabozantinib to be continued until progression or unacceptable toxicity
Study treatment must begin within 3 days (72 hours) of randomization. Participants in Arm A will 
continue nivolumab until progression, unacceptable toxicity, withdrawal of consent, or a 
maximum of 2 years from the first dose in Cycle 1, whichever occurs first. Cabozantinib (Arm A) 
may be continued until progression, unacceptable toxicity, or withdrawal of consent, whichever 
occurs first, and may extend beyond 2 years from the first dose in Cycle 1. See Table 7.1-1 and 





Table 7.1-2 for the dosing schedule. Study drugs may be delayed for toxicity (See Section 7.4.1).
Treatment may be continued beyond investigator-assessed progression if the investigator confirms 
that the participant meets the criteria specified in Section 8.1.4.
A negative pregnancy test should be documented within 24 hours prior to the initial dose of the 
investigational product and then performed every 4 weeks 7 days during treatment. On-study 
laboratory assessments should be drawn within 72 hours prior to dosing and will be assessed at the 
local laboratory.
Tumor assessments will occur in accordance with Section 2 and Section 9.1.2 until progression 
has been assessed by the investigator and confirmed by the blinded independent central review 
(BICR). Each site must submit scans on a rolling basis, preferably within 7 days of image 
acquisition, to a third-party vendor for BICR. If progression is assessed by the investigator, the 
site will inform the radiology vendor so that the BICR assessment of progressioncan be performed. 
The BICR assessment of progression will be completed, and the results provided to the site, within 
approximately 14 days, as specified in Section 9.1.2. 
PK and immunogenicity samples will be collected according to Table 9.5-1 and Table 9.5-2. 
Adverse event assessments should be documented at each clinic visit. 
Quality of Life will be assessed using the National Comprehensive Cancer Network (NCCN)
Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-19) and EuroQoL’s 
EQ-5D-3L. These questionnaires should be completed according to Section 2. 
The Treatment stage ends when the participant is discontinued from study therapy. 
Follow-up stage: The Follow-up stage begins when the decision to discontinue a participant from 
study therapy is made (no further treatment with study therapy). Participants must be followed for 
at least 100 days after last dose of study treatment. Follow-up visit #1 (FU1) should occur 30 days 
from the last dose (+/- 7) days or can be performed on the date of discontinuation if that date is 
greater than 42 days from last dose. Follow-up visit #2 (FU2) occurs approximately 100 days (+/-
7 days) from last dose of study drug. Both Follow Up visits should be conducted in person. AEs 
will be followed until the toxicities resolve, return to baseline, or are deemed irreversible. The 
FKSI-19 and EQ-5D-3L will be completed as described in Section 2.
Participants who discontinued study treatment without BICR confirmed radiographic progression
will continue to have tumor assessments performed according to the frequency described in 
Sections 2 and 9.1.2, even if new anti-tumor therapy has been initiated. If progression is assessed 
by the investigator, the site will inform the radiology vendor, so that the BICR assessment of 
progression can be performed. Participants whose progression is not confirmed by the BICR will 
be required to continue tumor assessments (if clinically feasible) according to the protocol-
specified schedule or sooner if clinically indicated until BICR confirms progression on a 
subsequent tumor assessment (See Section 9.1.2.2 for additional details).
After the Follow-up 2 Visit, all participants will be followed for overall survival status every 
3 months (+/- 14 days) until death, withdrawal of consent, loss to follow-up, or end of study. 
Survival status can be ascertained in person or by telephone contact. If new anti-tumor therapy is 





initiated for either progression or a secondary malignancy at any time during this period, this and 
all other pertinent data obtained should be recorded on the appropriate Case Report Form (CRF). 
5.1.1 Data Monitoring Committee and Other External Committees
To provide independent oversight of safety, efficacy, and study conduct, a data monitoring 
committee (DMC) will be instituted. The DMC will meet regularly to ensure that participant safety 
is carefully monitored, including a safety assessment after the first 30 participants are randomized
including participants in Arm B prior to global Revised Protocol 01 and are followed for at least 6 
weeks and then again after the first 75 participants are randomized and followed for at least 6 
weeks. The DMC will convene additional ad hoc meetings if necessary. Following each meeting, 
the DMC will recommend continuation, modification, or discontinuation of the study based on 
observed toxicities. The DMC will also review the interim analysis results and inform BMS 
whether stopping criteria for superiority are met at that time. A separate DMC charter will describe 
the activities of this committee in more detail.
Blinded independent central review (BICR) will be utilized in this study for determination of PFS 
endpoint. The BICR will review all available tumor assessment scans for all randomized 
participants. Details of BICR responsibilities and procedures will be specified in the BICR charter.
5.2 Number of Participants
Approximately 850 participants will be enrolled in order to randomize approximately 
638 participants (319 per Arm A and per Arm C). The number of randomized participants with 
favorable risk disease will be capped at approximately 25% (160) participants.
5.3 End of Study Definition
The start of the trial is defined as the first visit for the first participant screened. End of trial is 
defined as the last visit or scheduled procedure shown in the Schedule of Activities for the last 
participant. Study completion is defined as the final date on which data for the endpoint of overall 
survival was or is expected to be collected, if this is not the same.
5.4 Scientific Rationale for Study Design
Please refer to Section 3.1 for details of the rationale for evaluating the combination of nivolumab 
with cabozantinib (doublet regimen) in this study. 
5.4.1 Rationale for Open-Label Design
The trial will have an open-label design with a blinded independent central review. Different 
dosing schedules and use of both IV infusions and oral medications across the 2 different arms 
make blinding the trial impractical. The complexity of including multiple visits for placebo 
infusions are burdensome for this participant population. Nivolumab is associated with some 
toxicities that are also common to cabozantinib and sunitinib (eg, diarrhea, hepatotoxicity), and 
the management of these common toxicities are different for immuno-oncology agents (eg,
typically requiring steroids) vs TKIs (eg, typically requiring dose delay and reductions). Therefore, 
an open-label trial is preferable for participant safety as it allows the optimal management of 
toxicities.





5.4.2 Rationale for Choice of Primary Endpoint
The primary endpoint to be evaluated is PFS per BICR in all randomized participants. PFS has
been an acceptable endpoint to support regulatory approvals in first-line mRCC. Sorafenib, 
sunitinib, bevacizumab, and pazopanib were approved based on an increase in PFS. While OS 
remains the “gold standard” for oncology trials, as more active agents gain approval in RCC, 
subsequent treatment with these agents confounds the effect of first-line treatment on OS.
Therefore, PFS remains an important indicator of clinical benefit in first-line mRCC and has been 
chosen as the primary endpoint for this trial.
The primary efficacy analysis population includes all randomized participants, including those 
with favorable, intermediate, or poor risk disease per IMDC prognostic criteria. Favorable risk will 
be capped at 25% to represent the normal frequency of favorable risk group in mRCC. Several 
TKIs were approved as the first line treatment for mRCC in all risk groups. The combination 
regimen of a TKI is likely to benefit across all IMDC risk groups.  Nivolumab and cabozantinib 
should be evaluated in this population for the primary analysis versus Arm C (sunitinib) as the 
comparator.
5.5 Justification for Dose
5.5.1 Dosing for Sunitinib Monotherapy in Arm C
Dosing for sunitinib monotherapy in Arm C uses the standard dosing schedule found in the 
sunitinib prescribing information.33
5.5.2 Dosing for Cabozantinib Doublet and Triplet Therapy in Arm A and 
Arm B
Dosing for nivolumab combined with cabozantinib (doublet regimen) was determined based on a 
phase 1b/2 trial (NCT02496208) conducted with the combination at NCI/NIH (see Section 
3.2.1.4).
Note: Arm B (triplet regimen) in the original protocol has been removed from this Revised 
Protocol 01.  It is more appropriate to study nivolumab ipilimumab containing regimen (e.g. Arm 
B, triplet regimen) versus a control arm of nivolumab and ipilimumab. 
5.5.3 Dosing Rationale for Nivolumab 240 mg flat dose Q2W
A flat dose of nivolumab 240 mg every 2 weeks will be administered in Arm A and in the 
maintenance phase of Arm B in combination with cabozantinib. Nivolumab 3mg/kg once every 2 
weeks has been shown to be similar to 240 mg flat dose every 2 weeks, and is currently FDA 
approved, based on clinical data and modeling and simulation approaches using population PK 
(PPK) and exposure-response analyses of data from studies in multiple tumor types (melanoma, 
non-small-cell lung cancer [NSCLC], renal cell carcinoma [RCC]) and urothelial carcinoma where 
body weight normalized dosing (mg/kg) has been used.
PPK analyses have shown that the PK of nivolumab is linear with proportional exposure over a 
dose range of 0.1 to 10 mg/kg, and no differences in PK across ethnicities and tumor types were 
observed. Nivolumab clearance and volume of distribution were found to increase as the body 





weight increases, but less than proportionally with increasing weight, indicating that mg/kg dosing 
represents an over-adjustment for the effect of body weight on nivolumab PK. The PPK model 
developed using data from NSCLC participants was updated, using data from participants 
investigating nivolumab in the treatment of melanoma, NSCLC, and RCC. In this dataset, the 
median (minimum to maximum) weight was 77 kg (35 to 160 kg) and thus, an approximately 
equivalent dose of 3 mg/kg for an 80 kg participant, nivolumab 240 mg Q2W was selected for 
future studies. To predict relevant summary exposures of nivolumab 240 mg Q2W, the PPK model 
was used to simulate nivolumab 3 mg/kg Q2W and 240 mg Q2W. In the simulations, the simulated 
participant populations consisted of 1000 participants per treatment arm randomly sampled from 
aforementioned pooled database of cancer participants. Because no differences in PK were noted 
across ethnicities and tumor types, these simulated melanoma, NSCLC and RCC data will be 
applicable to participants with other tumor types. The simulated measure of exposure of interest, 
time-averaged concentrations (Cavgss) for 240 mg Q2W were predicted to be similar for all 
participants in reference to 80 kg participants receiving 3 mg/kg Q2W.
Additionally, nivolumab is safe and well tolerated up to 10 mg/kg Q2W dose level. Adverse events 
have been consistent across tumor types following monotherapy and have not demonstrated clear 
dose-response or exposure-response relationships. Additionally, the simulated median and 95th 
prediction interval of nivolumab summary exposures across a wide body weight range (35 - 160 
kg) are predicted to be maintained below the corresponding observed highest exposure 
experienced in nivolumab, ie, 95th percentile following nivolumab 10 mg/kg Q2W from clinical 
study CA209003. Thus, while participants in the lower body weight ranges would have greater 
exposures than 80 kg participants, the exposures are predicted to be within the range of observed 
exposures at doses (up to 10 mg/kg Q2W) used in the nivolumab clinical program, and are not 
considered to put participants at increased risk. Additionally, for participants with greater body 
weights, the simulated ranges of exposures are also not expected to affect efficacy, because the 
exposures predicted following administration of a 240 mg Q2W are on the flat part of the exposure-
response curves for previously investigated tumors, melanoma and NSCLC. Given the similarity 
of nivolumab PK across many tumor types, including RCC, and the similar exposures predicted 
following administration of 240 mg flat dose compared to 3 mg/kg, it was shown that the safety 
and efficacy profile of 240 mg nivolumab will be similar to that of 3 mg/kg nivolumab.
5.5.4 Rationale for Dosing Duration for Nivolumab
The optimal duration of immunotherapy is an important question and continues to be investigated. 
Clinical trials across different tumors types in the nivolumab and ipilimumab development 
program indicate that most of the responses occur early, with a median time to response of 2-4 
months, and emerging data suggests that benefit can be maintained in the absence of continued 
treatment. A recent analysis in a melanoma study suggests the majority of patients who discontinue 
nivolumab and/or ipilimumab for toxicity maintain disease control in the absence of further 
treatment.44 Furthermore, a limited duration of ipilimumab, including only 4 induction doses, 
resulted in long term survival in patients with metastatic melanoma, with a sustained plateau in 
survival starting around 2 years after the start of treatment.45





Accumulating data suggest that 2 years of PD-1 checkpoint inhibitor treatment may be sufficient 
for long term benefit. CA209003, a dose-escalation cohort expansion trial evaluating the safety 
and clinical activity of nivolumab in patients with previously treated advanced solid tumors 
(including 129 subjects with NSCLC), specified a maximum treatment duration of 2 years. Among 
16 subjects with non-small cell lung cancer (NSCLC) who discontinued nivolumab after 
completing 2 years of treatment, 12 subjects were alive >5 years and remained progression-free 
without any subsequent therapy (2) In the CA209003 NSCLC cohort, the overall survival (OS) 
curve begins to plateau after 2 years, with an OS rate of 25% at 2 years and 18% at 3 years.46
These survival outcomes are similar to Phase 3 studies in previously treated NSCLC, in which 
nivolumab treatment was continued until progression or unacceptable toxicity (2 year OS rates of 
23% and 29%, and 3-year OS rates of 16%-18% for squamous and non-squamous NSCLC 
respectively).47
Similar results have been reported in clinical studies of pembrolizumab, another PD-1 inhibitor. 
Keynote-010 was a randomized Phase 3 trial of pembrolizumab (at either 2 mg/kg or 10 mg/kg
every 3 weeks) versus docetaxel in subjects with previously treated, PD-L1-positive, advanced 
NSCLC which specified a maximum treatment duration of 2 years for pembrolizumab. OS was 
significantly longer with both pembrolizumab 2 mg/kg (HR 0.72, p = 0.00017) and pembrolizumab 
10 mg/kg (HR 0.60, p < 0.00001) compared to docetaxel, with an OS plateau developing beyond 
2 years in both pembrolizumab arms. Among 690 patients who received pembrolizumab, 47 
patients completed 2 years of pembrolizumab and stopped treatment. Most were able to maintain 
their response, including those with stable disease, with only 2 patients (4%) having confirmed 
progression after stopping at 2 years.48
Keynote-006 was a randomized phase 3 study of pembrolizumab versus ipilimumab in patients 
with advanced melanoma, which also specified a maximum 2 year duration of pembrolizumab 
treatment. 104 (19%) of 556 patients randomized to pembrolizumab completed 2 years of 
treatment. With a median follow-up of 9 months after completion of pembrolizumab, the estimated 
risk of progression or death was 9% in these patients.49
Taken together, these data suggest that treatment beyond 2 years is unlikely to confer additional 
clinically meaningful benefit and that the risk of progression after discontinuing treatment at 2 
years is low.
In contrast, a shorter duration of nivolumab of only 1 year was associated with increased risk of 
progression in previously treated patients with NSCLC, suggesting that treatment beyond 1 year 
is likely needed. In CA209153, patients with previously treated advanced NSCLC who completed
1 year of nivolumab therapy were randomized to either continue or stop treatment, with the option 
of retreatment upon progression. Among 163 patients still on treatment at 1 year and without 
progression, those who were randomized to continue nivolumab had significant improvement in 
progression-free survival (PFS) compared to those who were randomized to stop treatment, with 
median PFS (post-randomization) not reached vs 10.3 months, respectively; HR=0.42 (95% CI, 
0.25 to 0.71). With a median follow-up of 14.9 months post-randomization, there also was a trend 
for patients on continued treatment to live longer (OS HR = 0.63 [95% CI: 0.33, 1.20]). Of note,  





the PFS curves in both groups plateau approximately 1 year after randomization (i.e., 2 years after 
treatment initiation), suggesting that there may be minimal benefit in extending treatment beyond 
a total of 2 years.50
Collectively, these data suggest that there is minimal if any benefit derived from continuing I-O 
treatment beyond two years in advanced tumors. However, even though immunotherapy is well 
tolerated, patients will be at risk for additional toxicity with longer term treatment. Therefore, in 
this study, treatment will be given for a maximum of 2 years from the start of study treatment.
6 STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Participants must have signed and dated an IRB/IEC approved written informed consent 
form in accordance with regulatory and institutional guidelines. This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
participant care. 
b) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
and laboratory testing.
2) Type of Participant and Target Disease Characteristics
a) Histological confirmation of RCC with a clear-cell component, including participants who 
may also have sarcomatoid features
b) Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC 
Stage IV) RCC
c) No prior systemic therapy for RCC with the following exception:
i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such 
therapy did not include an agent that targets VEGF or VEGF receptors and if 
recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant 
therapy.
d) Karnofsky Performance Status (KPS)  70% (See Appendix 7)
e) Measurable disease as per RECIST v1.1 per investigator. (See Appendix 8)
f) Either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue 
sections, preferably obtained within 3 months but no more than 12 months prior to 
enrollment, with an associated pathology report, must be submitted to the central laboratory 
during screening. Biopsy should be excisional, incisional or core needle. Fine needle 
aspiration is unacceptable for submission. In participants who received prior adjuvant or
neoadjuvant therapy, the tumor sample must have been obtained after completion of 
adjuvant or neoadjuvant therapy. Upon receipt of the tumor sample, the central lab will 
determine PD-L1 expression level by IHC testing (see Section 9.8.2). In order to be 
randomized in the IRT system, a participant must be classified as PD-L1 expression ≥ 1%, 
PD-L1 expression < 1%, or PD-L1 expression indeterminate. Sites will be informed when 
the submitted tumor sample is insufficient for PD-L1 testing by the central lab.





g) Participants with favorable, intermediate and poor risk categories will be eligible for the 
study. To be eligible for the Intermediate and Poor-Risk cohort, at least one of the following 
prognostic factors as per International Metastatic RCC Database Consortium (IMDC) must 
be present: (See Appendix 6)
i) KPS equal to 70%
ii) Less than 1 year from initial diagnosis (including original localized disease if 
applicable) to randomization
iii) Hemoglobin < lower limit of normal (LLN)
iv) Corrected calcium concentration > 10 mg/dL
v) Absolute neutrophil count > ULN
vi) Platelet count > ULN
If none of the above factors are present, participants are only eligible for the favorable-risk 
cohort. Approximately 160 favorable risk participants will be randomized. Enrollment of 
favorable risk participants may be closed earlier than enrollment for intermediate and poor 
risk participants.
3) Age and Reproductive Status
a) Males and Females, ages 18 or age of majority 
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours 
prior to the start of study treatment
c) Women must not be breastfeeding
d) Women of childbearing potential (WOCBP) must agree to follow instructions for 
method(s) of contraception for the duration of study treatment and 5 months after the last 
dose of study treatment (ie, 30 days [duration of ovulatory cycle] plus the time required for 
the investigational drug to undergo approximately five half-lives).
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of study treatment and 7 months after the last 
dose of study treatment (ie, 90 days [duration of sperm turnover] plus the time required for 
the investigational drug to undergo approximately five half-lives).
f) Azoospermic males are exempt from contraceptive requirements. WOCBP who are 
continuously not heterosexually active are also exempt from contraceptive requirements, 
and still must undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP, and male participants who are sexually active with WOCBP, 
on the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on the use of highly effective methods of contraception (Appendix 4) 
which have a failure rate of < 1% when used consistently and correctly.
6.2 Exclusion Criteria
1) Medical Conditions
a) Any active CNS metastases. Participants with treated, stable CNS metastases for at least 1 
month are eligible as long as they meet the following criteria:





Treated CNS metastases are defined as having no ongoing requirement for corticosteroids 
for at least 2 weeks prior to randomization and no evidence of progression or hemorrhage 
after treatment completed at least 1 month prior to randomization, as ascertained by clinical 
examination and brain imaging (MRI or CT). (Stable dose of anticonvulsants is allowed). 
Treatment for CNS metastases may include whole brain radiotherapy, radiosurgery (eg, 
RS, gamma knife, LINAC, or equivalent) or a combination as deemed appropriate by the 
treating physician. Participants with CNS metastases treated by neurosurgical resection or 
brain biopsy performed within 1 month prior to randomization are not eligible. Baseline 
imaging of the brain is required within 28 days prior to randomization.
b) Any active, known or suspected autoimmune disease. Participants with type I diabetes 
mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as 
vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected 
to recur in the absence of an external trigger (e.g. celiac disease) are permitted to enroll.
c) Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg 
daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
d) Prior malignancy active within the previous 3 years except for locally curable cancers that 
have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder 
cancer, or carcinoma in situ of the prostate, cervix, or breast
e) Any tumor invading the SVC or other major blood vessels
f) Any tumor invading the GI tract or any evidence of endotracheal or endobronchial tumor 
within 30 days prior to randomization
g) Known history of positive test for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed 
at sites where mandated locally (sites in Germany, see Appendix 12).
h) Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis, 
aortic aneurysm, aortic dissection) that, in the investigator’s opinion, would increase the 
risk associated with study participation or study drug administration or interfere with the 
interpretation of safety results
i) History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel 
obstruction, or gastric outlet obstruction within the past 6 months prior to randomization
j) Impairment of gastrointestinal function or gastrointestinal disease that may significantly 
alter the absorption of cabozantinib or sunitinib (eg, malabsorptive disorder, ulcerative 
disease, uncontrolled nausea, vomiting, diarrhea, or small bowel resection)
k) Serious, non-healing wound or ulcer within 30 days prior to randomization
l) Evidence of active bleeding or bleeding susceptibility; or medically significant hemorrhage 
within prior 3 months prior to randomization
m) Uncontrolled adrenal insufficiency
n) History of cerebrovascular accident (CVA) including transient ischemic attack within the 
past 6 months prior to randomization





o) History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within past 6 months 
prior to randomization unless stable, asymptomatic, and treated with low molecular weight 
heparin (LMWH) for at least 3 weeks prior to randomization
p) Any unstable cardiac arrhythmia within 6 months prior to randomization
q) Prolongation of the Fridericia corrected QT (QTcF) interval defined as > 450 msec for 
males and > 470 msec for females, where QTcF = QT / 3√RR with triplicate measurements
r) Poorly controlled hypertension (defined as systolic blood pressure (SBP) of > 150 mmHg 
or diastolic blood pressure (DBP) of > 90 mmHg), despite antihypertensive therapy
s) History of any of the following cardiovascular conditions within 6 months of 
randomization: cardiac angioplasty or stenting, myocardial infarction, unstable angina, 
coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, class III or 
IV congestive heart failure (CHF), as defined by the New York Heart Association (NYHA)
t) Any radiologic or clinical evidence of pancreatitis within 30 days prior to randomization
u) Inability to swallow oral medications
2) Prior/Concomitant Therapy
a) Prior treatment with VEGF, MET, AXL, KIT, or RET targeted therapy (including, but not 
limited to, sunitinib, pazopanib, axitinib, tivozanib, sorafenib, lenvatinib, bevacizumab, 
and cabozantinib).
b) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or 
checkpoint pathways.
c) Concomitant strong CYP3A4 inducers or inhibitors within 14 days prior to randomization. 
Please refer to Appendix 9 for a list of common strong CYP3A4 inducers and inhibitors.
d) Concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or 
warfarin-related agents, thrombin or Factor Xa inhibitors. Aspirin (up to 325 mg/day) and 
prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted.
e) Major surgery less than 6 weeks, nephrectomy less than 4 weeks, prior to randomization,  
with complete wound healing and no ongoing post-operative complications.
f) Any of the following prior radiotherapy procedures:
i) Radiotherapy to the thoracic cavity or abdomen within 4 weeks prior to 
randomization
ii) Radiotherapy to bone lesions within 2 weeks prior to randomization
iii) Radiotherapy to any other site within 4 weeks prior to randomization
NOTE: In all cases, there must be complete recovery and no ongoing complications from 
prior radiotherapy.
g) Treatment with botanical preparations (eg herbal supplements or traditional Chinese 
medicines) intended for general health support or to treat the disease under study within 2
weeks prior to randomization.
h) Participants who have received a live/attenuated vaccine within 30 days of first treatment.
3) Physical and Laboratory Test Findings
a) Ejection fraction  50% on screening echocardiogram or MUGA
b) WBC < 2000/μL





c) Neutrophils < 1500/μL
d) Platelets < 100 x 103/μL
e) Hemoglobin < 9.0 g/dL (support with transfusion is acceptable)
f) Serum creatinine > 1.5 x ULN unless calculated creatinine clearance ≥ 40 mL/min (using 
the Cockcroft-Gault formula)
g) AST/ALT > 3.0 x ULN
h) Total bilirubin > 1.5 x ULN (except participants with Gilbert Syndrome who must have a 
total bilirubin level of < 3.0 x ULN)
i) Urine protein/creatinine ratio (UPCR) > 1.5, unless 24-hour urine protein is ≤ 1.5 g
j) INR > 1.5
k) Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of 
virus, eg, hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (anti-HCV) 
positive (except if HCV-RNA negative)
4) Allergies and Adverse Drug Reaction
a) History of allergy or hypersensitivity to study drug components
b) No history of severe hypersensitivity to a monoclonal antibody
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated. (Note: under specific 
circumstances, and only in countries where local regulations permit, a person who has been 
imprisoned may be included as a participant. Strict conditions apply and Bristol-Myers 
Squibb approval is required.)
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
6.3.1 Meals and Dietary Restrictions
For participants in Arms A (and Arm B participants enrolled prior to Revised Protocol 01), 
cabozantinib should not be taken with grapefruit/grapefruit juice or Seville oranges.
For participants in Arm C, sunitinib should not be taken with grapefruit/grapefruit juice.
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomized. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants, to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory 
authorities. Minimal information includes date of consent, demography, screen failure details, 
eligibility criteria, and any serious AEs.





6.4.1 Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment of a participant that has 
discontinued the study as a pre-treatment failure (ie, participant has not been randomized / has not 
been treated). If re-enrolled, the participant must be re-consented.
Retesting of laboratory parameters and/or other assessments within any single Screening or 
Lead-in period will be permitted (in addition to any parameters that require a confirmatory value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participant’s most current, clinical state.
Laboratory parameters and/or assessments that are included in Table 2-1 Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participants. Consultation 
with the BMS Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter is clinically relevant.
7 TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
randomization or treatment allocation.
Study treatment includes both Investigational [Medicinal] Product (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a reference 
in a clinical study, including products already with a marketing authorization but used or 
assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-
investigational products.





Table 7-1: Study treatments for CA2099ER 
Product Description / 










100 mg (10 mg/mL) IP Open Label
Vial
(multiple vials per carton)
Store at 2° - 8 °C. Protect 
from light and freezing
Ipilimumab Solution for
Injection (see Note)
200 mg (5mg/mL) IP Open Label
Vial
(multiple vials per carton)
Store at 2° - 8 °C. Protect 
from light and freezing
Cabozantinib
Tablet
20 mg IP Open Label Tablets in a bottle
Refer to storage 




12.5 mg IP Open Label
Capsules in various 
packaging configurations
Refer to storage 
conditions on container 
label/package insert
*May be labeled as “BMS-936558-01” or “Nivolumab”
** Sunitinib may be obtained by the investigational sites in certain countries as local commercial product (which may be available as a different potency/package 
size than listed above) if local regulations allow and agreed to by BMS.
Note: Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants previously randomized to Arm B continue 
with Arm B treatment and continue with Arm B clinically planned events, per protocol
Premedications or medications used to treat infusion-related reactions should be sourced by the investigative sites if available and
permitted by local regulations. Solutions used as diluent (ie, 0.9% Sodium Chloride Injection or 5% Dextrose Injection) should also be
sourced by investigative sites if available and permitted by local regulations.






The selection and timing of dose for each participant is presented in Table 7.1-1 and the dosing 
scheduled by cycle is presented in Table 7.1-2.
Table 7.1-1: Selection and Timing of Dose
Arm Study 
Treatment
Dosage level(s) and 
Formulation




Nivolumab 240 mg IV Every 2 weeks IV




Nivolumab 3 mg/kg IV for 4 doses
then 240 mg IV
Every 3 weeks (Q3W) for 4 doses 
then every 2 weeks (Q2W)
IV
Ipilimumab 1 mg/kg IV for 4 doses Every 3 weeks (Q3W) for 4 doses IV
Cabozantinib 40 mg (20 mg tablets) Once daily (QD) PO
C Sunitinib 50 mg (12.5 mg capsules) A 6 week cycle, consisting of
once daily (QD) regimen for 4 
weeks followed by no treatment 
for 2 weeks.
PO
Abbreviations: IV=intravenous; PO= by mouth.  
Note: Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants 
previously randomized to Arm B continue with Arm B treatment and continue with Arm B clinically planned events, 
per protocol
Table 7.1-2: Dosing Schedule for CA2099ER
Arm Cycle 1 Cycle 2 Cycle 3 Cycle 4






(each cycle = 2 weeks)
Nivolumab 




40 mg PO QD
Nivolumab 




40 mg PO QD
Nivolumab 240 




40 mg PO QD
Nivolumab 




40 mg PO QD
Nivolumab 









(Cycle 1 to 4 = 3 
weeks, 
Cycle 5 and subsequent 
cyces = 2 weeks)
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab








40 mg PO QD
Nivolumab




40 mg PO QD





Table 7.1-2: Dosing Schedule for CA2099ER
Arm Cycle 1 Cycle 2 Cycle 3 Cycle 4





(each cycle = 6 weeks, 
treatment for 4 weeks 
then 2 weeks off each 
cycle)
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Sunitinib
50 mg PO QD 
x 4 weeks
Abbreviations: IV=intravenous; PO= by mouth; QD= once daily
Note: Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm B. Participants 
previously randomized to Arm B continue with Arm B treatment and continue with Arm B clinically planned events, 
per protocol
Participants should begin study treatment within 3 days (72 hours) of randomization. 
For Arm A, participants should receive nivolumab at a dose of 240 mg as an approximately 
30 minute infusion on Day 1 of each treatment cycle until progression, unacceptable toxicity, 
withdrawal of consent, completion of 24 months of treatment (from the first dose on Cycle 1), or
the end of the study, whichever occurs first. The first cabozantinib dose should be given in the 
evening on Day 1, Cycle 1 (after the Cycle 1 nivolumab dose).
For Arm B (Note: only applicable to participants who randomized to Arm B prior to Revised 
Protocol 01), when nivolumab and ipilimumab are to be administered on the same day, nivolumab 
is to be administered first. Nivolumab infusion (approximately 30 minutes) must be promptly 
followed by a flush of diluent to clear the line of nivolumab before starting the ipilimumab 
infusion. The second infusion will always be the ipilimumab study drug (approximately 30 minutes
infusion) and will start after the infusion line has been flushed, filters changed and participant has 
been observed to ensure no infusion reaction has occurred. The time in between infusions is 
expected to be at least 30 minutes (from the end of the nivolumab infusion to the start of the 
ipilimumab infusion). The first cabozantinib dose should be given in the evening on Day 1, Cycle 
1 (after the Cycle 1 nivolumab and ipilimumab doses).
Starting with Cycle 5 in Arm B, participants should receive nivolumab at a dose of 240 mg as a 
30 minute infusion on Day 1 of each treatment cycle until progression, unacceptable toxicity, 
withdrawal of consent, completion of 24 months of treatment (from the first dose on Cycle 1), or 
the end of the study, whichever occurs first.
Dosing calculations for nivolumab and ipilimumab should be based on the body weight assessed 
at baseline. It is not necessary to re-calculate subsequent doses if the participant weight is within 
10% of the weight used to calculate the previous dose. All doses should be rounded up or to the 
nearest milligram per institutional standard.
There will be no dose escalations or reductions of nivolumab or ipilimumab allowed. Participants 
may be dosed with nivolumab no less than 12 days from the previous dose during q2w cycles. 





Participants may be dosed with nivolumab and ipilimumab no less than 19 days from the previous 
dose during q3w cycles (ie, Cycles 1-4 in Arm B). Participants in Arm B may be dosed with the 
first nivolumab maintenance dose (Cycle 5) no less than 19 days from the previous nivolumab and 
ipilimumab doses. Premedications are not recommended for the first dose of nivolumab or 
ipilimumab. 
Participants should be carefully monitored for infusion reactions during nivolumab and/or 
ipilimumab administration. If an acute infusion reaction is noted, participants should be managed 
according to Section 7.4.4.
Doses of nivolumab and/or ipilimumab may be interrupted, delayed, or discontinued depending 
on how well the participant tolerates the treatment. Dosing visits are not skipped, only delayed.
The only exception is Cycle 4 in Arm B, which may be skipped (omitted) only for the reasons 
specified in Section 7.4.3.1and Section 8.1.1 below.
7.1.1 Nivolumab
Nivolumab Injection, 100 mg/10 mL (10 mg/mL) is to be administered as an IV infusion through 
a 0.2-micron to 1.2-micron pore size, low-protein binding in-line filter at the protocol-specified 
doses. It is not to be administered as an IV push or bolus injection. Please refer to the 
Investigational Brochure/pharmacy manual for further details regarding storage, preparation and 
administration. Care must be taken to assure sterility of the prepared solution as the product does 
not contain any antimicrobial preservative or bacteriostatic agent. 
7.1.2 Ipilimumab (Participants Randomized to Arm B Prior to Revised 
Protocol 01)
For details regarding ipilimumab storage, preparation, and administration, please refer to the 
instructions in the ipilimumab IB and/or pharmacy manual.
Separate infusion bags and filters should be used when administering nivolumab and ipilimumab 
on the same day.
Care must be taken to assure sterility of the prepared solutions, since the drug product does not 
contain any antimicrobial preservatives or bacteriostatic agents.  
7.1.3 Cabozantinib
Cabozantinib is taken orally on an empty stomach, preferably at bed time. Participants should fast
(with the exception of water) for at least 2 hours before until 1 hour after each dose of cabozantinib. 
Cabozantinib tablets should not be crushed or chewed. Cabozantinib should not be taken with 
grapefruit/grapefruit juice or Seville oranges. Missed doses of cabozantinib should not be taken 
within 12 hours of the next dose.
Dispense cabozantinib tablets in their original containers.
7.1.4 Sunitinib
Sunitinib is taken orally without regard to meals. Participants are to avoid grapefruit/grapefruit 
juice while on treatment with sunitinib.





7.2 Method of Treatment Assignment
All participants will be centrally randomized using an Interactive Response Technology (IRT). 
Before the study is initiated, each user will receive log in information and directions on how to 
access the IRT. Specific instructions for using IRT will be provided to the investigational site in a 
separate document. 
The investigator or designee will register the participant for enrollment by following the 
enrollment procedures established by BMS. 
Once enrolled in IRT, enrolled participants that have met all eligibility criteria, including 
determination of PD-L1 expression in the tumor sample submitted to and evaluated by the central 
laboratory, will be ready to be randomized through the IRT prior to the start of study treatment 
administration for each participant. The site will record the treatment assignment on the applicable 
case report form, if required.
Study treatment will be dispensed at the study visits as listed in Schedule of Activities (Section 2). 
7.3 Blinding
Not applicable as this is an open-label study; however, the specific treatment to be taken by a 
participant will be assigned using an Interactive Response Technology (IRT). 
Treatment assignments will be released to the bioanalytical laboratory in order to minimize 
unnecessary analysis of samples.
BICR will remain blinded to treatment assignment.
7.4 Dosage Modification 
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
In Arm A and Arm B, the assessment of causality for any AE should be performed independently 
for each study drug in the combination regimen.
In the doublet treatment arm (Arm A), cabozantinib and nivolumab will be administered at Cycle 
1. After Cycle 1, modifications in cabozantinib dosing (delay, reduction/escalation, and 
discontinuation) may occur as outlined in Section 7.4.1, Section 7.4.2, and Section 8. After Cycle 
1, nivolumab may be modified as outlined in Section 7.4.1, Section 7.4.2, and Section 8.
In the triplet treatment arm (Arm B), cabozantinib, nivolumab, and ipilimumab will be 
administered at Cycle 1. After Cycle 1, modifications in cabozantinib dosing (delay, 
reduction/escalation, and discontinuation) may occur as outlined in Section 7.4.1, Section 7.4.2, 
and Section 8. After Cycle 1, nivolumab or ipilimumab may be modified as outlined in 
Section 7.4.1, Section 7.4.2, and Section 8.





In Arm C, sunitinib will be administered at Cycle 1. After Cycle 1, modifications in sunitinib 
dosing (delay, reduction/escalation, and discontinuation) may occur as outlined in Section 7.4.1, 
Section 7.4.2, and Section 8.
7.4.1 Dose Delay Criteria 
Dose delay criteria for management of adverse events during nivolumab, ipilimumab, 
cabozantinib, or sunitinib treatment are outlined in this section. 
Dosing of nivolumab (in Arm A) or nivolumab and ipilimumab (in Arm B) may be delayed without 
delay of cabozantinib dosing if toxicity is felt to be related to only nivolumab (Arm A) or 
nivolumab and ipilimumab (Arm B) and not related to cabozantinib. Conversely, dosing of 
cabozantinib may be delayed without delay of nivolumab dosing (in Arm A) or nivolumab and 
ipilimumab dosing (in Arm B) if toxicity is felt to be related to only cabozantinib and not related 
to nivolumab (Arm A) or nivolumab and ipilimumab (Arm B). However, if toxicity is considered 
related to all study drugs or if the investigator is unable to determine which study drug is the cause 
of the AE, then all study drugs in the combination should be delayed.
Participants who require dose delay should be re-evaluated weekly or more frequently if clinically 
indicated and resume dosing when re-treatment criteria are met (see Section 7.4.3).
7.4.1.1 Dose Delay Criteria for Nivolumab and Ipilimumab
In Arm A, nivolumab administration should be delayed, and in Arm B, both nivolumab and 
ipilimumab administration should be delayed, for any of the following:
 Any Grade  2 non-skin, drug-related AE, with the exception of fatigue
 Grade 2 drug-related creatinine, AST, ALT, and/or total bilirubin abnormalities
 Any Grade 3 skin, drug-related AE
 Any Grade 3 drug-related laboratory abnormality, with the following exceptions:
o Grade 3 lymphopenia does not require dose delay
o Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatitis do not require a dose delay. 
o Grade ≥ 3 AST, ALT or total bilirubin will require dose discontinuation (see section 8.1.1)
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
During Cycles 1-4 in Arm B, both nivolumab and ipilimumab must be delayed at the same time.
Immuno-oncology agents, such as nivolumab and ipilimumab, are associated with AEs that differ 
in severity and duration than AEs caused by other therapeutic classes. Early recognition and 
management of AEs associated with immuno-oncology agents may mitigate severe toxicity. 
Management Algorithms have been developed to assist investigators in assessing and managing 













The management algorithms recommended for use in CA2099ER are included in Appendix 5.
7.4.1.2 Dose Delay Criteria for Cabozantinib
Cabozantinib dosing should be delayed for the following: 
 Urine protein/creatinine ratio (UPCR) > 2.0 or urine dipstick protein ≥ 3+ or urine protein >
2.0 g / 24 hours. Obtain 24 hour urine protein prior to next dosing visit.
 Grade 3 prolonged QTc interval (ie, QTcF interval > 500 msec on at least 2 out of 3 separate 
ECGs performed at least 3 minutes apart)
 Any Grade 2 or 3 drug-related venous thrombosis requiring anticoagulation, with the following 
exception:
 Any recurrent or worsening venous thromboembolic event after restarting cabozantinib 
will require discontinuation
 Any other Grade 2 drug-related adverse event or grade 2 drug-related laboratory abnormality 
(e.g., AST, ALT, total bilirubin) that persists for more than 1 week or worsens despite 
supportive care management, with the following exception:
 Any Grade 2 drug-related hemorrhage requires dose delay
 Grade ≥ 2 arterial thromboembolic events, including cerebrovascular ischemia, cardiac 
ischemia/infarction, peripheral or visceral arterial ischemia, require discontinuation
 Sustained Grade 3 drug-related hypertension (systolic BP  160 mm Hg or diastolic BP  100 
mm Hg). NOTE: Stopping or reducing the dose of cabozantinib is expected to cause a decrease 
in BP. The treating physician should monitor the participant for hypotension and adjust the 
number and dose of antihypertensive medications accordingly.
 Any other Grade 3 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
 Grade  3 drug-related hemorrhage requires discontinuation (Section 8.1.2).
 Drug-related AST or ALT > 8 x ULN requires discontinuation (Section 8.1.2).
 Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN, consistent with potential 
drug-induced liver injury (see Section 9.2.7), requires discontinuation (Section 8.1.2)
 Grade 3 drug-related amylase or lipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis do not require dose delay. In such cases, more 
frequent monitoring (eg, weekly) of amylase and lipase is recommended. If amylase or 
lipase worsen to Grade 4 severity or the participant develops symptoms or clinical 
manifestations of pancreatitis, dosing should be delayed.
 Grade 4 drug-related amylase or lipase abnormalities require dose delay. Participants should 
be monitored for development of symptoms or clinical manifestations of pancreatitis.
 Grade 4 drug-related electrolyte abnormalities require dose delay. Electrolyte correction with 
supplementation/appropriate management should be promptly initiated.





 Grade 4 drug-related neutropenia, lymphopenia, leukopenia, anemia, or thrombocytopenia
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying cabozantinib dosing
 For participants scheduled for major surgery, including dental surgery which may impact bone 
healing, cabozantinib dosing should be delayed at least 28 days prior to scheduled surgery. The 
treating physician should use clinical judgment with regard to the risks and benefits of the 
planned surgical procedure if it is not possible to delay cabozantinib dosing for 28 days prior 
to the procedure. A delay of cabozantinib dosing of 5 to 7 days is recommended for healing 
for minor surgery.
As a general approach, all AEs related to cabozantinib should be managed with supportive care 
when possible at the earliest signs of toxicity. Calcium, magnesium, potassium, and phosphorus 
should be kept above the lower limits of the laboratory normal values. Please refer to the 
cabozantinib IB, Appendix 10, and Appendix 11 for additional information regarding dose 
modifications and AE management.21
7.4.1.3 Dose Delay Criteria for Sunitinib
Sunitinib dose delays should be based on instructions in the approved product label and should be 
considered for any severe or intolerable drug-related adverse events.
Within a cycle, missed doses of sunitinib should be skipped. Participants should never be dosed 
during the 2-week off period of each 6-week cycle, even if treatment delays occurred earlier in the 
cycle and therapy is ready to be resumed. If treatment is delayed past the end of the 6-week cycle, 
the start of the next cycle should be delayed until treatment with sunitinib resumes.
Prior to resuming therapy after a dose delay, refer to Section 7.4.2 for dose reduction 
recommendations and Section 8 for discontinuation criteria.
For this protocol, sunitinib dosing should be delayed for any of the following:
 Urine protein/creatinine ratio (UPCR) ≥ 2.0 or urine dipstick protein ≥ 3+ or urine protein 
≥ 2.0 g / 24 hours. Obtain 24 hour urine protein prior to next dosing visit.
 Grade 3 prolonged QTc interval (ie, QTcF interval > 500 msec on at least 2 out of 3 separate 
ECGs performed at least 3 minutes apart)
 Any Grade 2 or 3 drug-related venous thrombosis requiring anticoagulation, with the following 
exception:
 Any recurrent or worsening venous thromboembolic event after restarting sunitinib will 
require discontinuation
 Any other Grade 2 drug-related adverse event that persists or worsens despite supportive care 
management, with the following exception:
 Any Grade 2 drug-related hemorrhage requires dose delay
 Grade ≥ 2 arterial thromboembolic events, including cerebrovascular ischemia, cardiac 
ischemia/infarction, peripheral or visceral arterial ischemia, require discontinuation
 Grade 3 drug-related hypertension (systolic BP  160 mm Hg or diastolic BP  100 mm Hg). 
NOTE: Stopping or reducing the dose of sunitinib is expected to cause a decrease in BP. The 





treating physician should monitor the participant for hypotension and adjust the number and 
dose of antihypertensive medications accordingly.
 Any other Grade 3 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
 Grade  3 drug-related hemorrhage requires discontinuation (Section 8.1.2).
 Drug-related AST or ALT > 8 x ULN requires discontinuation (Section 8.1.2).
 Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN, consistent with potential 
drug-induced liver injury (see Section 9.2.7), requires discontinuation (Section 8.1.2)
 Grade 3 drug-related amylase or lipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis do not require dose delay. In such cases, more 
frequent monitoring (eg, weekly) of amylase and lipase is recommended. If amylase or 
lipase worsen to Grade 4 severity or the participant develops symptoms or clinical 
manifestations of pancreatitis, dosing should be delayed.
 Grade 4 drug-related amylase or lipase abnormalities require dose delay. Participants should 
be monitored for development of symptoms or clinical manifestations of pancreatitis.
 Grade 4 drug-related electrolyte abnormalities require dose delay. Electrolyte correction with 
supplementation/appropriate management should be promptly initiated.
 Grade 4 drug-related neutropenia, lymphopenia, leukopenia, anemia, or thrombocytopenia
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying sunitinib dosing
 For participants scheduled for major surgery, including dental surgery which may impact bone 
healing, sunitinib dosing should be delayed at least 28 days prior to scheduled surgery. The 
treating physician should use clinical judgment with regard to the risks and benefits of the 
planned surgical procedure if it is not possible to delay sunitinib dosing for 28 days prior to 
the procedure. A delay of sunitinib dosing of 5 to 7 days is recommended for healing for minor 
surgery.
As a general approach, all AEs related to sunitinib should be managed with supportive care when 
possible at the earliest signs of toxicity. Calcium, magnesium, potassium, and phosphorus should 
be kept above the lower limits of the laboratory normal values. Please refer to the sunitinib 
approved product label and Appendix 10 for additional information regarding AE monitoring and
management.
7.4.2 Dose Reductions and Escalations
Dose reductions are permitted for cabozantinib and sunitinib but not for nivolumab and ipilimumab 
(see Table 7.4.2-1). 














0 (starting dose) 40 mg daily 50 mg daily 3mg/kg 1 mg/kg 240 mg



















-1 20 mg daily 37.5 mg daily - - -
-2 20 mg every other day 25 mg daily - - -
7.4.2.1 Dose Reduction and Escalation for Nivolumab and Ipilimumab
No dose reductions or dose escalations of nivolumab or ipilimumab are allowed.
7.4.2.2 Dose Reduction and Escalation for Cabozantinib
Dose reductions and dose escalations for adverse event management are allowed for cabozantinib 
(Table 7.4.2-1). Cabozantinib doses will not be re-escalated once reduced, unless a concomitant 
strong CYP3A4 inducer is started (see below). The only exception is participants who continue on 
cabozantinib alone after discontinuation of nivolumab alone (Arm A) or discontinuation of both 
nivolumab and ipilimumab (Arm B) who may re-escalate one dose level if the prior dose reduction 
was due to a toxicity felt by the investigator to have been mainly related to nivolumab and/or 
ipilimumab.
After toxicity requiring a dose delay has improved and meets the criteria to resume dosing (Section 
7.4.3.2), participants who were receiving cabozantinib 40 mg daily prior to the delay will resume 
cabozantinib at 20 mg daily. Participants who were receiving cabozantinib 20 mg daily prior to 
the delay and require another dose delay will resume cabozantinib at 20 mg every other day. If 
more than 2 dose reductions are necessary (ie, reduction to less than 20 mg every other day), 
cabozantinib must be permanently discontinued (Section 8.1.2). 
Participants who required a dose delay due to Grade 3 hypertension, which improved with 
antihypertensive medications, or any Grade 2 or 3 drug-related adverse event or asymptomatic 
laboratory abnormality that improved to Grade ≤ 1 within 7 days with supportive medical care 
may resume cabozantinib at the same dose or a reduced dose, at the discretion of the investigator.
Participants with asymptomatic Grade 2 drug-related AST, ALT or total bilirubin elevation, or 
Grade 3 drug-related lipase or amylase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis may reduce cabozantinib by one dose level, without delaying 
dosing, at the discretion of the investigator.  See also section 7.4.1.2.
In Participants Who Start Taking a Concomitant Strong CYP3A4 Inhibitor: Reduce the daily 
cabozantinib dose by 20 mg (for example, from 40 mg to 20 mg daily). Resume the dose that was 
used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the strong 
inhibitor (see Prescribing Information for cabozantinib).
7.4.2.3 Dose Reduction and Escalation for Sunitinib
Sunitinib Dose Reductions are permitted as per the approved product label for safety reasons or 
when a concomitant strong CYP3A4 inhibitor is needed (Appendix 9). Selection of an alternative 





concomitant medication with minimal or no enzyme inhibition potential is recommended 
whenever possible. 
After toxicity requiring a dose delay has improved and meets the criteria to resume dosing 
(Section 7.4.3.3), participants should resume sunitinib at one dose level reduction. Dose reductions 
should occur in 12.5 mg decrements. No more than 2 dose reductions are allowed. If more than 2 
dose reductions are necessary (ie, reduction to less than 25 mg daily), the participant must be 
permanently discontinued (Section 8.1.3).
Participants who required a dose delay due to Grade 3 hypertension, which improved with 
antihypertensive medications, or any Grade 2 or 3 drug-related adverse event or asymptomatic 
laboratory abnormality that improved to Grade ≤ 1 within 7 days with supportive medical care
may resume sunitinib at the same dose or a reduced dose, at the discretion of the investigator.
At the time a dose reduction is considered, also refer to Section 7.4.2.3 for dose delay
recommendations and Section 8.1.3 for discontinuation criteria.
Sunitinib Dose Escalations are permitted as per the approved product label when a concomitant 
CYP3A4 inducer is needed (Appendix 9). Selection of an alternative concomitant medication with 
minimal or no enzyme induction potential is recommended whenever possible. 
7.4.3 Criteria to Resume Treatment
7.4.3.1 Criteria to Resume Nivolumab and Ipilimumab Treatment
Delayed doses of nivolumab and/or ipilimumab should be administered as soon as the participant 
meets criteria to resume treatment. If a dose has been delayed, the participant should not wait until 
the next scheduled dosing date.
Participants may resume treatment with study drug when the drug-related AE(s) resolve to 
Grade  1 or baseline value, with the following exceptions:
 Participants may resume treatment in the presence of Grade 2 fatigue. 
 Participants who have not experienced a Grade 3 drug-related skin AE may resume treatment 
in the presence of Grade 2 skin toxicity. 
 For participants with Grade 2 AST, ALT, and/or total bilirubin abnormalities, dosing may 
resume when laboratory values return to baseline and management with corticosteroids, if 
needed, has been completed.
 Drug-related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline before 
treatment is resumed. Participants with persistent Grade 1 pneumonitis after completion of a 
steroid taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by the BMS Medical Monitor or designee.
 Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment.
 If treatment is delayed > 6 weeks, the participant must be permanently discontinued from study 
therapy, except as specified in Section 8.1.1.





For Arm B participants who delay nivolumab and ipilimumab dosing after Cycle 1 or 2, both 
nivolumab and ipilimumab must be resumed on the same day when the criteria to resume treatment 
are met. 
For Arm B participants who delay nivolumab and ipilimumab dosing after Cycle 3 due to any
drug-related AE meeting dose delay criteria that does not resolve within 14 days or requires 
treatment with systemic corticosteroids, it is acceptable to omit Cycle 4 if the investigator feels 
that ipilimumab was the main cause of the toxicity requiring dose delay. In this situation, when the 
participant meets criteria to resume nivolumab, the participant may proceed to Cycle 5 and begin 
nivolumab monotherapy maintenance.
7.4.3.2 Criteria to Resume Cabozantinib Treatment
Participants may resume treatment with cabozantinib when the drug-related AE(s) resolve to 
Grade  1 or baseline value, with the following exceptions:
 Participants may resume dosing in the presence of Grade 2 fatigue
 Participants who delayed dosing due to prolonged QTcF may resume dosing at one reduced 
dose level once QTcF returns to ≤ 500 msec
 Participants who delayed dosing due to UPCR > 2.0 or urine dipstick protein ≥ 3+ or urine 
protein > 2.0 g / 24 may resume dosing at one dose level reduction when UPCR is ≤ 2.0 or 24 
hour urine protein ≤ 2.0 g /24
 Participants who delayed dosing due to Grade 3 hypertension may resume dosing at the same 
dose or at one dose level reduction, at the discretion of the investigator, when hypertension has 
improved to Grade  2
 Participants who delayed dosing due to Grade 4 lipase or amylase abnormalities may resume 
dosing upon resolution to Grade  2
 Participants who delayed dosing due to major surgery should not resume cabozantinib until 
complete wound healing has taken place. Following cabozantinib resumption, participants 
should be monitored for wound dehiscence, wound infections, and other signs of impaired 
wound healing.
 Participants who develop a pulmonary embolism and/or DVT should have study treatment 
interrupted until therapeutic anticoagulation is established. Treatment with cabozantinib may 
be resumed in subjects with pulmonary embolism or DVT if it is determined that the event is 
uncomplicated and that the subject is deriving clinical benefit from cabozantinib treatment and 
that anticoagulation does not place them at a significant risk that outweighs the benefit of 
resuming treatment per discretion of the investigator.
 Participants who delayed dosing due to  Grade 2 hemorrhage may resume dosing if bleeding 
is under control (recovered to at least Grade 1 level) and has a low risk of recurrence
 If treatment is delayed > 6 weeks for any reason, the participant must be permanently 
discontinued from study therapy, except in cases where permission to resume treatment is 
granted by the BMS Medical Monitor or designee.





7.4.3.3 Criteria to Resume Sunitinib Treatment
Within a cycle, missed doses of sunitinib should be skipped and not replaced. Participants should 
never be dosed during the 2-week off period of each 6-week cycle, even if treatment delays 
occurred earlier in the cycle and therapy is ready to be resumed. If treatment is delayed past the 
end of the 6-week cycle, the start of the next cycle should be delayed until treatment with sunitinib 
resumes.
Participants may resume treatment with sunitinib when the drug-related AE(s) resolve to Grade  1 
or baseline value, with the following exceptions:
 Participants may resume dosing in the presence of Grade 2 fatigue
 Participants who delayed dosing due to prolonged QTcF may resume dosing at one reduced 
dose level once QTcF returns to ≤ 500 msec
 Participants who delayed dosing due to UPCR ≥ 2.0 or urine dipstick protein ≥ 3+ may resume 
dosing at one dose level reduction when 24 hour urine protein < 2.0 g
 Participants who delayed dosing due to Grade 3 hypertension may resume dosing at the same 
dose or at one dose level reduction, at the discretion of the investigator, when hypertension has 
improved to Grade  2
 Participants who delayed dosing due to Grade 4 lipase or amylase abnormalities may resume 
dosing upon resolution to Grade  2
 Participants who develop a pulmonary embolism and/or DVT should have study treatment 
interrupted until therapeutic anticoagulation is established. Treatment with cabozantinib may 
be resumed in subjects with pulmonary embolism or DVT if it is determined that the event is 
uncomplicated and that the subject is deriving clinical benefit from cabozantinib treatment and 
that anticoagulation does not place them at a significant risk that outweighs the benefit of 
resuming treatment per discretion of the investigator.
 Participants who delayed dosing due to  Grade 2 hemorrhage may resume dosing if bleeding 
is under control (recovered to at least Grade 1 level) and has a low risk of recurrence
 If treatment is delayed > 6 weeks for any reason, the participant must be permanently 
discontinued from study therapy, except in cases where permission to resume treatment is 
granted by the BMS Medical Monitor or designee.
7.4.4 Treatment of Nivolumab- or Ipilimumab-Related Infusion Reactions
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, they are 
unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such a 
reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, 
arthralgias, hypotension, hypertension, bronchospasm, or other allergic-like reactions. Regardless 
of whether or not the event is attributed to the study drugs, all Grade 3 or 4 infusion reactions 
should be reported within 24 hours to the study BMS Medical Monitor or designee and reported 
as an SAE if it meets the criteria. Infusion reactions should be graded according to NCI CTCAE 
(Version 4) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:





For Grade 1 symptoms: (mild reaction; infusion interruption not indicated; intervention not 
indicated):
 Remain at bedside and monitor participant until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg at least 30 minutes before 
additional study drug administrations.
For Grade 2 symptoms: (moderate reaction required therapy or infusion interruption but responds 
promptly to symptomatic treatment (eg, antihistamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for  24 
hours):
 Stop the study drug infusion, begin an IV infusion of normal saline, and treat the participant 
with diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 
1000 mg; remain at bedside and monitor participant until resolution of symptoms. 
Corticosteroid and/or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor participant closely. If symptoms recur, 
then no further study dug will be administered at that visit.
 For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg 
should be administered at least 30 minutes before study drug infusions. If necessary, 
corticosteroids (up to 25 mg of hydrocortisone or equivalent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prolonged [ie, not rapidly responsive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improvement; hospitalization indicated for other clinical sequelae (eg, renal impairment, 
pulmonary infiltrates). Grade 4: Life-threatening; pressor or ventilatory support indicated):
 Immediately discontinue infusion of study drug. Begin an IV infusion of normal saline and 
treat the participant as follows: Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Participant should be monitored 
until the Investigator is comfortable that the symptoms will not recur. Study drug will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor participant until recovery of the 
symptoms.
In case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 





study Participants. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment
should not be dispensed and contact BMS immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
 Further guidance and information for final disposition of unused study treatment are provided 
in Appendix 2.
7.5.1 Retained Samples for Bioavailability / Bioequivalence
Not applicable.
7.6 Treatment Compliance
Study treatment compliance will be periodically monitored by drug accountability (including 
review of dosing diary cards, as applicable). Drug accountability should be reviewed by the site 
study staff at each visit to confirm treatment compliance. Sites should discuss discrepancies with 
the participant at each on-treatment study visit. 
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unless utilized to treat a drug related 
adverse event):
 Immunosuppressive agents
 Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.3)
 Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
extensive, non-palliative radiation therapy, or standard or investigational agents)
 Chronic co-administration of cabozantinib with strong inducers of the CYP3A4 family (eg, 
phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John’s Wort) 
may significantly decrease cabozantinib concentrations and must be avoided. Selection of 
alternate concomitant medications with no or minimal CYP3A4 enzyme induction potential is 
recommended. Caution must be used when discontinuing treatment with a strong CYP3A4 
inducer in a subject who has been concurrently receiving a stable dose of cabozantinib, as this 
could significantly increase the exposure to cabozantinib.
 Any botanical preparation (eg herbal supplements or traditional Chinese medicines) intended 
to treat the disease under study or provide supportive care. Use of marijuana and its derivatives 
for treatment of symptoms related to cancer or cancer treatment are permitted if obtained by 





medical prescription or if its use (even without a medical prescription) has been legalized 
locally.  
 Any live/attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and
measles, mumps, rubella (MMR)) during treatment and until 100 days post last dose.
Supportive care for disease-related symptoms may be offered to all participants on the trial.
7.7.2 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization are excluded. Inhaled or topical steroids, and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
7.7.2.1 Restrictions and Precautions for Cabozantinib
Cabozantinib is highly protein bound (99.9%) to human plasma proteins. Concomitant 
medications that are highly protein bound (eg, diazepam, furosemide, dicloxacillin, propanolol) 
should be used with caution. Because warfarin is a highly protein bound drug with a low 
therapeutic index, administration of warfarin should be avoided in participants receiving 
cabozantinib in Arms A and B. 
Cabozantinib has been associated with a mild prolongation of the QTc interval. Caution should be 
used when treating participants on cabozantinib in Arms A and B with other drugs associated with 
QTc prolongation. Additional QTc monitoring is suggested for participants who are treated 
concomitantly with QTc prolonging drugs.
Low-dose aspirin for cardioprotection (as per local applicable guidelines) and low-dose low 
molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of 
LMWH is allowed in participants without known brain metastases who are on a stable dose of 
LMWH for at least 3 weeks before first dose of study treatment, and who have had no clinically 
significant hemorrhagic complications from the anticoagulation regimen or the tumor.
While on study, invasive dental procedures (eg, extractions, dental implants) should be avoided 
and conservative dental therapy, such as endodontic therapy (root canal treatment) would be 
preferred. After a surgical dental procedure, allow complete wound healing before resuming with 
cabozantinib treatment. 
7.7.2.2 Restrictions and Precautions for Sunitinib
Sunitinib is metabolized by CYP3A4. Arm C participants who initiate CYP3A4 
inhibitors/inducers after randomization should follow sunitinib dose modification instructions.
Sunitinib has been shown to prolong the QTc interval. Concomitant treatment with dysrhythmic 
drugs (ie, terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, haloperidol, 
risperidone, and indapamide) is not recommended.
Medications taken within 4 weeks prior to study drug administration must be recorded on the CRF.





7.7.2.3 Imaging Restriction and Precautions
It is the local imaging facility’s responsibility to determine, based on participant attributes 
(eg, allergy history, diabetic history and renal status), the appropriate imaging modality and 
contrast regimen for each participant. Imaging contraindications and contrast risks should be 
considered in this assessment. Participants with renal insufficiency should be assessed as to 
whether or not they should receive contrast and if so, what type and dose of contrast is appropriate. 
Specific to MRI, participants with severe renal insufficiency (ie, estimated glomerular filtration 
rate [eGFR] < 30 mL/min/1.73 m2) are at increased risk of nephrogenic systemic fibrosis. MRI 
contrast should not be given to this participant population. In addition, participants are 
contraindicated from MRI if they have tattoos, metallic implants, pacemakers, etc.
The ultimate decision to perform MRI in an individual participant in this study rests with the site 
radiologist, the investigator and the standard set by the local Ethics Committee.
7.7.3 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg 
daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for 
prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions 
(eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.
Concomitant medications are recorded at baseline and throughout the treatment phase of the study 
in the appropriate section of the CRF. All medications (prescriptions or over the counter 
medications) continued at the start of the study or started during the study and different from the 
study drug must be documented in the concomitant therapy section of the CRF.
7.8 Treatment After the End of the Study
At the conclusion of the study, participants who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study treatment for the maximum treatment duration specified in 
protocol Section 7.1. Study treatment will be provided via an extension of the study, a rollover 
study requiring approval by responsible health authority and ethics committee or through another 
mechanism at the discretion of BMS.
BMS reserves the right to terminate access to BMS supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) the development of the nivolumab, 
ipilimumab, cabozantinib, or sunitinib is terminated for other reasons, including but not limited to 
lack of efficacy and/or not meeting the study objectives; c) the participant can obtain medication 
from a government sponsored or private health program. In all cases BMS will follow local 
regulations.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Participants MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:





 Participant’s request to stop study treatment. Participants who request to discontinue study 
treatment will remain in the study and must continue to be followed for protocol specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provide this information
 Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the best 
interest of the participant
 Termination of the study by Bristol-Myers Squibb (BMS)
 Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness. (Note: Under 
specific circumstances, and only in countries where local regulations permit, a participant who 
has been imprisoned may be permitted to continue as a participant. Strict conditions apply and 
BMS approval is required.)
 Criteria listed in 8.1.1
 Disease progression of RCC or occurrence of a secondary malignancy which requires systemic 
therapy for treatment
Refer to the Schedule of Activities for data to be collected at the time of treatment discontinuation 
and follow-up and for any further evaluations that can be completed.
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the study treatment will be permanently 
discontinued in an appropriate manner (eg, dose tapering if necessary for participant safety). Please 
call the BMS Medical Monitor within 24 hours of awareness of the pregnancy. If the investigator 
determines a possible favorable benefit/risk ratio that warrants continuation of study treatment, a 
discussion between the investigator and the BMS Medical Monitor/designee must occur.
All participants who discontinue study treatment should comply with protocol specified follow-up 
procedures as outlined in Section 2. The only exception to this requirement is when a participant
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is discontinued prior to the participant’s completion of the study, the reason for 
the discontinuation must be documented in the participant’s medical records and entered on the 
appropriate case report form (CRF) page.
8.1.1 Nivolumab and Ipilimumab Dose Discontinuation (Arms A and B)
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
The assessment for discontinuation of nivolumab, ipilimumab, and cabozantinib should be made 
separately for each study drug. Although there is overlap among the discontinuation criteria, if 





discontinuation criteria are met for one study drug but not the other(s), it may be acceptable to 
continue treatment with the study drug(s) that are not felt to be related the toxicity, as specified 
below. If the investigator considers the toxicity to be related to all study drugs or is unable to 
determine which of the study drug(s) in Arm A or Arm B are the cause of toxicity, then all study 
drugs in the treatment regimen should be discontinued, and the recommendations for management 
of toxicity related to all study drugs should be promptly initiated.
Nivolumab and/or ipilimumab treatment should be permanently discontinued for any of the
following:
 Any Grade 2 drug-related uveitis, eye pain or blurred vision that does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-treatment period OR requires 
systemic treatment 
 Any Grade 3 non-skin, drug-related adverse event lasting > 7 days, or recurs with the following 
exceptions for laboratory abnormalities, diarrhea, colitis, neurologic toxicity, drug-related 
uveitis, pneumonitis, bronchospasm, hypersensitivity reactions, infusion reactions, and 
endocrinopathies:
 Grade 3 drug-related diarrhea, colitis, neurologic toxicity, uveitis, pneumonitis, 
bronchospasm, myocarditis, hypersensitivity reaction, or infusion reaction of any duration 
requires discontinuation. NOTE: The diagnosis of colitis should be supported by findings 
on colonoscopy whenever possible.
 Grade 3 drug-related endocrinopathies, adequately controlled with only physiologic 
hormone replacement do not require discontinuation. Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement.
 Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
 Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuation
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
require discontinuation:
o Grade ≥ 3 drug-related AST, ALT or Total Bilirubin requires discontinuation*
o Concurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
* In most cases of Grade 3 AST or ALT elevation, study drug(s) will be 
permanently discontinued. If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study drug(s), a discussion 
between the investigator and the BMS Medical Monitor/designee must occur.
 Any Grade 4 drug-related adverse event or laboratory abnormality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the following events which do not 
require discontinuation:
 Grade 4 neutropenia ≤ 7 days
 Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase





 Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset
 Grade 4 drug-related endocrinopathy adverse events, such as, hyper- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately controlled with physiologic 
hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, 
respectively, may not require discontinuation after discussion with and approval from the 
BMS Medical Monitor or designee.
 Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires 
discontinuation, with the following exceptions:
 Dosing delays to allow for prolonged steroid tapers to manage drug-related adverse events 
are allowed. 
 Dosing delays lasting > 6 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS Medical Monitor or designee. 
Prior to re-initiating treatment in a participant with a dosing delay lasting > 6 weeks, the BMS 
Medical Monitor or designee must be consulted. Tumor assessments should continue as per 
protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory studies 
should also continue every 6 weeks or more frequently if clinically indicated during such dosing 
delays.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued nivolumab 
dosing.
Participants in Arm B who meet any of the discontinuation criteria above prior to Cycle 3 must 
discontinue both nivolumab and ipilimumab and may not receive nivolumab monotherapy 
maintenance. 
Participants in Arm B who meet any of the discontinuation criteria above after Cycle 3 or Cycle 4 
may be able to proceed to Cycle 5 (skipping Cycle 4 if needed) to begin nivolumab monotherapy 
maintenance if the toxicity is felt to be related mainly to ipilimumab, only after discussion with 
and approval by the BMS Medical Monitor or designee.
8.1.2 Cabozantinib Dose Discontinuation
Permanently discontinue cabozantinib for participants with any of the following:
 Any requirement for more than 2 cabozantinib dose reductions (ie, reduction to less than 20 
mg every other day)
 Any Grade  2 drug-related arterial thromboembolic events, including cerebrovascular 
ischemia, cardiac ischemia/infarction, peripheral or visceral arterial ischemia
 Any Grade ≥ 3 drug-related hemorrhage
 Grade 4 hypertension or persistent Grade 3 hypertension despite optimal medical management 
and cabozantinib dose reduction
 Drug-related reversible posterior leukoencephalopathy syndrome





 Development of drug-related fistula or GI perforation
 Drug-related nephrotic syndrome
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
requires discontinuation:
 AST or ALT > 8 x ULN.
 Concurrent AST or ALT > 3 x ULN and total bilirubin >2 x ULN, consistent with potential 
drug-induced liver injury (see Section 9.2.7).
 Any Grade 4 drug-related adverse event or laboratory abnormality, with the following 
exceptions:
 Grade 4 neutropenia  7 days
 Grade 4 lymphopenia or leukopenia
 Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatitis
 Isolated Grade 4 electrolyte abnormalities that are not associated with clinical sequelae and 
are corrected with supplementation/appropriate management within 72 hours of their onset
 Any dosing interruption lasting > 6 weeks unless the BMS Medical Monitor or designee is 
consulted and agrees with the rationale for resuming therapy after a delay > 6 weeks. Note that
tumor assessments should continue as per protocol even if dosing is interrupted.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued 
cabozantinib dosing.
8.1.3 Sunitinib Dose Discontinuation
Treatment with sunitinib should be permanently discontinued for any of the following:
 Any requirement for more than 2 sunitinib dose reductions (ie, reduction to less than 25 mg 
daily)
 Any Grade drug-related arterial thrombosis.
 Grade  drug-related hemorrhage or recurrent Grade 3 drug-related hemorrhage after dose 
reduction.
 Grade 4 drug-related symptomatic venous thrombosis.
 Grade 4 drug-related cardiac toxicity.
 Grade 4 hypertension or persistent Grade 3 hypertension despite optimal medical management 
and sunitinib dose reduction
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
requires discontinuation:
o AST or ALT > 8 x ULN.
o Concurrent AST or ALT > 3 x ULN and total bilirubin >2 x ULN, consistent with 
potential drug-induced liver injury (see Section 9.2.7).
 Any other Grade 4 drug-related adverse event or laboratory abnormality, with the following 
exceptions:





 Grade 4 neutropenia  7 days
 Grade 4 lymphopenia or leukopenia
 Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatitis
 Isolated Grade 4 electrolyte abnormalities that are not associated with clinical sequelae and 
are corrected with supplementation/appropriate management within 72 hours of their onset
 Any dosing interruption lasting > 6 weeks unless the BMS Medical Monitor or designee is 
consulted and agrees with the rationale for resuming therapy after a delay > 6 weeks. Note that 
tumor assessments should continue as per protocol even if dosing is interrupted.
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the participant with continued sunitinib 
dosing.
8.1.4 Treatment Beyond Disease Progression
Accumulating evidence indicates a minority of participants treated with immunotherapy or 
anti-angiogenic therapy may derive clinical benefit despite initial evidence of PD.19,51,52
Participants, regardless of study arm, will be permitted to continue treatment beyond initial 
RECIST 1.1 defined PD, assessed by the investigator, up to a maximum of 24 months from the 
date of first dose, as long as they meet the following criteria:
 Investigator-assessed clinical benefit
 Tolerance of study drug
 Stable performance status
 Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (eg, CNS metastases)
 Participant provides written informed consent prior to receiving additional treatment with the 
study drug regimen. All other elements of the main consent including description of reasonably 
foreseeable risks or discomforts, or other alternative treatment options will still apply.
A radiographic assessment/ scan should be performed within 6 weeks of initial investigator-
assessed progression to determine whether there has been a decrease in the tumor size or continued 
PD. The assessment of clinical benefit should be balanced by clinical judgment as to whether the 
participant is clinically deteriorating and unlikely to receive any benefit from continued treatment 
with nivolumab.
If the investigator feels that the participant continues to achieve clinical benefit by continuing 
treatment, the participant should remain on the trial and continue to receive monitoring according 
to the Schedule of Activities Schedule in Section 2.  Treatment may be continued beyond 
investigator-assessed progression if the investigator confirms that the participant meets the criteria 
specified in Section 8.1.4.
For the participants who continue study therapy beyond progression, further progression is defined 
as an additional 10% increase in tumor burden with a minimum 5 mm absolute increase from time 
of initial PD. This includes an increase in the sum of diameters of all target lesions and/ or the 





diameters of new measurable lesions compared to the time of initial PD. It is recommended that 
study treatment should be discontinued permanently upon documentation of further progression.
New lesions are considered measureable at the time of initial progression if the longest diameter 
is at least 10 mm (except for pathological lymph nodes which must have a short axis of at least15 
mm). Any new lesion considered non-measureable at the time of initial progression may become 
measureable and therefore included in the tumor burden if the longest diameter increases to at least 
10 mm (except for pathological lymph nodes which must have a short axis of at least 15 mm). In 
situations where the relative increase in total tumor burden by 10% is solely due to inclusion of 
new lesions which become measurable, these new lesions must demonstrate an absolute increase 
of at least 5 mm.
8.1.5 Post-Study Treatment Follow-up
In this study, overall survival is a key endpoint of the study. Post-study treatment follow-up is of 
critical importance and is essential to preserving participant safety and the integrity of the study. 
Participants who discontinue study treatment must continue to be followed for collection of 
outcome and/or survival follow-up data as required and in line with Section 5 until death or the 
conclusion of the study.
BMS may request that survival data be collected on all treated/randomized participants outside of 
the protocol defined window (See Section 2). At the time of this request, each participant will be 
contacted to determine their survival status unless the participant has withdrawn consent for all 
contacts or is lost to follow-up.
8.2 Discontinuation from the Study
Participants who request to discontinue study treatment will remain in the study and must continue 
to be followed for protocol specified follow-up procedures. The only exception to this is when a 
participant specifically withdraws consent for any further contact with him/her or persons 
previously authorized by participant to provide this information. 
 Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
 The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study treatment only 
or also from study procedures and/or post treatment study follow-up, and entered on the 
appropriate CRF page.
 In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
 If the participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.3 Lost to Follow-Up
 All reasonable efforts must be made to locate participants to determine and report their ongoing 
status. This includes follow-up with persons authorized by the participant.





 Lost to follow-up is defined by the inability to reach the participant after a minimum of three
documented phone calls, faxes, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in the participant’s medical records.
 If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
 If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the participant’s informed consent, then the investigator may use a 
Sponsor retained third-party representative to assist site staff with obtaining participant’s 
contact information or other public vital status data necessary to complete the follow-up 
portion of the study. 
 The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.
 If after all attempts, the participant remains lost to follow-up, then the last known alive date as 
determined by the investigator should be reported and documented in the participant’s medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
 Study procedures and timing are summarized in the Schedule of Activities. 
 Protocol waivers or exemptions are not allowed.
 All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
 Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.
 All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria before randomization. The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
 Procedures conducted as part of the participant’s routine clinical management (eg, blood count) 
and obtained before signing of informed consent may be utilized for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
Additional measures, including non-study required laboratory tests, should be performed as 
clinically indicated or to comply with local regulations. Laboratory toxicities (eg, suspected drug 
induced liver enzyme evaluations) will be monitored during the follow-up phase via on site/local 
labs until all study drug related toxicities resolve, return to baseline, or are deemed irreversible.
If a participant shows pulmonary-related signs (hypoxia, fever) or symptoms (eg, dyspnea, cough, 
fever) consistent with possible pulmonary adverse events, the participant should be immediately 





evaluated to rule out pulmonary toxicity, according to the suspected pulmonary toxicity 
management algorithm in the BMS-936558 (nivolumab) Investigator Brochure.
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating physician. Additional testing or 
assessments may be performed as clinically necessary or where required by institutional or local 
regulations.
9.1 Efficacy Assessments
Study evaluations will take place in accordance with the Schedule of Activities in Section 2.
Images will be submitted to an imaging core lab. Sites should be trained prior to scanning the first 
study participant. Image acquisition guidelines and submission process will be outlined in the 
CA2099ER Imaging Manual to be provided by the core lab. 
9.1.1 Methods of Measurements
The following imaging assessments should be performed at pre-specified intervals: CT of the 
chest, CT or MRI of the abdomen, pelvis, and other known sites of disease.
 CT scans should be acquired with slice thickness of 5 mm or less with no intervening gap 
(continuous) 
 Should a participant have a contraindication for CT IV contrast, a non-contrast CT of the chest 
and a contrast enhanced MRI of the abdomen and pelvis and other sites of disease may be 
obtained. MRIs should be acquired with slice thickness of 5 mm or less with no gap 
(continuous).
 Every attempt should be made to image each participant using an identical acquisition protocol 
on the same scanner for all imaging time points
 PET alone will not be considered for the disease assessment. Complementary CT and/or MRI 
or biopsy must be performed in such cases. 
Note: Use of CT component of a PET/CT scanner: Combined modality scanning, such as with 
FDG-PET/CT, is increasingly used in clinical care and is a modality/technology that is in rapid 
evolution; therefore, the recommendations outlined here may change rather quickly with time. 
At present, low-dose or attenuation correction CT portions of a combined FDG-PET/CT are of 
limited use in anatomically-based efficacy assessments, and it is, therefore, suggested that they 
should not be substituted for dedicated diagnostic contrast enhanced CT scans for 
anatomically-based RECIST (Appendix 8) measurements. However, if a site can document 
that the CT performed as part of a FDG-PET/CT is of identical diagnostic quality to a 
diagnostic CT (with IV and oral contrast), then the CT portion of the FDG-PET/CT can be 
used for RECIST 1.1 measurements. Note, however, that the FDG-PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially 
performed. 





9.1.2 Imaging and Clinical Assessment 
Images will be submitted to an imaging core lab. Sites should be trained prior to scanning the first 
study participant. Image acquisition guidelines and submission process will be outlined in the 
CA2099ER Imaging Manual to be provided by the core lab. 
Baseline imaging, including CT/MRI of the chest, abdomen, pelvis, and all known sites of disease
performed within 28 days prior to randomization, should be submitted to the imaging core lab.
Baseline brain MRI (preferred) or CT scan should also be performed within 28 days prior to 
randomization and submitted to the imaging core lab. Participants who are found to have untreated 
brain metastases on the baseline brain scan may not be randomized.
9.1.2.1 Investigator Assessment of Progression
The same method of assessment used at Screening should be used for on-study time points. Brain 
MRI or CT scans during on-study time points and the follow-up phase are only required in 
participants with a history of CNS metastases prior to randomization or if clinically indicated for 
new signs or symptoms that suggest new or worsening CNS metastases. 
Post-baseline tumor assessments will be performed at the time points described below until 
progression assessed by the investigator and confirmed by BICR, death, or withdrawal from the 
study, whichever occurs first. 
 First tumor assessment post-baseline should be performed at Week 12 (± 7 days) following 
randomization. Use same imaging method as was used at screening/baseline. 
 Subsequent tumor assessments should occur at every 6 weeks until Week 60. Allowable 
window for assessments is ± 7 days until Week 60. After Week 60, tumor assessments should 
occur every 12 weeks (± 14 days) until radiographic progression, assessed by the investigator 
and confirmed by the BICR. 
 Additional imaging of potential disease sites should be performed whenever disease 
progression or a secondary malignancy is suspected. In participants with no history of brain 
lesions prior to randomization, brain MRI or CT on-study treatment should be obtained if 
clinically indicated. Bone imaging during on-study treatment and follow-up periods should be 
obtained if clinically indicated.
 Tumor assessments are to continue for all randomized participants according to the protocol 
schedule until radiographic progression has been assessed by the investigator and confirmed 
by the BICR, regardless of whether study drug dosing is delayed, reduced, or discontinued.
The investigator (in consultation with the local radiologist as needed) will complete tumor 
assessments using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria on all 
imaging time points specified in the protocol. Any additional imaging that may demonstrate tumor 
response or progression, including scans performed at unscheduled time points and/or at an outside 
institution, should also be collected for the investigator to complete RECIST 1.1 tumor 
assessments on these images and to submit them for BICR review.





All study treatment decisions will be based on the investigator’s assessment of tumor images and 
not on the BICR assessment.
9.1.2.2 BICR Assessment of Progression
Sites should submit all scans to a BICR on a rolling basis, preferably within 7 days of scan 
acquisition, throughout the duration of the study. BICR will review scans on a rolling basis and 
remain blinded to treatment arm and investigator assessment of submitted scans. When progression
per RECIST 1.1 criteria is assessed by the investigator, the site will inform the imaging core lab,
so that the BICR assessment of progression can be performed. The BICR review will be completed 
and the results provided to the site within approximately 14 days of receipt of the scans, provided 
there are no pending imaging queries to the site. 
Participants whose progression is not confirmed by the BICR will be required to continue tumor 
assessments (if clinically feasible) according to the protocol-specified schedule or sooner if 
clinically indicated until the BICR confirms progression on a subsequent tumor assessment. Also, 
if participants discontinue treatment without radiographic progression, tumor assessments will 
continue according to the protocol specified schedule, as noted in Section 2, until progression has 
been confirmed by BICR.
All study treatment decisions will be based on the investigator’s assessment of tumor images and 
not on the BICR assessment. The BICR assessment of progression is only relevant for determining 
when tumor assessments for a given participant are no longer required to be submitted to the 
imaging vendor.
9.1.3 Imaging Restriction and Precautions
Table 9.1.3-1 provides a summary of the alternative methods, acceptable per protocol, in the event 
of contraindications for use of IV and oral contrast, and or/MRI. 
Table 9.1.3-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions
Anatomic Region Preferred Method Alternative Methods
Chest, abdomen, 
and pelvis
Note: Scan must 
cover lung apices to 
diaphragm, 
diaphragm through 
entire liver, and to 
below the pubic 
symphysis
CT with IV contrast
For chest:
 CT without contrast can be used only if the participant has a 
clinical contraindication for iodine-based IV contrast (eg,
hypersensitivity, renal insufficiency)
For abdomen and pelvis:
 MRI with gadolinium-based IV contrast is the first alternative 
method if the participant has a clinical contraindication for 
iodine-based IV contrast
 CT without contrast can be used as the second alternative 
method only if the participant has a clinical contraindication 
for both contrast-enhanced CT and MRI.
Brain MRI with IV contrast
 CT with IV contrast is the first alternative method if IV 
gadolinium is clinically contraindicated. 





Table 9.1.3-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions
Anatomic Region Preferred Method Alternative Methods
 MRI without contrast can be used as a second alternative 
method if a participant has clinical contraindications for both 
contrast-enhanced CT and MRI
Bone Bone scintigraphy PET (18F-fluoride NaF or FDG) and 99m Technetium SPECT
Notes:
1. CT scans must be performed with slices thickness of  5 mm are required. The reconstruction interval should be 
equal to slice thickness to avoid gap. 
2. The same modality for a given anatomical coverage and the same scanning procedure (most importantly: 
reconstruction slice thickness, anatomic coverage, use of IV contrast) should be consistent between baseline and 
all subsequent follow-up scanning. If possible, the same scanner or an equivalent scanners should be used 
throughout the study. 
3. For abdomen and pelvis CT scans, oral contrast is recommended as per institutional standards. 
4. MRI should include T1 and T2-weighted sequences with T1-weighted at both pre- and post-contrast. 
5. If bone scan shows hotspots indicative of metastases, further investigation with X-ray, CT, or MRI is warranted. 
6. All scans generated should be exportable in electronic format (DICOM) to enable secure and rapid electronic 
transmission to the designated central imaging laboratory. 
The use of gadolinium-based contrast agents in participants with acute or chronic renal 
insufficiency, with a glomerular filtration rate (GFR) less than 30 mL per minute per 1.73m2 or 
with any acute renal failure caused by hepatorenal syndrome or perioperative liver transplantation, 
is not recommended. 
If gadolinium is contraindicated, proceed without contrast but reason for not using contrast must 
be documented. 
9.1.4 Outcomes Research Assessments 
Participant-reported outcomes will be captured through the use of 2 validated self-reported 
questionnaires: the National Comprehensive Cancer Network (NCCN) Functional Assessment of 
Cancer Therapy - Kidney Symptom Index (FKSI-19), and the EuroQoL Group’s EQ-5D-3L. 
9.1.4.1 FKSI-19
The NCCN FKSI-19 53 54 is a 19-item scale that measures tumor specific HrQoL in kidney cancer 
participants. The FKSI-19 uses 5 Likert-type response categories that range from “not at all” to 
“very much.” Participants are asked to circle the response category that best characterizes their 
response over the last 7 days on 19 items that include symptoms such as lack of energy, fatigue, 
appetite, coughing, shortness of breath, pain, nausea, and ability to work. The instrument yields a 
total score and three subscale scores: Disease Related Symptoms (DRS), Treatment Side Effects 
(TSE), and Functional Well Being (FWB). A higher score indicates fewer symptoms.






The 3-level version of the EQ-5D (EQ-5D-3L)55 will be used to assess treatment effects on 
perceived health status and to generate utility data for health economic evaluations. The EQ-5D-
3L is a generic multi-attribute health-state classification system by which health is described in 5 
dimensions (ie, mobility, self-care, usual activities, pain/discomfort, and anxiety) and depression. 
Each dimension is evaluated using 3 levels: no problems, some problems, and severe problems.
Responses to these 5 dimensions are converted into 1 of 243 unique EQ-5D health state 
descriptions, which range between no problems on all 5 dimensions [11111] to severe/extreme 
problems on all 5 dimensions [33333]. Using appropriate country-specific value weighting 
algorithms, a respondent’s self-described health state can be converted into a utility index 
representing the societal desirability of his/her own health. In addition, the EQ-5D includes a VAS 
allowing a respondent to rate his/her health on a scale 0–100, with 0 being the worst health state 
and 100 being the best health state imaginable.
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3
Immune-mediated adverse events (IMAEs, imAEs) are AEs consistent with an immune-mediated 
mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection 
or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology 
which were exacerbated by the induction of autoimmunity. Information supporting the assessment 
will be collected on the participant’s case report form.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information should begin at initiation of study treatment until the 
timepoints specified in the Schedule of Activities (Section 2). Nonserious AE information should 
also be collected from the start of a placebo lead-in period or other observational period intended 
to establish a baseline status for the participants.
Sections 5.6.1 and 5.6.2 in the Investigator Brochures (IBs) for Nivolumab28 and Ipilimumab29
represent the Reference Safety Information (also Appendix K in the IB for cabozantinib21) to 
determine expectedness of serious adverse events for expedited reporting. Following the 
participant’s written consent to participate in the study, all SAEs, whether related or not related to 
study drug, must be collected, including those thought to be associated with protocol-specified 
procedures.





All SAEs must be collected that occur during the screening period and within 100 days of the last 
dose of study treatment. For participants randomized to treatment and never treated with study 
drug, SAEs should be collected for 30 days from the date of randomization. If applicable, SAEs 
must be collected that relate to any later protocol-specified procedure (eg, a follow-up skin biopsy).
The investigator must report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure.
 Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF section.
 All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3. 
 The investigator will submit any updated SAE data to the sponsor within 24 hours of this being 
available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participation, the investigator must promptly notify the sponsor.
The method of evaluating, and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a participant. Care should be taken not to introduce bias when 
collecting AE and/or SAEs. Inquiry about specific AEs should be guided by clinical judgement in 
the context of known adverse events, when appropriate for the program or protocol.
9.2.3 Follow-up of AEs and SAEs
 Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Appendix 3).
 Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate.
 All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities that are reported/identified during the course of the study.
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in 
Section 9.2 will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3).
Further information on follow-up procedures is given in Appendix 3.





9.2.4 Regulatory Reporting Requirements for SAEs
 Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
 An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the Investigator Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
Sponsor or designee will be reporting adverse events to regulatory authorities and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and FDA 
Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR (Suspected, Unexpected 
Serious Adverse Reaction) is a subset of SAEs and will be reported to the appropriate regulatory 
authorities and investigators following local and global guidelines and requirements.
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subsequently discovered that a participant is 
pregnant or may have been pregnant at the time of study exposure, including during at least 5 
months (5 half-lives + 30 days) after product administration for WOCBP, 7 months (5 half lives + 
90 days) after product administration for male participants with partners who are WOCBP, the 
investigator must immediately notify the BMS Medical Monitor/designee of this event and 
complete and forward a Pregnancy Surveillance Form to BMS Designee within 24 hours of 
awareness of the event and in accordance with SAE reporting procedures described in Appendix 
3.
In most cases, the study treatment will be permanently discontinued in an appropriate manner 
(eg, dose tapering if necessary for participant safety). Please call the BMS Medical Monitor within 
24 hours of awareness of the pregnancy.
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
participant.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collect any pregnancy surveillance 
information from the female partner, the female partner must sign an informed consent form for 
disclosure of this information. Information on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.





 Any laboratory test result that is clinically significant or meets the definition of an SAE 
 Any laboratory test result abnormality that required the participant to have study treatment
discontinued or interrupted
 Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9.2 and Appendix 3 for reporting 
details).
Potential drug induced liver injury is defined as: 
 AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
 Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
 No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required or not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
9.3 Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product that 
is considered both excessive and medically important. All occurrences of overdose must be 
reported as SAEs (see Section 9.2).
9.4 Safety
Planned time points for all safety assessments are listed in the Schedule of Activities (see Section 
2).
9.4.1 Clinical Safety Laboratory Assessments









Total leukocyte count, including differential
Platelet count
Prothrombin time (PT)/ International normalized ratio (INR)























Urine protein/creatinine ratio (UPCR)
Serology
Serum for hepatitis C antibody, HCV RNA, hepatitis B surface antigen (screening only).
HIV, if mandated locally. (Sites in Germany, see Appendix 12)
Other Analyses
Thyroid stimulating hormone (TSH) with free thyroxine (fT3) and free triiodothyronine (fT4)
(screening only); TSH with reflexive fT3 and fT4 during study and follow up
Pregnancy test (WOCBP only: screening and during study)
Follicle stimulating hormone (FSH) (screening only for women under 55 years old to confirm 
menopause as needed)
9.4.2 Imaging Safety Assessment
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment. 
9.5 Pharmacokinetics and Immunogenicity
CA2099ER Global Revised Protocol 01
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B. Participants previously randomized to Arm B continue with Arm B treatment and continue with 
Arm B clinical planned events, per protocol.
Samples for nivolumab, ipilimumab, and cabozantinib PK and nivolumab and ipilimumab 
immunogenicity assessments will be collected for participants in Arm A (doublet) receiving 
nivolumab combined with cabozantinib and in Arm B (triplet) receiving nivolumab and 
ipilimumab combined with cabozantinib as described in Table 9.5-1 and Table 9.5-2, respectively. 





Ipilimumab samples will be collected and only analyzed if needed. Treatment assignments will be 
released to the bioanalytical laboratory in order to minimize unnecessary analysis of samples. All 
timepoints for nivolumab/ipilimumab sampling are relative to the start of study drug 
administration for nivolumab in Arms A and B. All timepoints for cabozantinib PK sampling are 
relative to the start of study drug administration for nivolumab in Arms A and B and should be 
drawn approximately at least 8 hours after the previous evening cabozantinib dose. 
All on-treatment timepoints are intended to align with days on which study drug is administered. 
If it is known that a dose is going to be delayed, then the predose sample for nivolumab/ipilimumab 
and cabozantinib, if appropriate, should be collected just prior to the delayed dose. However, if a 
predose sample for nivolumab/ipilimumab is collected but the dose is subsequently delayed, an 
additional predose sample should not be collected. Further details of sample collection, processing, 
and shipment will be provided in the laboratory/procedure manual.
Blood samples should be drawn from a site other than the infusion site (ie, contralateral arm) on 
days of infusion. If the infusion was interrupted, the interruption details will also be documented 
on the CRF. Further details of pharmacokinetic sample collection and processing will be provided 
to the site in the laboratory/procedure manual.
Samples collected from participants for immunogenicity analyses of nivolumab be evaluated for 
the development of Anti-Drug Antibody (ADA) by validated immunoassays. Samples may also 
be analyzed for neutralizing ADA. 
Serum concentration analyses for nivolumab and/or ipilimumab will be performed by validated 
immunoassay bioanalytical method(s) for nivolumab and ipilimumab. Plasma concentration 
analyses for cabozantinib will be performed by validated liquid chromatography tandem-mass 
spectrometry (LC-MS-MS).
In addition, selected serum samples may be analyzed by an exploratory method that measures 
nivolumab and ipilimumab, or detect anti-drug antibodies for technology exploration purposes; 
exploratory results will not be reported. The corresponding serum samples designated for either 
PK, immunogenicity or biomarker assessments may also be used for any of those analyses, if 
required (eg, insufficient sample volume to complete testing or to follow up on suspected
immunogenicity related AE). 





Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule for Arm A (Doublet)
Study Day
a









Blood Sample for 
Nivolumab for Arm A
Immunogenicity 
Blood Sample for 
Nivolumab for Arm A
Pharmacokinetic 








C3/D1 Predose nivo 00:00 X
e
C4/D1 Predose nivo 00:00 X X X
e
C7/D1 Predose nivo 00:00 X X Xe
C15/D1 Predose nivo 00:00 X X
C23/D1 Predose nivo 00:00 X X
Every 16 weeks from 
C23 to 2 years
Predose nivo 00:00 X X
Follow-up Samples -
Approximately 30 and 
100 days from the 
discontinuation of 
study drug
NA NA X X
Abbreviations: C=cycle; D=day; EOI=end of infusion; NA=not applicable; nivo=nivolumab
a If a participant discontinues study drug treatment during the sampling period, they will move to sampling at the follow-up visits.
b Predose: All predose samples for nivolumab should be taken prior to the start of nivolumab infusion.  
c Though cabozantinib will be dosed in the evening on Day 1 of Cycle 1, the cabozantinib predose sample on Day 1 can be drawn at the same time nivolumab 
predose sample is drawn.
d EOI-nivo : End of Infusion samples for nivolumab should be collected immediately (preferably within 2-5 minutes) prior to the end of infusion. If the end of 
infusion is delayed, the collection of the EOI samples should be delayed accordingly. EOI samples may not be collected from the same IV access as drug was 
administered, refer to the laboratory manual for additional instructions.





e Cabozantinib is preferably dosed at bedtime. A PK sample for cabozantinib will be drawn at the same time when predose PK samples for nivolumab are drawn 
as long at the time of the draw for cabozantinib is approximately at least 8 hours after the previous evening dose of cabozantinib.





Table 9.5-2: Pharmacokinetic (PK) and Immunogenicity Sampling Schedule for Arm B (Triplet)
Study Day
a
(C1 to C4 Cycles 
= 3 weeks then C5 



































c 00:00 X X X X X
d
C1/D1 EOI-ipi
e 01:30 X X
C2/D1 Predose nivo 00:00 X
f
C3/D1 Predose nivo 00:00 X X X X X
f
C5/D1 Predose nivo 00:00 X X X X Xf
C13/D1 Predose nivo 00:00 X X
C21/D1 Predose nivo 00:00 X X
Every 16 weeks 
from C21 to 2 
years
Predose nivo 00:00 X X
Follow-up Samples 
- Approximately 30 
and 100 days from 
the discontinuation 
of study drug
NA NA X X X X
a If a participant discontinues study drug treatment during the sampling period, they will move to sampling at the follow-up visits.
Abbreviations: C=cycle; D=day; EOI=end of infusion; ipi=ipilimumab; NA=not applicable; nivo=nivolumab
b Ipilimumab samples will be collected and only analyzed if needed.
c Predose: All predose samples for nivolumab and/or ipilimumab should be taken prior to the start of nivolumab infusion.
d Though cabozantinib will be dosed in the evening on Day 1 of Cycle 1, the cabozantinib predose sample on Day 1 can be drawn at the same time nivolumab 
predose sample is drawn.





e EOI-ipi: The end of infusion (EOI) samples for both nivolumab and ipilimumab should be collected immediately (preferably within 2-5 minutes) prior to the 
end of ipilimumab infusion. If the end of infusion is delayed, the collection of the EOI samples should be delayed accordingly. EOI samples may not be collected 
from the same IV access as drug was administered, refer to the laboratory manual for additional instructions.
f
Cabozantinib is preferably dosed at bedtime. A PK sample for cabozantinib should be drawn at the same time when predose PK samples for nivolumab and 
ipilimumab are drawn as long at the time of the draw for cabozantinib is approximately at least 8 hours after the previous evening dose of cabozanitinib.






Refer to Section 9.8.
9.7 Pharmacogenomics
Refer to Section 9.8.6.
9.8 Biomarkers
9.8.1 Additional Research Collection
This protocol will include residual sample storage for additional research (AR).
For All US sites:
Additional research is required for all study participants.
• If the IRB/ethics committees and site agree to the mandatory additional research retention 
and/or collection, then the study participant must agree to the mandatory additional 
research as a requirement for inclusion in the study.
For non-US Sites
Additional research is optional for all study participants, except where retention and/or collection 
is prohibited by local laws or regulations, ethics committees, or institutional requirements. 
This collection for additional research is intended to expand the translational R&D capability at 
Bristol-Myers Squibb, and will support as yet undefined research aims that will advance our 
understanding of disease and options for treatment. It may also be used to support health authority 
requests for analysis, and advancement of pharmacodiagnostic development to better target drugs 
to the right participants.  This may also include genetic/genomic exploration aimed at exploring 
disease pathways, progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for additional research will be vetted through a diverse 
committee of the study sponsor’s senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scientific research activities.
 Residual whole blood (DNA), serum, plasma, PBMCs, tumor tissue from whole blood (DNA), 
serum biomarkers, plasma biomarkers, PBMCs, tumor biopsy collections (see Table 9.8.1-1) 
will also be retained for additional research purposes
Samples kept for future research will be stored at the BMS Biorepository in Hopewell, NJ, USA 
or an independent, BMS-approved storage vendor.
 The manager of these samples will ensure they are properly used throughout their usable life 
and will destroy the samples at the end of the scheduled storage period, no longer than fifteen 
(15) years after the end of the study or the maximum allowed by applicable law.
 Transfers of samples by research sponsor to third parties will be participant to the recipient’s 
agreement to establish similar storage procedures.





Samples will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held by the Investigator at the clinical site, so there is no direct ability for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing will be provided to the site in the procedure 
manual.
Table 9.8.1-1: Residual Sample Retention for Additional Research Schedule
Sample Type Timepoints for which residual samples will be retained






Sufficient tumor tissue specimens, preferably collected within 3 months but no more than 12 
months prior to enrollment with an associated pathology report, will be required in the form of a 
formalin-fixed paraffin-embedded block or 20 unstained slides. A minimum of 10 slides will be 
acceptable if tumor tissue is limited. In these situations, it is recommended to consult with the 
protocol team to discuss the specifics of the case. In addition, it is recommended, although 
optional, for tumor tissue samples to be collected upon progression. These samples may be used 
for the assessment of markers implicated in resistance.
The tumor tissue samples may be used to assess putative predictive biomarkers of nivolumab,
ipilimumab, and cabozantinib efficacy and/or to better characterize the tumor-immune 
microenvironment. Baseline tumor tissue samples will be evaluated for PD-L1 by IHC during 
screening by the central lab pathologist, who will determine the number of tumor cells with 
membranous staining among a minimum of 100 evaluable tumor cells. Participants will be 
stratified at randomization as either PD-L1 expression ≥ 1% versus PD-L1 expression < 1% or 
indeterminate (ie, sample contains at least 100 evaluable tumor cells but membrane scoring is 
hampered by high cytoplasmic staining). 
Various other markers with potential predictive value for the treatment of RCC with nivolumab,
ipilimumab and other immunotherapies are currently under investigation and may be assessed in 
this study. These tumor tissue biomarkers include, but are not limited to PD-L1, PD-1, PD-L2, 
TILs or subpopulations of TILs and a Th1 immune mRNA expression signature. Evaluation of 
MET, AXL, and other markers may be performed by IHC or other methods. Tumor samples may 
also be used to further characterize the tumor-immune microenvironment, including but not limited 
to other T cell checkpoint receptors and ligands (eg, Lag-3, Tim-3), and intratumoral immune cell 
subsets, including T-regulatory cells, myeloid derived suppressor cells, macrophages, natural killer 
(NK) cells and B cells. These samples may also be used to investigate the effect of nivolumab, 





ipilimumab, and cabozantinib on the expression of potentially relevant predictive and/or 
prognostic RCC biomarkers. Both the baseline tumor sample and the sample collected upon 
progression may be retrospectively assessed for the expression of other immune related genes, 
RNAs and/or proteins, or for the presence of immune cell populations using a variety of 
methodologies inclusive of, but not limited to IHC, RNA Scope, qRT-PCR, RNA seq, genetic 
mutation detection (including whole exome sequencing) and fluorescent in-situ hybridization 
(FISH).
9.8.3 Exploratory Serum and Plasma Biomarkers
Blood samples for exploratory serum and plasma biomarker analyses will be drawn at the specified 
time points. Serum and plasma samples may be assessed by ELISA, seromics, microRNA 
profiling, circulating tumor DNA measurements, metabolomics and/or other relevant 
multiplex-based protein assay methods for immune or RCC-related factors that will predict for 
clinical benefit or correlate with treatment-related adverse events. Potential serum and plasma-
based biomarkers to potentially b investigated include, but are not limited to levels of soluble PD-
L1, anti-tumor antibodies, cytokines, chemokines, inflammatory factors, angiogenic biomarkers 
(eg, VEGF-A, soluble VEGF2) NKG2D ligands (eg, soluble MICA), circulating tumor DNA, and 
microRNAs (such as, but not limited to, miR-513 and miR19b).  
9.8.4 Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are an immune cell population capable of suppressing 
T cell activation and proliferation. MDSCs will be measured at baseline to assess associations with 
outcome. 
9.8.5 PBMC for Flow Cytometry
Exploratory flow cytometry analysis will be used to assess baseline and on-treatment alterations 
in the composition/ activation status of cell subsets. Lymphocyte subsets to be assayed may 
include, but are not limited to, CD4+ and CD8+ subsets (activated, effector/memory, regulatory) 
and populations of those cells as defined by the expression of activation, exhaustion or signaling 
markers.
9.8.6 Whole Blood for Genotyping
Whole blood samples for exploratory pharmacogenetic assessment will be collected from all 
participants. Genomic DNA will be extracted and subsequently assessed for SNPs and other 
genetic variations in candidate genes that may predispose participants to clinical benefit or adverse 
events (unless restricted by local requirements). Such genes include, but are not limited to, PD-1, 
PD-L1, PD-L2 and CTLA-4. Additional use of these data may include correlative analyses aimed 
at identifying genotypic associations with clinically relevant biomarkers identified by other 
methodologies described in this section (including whole exome sequencing). Genomic DNA from 
whole blood will be collected and may be used as a comparator for subjects with tumors examined 
by whole exome or genome analysis.
9.8.7 Other Assessments
Not applicable.





9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Economics parameters will be 
evaluated in this study as noted in Section 2.
Medical resource utilization and health economics data, associated with medical encounters, will 
be collected in the CRF by the investigator and study-site personnel for all participants throughout 
the study. Protocol-mandated procedures, tests, and encounters are excluded. 
The data collected may be used to conduct exploratory economic analyses and will include:
 Number and duration of medical care encounters, including surgeries, and other selected 
procedures (inpatient and outpatient)
 Duration of hospitalization (total days length of stay, including duration by wards; eg, intensive 
care unit)
 Number and character of diagnostic and therapeutic tests and procedures
 Outpatient medical encounters and treatments (including physician or emergency room visits, 
tests and procedures, and medications)].
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
The sample size of this study accounts for the primary endpoint of progression-free survival (PFS) 
per BICR in all randomized participants. Assuming a 25% screen failure rate, it is expected that 
approximately 850 participants will need to be enrolled in order to randomize 638 participants 
(319 per arm) in a 1:1 ratio. To represent the normal frequency of the favorable risk group in 
mRCC, the favorable risk participants are capped at approximate 25%; thus, at most 212 favorable 
risk participants (106 per arm) will be enrolled to randomize 160 favorable risk participants in a 
1:1 ratio. The rest of the enrolled participants will provide approximately 478 intermediate/poor 
risk randomized participants (239 per each arm).
The overall alpha for this study is 0.05 (two-sided). PFS will be evaluated for treatment effect at 
an alpha of 0.05 (two-sided), with at least 95% power. No interim analysis of PFS is planned. OS 
will be evaluated for treatment effect at an alpha level of 0.05 (two-sided) with 80% power, 
accounting for two formal interim analyses to assess efficacy.
Sample Size Justification for Primary PFS Endpoint
The primary endpoint of PFS per BICR of Arm A versus Arm C analysis will be conducted on all 
randomized participants. The PFS analysis will occur after approximately 9-10 months minimum 
follow-up on all randomized subjects by which approximately 350 events from Arm A and Arm 
C are expected. The 350 PFS events provide at least 95% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C with a type I error of 0.05 (two-sided). The HR of 0.68 corresponds to a 47% 
increase in the median PFS, assuming a median PFS of 18.2 months for Arm A and 12.4 months 
for Arm C. It is projected that an observed HR of 0.811 or less, which corresponds to a 2.89 month 
or greater improvement in median PFS (12.4 versus 15.3 months), would result in a statistically 
significant improvement in PFS for the Arm A versus Arm C comparison. 





If the formal analysis of PFS among all randomized participants is statistically significant, the 
formal interim analysis of OS among all randomized participants will be tested, as per hierarchical 
testing procedure. 
Sample Size Computation for Secondary OS Endpoint
The secondary endpoint of OS in all randomized participants specifies the comparison of Arm A 
versus Arm C. Among all randomized participants, approximately 254 events (ie, deaths) in Arm 
A and Arm C provides at least 80% power to detect a HR of 0.70 for OS of Arm A and Arm C 
with an overall type 1 error of 0.05 (two-sided) for each test. The HR of 0.70 corresponds to a 43% 
increase in the median OS, assuming a median OS of 47.1 months for Arm A and 33 months for 
Arm C.
Two formal interim analyses of OS are planned for this study. The first interim analysis is planned 
at the time of final PFS analysis and it is expected to observe 165 OS events (65% of the targeted 
OS events for final analysis) and the second interim analysis is planned to occur after observing
approximately 211 events (83% of targeted OS events needed for final analysis). The stopping 
boundaries at interim and final analyses will be derived based on the number of deaths using 
O’Brien and Fleming  spending function. For example, with 165, 211, and 254 observed events 
in Arm A and Arm C at the first interim, second interim, and final analyses, the respective stopping 
boundaries would be α=0.011 (two-sided), α=0.025 (two-sided), and α=0.041 (two-sided). If the 
first interim analysis is performed exactly at 165 deaths, it is projected that an observed HR of 
0.673 or less, which corresponds to a 16.0 month or greater improvement in median OS (33 versus 
49 months), would result in a statistically significant improvement in OS for the Arm A versus 
Arm C comparison. At the second interim analysis with 211 deaths, it is projected that an observed 
HR of 0.734 or less, which corresponds to a 12.0 month or greater improvement in median OS (33
versus 45 months), would result in a statistically significant improvement in OS for the Arm A 
versus Arm C comparison. At the time of final OS analysis when there are 254 deaths, it is 
projected that an observed HR of 0.774 or less, which corresponds to a 9.6 month or greater 
improvement in median OS (33 versus 42.6 months), would result in a statistically significant 
improvement in OS for the Arm A versus Arm C comparison.
Assuming a constant accrual rate (an average rate of 3 participants/month in the first 4 months, 
afterwards an average rate of 42 participants/month), the accrual will take approximately 19 
months. The final PFS analysis will not occur prior to these conditions being met:
 at least 8 months minimum follow-up on all randomized subjects;
 at least 283 PFS events, which provide at least 90% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C; and 
 at least 149 OS events, which provide 66% power if the target HR for OS was 0.60. (Note that 
if the analysis of first interim analysis OS takes place with 149 OS events, the alpha spending 
for the OS comparison would be 0.007 with a critical HR=0.643.)





This expected PFS analysis will occur at approximately 29 months from FPFV. The second interim 
and final analyses of OS are expected to occur approximately 34 months and 40 months from 
FPFV, respectively. Table 10.1-1 summarizes the results of these calculations.
Table 10.1-1: Summary of sample size parameters and schedule of analyses
Primary/Secondary 
Endpoints
PFS (Primary) OS (Secondary)a
Primary analysis population All Randomized Participants
Accrual rate per month for all 
randomized population





0.05 2-sided (0.011 at IA1, 0.025 at IA2, 
0.041 at FA)
Hypothesized median control 
vs exp (months) 
12.4 vs 18.2 33 vs 47.1
Hypothesized hazard ratio 0.68 0.70
Critical hazard ratio (observed 
hazard ratio at which a 
statistically significant 
difference would be observed) / 
Difference in median (months) 
Corresponding to a minimal 
clinically significant effect size 
(FA)b
0.811 / 2.89 0.774 / 9.6
Critical HR at interim analysis-
1(IA1) /effect size
N/A 0.673 / 16.0
Expected number of event for 
IA1 (percentage of target 
events)
N/A 165 (65%) 
Timing of IA1 from FPFV 
(months)
N/A 29
Critical HR at interim analysis-
2(IA2) /effect size
N/A 0.734 / 12.0
Expected number of event for 
IA2 (percentage of target 
events)
N/A 211 (83%) 
Timing of IA2 from FPFV 
(months)
N/A 34
Accrual duration (months) 19 19
Timing of final analysis (FA) 
from FPFV (months)
29 40
Sample size 638 638





Table 10.1-1: Summary of sample size parameters and schedule of analyses
Primary/Secondary 
Endpoints
PFS (Primary) OS (Secondary)a
Target number of events (Event 
Goal)
350 254
a OS analyses is participant to significance in hierarchical testing strategy for each pairwise comparison.
b The difference in median (months) only applies if the control group median is exactly as hypothesized.
10.2 Populations for Analyses
All analyses will be performed using the treatment arm as randomized (intent to treat), with the 
exception of dosing and safety, for which the treatment arm as received will be used. For purposes 
of analysis, the following populations are defined in Table 10.2-1, and all populations for analyses 
given in this table refer to those participants in Arm A and Arm C. Those participants who 
randomized to Arm B prior to Revised Protocol 01 will be considered as part of the population of 
interest for descriptive summary of efficacy and safety analyses.
Table 10.2-1: Populations for Analyses
Population Description
All Enrolled Participants All participants who sign informed consent and were registered into the IRT.
All Randomized Participants All participants who were randomized will be used for the analysis of 
demography, protocol deviations, baseline characteristics, primary efficacy 
analysis, secondary efficacy analyses, and outcome research analysis which
will be performed for this population.
All Treated Participants All participants who received at least one dose of any study medication. This 
is the primary population for exposure and safety analyses.
Pharmacokinetic Participants All participants with available data from randomized participants dosed with 
nivolumab, or cabozantinib.
Immunogenicity Participants All participants with available data from randomized participants dosed with 
nivolumab.
Biomarker Participants All participants with available biomarker data from randomized participants.
10.3 Statistical Analyses
The statistical analysis plan will be developed and finalized before database lock and will describe 
the selection of participants to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. Below is a summary of planned statistical analyses of the 
primary and secondary endpoints. A description of the participant population will be included in 
the statistical output reported, including subgroup of age, gender, and race.






The efficacy analyses will be performed in all randomized participants in Arm A and Arm C. 
Descriptive summary of efficacy will be provided for participants randomized in Arm B.
Table 10.3.1-1: Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary The primary endpoint of this study is to compare PFS per BICR of Arm A (doublet) versus 
Arm C (single agent), in all randomized participants. 
PFS is defined as the time between the date of randomization and the first date of the 
documented progression, or death due to any cause, whichever occurs first. Participants who 
die without a reported progression (and die without start of subsequent anti-cancer therapy)
will be considered to have progressed on the date of their death. Participants who did not 
progress or die will be censored on the date of their last evaluable tumor assessment on or prior 
to initiation of subsequent anti-cancer therapy. Participants who did not have any on study 
tumor assessments and did not die will be censored on their date of randomization. Participants 
who started anticancer therapy (including tumor-directed radiotherapy and tumor-directed 
surgery) without a prior reported progression will be censored on the date of their last evaluable 
tumor assessment on or prior to the initiation of first subsequent anti-cancer therapy.
The primary formal comparisons of PFS will be conducted using a two-sided 0.05 stratified 
log-rank test for each comparison, with IMDC scores, PD-L1 tumor expression, and region at 
screening per IRT as stratification factors among all randomized participants.
Median PFS will be estimated via the Kaplan-Meier product limit method. Two-sided 95% CI 
for the median PFS will be computed for each randomized arm. 
Kaplan-Meier plots of PFS will be presented. Hazard ratios (HR) and corresponding two-sided 
95% confidence intervals (CI) will be estimated using a Cox proportional hazards model, with 
treatment arm as a single covariate, stratified by the stratification factors, corresponding to the 
comparison of PFS.
The totality of PFS results will be presented in a single graphical display that includes Kaplan-
Meier curves for all treatment arms, the log-rank p-values for the formal comparisons, the HRs 
and corresponding CIs, and the median PFS estimates and corresponding CIs.
The following supportive analyses of PFS will also be conducted: 
A stratified multivariate Cox regression model will be used in order to estimate the treatment 
effect after adjustment for possible imbalances in known or potential prognostic factors. The 
covariates included in this model will be specified in the statistical analysis plan. 
PFS using an un-stratified log rank test. The hazard ratio associated with treatment will be 
presented along with the associated two-sided 95% CIs.
PFS accounting for missing tumor assessment prior to PFS event (progression or death). This 
analysis will be performed only if at least 10% of events have missing prior tumor assessment. 
It will apply the following restriction to the primary definition: If the elapsed time between the 
PFS event and the last assessment immediately prior to the event is two or more missed visits 
(more than 12 weeks - 10 days), the participant’s PFS will be censored at his/her last tumor 
assessment prior to the PFS event.
Secondary The first secondary endpoint is to compare OS of Arm A versus Arm C in all randomized 
participants. OS is defined as the time between the date of randomization and the date of 
death due to any cause. A participant who has not died will be censored at the last known 
alive date. 
At the time of the primary endpoint analysis, there will be a first interim analysis of OS. The 
second interim analysis and the final analysis of OS are planned to occur approximately 34
months and 40 months from FPFV, respectively. OS will be compared between these 
treatment arms using a two sided, 0.05 level log-rank test (adjusted for interim analyses), 
stratified using IMDC scores, PD-L1 tumor expression, and region at screening as 





Table 10.3.1-1: Efficacy Analyses
Endpoint Statistical Analysis Methods
stratification factors among all randomized participants. A similar analysis as in PFS will be 
conducted for OS. Hazard ratio (HR) and corresponding two-sided 95% confidence intervals 
(CI) will be estimated using a Cox proportional hazards model, with treatment arm as a single 
covariate, stratified by the stratification factors, corresponding to the comparison of OS.
The second secondary endpoint evaluates ORR per BICR for all randomized participants. 
ORR is defined as the proportion of randomized participants who achieve a best response of 
complete response (CR) or partial response (PR) using the RECIST 1.1 criteria. Best overall 
response.
(BOR) is defined as the best response designation recorded between the date of randomization 
and the date of objectively documented progression per RECIST 1.1 or the date of subsequent 
therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs 
first. For participants without document progression or subsequent therapy, all available 
response designations will contribute to the BOR assessment. Duration of response (DOR) is 
defined as the time between the date of first confirmed documented response (CR or PR) to the 
date of first documented tumor progression (per RECIST 1.1) or death due to any cause, 
whichever occurs first. Participants who neither progress nor die will be censored on the date 
of their last tumor assessment. Responders who started anti-cancer therapy without a prior 
reported progression will be censored on the date of their last evaluable tumor assessment prior 
to the initiation of first subsequent anti-cancer therapy. TTR is defined as the time from 
randomization to the date of the first confirmed documented response (CR or PR), as assessed 
by BICR. DOR and TTR will be evaluated for responders (CR or PR) only.
Tumor assessments are scheduled to be performed at Week 12 following randomization, every 
6 weeks for the first 12 months and then every 12 weeks until progression.
ORR will be analyzed at the time of the final PFS analysis. ORRs and corresponding 95% exact 
CIs will be calculated using the Clopper Pearson method within each treatment arms. An 
estimate of the response rate and an associated exact two-sided 95% CI (Clopper and Pearson) 
will be presented, by treatment group. Sensitivity analysis based on investigator-determined 
ORR may also be performed. DOR and TTR will also be evaluated.
Exploratory Will be described in the statistical analysis plan finalized before database lock.
10.3.2 Safety Analyses
The safety analyses will be performed in all treated participants in Arm A and Arm C. Participants 
treated in Arm B will be considered in select safety analyses.
Table 10.3.2-1: Safety Analyses
Endpoint Statistical Analysis Methods
Primary The primary endpoint is related to efficacy and there are no primary safety endpoints.
Secondary Safety will be analyzed at the time of the primary endpoint analysis. Descriptive statistics of 
safety will be presented using the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 by treatment arm. All AEs, drug-related 
AEs, SAEs and drug-related SAEs, imAEs, and select AEs will be tabulated using the worst 
grade per NCI CTCAE version 4.0 criteria by system organ class and preferred term. On-
study lab parameters including hematology, coagulation, chemistry, liver function and renal 
function will be summarized using worse grade per NCI CTCAE version 4.0 criteria.
Exploratory Will be described in the statistical analysis plan finalized before database lock.





10.3.3 Other Analyses 
Pharmacokinetic, pharmacodynamic, and biomarker exploratory analyses will be described in the 
statistical analysis plan finalized before database lock. The population pharmacokinetics analysis 
and pharmacodynamic analyses will be presented separately from the main clinical study report. 
Immunogenicity may be reported for ADA positive status (such as persistent positive, other 
positive, only last sample positive, baseline positive) and ADA negative status, relative to baseline. 
In addition, presence of neutralizing antibody may be reported, if applicable. Effect of 
immunogenicity on safety/efficacy and biomarkers and PK may be explored.
10.3.3.1 Outcomes Research Analyses 
Clinically meaningful score changes (from baseline) reported in the literature were used to define 
improvement and deterioration. Table 10.3.3.1-1 provides the thresholds for clinically meaningful 
score changes to be used for the patient-reported outcome scales in this study. For domains without 
clinically meaningful score changes in the literature, thresholds values were derived using the 
general guide for calculating thresholds for FACIT instruments provided by Yost and Eton 
(2005).56
Table 10.3.3.1-1: Thresholds Values for Change Scores Judged to be Important to 
Patients
Instruments and Domains Thresholds 




Disease Related Symptoms Score
Disease Related Symptoms Emotional Score
Disease Related Symptoms Physical Score
Functional Well Being Score














10.3.4 Interim Analyses 
Two interim analyses of OS are planned for this study.  The first interim analysis of OS is planned 
at the time of final PFS analysis and expected after observing 165 deaths (approximately 65% of 
the targeted OS events) have been observed among all randomized participants in Arm A and Arm 
C based on above accrual rate and the exponential distribution in each arm. These formal 
comparisons of OS will allow for early stopping for superiority, and the boundaries for declaring 
superiority will be derived based on the actual number of deaths using Lan-DeMets spending 
function with O’Brien and Fleming type of boundary in EAST version 6. If the first interim 
analysis is performed exactly at 165 deaths, the boundary in terms of statistical significance for 
declaring superiority would be 0.011 (HR=0.673 with 16 months improvement in median OS for 
the Arm A versus Arm C comparison (33 versus 49 months)). The second interim analysis of OS 





is expected after observing 211 deaths (approximately 83% of the targeted OS events) have been 
observed among all randomized participants based on above accrual rate and the exponential 
distribution in each arm. The boundary for declaring superiority in terms of statistical significance 
for the second interim analysis after 211 events would be 0.025 (HR=0.734 with 12 months 
improvement in median OS for the doublet versus sunitinib comparison (33 versus 45 months).
The boundary for declaring superiority in terms of statistical significance for the final analysis 
after 254 events would be 0.041 (HR=0.774 with 9.6 months improvement in median OS for the 
Arm A versus Arm C comparison (33 versus 42.6 months). More details are summarized in Table 
10.1-1. An independent statistician external to BMS will perform interim analysis in conjunction 
with a review by a data monitoring committee.
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APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
AE adverse event
ACLS advanced cardiac life support
AHA alpha hydroxy acid
AI accumulation index
AIDS acquired immunodeficiency syndrome
AJCC American Joint Committee on Cancer
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANOVA analysis of variance
APC antigen-presenting cell
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration-time curve
AUC(INF) area under the concentration-time curve from time zero extrapolated to 
infinite time
AUC(0-T) area under the concentration-time curve from time zero to the time of the 
last quantifiable concentration
AUC(TAU) area under the concentration-time curve in one dosing interval
A-V atrioventricular
AXL member of the TAM (Tyro-3, Axl, Mer) receptor tyrosine kinases (RTK) 
subfamily
-HCG beta-human chorionic gonadotrophin
Bcl-xL anti-apoptotic member of the B-cell lymphoma 2 (BCL-2) protein family
BICR blinded independent central review
BID, bid bis in die, twice daily
BLQ below limit of quantification 
BMI body mass index
BMS Bristol-Myers Squibb






BOR best overall response
BP blood pressure
BTLA B and T lymphocyte attenuator
BUN blood urea nitrogen
C Celsius
C cycle
C12 concentration at 12 hours
C24 concentration at 24 hours
Ca, Ca++ calcium
Cavg average concentration
Cavgss average concentration at steady state
CBC complete blood count
CD cluster of differentiation
CD3, CD8, CD14, 
CD28
cluster of differentiation 3, 8, 14, 28
CD137 member of the tumor necrosis factor (TNF) receptor family. Alternative 
names are TNF receptor superfamily member 9 (TNFRSF9), 4-1BB and 
induced by lymphocyte activation (ILA)
Cexpected-tau expected concentration in a dosing interval
CFR Code of Federal Regulations 




CLT total body clearance
CLT/F (or CLT) apparent total body clearance
CLT/F/fu or 
CLT/fu
Apparent clearance of free drug or clearance of free if (if IV)
cm centimeter
Cmax, CMAX maximum observed concentration






c-MET tyrosine-protein kinase mesenchymal-epithelial transition (MET) or 
hepatocyte growth factor receptor, is a protein that in humans is encoded 
by the MET gene
CMH Cochran-Mantel-Haenzel
Cmin, CMIN minimum observed concentration
CMV cytomegalovirus
CNS central nervous system
CONSORT Consolidated standards of reporting trials
CR complete response
CRC Clinical Research Center
CRF Case Report Form, paper or electronic
CT computed tomography
CTAg clinical trial agreement
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 cytotoxic T lymphocyte antigen-4
Ctrough Trough observed plasma concentration




DBP diastolic blood pressure
D/C discontinue
DILI drug induced liver injury
dL deciliter
DMC data monitoring committee
DNA deoxyribonucleic acid
DOR duration of response
DSM IV Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
DVT deep vein thrombosis
EA extent of absorption
EC50 half maximal effective concentration







eCRF Electronic Case Report Form
EDC Electronic Data Capture
EEG electroencephalogram
e.g., eg exempli gratia (for example)
eGFR estimated glomerular filtration rate
ELISA enzyme-linked immunosorbent assay
EOI end of infusion
EQ-5D-3L EuroQoL Group’s instrument to measure general health status
ESR Expedited Safety Report
F bioavailability
FA final analysis 
FDA Food and Drug Administration
FDG-PET fludeoxyglucose- positron emission tomography
FFPE formalin-fixed, paraffin-embedded
FISH fluorescent in-situ hybridization
FKSI-19 Functional Assessment of Cancer Therapy - Kidney Symptom Index
FLT-3 Fms-related tyrosine kinase 3
FSH follicle stimulating hormone




GCP Good Clinical Practice
GGT gamma-glutamyl transferase




HBsAg hepatitis B surface antigen






HBV hepatitis B virus
hCG, HCG human chorionic gonadotropin
HCO3
- bicarbonate
HCV hepatitis C virus
HFS hand foot syndrome
HIV Human Immunodeficiency Virus
HR heart rate, hazard ratio
HrQoL health-related quality of life
HRT hormone replacement therapy
ICD International Classification of Diseases
IC50 half maximal inhibitory concentration
ICH International Conference on Harmonisation 
ICOS inducible co-stimulator
i.e., ie id est (that is)







IMAEs, imAEs immune-mediated adverse events
IMDC International Metastatic Renal Cell Carcinoma Database Consortium
IMP investigational medicinal products
IND Investigational New Drug Exemption
INR international normalized ratio
IP investigational product
ipi ipilimumab
iRAEs immune-related adverse events
IRB Institutional Review Board






IRC independent radiologic review committee
IRT Interactive Response Technology
IU International Unit
IV intravenous
K slope of the terminal phase of the log concentration-time curve
K3EDTA potassium ethylenediaminetetraacetic acid
K, K+ potassium
kg kilogram
KIT platelet-derived growth factor receptors (PDGFRs)
KPS Karnofsky Performance Status
L liter
LAM Lactation amenorrhea method
LC liquid chromatography
LC-MS-MS liquid chromatography tandem-mass spectrometry
LDH lactate dehydrogenase
LFT liver function test
LINAC linear accelerator 
LLN lower limit of normal
LMWH low molecular weight heparin
ln natural logarithm
MDSCs myeloid-derived suppressor cells
MER proto-oncogene tyrosine-protein kinase MER is an enzyme that in 
humans is encoded by the MERTK gene
MET mesenchymal-epithelial transition factor, a tyrosine kinase receptor
mg milligram
Mg, Mg++ magnesium
MHC major histocompatibility complex
min minute
mL milliliter
MLR mixed lymphocyte reaction






mmHg millimeters of mercury
mOS median overall survival
mRCC metastatic renal cell carcinoma
MRI magnetic resonance imaging
MS mass spectrometry
MSKCC Memorial Sloan Kettering Cancer Center
MTD maximum tolerated dose
mTOR mammalian target of rapamycin
mUC metastatic urothelial carcinoma
MUGA multigated acquisition scan
mWHO modified World Health Organization
g microgram
N number of subjects or observations
N/A, NA not applicable
Na, Na+ sodium
NaF Sodium fluoride
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
NE not evaulable
ng nanogram
NIMP non-investigational medicinal products 
nivo nivolumab
NK natural killer
NKG2D encoded by KLRK1 gene which is located in the NK-gene complex 
(NKC)
NR not reached
NSAID nonsteroidal anti-inflammatory drug
NSCLC non-small cell lung cancer
ORR objective response rate
OS overall survival







PCR polyermase chain reaction
PD progressive disease, disease progression
PD pharmacodynamics
PD-1 programmed death-1
PD-L1 programmed death-ligand 1
PE pulmonary embolism
PET positron emission tomography
PFS progression-free survival
PK pharmacokinetics
PO per os (by mouth route of administration)
PR partial response
PT prothrombin time
PTT partial thromboplastin time
Q2W, Q3W every 2 weeks, every 3 weeks
QC quality control
QD, qd quaque die, once daily
qRT-PCR quantitative real time polyermase chain reaction
QTcF Fridericia corrected QT
R2 coefficient of determination
RBC red blood cell
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
RET proto-oncogene encodes a receptor tyrosine kinase for members of the 
glial cell line-derived neurotrophic factor family of extracellular 
signalling molecules
RNA ribonucleic acid
ROS1 proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans 
is encoded by the ROS1 gene
ROW rest of the world
RR respiratory rate







RTK receptor tyrosine kinases
SAE serious adverse event
SBP systolic blood pressure
SCC squamous cell carcinoma
SD standard deviation, stable disease
SNP single-nucleotide polymorphism
SOP Standard Operating Procedures
Subj subject




TAO Trial Access Online, the BMS implementation of an EDC capability
TCR T-cell receptor
T-HALF Half life
TID, tid ter in die, three times a day
TIE-2 tunica interna endothelial cell kinase 2
TIL tumour-infiltrating lymphocyte,
TKIs tyrosine kinase inhibitors
Tmax, TMAX time of maximum observed concentration
Tregs regulatory T cells
TRKB tropomyosin receptor kinase B (TrkB), also known as tyrosine receptor 
kinase B
TSH thyroid stimulating hormone
TTR time to response
TYRO3 tyrosine-protein kinase receptor TYRO3 is an enzyme that in humans is 
encoded by the TYRO3 gene
ULN upper limit of normal
UPCR urine protein to creatinine ratio
UV ultraviolet






VAS visual analog rating scale
VEGF vascular endothelial growth factor
VEGFR2 vascular endothelial growth factor receptor 2
Vss/F (or Vss) apparent volume of distribution at steady state
Vz volume of distribution of terminal phase (if IV and if multi-exponential 
decline)
W washout
WBC white blood cell
WHO World Health Organization
wks weeks
WOCBP women of childbearing potential
WNOCBP women not of childbearing potential
x g times gravity
XL184 cabozantinib





APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS
The term ‘Participant’ is used in the protocol to refer to a person who has consented to participate 
in the clinical research study. The term ‘Subject’ used in the CRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
 Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP), 
 as defined by the International Council on Harmonisation (ICH)
 in accordance with the ethical principles underlying European Union Directive 2001/20/EC
 United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) 
 applicable local requirements.
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will receive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to the Sponsor or designee immediately. A 
potential serious breach is defined as a Quality Issue (eg, protocol deviation, etc) that is likely to 
affect, to a significant degree one or more of the following: (1) the physical, safety or mental 
integrity of one or more subjects/participants; (2) the scientific value of the trial (eg, reliability and 
robustness of generated data). Items (1) or (2) can be associated with either GCP Regulation(s) or 
Trial protocol(s).
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant recruitment materials (eg,
advertisements), and any other written information to be provided to subjects/participants. The 
investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or 
product labeling information to be provided to subjects/participants and any updates. 





The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects/participants. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation or change will be submitted, as 
soon as possible to:
 IRB/IEC 
 Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be used to obtain consent from 
subjects//participants currently enrolled in the study if they are affected by the amendment; and 
(3) the new form must be used to obtain consent from new subjects/participants prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects/participants are clearly and fully informed about the 
purpose, potential risks, and other critical issues regarding clinical studies in which they volunteer 
to participate. 
In situations where consent cannot be given to subjects/participants, their legally acceptable 
representatives (as per country guidelines) are clearly and fully informed about the purpose, 
potential risks, and other critical issues regarding clinical studies in which the participant
volunteers to participate. 





Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample 
informed consent form which will include all elements required by ICH, GCP and applicable 
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Investigators must:
 Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
 Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details of the study.
 Obtain an informed consent signed and personally dated by the participant or the participant's 
legally acceptable representative and by the person who conducted the informed consent 
discussion. 
 Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects/participants, prior to the beginning of 
the study, and after any revisions are completed for new information.
If informed consent is initially given by a participant’s legally acceptable representative or legal 
guardian, and the participant subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a person designated by the investigator, 
should fully inform the participant or the participant's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects/participants must be protected, 
respecting the privacy and confidentiality rules applicable to regulatory requirements, the 
subjects'/participants’ signed ICF and, in the US, the subjects’/participants’ signed HIPAA 
Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to participant records. 
Subjects/participants unable to give their written consent (eg, stroke or subjects/participants with 
or severe dementia) may only be enrolled in the study with the consent of a legally acceptable 
representative. The participant must also be informed about the nature of the study to the extent 
compatible with his or her understanding, and should this participant become capable, he or she 
should personally sign and date the consent form as soon as possible. The explicit wish of a 
participant who is unable to give his or her written consent, but who is capable of forming an 





opinion and assessing information to refuse participation in, or to be withdrawn from, the clinical 
study at any time should be considered by the investigator.
The rights, safety, and well-being of the study subjects/participants are the most important 
considerations and should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.






Supplied by BMS (or its vendors): Records or logs must comply with applicable 
regulations and guidelines and should include:
 amount received and placed in storage area
 amount currently in storage area
 label identification number or batch number
 amount dispensed to and returned by each 
participant, including unique participant identifiers
 amount transferred to another area/site for 
dispensing or storage
 nonstudy disposition (eg, lost, wasted) 
 amount destroyed at study site, if applicable
 amount returned to BMS
 retain samples for 
bioavailability/bioequivalence/biocomparability, if 
applicable 
 dates and initials of person responsible for 
Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
Sourced by site, and not supplied by 
BMS or its vendors (examples include 
IP sourced from the sites stock or 
commercial supply, or a specialty 
pharmacy)
The investigator or designee accepts responsibility for 
documenting traceability and study drug integrity in 
accordance with requirements applicable under law and 
the SOPs/standards of the sourcing pharmacy.   
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillance form, respectively.  If 
electronic SAE form is not available, a paper SAE form can be used. Spaces may be left blank 





only in those circumstances permitted by study-specific CRF completion guidelines provided by 
Sponsor or designee. 
The confidentiality of records that could identify subjects/participants must be protected, 
respecting the privacy and confidentiality rules in accordance with the applicable regulatory 
requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task For electronic CRFs, review and approval/signature is completed electronically through the 
BMS electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the BMS electronic data capture tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of study records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents:
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.





If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vendor or sourced by the investigator) 
such as partially used study treatment containers, vials and syringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including 
its vendors
Any unused study treatments supplied by BMS 
can only be destroyed after being inspected 
and reconciled by the responsible Study 
Monitor unless study treatments containers 
must be immediately destroyed as required for 
safety, or to meet local regulations (eg,
cytotoxics or biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or commercial supply, or a specialty 
pharmacy)
It is the investigator’s or designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
 On-site disposal practices must not expose humans to risks from the drug.
 On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
 Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
 Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
 Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.





It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non- study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
CLINICAL STUDY REPORT
A Signatory Investigator must be selected to sign the clinical study report. 
For each CSR related to this protocol, the following criteria will be used to select the signatory 
investigator:
 National Coordinating Investigator 
 Study Steering Committee chair or their designee
 Participant recruitment (eg, among the top quartile of enrollers)
 Involvement in trial design
 Regional representation (eg, among top quartile of enrollers from a specified region or country)
 Other criteria (as determined by the study team)
SCIENTIFIC PUBLICATIONS
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study site or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTAg.
Scientific Publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effort between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
principal investigator, sub-investigator or any other member of the study staff without the prior 
written consent of the Sponsor.  
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship selection is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors must meet all 4 ICMJE criteria for 
authorship:
1) Substantial intellectual contribution to the conception or design of the work; or the acquisition 
of data (ie, evaluable subjects with quality data), analysis, or interpretation of data for the work 
(eg, problem solving, advice, evaluation, insights and conclusion); AND
2) Drafting the work or revising it critically for important intellectual content; AND
3) Final approval of the version to be published; AND





4) Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Those who make the most significant contributions, as defined above, will be considered by BMS 
for authorship of the primary publication. Sub-investigators will generally not be considered for 
authorship in the primary publication. Geographic representation will also be considered.  
Authors will be listed by order of significant contributions (highest to lowest), with the exception 
of the last author. Authors in first and last position have provided the most significant contributions 
to the work. 
For secondary analyses and related publications, author list and author order may vary from 
primary to reflect additional contributions.





APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation participant administered study drug and 
that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study drug, whether or not 
considered related to the study drug.






Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 
o a visit to the emergency room or other hospital department < 24 hours, that does 
not result in admission (unless considered an important medical or life-
threatening event)
o elective surgery, planned prior to signing consent
o admissions as per protocol for a planned medical/surgical procedure
o routine health assessment requiring admission for baseline/trending of health 
status (e.g., routine colonoscopy)
o medical/surgical admission other than to remedy ill health and planned prior to 
entry into the study. Appropriate documentation is required in these cases
o admission encountered for another life circumstance that carries no bearing on 
health status and requires no medical/surgical intervention (e.g., lack of housing, 
economic inadequacy, caregiver respite, family circumstances, administrative 
reason)
o admission for administration of anticancer therapy in the absence of any other 
SAEs (applies to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug induced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 





Suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
treatment is an SAE. 
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See Section 9.2.5
for reporting pregnancies).
Any component of a study endpoint that is considered related to study therapy should be reported 
as SAE (e.g., death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
The causal relationship to study drug is determined by a physician and should be used to 
assess all adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug 
administration and the AE.
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE. 
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. (Note: 
Follow-up SAE reports must include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study drug or if new 
information becomes available, the SAE report must be updated and submitted within 24 
hours to BMS (or designee) using the same procedure used for transmitting the initial SAE 
report.
All SAEs must be followed to resolution or stabilization.





REPORTING OF SAES TO SPONSOR OR DESIGNEE
 SAEs, whether related or not related to study drug, and pregnancies must be 
reported to BMS (or designee) within 24 hours of awareness of the event.
 SAEs must be recorded on the SAE Report Form; pregnancies on a Pregnancy 
Surveillance Form (electronic or paper forms).
 The preferred method for SAE data reporting collection is through the eCRF.
 The paper SAE/pregnancy surveillance forms are only intended as a back-up option 
when the eCRF system is not functioning.
o In this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission 
is the required method for reporting. In the event the electronic system is unavailable for 
transmission, paper forms must be used and submitted immediately. When paper forms are 
used, the original paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
Information list





APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
 Premenarchal
 Premenopausal female with 1 of the following:
 Documented hysterectomy
 Documented bilateral salpingectomy
 Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
 Postmenopausal female
 A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 45 
years in the absence of other biological or physiological causes. In addition, females under 
the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 
mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 5 months after the end of study 
treatment.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
 Combined (estrogen- and progestogen-containing) hormonal contraception associated with 









 Progestogen-only hormonal contraception associated with inhibition of ovulationb 
 oral 
 injectable 
Highly Effective Methods That Are User Independent
 Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationb
 Intrauterine hormone-releasing system (IUS)c
 Intrauterine device (IUD)c
 Bilateral tubal occlusion
 Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
 Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
 It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
 WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
 Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abstinence 
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study medications will not alter hormonal exposures such that contraception would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods 
of contraception should be utilized. 
c Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Unacceptable as a Sole Method of Contraception
 Male or female condom with or without spermicide.  Male and female condoms cannot be 
used simultaneously





 Diaphragm with spermicide
 Cervical cap with spermicide
 Vaginal Sponge with spermicide
 Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
 Periodic abstinence (calendar, symptothermal, post-ovulation methods)
 Withdrawal (coitus interruptus).
 Spermicide only
 Lactation amenorrhea method (LAM)
* Local laws and regulations may require use of alternative and/or additional contraception 
methods.
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
 Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.
 Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study treatment.
 Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 7 months after the end of 
treatment in the male participant.
 Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 7 months after the end of study treatment.
 Refrain from donating sperm for the duration of the study treatment and until 7 months after 
the end of study treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follow-up and Reporting





APPENDIX 5 MANAGEMENT ALGORITHMS
These general guidelines constitute guidance to the Investigator and may be supplemented by 
discussions with the Medical Monitor representing the Sponsor. The guidance applies to all 
immuno-oncology agents and regimens.
A general principle is that differential diagnoses should be diligently evaluated according to 
standard medical practice. Non-inflammatory etiologies should be considered and appropriately 
treated.
Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. The 
oral equivalent of the recommended IV doses may be considered for ambulatory patients with 
low-grade toxicity. The lower bioavailability of oral corticosteroids should be taken into account 
when switching to the equivalent dose of oral corticosteroids.
Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.
The frequency and severity of the related adverse events covered by these algorithms will depend 
on the immuno-oncology agent or regimen being used.








































APPENDIX 6 INTERNATIONAL METASTATIC RCC DATABASE 




Time from initial diagnosis (including original localized disease if applicable) to treatment < 1 year
Laboratory 
Hemoglobin < LLN
Corrected calcium > 10 mg/dL
Absolute neutrophil count > ULN
Platelet count > ULN
Note: The corrected calcium criterion was adapted from to Heng et al, 2009 to account for local laboratories that may 
not provide an ULN for corrected calcium.
Abbreviations: KPS= Karnofsky Performance Status; LLN = Lower limit of normal; ULN = Upper limit of normal
Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 - serum albumin [g/dL]), where 
4.0 represents the average albumin level in g/dL.
Corrected calcium (mmol/L) = measured total Ca (mmol/L) + 0.02 (40 - serum albumin [g/L]), 
where 40 represents the average albumin level in g/L
Risk Group Based on Number of Adverse Prognostic Factors




Reference: Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal 
cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. 
J Clin Oncol 2009; 27(34):5794-5799.





APPENDIX 7 PERFORMANCE STATUS SCORES
SCALES
STATUS KARNOFSKY ZUBROD-ECOG-WHO STATUS
Normal, no complaints 100 0 Normal activity
Able to carry on normal 
activities Minor signs or 
symptoms of disease
90 0
Normal activity with effort 80 1 Symptoms, but fully 
ambulatory
Cares for self. Unable to 
carry on normal activity or 
to do active work
70 1
Requires occasional 
assistance, but able to care 
for most of his needs
60 2 Symptomatic, but in bed 
< 50% of the day.
Requires considerable 
assistance and frequent 
medical care
50 2
Disabled. Requires special 
care and assistance
40 3 Needs to be in bed 




though death non imminent
30 3




20 4 Unable to get out of bed
Moribund 10 4
Dead 0 5 Dead





APPENDIX 8 RADIOLOGIC EVALUATION CRITERIA IN SOLID TUMOURS 
VERSION 1.1 (RECIST CRITERIA 1.1)
1 ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE 
DISEASE
Subjects must have measureable disease to be eligible for this study.
To assess objective response or future progression, it is necessary to estimate the overall tumor
burden at baseline and use this as a comparator for subsequent measurements. Measurable disease 
is defined by the presence of at least 1 measurable tumor lesion. When computed tomography (CT)
scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness.
At baseline, tumor lesions/lymph nodes will be categorized measurable or nonmeasurable, which 
are discussed below.
1.1 Measurable Lesions
Measurable lesions must be accurately measured in at least 1 dimension (longest diameter in the 
plane of the measurement to be recorded) with a minimum size of:
 10 mm by CT/magnetic resonance imaging (MRI) scan - (CT/MRI scan slice thickness no 
greater than 5 mm)
 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured 
with calipers should be recorded as nonmeasurable)
 20 mm by chest x-ray
 Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be  15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis 
will be measured and followed.
1.2 Non-measurable Lesions
 All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph 
nodes with  10 to < 15 mm short axis), as well as truly non-measurable lesions
 Lesions considered truly nonmeasurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
and abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques.
1.3 Special Considerations Regarding Lesion Measurability
1.3.1 Bone Lesions
 Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques to measure bone lesions. However, these techniques can be used 
to confirm the presence or disappearance of bone lesions. 
 Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components that 
can be evaluated by cross sectional imaging techniques such as CT or MRI, can be considered





measurable lesions if the soft tissue component meets the definition of measurability described 
above.
 Blastic bone lesions are nonmeasurable.
1.3.2 Cystic Lesions
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor nonmeasurable) since they are, by 
definition, simple cysts. 
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions 
if they meet the definition of measurability described above. However, if non-cystic lesions 
are present in the same subject, these are preferred for selection as target lesions.
1.3.3 Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable, unless there has been demonstrated progression in 
the lesion. Measurable lesions may be in an irradiated field as long as there is documented 
progression, and the lesion(s) can be reproducibly measured.
1.4 Specifications by Methods of Measurements
1.4.1 Measurement of Lesions
All measurements should be recorded in metric notation (mm). All baseline evaluations should be 
performed as close as possible to the treatment start and never more than 30 days before the 
beginning of the treatment.
1.4.2 Method of Assessment
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation should 
always be done rather than clinical examination, unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.
1.4.2.1 CT/MRI Scan
CT/MRI is the best currently available and reproducible method to measure lesions selected for 
response assessment. Measurability of lesions on CT/MRI scan is based on the assumption that 
CT/MRI slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, 
the minimum size for a measurable lesion should be twice the slice thickness.
1.4.2.2 Chest X-ray
Chest CT is preferred over chest X-ray, particularly when progression is an important endpoint,
since CT is more sensitive than X-ray in identifying new lesions. However, lesions on chest X-ray 
may be considered measurable if they are clearly defined and surrounded by aerated lung.
1.4.2.3 Clinical Lesions 
Clinical lesions will only be considered measurable when they are superficial and  10 mm 
diameter as assessed using calipers. For the case of skin lesions, documentation by color 





photography including a ruler to estimate the size of the lesion is suggested. As previously noted, 
when lesions can be evaluated by both clinical examination and imaging, imaging evaluation 
should be undertaken since it is more objective and may also be reviewed at the end of the study.
1.4.2.4 Ultrasound
Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement. If new lesions are identified by ultrasound in the course of the study, confirmation 
by CT or MRI is advised. 
1.4.2.5 Endoscopy, Laparoscopy
The utilization of these techniques for objective tumor evaluation is not advised.
1.4.2.6 Tumor Markers 
Tumor markers alone cannot be used to assess objective tumor response.
2 BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’
LESIONS
2.1 Target Lesions
When more than 1 measurable lesion is present at baseline, all lesions up to a maximum of 
5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline.
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, and should lend themselves to reproducible repeated
measurements.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted below, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.
2.1.1 Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes, which are defined as 
measurable and may be identified as target lesions, must meet the criterion of a short axis of 
 15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. Nodes 
that have a short axis < 10 mm are considered nonpathological and should not be recorded or 
followed.
2.2 Non-target Lesions
All other lesions (or sites of disease), including pathological lymph nodes, should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required, and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases, ‘unequivocal
progression’. In addition, it is possible to record multiple non-target lesions involving the same 





organ as a single item on the case record form (e.g., ‘multiple enlarged pelvic lymph nodes’ or 
‘multiple liver metastases’).
3 TUMOR RESPONSE EVALUATION 
3.1 Evaluation of Target Lesions
 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to < 10 mm.
 Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions,
taking as reference the baseline sum diameters.
 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also 
considered progression).
 Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum on study.
3.1.1 Special Notes on the Assessment of Target Lesions
3.1.1.1 Lymph Nodes
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes, which are defined as 
measurable and may be identified as target lesions, must meet the criterion of a short axis of  15 
mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. Nodes 
that have a short axis <10 mm are considered nonpathological and should not be recorded or 
followed.
3.1.1.2 Target Lesions That Become ‘Too Small to Measure’
All lesions (nodal and nonnodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm). If the radiologist is 
able to provide an actual measurement, that should be recorded even if it is below 5 mm.
However, when such a lesion becomes difficult to assign an exact measure to then:
 If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement 
should be recorded as 0 mm.
 If the lesion is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned (Note: In case of a lymph node believed to be present and 
faintly seen but too small to measure, a default value of 5 mm should be assigned in this 
circumstance as well). This default value is derived from the 5 mm CT slice thickness (but 
should not be changed with varying CT slice thickness).
3.1.1.3 Target Lesions that Split or Coalesce on Treatment
 When non-nodal lesions fragment, the longest diameters of the fragmented portions should be 
added together to calculate the target lesion sum.





 As lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this instance should 
be the maximal longest diameter for the ‘coalesced lesion’
3.2 Evaluation of Non-target Lesions
While some non-target lesions may actually be measurable, they need not be measured and instead 
should be assessed only qualitatively at the time points specified in the protocol. 
 CR: Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size 
(< 10 mm short axis).
 PD: Unequivocal progression of existing non-target lesions. (Note: The appearance of 1 or 
more new lesions is also considered progression).
 NonCR/NonPD: Persistence of 1 or more non-target lesion(s).
3.2.1 Special Notes on Assessment of Non-target Lesions
The concept of progression of non-target disease requires additional explanation as discussed 
below.
3.2.1.1 When the Subject Also has Measurable Disease
 To achieve unequivocal progression on the basis of the non-target disease, there must be an 
overall level of substantial worsening in non-target disease, such that even in presence of SD 
or PR in target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy.
 A modest ‘increase’ in the size of 1 or more non-target lesions is usually not sufficient to 
quality for unequivocal progression status.
3.2.1.2 When the Subject has Only Non-measurable Disease
 To achieve unequivocal progression on the basis of the non-target disease, there must be an 
overall level of substantial worsening, such that the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.
 A modest increase in the size of 1 or more non-target lesions is usually not sufficient to qualify 
for unequivocal progression status.
 Because worsening in non-target disease cannot be easily quantified (by definition, if all 
lesions are nonmeasurable), a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease, ie, an increase in tumor burden representing an 
additional 73% increase in volume (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as ‘sufficient to require a change in therapy’.
 If unequivocal progression is seen, the subject should be considered to have had overall PD at 
that point. 






Tumor markers will not be used to assess objective tumor responses.
3.3 New Lesions
The appearance of new malignant lesions denotes disease progression. The finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, change in 
imaging modality, or findings thought to represent something other than tumor (for example, some 
new bone lesions may be simply healing or flare of preexisting lesions). This is particularly 
important when the subject’s baseline lesions show PR or CR. For example, necrosis of a liver 
lesion may be reported on a CT scan report as a new cystic lesion, which it is not.
A lesion identified on a follow-up study in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate disease progression. An example of this is the subject
who has visceral disease at baseline and while on study, has a CT or MRI brain scan ordered that
reveals metastases. The subject’s brain metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely 
a new lesion, then progression should be declared using the date of the initial scan.
4 RESPONSE CRITERIA
4.1 Time Point Response
A response assessment should occur at each time point specified in the protocol.
For subjects who have measurable disease at baseline, Table 1 provides a summary of the overall 
response status calculation at each time point.
Table 1: Subjects with Target (+/– Non-target) Disease
Target Lesions Non-target Lesions New Lesions Overall Response
CR CR No CR
CR NonCR/nonPD No PR
CR Not evaluated No PR
PR




NonPD or not all 
evaluated
No SD
Not all evaluated NonPD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 
NE = not evaluable.





4.1.1 Missing Assessments and Not Evaluable Designation
When no imaging/measurement is done at a particular time point, the subject is not evaluable 
(NE) at that time point. If only a subset of lesion measurements are made at an assessment, the 
case is also considered NE at that time point, unless a convincing argument can be made that the 
contribution of the individual missing lesion(s) would not have changed the assigned time point 
response.
4.2 Best Overall Response: All Time Points
The best overall response is determined once all the data for the subject is known. It is the best 
response recorded from the start of the study treatment to the date of radiographic progression per 
RECIST 1.1 or the date of subsequent anti-cancer therapy (including tumor-directed radiotherapy 
and tumor-directed surgery), whichever occurs first, taking into account any requirement for 
confirmation. The subject’s best overall response assignment will depend on the findings of both 
target and non-target disease and will also take into consideration the appearance of new lesions.
Complete or partial responses may be claimed only if the criteria for each are met at a subsequent 
time point of ≥ 4 weeks later. In this circumstance, the best overall response can be interpreted as 
specified in Table 2. 
When SD is believed to be best response, it must meet the protocol specified minimum time from 
baseline. In this protocol, measurements must have met the SD criteria at least once after study 
entry at a minimum interval of 6 weeks from randomization in order for SD to be the best response.
Table 2: Best Overall Response When Confirmation of CR and PR is 
Required
Overall Response Overall Response Best Overall Response
First Time Point Subsequent Time Point
CR CR CR
CR PR SD, PD, or PRa
CR SD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR PD
SD provided minimum criteria for 
SD duration met, otherwise, PD
CR NE
SD provided minimum criteria for 





SD provided minimum criteria for 
SD duration met, otherwise, PD
PR NE
SD provided minimum criteria for 
SD duration met, otherwise NE





Table 2: Best Overall Response When Confirmation of CR and PR is 
Required
Overall Response Overall Response Best Overall Response
NE NE NE
a Abbreviations: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 
NE = not evaluable.
If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the subject had PR, not CR at the 
first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
4.2.1 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tumor measurements 
must be confirmed by consecutive repeat assessments that should be performed no less than 28 
days after the criteria for response are first met. For this study, the next scheduled tumor assessment 
can meet this requirement.
4.3 Duration of Response
4.3.1 Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that progressive disease is objectively 
documented (taking as reference for PD the smallest measurements recorded on study), subsequent 
anti-cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery) is 
initiated, or the participant dies, whichever occurs first.
The duration of overall complete response is measured from the time measurement criteria are first 
met for CR until the first date that progressive disease is objectively documented, subsequent anti-
cancer therapy (including tumor-directed radiotherapy and tumor-directed surgery) is initiated, or 
the participant dies, whichever occurs first.
4.3.2 Duration of Stable Disease  
If SD is the best overall response, the duration of SD is measured from the date of randomization
until the criteria for progression are met, taking as reference the smallest sum on study (if the 
baseline sum is the smallest, this is the reference for calculation of PD), subsequent anti-cancer 
therapy (including tumor-directed radiotherapy and tumor-directed surgery) is initiated, or the 
participant dies, whichever occurs first..
Reference: Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised 
RECIST Guideline (Version 1.1). Eur J Cancer 2009;45:228-247.





APPENDIX 9 INDUCERS AND INHIBITORS OF CYP3A4






















Notes: The above list is not exhaustive. Please refer to the drug interaction tables at the link below for lists of 
substrates, inducers, and inhibitors of selected CYP450 isozyme pathways. 
(Http://medicine.iupui.edu/clinpharm/ddis/table.aspx).
Grapefruit, grapefruit juice and other foods that are known to inhibit CYP3A4 activity should be avoided during 
treatment.  
St. John’s Wort (Hypericum perforatum) is known to be an inducer of CYP3A4 and should be avoided during 
treatment.





APPENDIX 10 SUPPORTIVE CARE GUIDELINES FOR THE MANAGEMENT OF 
HAND FOOT SYNDROME (HFS)
Supportive Care Guidelines for the Management of Hand Foot Syndrome (HFS)
Management of HFS can begin before any symptoms occur. Several prophylactic measures may 
be taken to prevent or reduce the severity of HFS. Before therapy with begins, a full-body skin 
exam should be performed, with a special emphasis on hyperkeratotic areas on palms and soles 
and any deformities. Patients can receive a pedicure, using properly sterilized utensils, to remove 
any preexisting hyperkeratotic areas or calluses that may predispose them to developing HFS
reaction. Patients should be advised to reduce the exposure of their hands and feet to hot water, 
either through dishwashing or hot baths and showers, because this is believed to exacerbate 
symptoms, and patients frequently report symptomatic relief with cold water.
Before initiating treatment:
 Check condition of hands and feet
 Suggest a manicure/pedicure, when indicated
 Recommend pumice stone use for callus or ‘rough spot’ removal
During treatment:
 Avoid pressure points
 Avoid items that rub, pinch, or create friction
 Apply non-urea based skin-hydrating creams liberally
 Keratolytic creams: Use sparingly and only to affected (hyperkeratotic) areas.
Urea-based creams:
 Salicylic acid 6%
 Alpha hydroxy acid (AHA) based creams
 Concentrations of approximately 5-8% provide gentle chemical exfoliation
 Apply liberally two times each day
Topical analgesics like lidocaine 2% should be considered for pain control
Topical corticosteroids like clobetasol 0.05% should be considered for patients with grade 2 or 3 
hand-foot skin reaction. Avoid systemic steroids.
Cushions:
 Protect tender areas
 Use socks/gloves to cover moisturizing creams
 Wear well-padded footwear
 Use insole cushions or inserts (e.g., silicon, gel)
 Foot soaks with tepid water and Epsom salts





APPENDIX 11 SUPPORTIVE CARE GUIDELINES FOR THE MANAGEMENT OF 
DIARRHEA FOR CABOZANTINIB
Participants should be instructed to notify their physician immediately at the first signs of poorly 
formed or loose stool or an increased frequency of bowel movements. Guidelines for the 
evaluation and management of diarrhea are shown in Table 1. 
Administration of antidiarrheal/antimotility agents is recommended at the first sign of diarrhea as 
initial management. Some participants may require concomitant treatment with more than 1 
antidiarrheal agent. When therapy with antidiarrheal agent does not control diarrhea to tolerable 
levels, cabozantinib should be temporarily interrupted or dose reduced. When the diarrhea is 
controlled, retreatment with cabozantinib may be acceptable per investigator decision. 
In addition, general supportive measures should be implemented such as continuous oral isotonic 
hydration, correction of fluid and electrolyte abnormalities, small frequent meals, and stopping 
lactose-containing products, high-fat meals, and alcohol.
Recurrent or prolonged diarrhea can be associated with anal or perianal skin erosions which 
increase the risk for anal abscesses, fistulas, or proctitis. Good hygiene should be emphasized. 
Regular examinations of the perianal region should be performed wherever diarrhea has occurred 
during treatment with cabozantinib. Infections of the perianal region should be treated per local 
guidelines.





Table 1: Guidelines for Management of Treatment-Emergent Diarrhea for 
Cabozantinib
Status Management
Tolerable Grade 1-2 
(duration < 48 h)
 Continue with study treatment and consider dose reduction
 Initiate treatment with an antidiarrheal agent (e.g., loperamide 4 mg followed by 2 mg 
after each episode of diarrhea [maximum: 16 mg loperamide daily])
 Dietary modifications (e.g., small lactose-free meals, bananas and rice)
 Intake of isotonic fluids 1-1.5 L/day)
 Re-assess after 24 hours:
- Diarrhea resolving to baseline bowel habits: gradually add solid foods and 
discontinue or decrease antidiarrheal treatment after 12 h diarrhea-free interval
- Diarrhea not resolving: Continue/resume antidiarrheal treatment
Intolerable Grade 2, 
Grade 2 > 48h, or ≥ 
Grade 3
 Interrupt study treatment
 Ask participant to attend clinic
 Rule out infection (e.g., stool sample for culture)
- Administer antibiotics as needed, (e.g., if fever or Grade 3-4 neutropenia persists > 
24 h)
 Administer fluids 1-1.5L/day orally or IV, as appropriate for hydration or to correct 
electrolyte abnormalities
 For Grade 3-4 or complicated lower grade diarrhea consider hospitalization and IV 
hydration
 Re-assess after 24 hour
 Diarrhea resolving to baseline bowel habits or Grade ≤ 1: 
- Consider restarting study treatment at reduced dose
 Diarrhea not resolving:
- Start and or continue antidiarrheal treatment (e.g., loperamide 4 mg followed by 2 
mg after each episode of diarrhea [maximum 16 mg loperamide per day
- Consider starting second line antidiarrheal or referral to gastroenterologist





APPENDIX 12 COUNTRY SPECIFIC REQUIREMENTS
COUNTRY SPECIFIC REQUIREMENTS
Country Location Original language Country-specific language
Germany, Czech 
Republic, Romania at 
all sites where it is 
mandated by local or 
country regulations
Section 2 Schedule of Activities, 
Table 2-1, Screening Procedural 
Outline,  Laboratory Tests
Add “HIV” to the list of laboratory tests
Germany, Czech 
Republic, Romania at 
all sites where it is 
mandated by local or 
country regulations
Section 6.2 Exclusion
Criteria, Exclusion criterion 1 g)
“Known history of testing positive for human
immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS)”to be replaced
with “Positive test for HIV”.
Czech Republic Section 8.1:
Discontinuation from Study 
Treatment
Second paragraph modified to read:
“In the case of pregnancy, the investigator must 
immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the 
study treatment will be permanently discontinued in 
an appropriate manner (e.g., dose tapering if 
necessary for participant safety). Please call the 
BMS Medical Monitor within 24 hours of 
awareness of the pregnancy.”
The following statement is deleted:
“If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study 
treatment, a discussion between the investigator and 




Clinical Safety Laboratory 
Assessments
Serology section modified to read:
Serum for hepatitis C antibody, HCV RNA, 
hepatitis B surface antigen (screening only). HIV 
testing must be performed at sites where mandated 
by local or country regulations, see Appendix 12)





APPENDIX 13 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY
Overall Rationale for the Revised Protocol 01, 18-Dec-2017
This Global Revised Protocol 01 will stop enrollment into Arm B (nivolumab and ipilimumab 
combined with cabozantinib triplet regimen) and modify the primary efficacy analysis population 
to comprise all randomized participants, including International Metastatic RCC Database 
Consortium (IMDC) favorable risk participants. Recently reported results from the CheckMate 
214 (CA209214) study demonstrated that nivolumab in combination with ipilimumab yielded 
superior overall survival compared to sunitinib in participants with previously untreated, IMDC-
intermediate and poor risk mRCC; hence, the nivolumab and ipilimumab combination regimen is 
anticipated to become a new standard of care in this population. Given these results, it is no longer 
sufficient for the Arm B triplet regimen to demonstrate superiority over sunitinib, since the 
nivolumab and ipilimumab combination within the triplet regimen has already been shown to be 
superior to sunitinib in CA209214.   
As the Arm A doublet regimen (nivolumab combined with cabozantinib) does not build upon the 
nivolumab and ipilimumab combination regimen, there is no a priori assumption that the doublet 
would have superior efficacy to the nivolumab and ipilimumab combination.  Given that the 
nivolumab and ipilimumab combination in CA209214 did not demonstrate a similar clinical 
benefit in favorable risk participants as was shown in the intermediate and poor risk participants, 
a key strategic objective for the CA2099ER study is to broaden the first-line mRCC population 
that may benefit from a nivolumab combination to include all IMDC risk groups, including 
favorable risk.  The Arm C comparator (sunitinib) is indicated in first-line treatment of mRCC 
across all IMDC risk groups, and it remains an appropriate comparator for the Arm A doublet 
regimen.   
Because the evolving treatment landscape in first-line treatment of mRCC has made it impractical 
to use the same comparator for the doublet and triplet regimens, the study will cease enrollment to 
Arm B and will continue as a 2-arm randomization (1:1) comparison between Arm A and Arm C 
(sunitinib). The primary efficacy analysis population will also be changed to comprise all 
randomized participants to align with the objective of demonstrating clinical benefit across all 
IMDC risk groups. The participants at each site who were randomized to Arm B prior to the 
implementation of this revised protocol will continue the treatment plan and study procedures for 
Arm B, as specified in the original protocol version 08 Mar 2017.  
Secondary items incorporated into this Global Revised Protocol 01 include: (i) to add a Data 
Monitoring Committee review after 30 participants are treated for 6 weeks, (ii) to adjust, clarify 
and add exclusion criteria, (iii) to add treatment restrictions, (iv) to clarify criteria associated with 
hemorrhage with regard to resuming treatment, (v) to specify an additional precaution when 
sunitinib dosing is resumed, and (vi) to incorporate updated nivolumab clinical program protocol 
standards.
Tertiary items include: (i) incorporation of Administrative Letter 01and (ii) correction of 
typographical and grammatical errors.





This Revised Protocol 01 applies in all countries, at all sites, to all future participants enrolled in 
the study, and where applicable, to all participants currently enrolled in the study




Description of Change Brief Rationale
Title Page and 
Synopsis
Protocol Title
In the Protocol Title, Arm B wording is 
deleted.






Arm B wording is deleted.
Objectives and endpoints for 
intermediate/poor risk groups are deleted
Exploratory objectives for ipilimumab 
are deleted
Revised Protocol 01 stops randomization to Arm 
B. A favorable risk cap of 25% matches the 




Arm B wording is deleted. 
Number of Arms is revised from 3 to 2, 
and treatment allocation to 1:1.
Sample size is revised
Favorable risk cap is adjusted up to 25%
Schematic is revised
Impact of Revised Protocol 01 on Arm B 
patients is clarified
Revised Protocol 01 stops randomization to Arm 
B.
Synopsis, Table 
2-3, and Multiple 
Sections 5.1, 7, 
7.1, 7.1.2, 7.4, 
8.1.1, 9, 9.5
A paragraph is added to clarify the 
impact of Revised Protocol 01 on Arm B 
patients 
To clarify the impact of Revised Protocol 01 on 
Arm B patients in relevant protocol sections.
Procedural 
Outline Tables 2-
2, 2-3 and 2-4
Tumor Tissue row, Notes column - a 
paragraph is added to clarify procedures 
associated with Treatment beyond 
Progression
Procedure description was previously missing
Section 3.1 Study 
Rationale


















Updated wording from CA209214 is 
applied.
(Section numbering is adjusted from 
3.2.1.4 to 3.2.1.3, after deletion of prior 
section 3.2.1.3) 
Revised Protocol 01 stops randomization to Arm 
B.















Paragraph regarding cabozantinib 
efficacy is updated with ESMO data





Arm B wording is deleted.
Benefit risk assessment is adjusted to 
account for the 2 Arm study design





Data Monitoring Committee review after 
30 patients are treated for 6 weeks, is 
added.




Sample size is adjusted Revised Protocol 01 stops randomization to Arm 
B.





Arm B wording is deleted.
Number of Arms is revised from 3 to 2, 
and treatment allocation to 1:1.
Favorable risk cap is adjusted up to 25%






Arm B wording is deleted.
Number of Arms is revised from 3 to 2, 
and treatment allocation to 1:1.









Rationale for adjusting favorable risk cap 
to 25% is added




Arm B wording is deleted.
Rationale for adjusted cap to favorable 
risk group, is added
Revised Protocol 01 stops randomization to Arm 
B.
Favorable risk group cap is adjusted to 25%





in Arm A and 
Arm B
Arm B wording is deleted and supporting 
rationale added.




Arm B wording is deleted. Revised Protocol 01 stops randomization to Arm 
B.









Description of Change Brief Rationale
Dosing Duration 
for Nivolumab
With this revised protocol, the option for 
retreatment on study in subjects who 
progress after completing 2 years of 
nivolumab treatment will be removed 
from the protocol.
Recent evidence suggests that activity of 





Exclusion criteria 6.2.1a revises criteria 
for CNS metastases that are treated and 
stable, from at least 3 months to at least 1 
month
From 3 months to 1 month after a procedure, the 
risk of procedure-related complications is low, 




Exclusion criteria 6.2.1b adds ‘celiac 
disease’ as an example external trigger.
To address a request from the France Health 





Exclusion criteria 6.2.1o revises LMWH 
criteria for DVT and PE, from at least 6 
weeks to at least 3 weeks





Exclusion criteria 6.2.2e is revised to 
major surgery less than 6 weeks, 
nephrectomy less than 4 weeks, prior to 
randomization,  provided complete 
wound healing and no ongoing post-
operative complications.





An exclusion is added regarding 
botanical preparations









Exclusion criteria 6.2.3i adjusts UPCR 
limit to permit UPCR = 1.5, unless 24-
hour urine protein is ≤ 1.5 g
To adjust the UPCR limit. 
Section 7.1
Treatment
Clarification of a sentence revising 
‘...approximately 30 minutes...’ to read 
‘...at least 30 minutes...’.  For 
consistency, the phrase ‘but may be more 
or less depending on the situation’ is 
deleted.





Clarifies that Grade 2 drug-related 
adverse event or laboratory abnormality 
(e.g., AST, ALT, total bilirubin) that 
persists for more than 1 week or worsens 
despite supportive care management, will 
delay cabozantinib dosing
To clarify the conditions for delaying 
cabozantinib dosing, with respect to Grade 2 
drug-related AEs and/or lab abnormalities














The final paragraph refers the 
Investigator to the sunitinib label for 
additional information regarding 
monitoring of adverse events, in addition 
to management of adverse events.
To address a request from the France Health 
Authority regarding the monitoring and 





Participants with asymptomatic Grade 2 
drug-related AST, ALT or total bilirubin 
elevation, or Grade 3 drug-related lipase 
or amylase abnormalities that are not 
associated with symptoms or clinical 
manifestations of pancreatitis may reduce 
cabozantinib by one dose level, without 
delaying dosing, at the discretion of the 
investigator.








Bullet 4 is deleted: 
Participants with combined Grade 2 
AST/ALT AND total bilirubin values 
meeting discontinuation parameters 








Addition of a new bullet;
Subjects who develop a pulmonary 
embolism and/or DVT should have study 
treatment interrupted until therapeutic 
anticoagulation is established. Treatment 
with cabozantinib may be resumed in 
subjects with pulmonary embolism or 
DVT if it is determined that the event is 
uncomplicated and that the subject is 
deriving clinical benefit from 
cabozantinib  treatment and that 
anticoagulation does not place them at a 
significant risk that outweighs the benefit 
of resuming treatment per discretion of 
the investigator.
To specify a precaution when cabozantinib 
dosing is resuming
Section 7.7.1 Addition of a bullet regarding CYP3A4 
strong inducers
Addition of  restriction regarding use of 
botanical preparations
To add a restrictions regarding use of CYP3A4 
strong inducers and botanical preparations
Section 7.7.2.1 Language revises LMWH criteria for 
DVT and PE, from at least 6 weeks to at 
least 3 weeks
To shorten the requirement regarding LMWH 
treatment
Section 8.1.1 Addition of myocarditis to Nivolumab 
and or Ipilimumab discontinuation 
criteria
Myocarditis is a newly identified risk













Arm B wording is deleted.
Number of Arms is revised from 3 to 2, 
and treatment allocation to 1:1.
The analysis is revised from 
intermediate/poor risk groups to all risk 
groups 
Favorable risk cap is adjusted up to 25%
The sample size is adjusted from N=1014 
to N=580 randomized.
Analysis populations, Efficacy Analysis, 
Safety Analysis and Interim Analysis are 
revised accordingly.
To stop enrolment into Arm B (Nivolumab, 
Ipilimumab and Cabozantinib triplet) and to 
include favorable risk participants (capped at 
25%) in the primary data analysis
The TKI containing regimen is more 
appropriately studied in all risk groups.
Appendix 2 Deleted bullets describing records 
maintained by site
For consistency with revised protocol model 
document
Appendix 4 Add a barrier method of contraception 
for patients in Arms A and or B.
For consistency with SmPC label for 
cabozantinib
Appendix 7 Corrected status definitions of Zubrod-
ECOG-WHO scores
For consistency with current descriptions of 
scores
All Formatting and typographical corrections Minor, therefore have not been summarized
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1 BACKGROUND AND RATIONALE 
Although multiple agents are approved as monotherapies for the treatment of subjects with 
metastatic renal cell carcinoma (mRCC), the testing of combination therapies, in particular, 
treatment with immune-checkpoint inhibitors in combination with tyrosine kinase inhibitors 
(TKIs) has not been fully explored. While single agent therapies have improved outcomes, ongoing 
drug resistance and disease progression demonstrate an urgent need to find more effective 
therapies for mRCC subjects.. The CA2099ER trial will include previously untreated subjects with 
advanced RCC and uses the well-characterized immune checkpoint inhibitor nivolumab in 
combination with cabozantinib, a known standard-of-care in mRCC subjects. Nivolumab 
combined with cabozantinib may be an important step forward in evaluating combination regimens 
which could potentially optimize the management of previously untreated subjects with mRCC. 
Cabozantinib was shown to improve PFS and OS compared to everolimus, leading to its regulatory 
approval in a randomized phase 3 trial in subjects with advanced RCC that had progressed after 
anti-VEGFR therapy. Subsequently, a randomized phase 2 trial of cabozantinib vs sunitinib has 
demonstrated an improvement in ORR and PFS in intermediate- and poor-risk subjects with 
previously untreated mRCC (see Section 3.2.1.4 of the protocol). Cabozantinib has also been 
demonstrated to have effects on immune cells. In a study of 24 subjects with advanced urothelial 
carcinoma, cabozantinib treatment resulted in a decrease in circulating Tregs and increased PD-1 
expression on Tregs. Low Tregs at baseline were also predictive of improved response to 
cabozantinib and survival.0F1 
Given the promising clinical activity of cabozantinib in previously untreated mRCC and its 
potential immune effects, combining cabozantinib with nivolumab (in a doublet regimen) is a 
rational strategy to optimize first-line therapy in mRCC. An ongoing phase 1 study is evaluating 
both the doublet and triplet (nivolumab and ipilimumab combined with cabozantinib) regimens in 
subjects with refractory advanced urothelial cancer or other genitourinary tumors, including 
mRCC, and has defined dosing for both regimens that produces acceptable safety and tolerability 
(Section 3.2.1.5 of the protocol). CA209-9ER, 2-arm randomized phase 3 trial, will determine if 
the combination doublet regimen (nivolumab combined with cabozantinib) produces greater 
clinical benefit than sunitinib, a standard of care agent for subjects with previously untreated 
mRCC. In addition, this trial will reveal the adverse event profiles, quality of life measures, as well 
as exploratory biomarkers associated with these different first-line treatment regimens. 
Research Hypothesis: 
Treatment with nivolumab combined with cabozantinib (doublet regimen) will demonstrate an 
improvement in PFS per BICR compared to sunitinib monotherapy in subjects with previously 
untreated mRCC. 
Schedule of Analyses: 
This study will be monitored by an independent Data Monitoring Committee (DMC). Details are 
specified in the DMC charter. 
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The PFS analysis will occur after approximately 9-10 months minimum follow-up on all 
randomized subjects, which will be triggered by approximately 350 events from Arm A 
(nivolumab combined with cabozantinib; doublet regimen) and Arm C (sunitinib). 
Two interim analyses of OS are planned. The first interim analysis is planned at the time of final 
PFS analysis and expected after observing 165 deaths among the randomized subjects in Arm A 
and Arm C (65% of the targeted OS events for final analysis). The second interim analysis is 
expected after observing 211 deaths among the randomized subjects in Arm A and Arm C (83% 
of targeted OS events needed for final analysis. The final analysis of OS is expected after observing 
211 deaths among the randomized subjects in Arm A and Arm C. 
The final PFS analysis will not occur prior to these conditions being met: 
• at least 8 months minimum follow-up on all randomized subjects; 
• at  least 283 PFS events, which provide at least 90% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C; and  
• at least 149 OS events, which provide 66% power if the observed HR for OS was 0.60. 
The expected PFS analysis will occur at approximately 29 months from FPFV. The second interim 
and final analyses of OS are expected to occur approximately 34 months and 40 months from 
FPFV. 
Secondary endpoints will be analyzed at the time of the final analysis of PFS based on a 
hierarchical testing strategy. In the event that the interim analysis for superiority of overall survival 
is positive, final (CSR) analyses will be performed prior to achieving 254 deaths; additional details 
can be found in section 7.5.7. 
 
2 STUDY DESCRIPTION 
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B (nivolumab + ipilimumab combined with cabozantinib). Subjects previously randomized to Arm 
B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol. 
This is an open label, randomized trial of nivolumab combined with cabozantinib (doublet 
regimen) versus sunitinib in subjects with previously untreated (first line) advanced or metastatic 
RCC. Subjects will be randomized between Arm A and Arm C in a 1:1 ratio with approximately 
638 subjects (319 per arm) capped at approximate 25% to represent the normal frequency of 
favorable risk group in mRCC. The rest of the randomized subjects will provide approximately 
478 intermediate/poor risk randomized subjects (239 per arm). Subjects will be stratified at the 
time of randomization by IMDC prognostic score (0 [favorable risk] versus 1-2 [intermediate risk] 
versus 3-6 [poor risk]), PD-L1 tumor expression (≥ 1% versus < 1% or indeterminate), and region 
(US/Canada/Western Europe/Northern Europe versus rest of the world [ROW]). 
The subject is randomly assigned to 1 of the 2 treatment arms as noted in the study schematic 
below.  
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• Arm A (Doublet): Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD 
o Nivolumab to be continued until disease progression, unacceptable toxicity, or a 
maximum treatment of 2 years from the first dose in Cycle 1. 
o Cabozantinib to be continued until disease progression or unacceptable toxicity. 
 
• Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle. Cycles to be 
continued until progression or unacceptable toxicity. 
 
• Note - Randomization to Arm B stops with implementation of approved CA2099ER Global 
Revised Protocol 01. Treatment B continues only for subjects randomized to Arm B prior to 
implementation of Global Revised Protocol 01. 
o Arm B (Triplet): Nivolumab 3mg/kg IV + Ipilimumab 1 mg/kg IV, both Q3W x 4 doses 
+ Cabozantinib 40 mg PO QD  
 Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD. 
 Nivolumab to be continued until disease progression, unacceptable toxicity, or 
a maximum of 2 years from the first dose in Cycle 1. 
 Cabozantinib to be continued until progression or unacceptable toxicity. 
 
Once randomized subjects in Arm A will continue nivolumab until progression, unacceptable 
toxicity, withdrawal of consent, or a maximum of 2 years from the first dose in Cycle 1, whichever 
occurs first. Cabozantinib (Arm A) may be continued until progression, unacceptable toxicity, or 
withdrawal of consent, whichever occurs first, and may extend beyond 2 years from the first dose 
in Cycle 1. 
The study design schematic is presented in the figure below. 
Figure 2-1: Study Design Schematic 
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2.1 Treatment Assignment 
After the subject’s initial eligibility is established and informed consent has been obtained, the 
subject must be enrolled into the study by accessing an Interactive Response Technologies web-
based system (IRT) to obtain the subject number. All subjects will be centrally randomized using 
an Interactive Response Technology (IRT). Before the study is initiated, each user will receive log 
in information and directions on how to access the IRT.  
Every subject that signs the informed consent form must be assigned a subject number in IRT. The 
investigator or designee will register the subject for enrollment by following the enrollment 
procedures established by BMS. The following information is required for enrollment: 
• Date that informed consent was obtained 
• Date of birth 
• Sex at birth. 
Once enrolled in IRT, enrolled subjects that have met all eligibility criteria will be ready to be 
randomized through the IRT. The following information is required for subject randomization: 
• Subject number 
• Date of birth 
• IMDC Prognostic Score (0 versus 1-2 versus 3-6)  
• Region (US/Canada/W Europe/N Europe versus ROW) 
• PD-L1 tumor expression (≥ 1% versus < 1% or indeterminate) 
Subjects meeting all eligibility criteria will be randomized in a 1:1 ratio to Arm A (nivolumab 
combined with cabozantinib) or Arm C (sunitinib), stratified by the following factors: 
• IMDC Prognostic Score: 0 versus 1-2 versus 3-6 
• Region: US/Canada/W Europe/N Europe versus ROW 
• PD-L1 tumor expression: ≥ 1% versus < 1% or indeterminate 
The randomization procedures will be carried out via permuted blocks within each stratum. 
 
2.2 Blinding and Unblinding 
This is an open label study.  
2.3 Protocol Amendments 
 
Table 2.3-1: Protocol Amendments 




• Revised protocol 02 adjusts the timing of the PFS and OS 
interim analyses with modified hypothesized OS hazard 
ratio (HR). The number of randomized subjects is 
increased. 
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Table 2.3-1: Protocol Amendments 
Document  Date of Issue  Summary of Change  
• The interim analysis for ORR is removed, resulting in 
revised overall alpha for PFS and OS endpoints. 
• No change in eligibility or study procedure. 
• Clinical data for nivolumuab + ipilimumab in RCC has 
been updated. 
Other changes include more detail on PRO measures and updates 











Primary revisions: (i) To stop enrollment into Arm B 
(nivolumab, ipilimumab and cabozantinib triplet) and (ii) to 
include favorable risk subjects (capped at 25%) in the 
primary data analysis. 
Secondary items include: (i) to add a Data Monitoring 
Committee review after 30 subjects are treated for 6 
weeks, (ii) to adjust, clarify and add exclusion criteria, (iii) 
to add treatment restrictions, (iv) to clarify criteria 
associated with hemorrhage with regard to resuming 
treatment, (v) to specify an additional precaution when 
sunitinib dosing is resumed, and (vi) to apply newly 
updated Sponsor standards for nivolumab clinical protocols. 
Tertiary items include (i) incorporation of Administrative 
Letter 01 and (ii) correction of typographical and 
grammatical errors. 
 
2.4 Data Monitoring Committee 
An independent Data Monitoring Committee (DMC) has been established to provide oversight of 
safety and efficacy considerations, study conduct, and risk-benefit ratio. Following review, the 
DMC will recommend continuation, modification, or discontinuation of this study based on 
reported safety and efficacy data. Details of DMC responsibilities and procedures are specified in 
the DMC charter. Representatives of the Sponsor will serve only as coordinators of the committee, 
without having full member responsibilities or privileges. In addition, the Sponsor will 
independently review safety data in a blinded manner during the conduct of this trial to ensure that 
any safety issues are identified and addressed. 
The DMC will conduct the first review of the safety data after at least 30 subjects are treated and 
followed for at least 6 weeks. The DMC will conduct its second review of the safety data after at 
least 75 subjects are treated and followed for at least 6 weeks. The DMC will conduct its review 
of the safety data focusing on the initial approximately 12 Japanese subjects (6 per arm) treated 
and followed for at least 4 weeks. The DMC will then review safety and the available efficacy data 
pertaining to primary endpoint to evaluate safety in the context of benefit, every six months 
thereafter.  
The DMC will also review the formal final analysis of PFS (as per BICR) and first interim analysis 
of superiority of OS scheduled at around 29 months from FPFV. A second interim analysis of OS 
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will be at around 34 months from FPFV. BMS will remain blinded to OS interim analyses unless 
DMC decides to disclose the formal interim analysis to BMS.  
 
Details of the interim analyses can be found in section 7.5.7. 
 
2.5 Blinded Independet Central Review 
A blinded independent central review (BICR) committee has been established to provide an 
independent imaging review of images obtained in subjects participating in this study. Details of 
BICR responsibilities and processes may be found in the BICR Charter. The BICR determined 




• To compare PFS per BICR of nivolumab combined with cabozantinib (Arm A: doublet) 
with sunitinib (Arm C) in all randomized subjects.  
3.2 Secondary 
• To compare overall survival (OS) of Arm A with Arm C in all randomized subjects. 
• To evaluate the objective response rate (ORR) of Arm A with Arm C per BICR in all 
randomized subjects. 
• To assess overall safety and tolerability in all treated subjects.  
3.3 Exporatory 
• To explore potential predictive biomarkers of clinical response to nivolumab and 
cabozantinib combination. 
• To evaluate health related quality of life (HRQoL). 
• To characterize the pharmacokinetics of nivolumab and cabozantinib and explore exposure 
response relationships, if applicable. 
• To characterize the immunogenicity of nivolumab. 
• To assess PFS after next line of treatment (PFS2) in each arm.  
 
4 ENDPOINTS 
4.1 Primary Endpoints 
Progression-free survival (PFS) is the primary endpoint. Two definitions are used for the analysis 
of PFS. The primary definition accounts for subsequent therapy by censoring at the last evaluable 
tumor assessment on or prior to the date of subsequent therapy. The secondary definition is 
irrespective of subsequent therapy and does not account for subsequent therapy.  
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Clinical deterioration in the absence of unequivocal evidence of progression (per RECIST v1.1 
criteria) is not considered progression for purposes of determining PFS. 
PFS rate at time T is defined as the probability that a subject has not progressed and is alive at  
time T following randomization. PFS rates at fixed time points (e.g. 6 months, depending on the 
minimum follow-up) are defined as the probability that a subject has not progressed and is alive at 
time T following randomization. 
The first on-study tumor assessment is scheduled to be conducted at 12 weeks (± 1 week) following 
randomization. Subsequent tumor assessments are scheduled every 6 weeks (± 1 week) up to  
week 60, then every 12 weeks (± 2 weeks) until disease progression. 
4.1.1 Primary Definition of Progression-Free Survival (Accounting for 
Subsequent Therapy) 
The primary definition of PFS (PFS truncated at subsequent therapy, which includes anti-cancer 
therapy, tumor directed radiotherapy, or tumor directed surgery) is defined as the time between the 
date of randomization and the date of first documented tumor progression, based on BICR 
assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.  
Subjects who die without a reported progression will be considered to have progressed on the date 
of their death. The following censoring rules will be applied for the primary definition of PFS: 
• Subjects who did not progress or die will be censored on the date of their last evaluable tumor 
assessment. 
• Subjects who did not have any on study tumor assessments and did not die will be censored on 
their date of randomization. 
• Subjects who receive subsequent anti-cancer therapy prior to documented progression will be 
censored at the date of the last evaluable tumor assessment conducted on or prior to the date 
of initiation of the subsequent anti-cancer therapy. 
• Subjects who did not have a documented progression and received subsequent anti-cancer 
therapy will be censored at the date of the last evaluable tumor assessment conducted on or 
prior to the initiation of the subsequent anti-cancer therapy. 
Censoring rules for the primary definition of PFS (PFS truncated at subsequent therapy) are 
presented as follows and in Table 4.1.1-1. 
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Figure 4.1.1-1: PFS Primary Definition 
 
Table 4.1.1-1: Censoring Scheme Used in Primary Definition of PFS 
Situation  Date of Progression or Censoring  Outcome  
No baseline tumor assessments* Date of randomization  Censored  
No on study tumor assessments and 
no death*  Date of randomization Censored 
Subsequent anti-cancer therapy 
started without death or progression 
per RECIST v1.1 reported prior or 
on the same day 
Date of last evaluable tumor 
assessment prior to or on the date of 
initiation of the subsequent anti-
cancer therapy 
Censored  
Documented progression per 
RECIST v1.1 and no new anti-
cancer started before 
Date of the first documented 
progression per RECIST v1.1 
(excludes clinical progression) 
Progressed  
No progression and no death, and 
no new anti-cancer therapy started 
Date of last evaluable tumor 
assessment  
Censored  
Death without progression per 
RECIST v1.1 and no new anti-
cancer started before 
Date of death  Progressed  
* Tumor assessments and death if any, occurring after start of subsequent anti-cancer therapy are not considered. 
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4.1.2 Secondary Definition of Progression Free Survival (Irrespective of 
Subsequent Therapy) 
The secondary definition of PFS (ITT definition) is defined as the time between the date of 
randomization and the date of first documented tumor progression, based on BICR assessments 
(per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.  
Subjects who die without a reported progression will be considered to have progressed on the date 
of their death. The following censoring rules will be applied for the secondary definition of PFS: 
• Subjects who did not progress or die will be censored on the date of their last evaluable tumor 
assessment. 
• Subjects who did not have any on study tumor assessments and did not die will be censored on 
their date of randomization. 
Censoring rules for the secondary definition of PFS (ITT definition) are presented as follows and 
in Table 4.1.2-1. 
Figure 4.1.2-1: PFS Secondary Definition 
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Table 4.1.2-1: Censoring Scheme for Secondary Definition of PFS 
Situation Date of Progression of Censoring Outcome 
No baseline tumor assessment Date of randomization Censored 
No on-study tumor assessments and 
no death 
Date of randomization Censored 
Documented progression per 
RECIST v1.1   
Date of first documented 
progression per RECIST v1.1 
criteria (excludes clinical 
progression) 
Progressed 
No progression and no death Date of last evaluable tumor 
assessment 
Censored 
Death without progression per 
RECIST v1.1 
Date of death Progressed 
 
4.2 Secondary Endpoints 
 
4.2.1 Overall Survival 
Overall survival (OS) is defined as the time from randomization to the date of death from any 
cause. For subjects that are alive, their survival time will be censored at the date of last contact 
date (or “last known alive date”). Overall survival will be censored at the date of randomization 
for subjects who were randomized but had no follow-up. 
Follow-up visit #1 (FU1) should occur 30 days from the last dose and follow-up visit #2 (FU2) 
occurs approximately 100 days from last dose of study drug. After FU2, survival follow-up will 
be conducted every 3 months. 
4.2.2 Objective Response Rate 
Objective Response Rate (ORR) is defined as the number of randomized subjects who achieve a 
best response of confirmed complete response (CR) or confirmed partial response (PR) based on 
BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized subjects. 
Best Overall Response (BOR) is defined as the best response, as determined by the BICR, recorded 
between the date of randomization and the date of objectively documented progression per 
RECIST v1.1 criteria or the date of subsequent therapy (including tumor-directed radiotherapy and 
tumor-directed surgery), whichever occurs first. For subjects without documented progression or 
subsequent therapy, all available response designations will contribute to the BOR determination. 
Confirmation of response is required at least 4 weeks after the initial response. 
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4.2.2.1 Time to Response 
Time to Response (TTR) is defined as the time from randomization to the date of the first 
confirmed documented response (CR or PR), as assessed by the BICR. TTR will be evaluated for 
responders (confirmed CR or PR) only. 
4.2.2.2 Duration of Response 
Duration of Response (DOR) is defined as the time between the date of first confirmed documented 
response (CR or PR) to the date of the first documented tumor progression as determined by the 
BICR (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who 
start subsequent therapy without a prior reported progression will be censored at the last evaluable 
tumor assessments prior to initiation of the subsequent anti-cancer therapy. Subjects who die 
without a reported prior progression will be considered to have progressed on the date of their 
death. Subjects who neither progress nor die, DOR will be censored on the date of their last 
evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only. 
4.3 Safety Endpoints 
The assessment of safety will be based on the incidence of adverse events (AEs), serious adverse 
events (SAEs), adverse events leading to discontinuation, adverse events leading to dose 
modification, select adverse events (select AEs) for EU/ROW Submissions, immune-mediated 
AEs (IMAEs) for US Submission, other events of special interest (OEOSI), and deaths. The use 
of immune modulating concomitant medication will be also summarized. In addition clinical 
laboratory tests, and immunogenicity (i.e. development of anti-drug antibody) will be analyzed. 
4.4 Exploratory Endpoints 
4.4.1 Biomarkers 
Biomarkers potentially associated with clinical endpoints will be measured by analyzing tumor 
and blood samples. Biomarker endpoints include, but are not limited to, single-nucleotide 
polymorphisms (SNPs), proteins in tumor specimens and serum, and immune cell populations.  
4.4.1.1 PD-L1 Expression 
PD-L1 expression is defined as the percent of tumor cells membrane staining in a minimum of 100 
evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is 
referred to as quantifiable PD-L1 expression. If the PD-L1 staining could not be quantified, it is 
further classified as: 
1) Indeterminate: Tumor cell membrane staining hampered for reasons attributed to the biology 
of the tumor tissue sample and not because of improper sample preparation or handling. 
2) Not evaluable: Tumor tissue sample was not optimally collected or prepared and PD-L1 
expression is neither quantifiable nor indeterminate. Not evaluable can be determined from 
H&E process before the tumor biopsy specimen is sent for PD-L1 evaluation or from the H&E 
process during PD-L1 evaluation. 
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Subjects with missing PD-L1 expression are subjects with no tumor tissue sample available for 
evaluation. 
PD-L1 expression will be collected in the IRT as well as in the clinical database. Statistical analysis 
using PD-L1 expression will be solely based on PD-L1 expression data from clinical database. 
Efficacy endpoints defined above (PFS and ORR by BICR, OS) will be analyzed by PD-L1 
expression to explore the association of PD-L1 expression on tumor and/or tumor associated 
immune cells (TAIC) with clinical benefit. 
4.4.2 Clinical Outcomes Assessments 
The FSKI-19 and EQ-5D-3L patient-reported outcomes will be collected and analyzed in this 
study. 
4.4.2.1 FKSI-19 
The NCCN FKSI-19 is a 19-item scale that measures tumor specific HrQoL in kidney cancer 
subjects. The FKSI-19 uses 5 Likert-type response categories that range from “not at all” to “
very much.” Subjects are asked to circle the response category that best characterizes their 
response over the last 7 days on 19 items that include symptoms such as lack of energy, fatigue, 
appetite, coughing, shortness of breath, pain, nausea, and ability to work.The instrument yields a 
total score and three subscale scores: Disease Related Symptoms (DRS), Treatment Side Effects 
(TSE), and Functional Well Being (FWB). A higher score indicates fewer symptoms. 
If there are missing items, subscale scores can be prorated according to the standard FACT 
(Functional Assessment of Cancer Therapy) scoring methodology. This can be done using the 
following formula: 
 
𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷 𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑷𝑷𝑺𝑺𝑷𝑷 𝑺𝑺𝑺𝑺𝑷𝑷𝑷𝑷𝑷𝑷 =
[𝑺𝑺𝑺𝑺𝑺𝑺 𝑷𝑷𝒐𝒐 𝑰𝑰𝑷𝑷𝑷𝑷𝑺𝑺 𝑺𝑺𝑺𝑺𝑷𝑷𝑷𝑷𝑷𝑷𝑺𝑺] 𝒙𝒙 [𝑵𝑵 𝑷𝑷𝒐𝒐 𝑰𝑰𝑷𝑷𝑷𝑷𝑺𝑺𝑺𝑺 𝒊𝒊𝒊𝒊 𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑷𝑷𝑺𝑺𝑷𝑷]
[𝑵𝑵 𝑷𝑷𝒐𝒐 𝑰𝑰𝑷𝑷𝑷𝑷𝑺𝑺𝑺𝑺 𝑨𝑨𝒊𝒊𝑺𝑺𝑨𝑨𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷]
 
 
When there are missing data, prorating by subscale in this way is acceptable as long as more than 
50% of the items were answered.  The total score is then calculated as the sum of the un-weighted 
subscale scores. 
Table 4.4.2.1-1: Time Windows for FKSI-19 and EQ-5D-3L Assessments 
Nominal Time-Point (Cycle) Time Window 
Nivolumab+Cabozantinib (Arm A) treatment group 
Baseline (Cycle 1) Prior to first dose on Day 1 
Week 2 (Cycle 2) Nominal Day 15 (Day 2 thru Day 24, inclusive of Day 
15 + 9 days) 
Every 2 weeks thereafter (Cycles 3+) Nominal Days 29+ (+9 days/-5 days, inclusive) 
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Table 4.4.2.1-1: Time Windows for FKSI-19 and EQ-5D-3L Assessments 
Nominal Time-Point (Cycle) Time Window 
Nivolumab+Ipilimumab+Cabozantinib (Arm B) treatment group 
Baseline (Cycle 1) Prior to first dose on Day 1 
Week 3 (Cycle 2) Nominal Day 22 (Day 2 thru Day 38, inclusive of Day 
22 + 16 days) 
Every 3 weeks up to Week 9 (Cycles 3-4) Nominal Days 43 and 64 (+16 days/-5 days, inclusive) 
Week 12 (Cycle 5) Nominal Day 85 (+9 days/-5 days, inclusive) 
Every 2 weeks thereafter (Cycles 6+) Nominal Days 99+ (+9 days/-5 days, inclusive) 
Sunitinib (Arm C) treatment group 
Baseline (Cycle 1) Prior to first dose on Day 1 
Week 6 (Cycle 2) Nominal Day 43 (Day 2 thru Day 80, inclusive of Day 
43 + 37 days) 
Every 6 weeks thereafter (Cycles 3+) Nominal Days 85+ (+9 days/-5 days, inclusive) 
For all treatment groups 
Follow Up:  
Follow-Up 1 30 days from the last dose (± 7 days) or coincide with 
the date of discontinuation (± 7 days) if date of 
discontinuation is greater than 42 days after last dose.  
Follow-Up 2 100 days (± 7 days) from last dose of study treatment. 
Subjects must be followed for at least 100 days after 
last dose of study treatment. 
Survival Follow-Up i a 
(i = 1, 2, 3, 4, ...) 
3 months (± 14 Days) after Follow-up Visit 2, and 
subsequent survival follow-up visits every 3 months (± 
14 days).  
a Survival Follow-Up is only relevant for EQ-5D, not FKSI-19 assesments.  
 
4.4.2.2 EuroQoL EQ-5D-3L 
Subjects’ reports of general health status will be assessed using the EuroQoL Group’s EQ-5D-3L. 
EQ-5D-3L essentially has 2 components: the descriptive system and the visual analogue scale 
(VAS). 
The instrument’s descriptive system consists of 5 dimensions:  mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. Each dimension has 3 levels, reflecting "no health 
problems," "moderate health problems," and "extreme health problems." A dimension for which 
there are no problems is said to be at level 1, while a dimension for which there are extreme 
problems is said to be at level 3.  Thus, the vectors 11111 and 33333 represent the best health state 
and the worst health state, respectively, described by the EQ-5D-3L. Altogether, the instrument 
describes 35 = 243 health states. Empirically derived weights can be applied to an individual’s 
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responses to the EQ-5D-3L descriptive system to generate an index measuring the value to society 
of his or her current health. Such preference-weighting systems have been developed for the UK, 
US, Spain, Germany, and numerous other populations. For this study, EQ-5D-3L utility index 
values will be computed using a scoring algorithm based on the United Kingdom Time-Trade-Off 
(UK TTO) value set1F2 
In addition, the EQ-5D-3L includes a VAS, which allows respondents to rate their own current 
health on a 101-point scale ranging from 0=”worst imaginable” health to 100=“best imaginable” 
health state 2F3. 
A change from baseline of 0.08 for the EQ-5D-3L utility index score and of 7 for the EQ-5D-3L 
VAS are considered minimally important differences for the EQ-5D-3L3F4. 
All questionnaires completed at baseline and on-study will be assigned to a time-point according 
to the windowing criteria in Table 4.4.2.1-1 and included in the analysis. In case a subject has two 
on-study assessments within the same window, the assessment closest to the time-point will be 
used. And, in the case of two assessments at a similar distance to the time-point, the latest one will 
be chosen. In the event where the subject has no assessment at all in a specific window, the 
observation will be treated as missing for that time-point. 
 
4.4.3 Pharmacokinetics 
PK will be measured by the serum concentration of nivolumab and/or ipilimumab and/or 
cabozantinib. Samples will be collected to characterize pharmacokinetics of nivolumab and to 
explore exposure-safety and exposure-efficacy relationships.  
4.4.4 Immunogenicity 
Serum samples collected will be analyzed by a validated immunogenicity assay. Selected serum 
samples may be analyzed by an exploratory orthogonal method that measures anti-nivolumab.  
In addition, ad hoc serum samples designated for pharmacokinetic or biomarker assessments may 
also be used for immunogenicity analysis if required (e.g., insufficient volume for complete 
immunogenicity assessment or to follow up on suspected immunogenicity related AE). 
Further details on immunogenicity background and rationale, definitions, population for analyses 
and endpoints are described in APPENDIX 3.  
4.4.5 PFS2 
PFS on next-line therapy (PFS2) is defined as the time from randomization to objectively 
documented progression, per investigator assessment, after the next line of therapy or to death 
from any cause, whichever occurs first. Subjects who were alive and without progression after the 
next line of therapy will be censored at last known alive date.  
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The following censoring rules will be applied for PFS2: 
• Subjects who did not receive subsequent anti-cancer therapy (i.e. second-line therapy): 
− Subjects who died, the death date is the event date; 
− Else the subject’s PFS2 is censored at the last known alive date. 
• Subjects who received subsequent anti-cancer therapy (i.e. second-line therapy): 
− Subjects who had a disease progression after the start of subsequent anti-cancer therapy, 
this disease progression date is the event date; 
− Else if a subject died or start of second next line therapy, the date of min (death, start date 
of second next line therapy) is the event date; 
− Else the subject’s PFS2 is censored at the last known alive date. 
 
 




5 SAMPLE SIZE AND POWER 
The sample size calculations of this study summarized below are based on the target randomized 
subjects in Arm A and Arm C only. That is, the total randomized subjects will be higher than the 
target randomized subjects due to randomized subjects into Arm B prior to implementation of 
CA2099ER Global Revised Protocol 01, which stopped further randomization into Arm B. 
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The sample size of this study accounts for the primary endpoint of progression-free survival (PFS) 
per BICR in all randomized subjects. Assuming a 25% screen failure rate, it is expected that 
approximately 850 subjects will need to be enrolled in order to randomize 638 subjects (319 per 
arm) in a 1:1 ratio. To represent the normal frequency of the favorable risk group in mRCC, the 
favorable risk subjects are capped at approximate 25%; thus, at most 212 favorable risk subjects 
(106 per arm) will be enrolled to randomize 160 favorable risk subjects in a 1:1 ratio. The rest of 
the enrolled participants will provide approximately 478 intermediate/poor risk randomized 
subjects (239 per each arm). 
The overall alpha for this study is 0.05 (two-sided). PFS will be evaluated for treatment effect at 
an alpha of 0.05 (two-sided), with at least 95% power. No interim analysis of PFS is planned. OS 
will be evaluated for treatment effect at an alpha level of 0.05 (two-sided) with 80% power, 
accounting for two formal interim analyses to assess efficacy. 
Sample Size Justification for Primary PFS Endpoint 
The primary endpoint of PFS per BICR of Arm A versus Arm C analysis conducted on all 
randomized subjects. The PFS analysis will occur after approximately 9-10 months minimum 
follow-up on all randomized subjects, which will be triggered by approximately 350 events from 
Arm A and Arm C. The 350 PFS events provide at least 95% power to detect a HR of 0.68 for PFS 
of Arm A versus Arm C with a type I error of 0.05 (two-sided). The HR of 0.68 corresponds to a 
47% increase in the median PFS, assuming a median PFS of 18.2 months for Arm A and 12.4 
months for Arm C. It is projected that an observed HR of 0.811 or less, which corresponds to a 
2.89 month or greater improvement in median PFS (12.4 versus 15.3 months), would result in a 
statistically significant improvement in PFS for the Arm A versus Arm C comparison.  
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure.  
Sample Size Computation for Secondary OS Endpoint 
The secondary endpoint of OS in all randomized subjects specifies the comparison of Arm A 
versus Arm C. Among all randomized subjects, approximately 254 events (ie, deaths) in Arm A 
and Arm C provides at least 80% power to detect a HR of 0.70 for OS of Arm A and Arm C with 
an overall type 1 error of 0.05 (two-sided) for each test. The HR of 0.70 corresponds to a 43% 
increase in the median OS, assuming a median OS of 47.1 months for Arm A and 33 months for 
Arm C. 
Two formal interim analyses of OS are planned for this study. The first interim analysis is planned 
at the time of final PFS analysis and it is expected to observe 165 OS events (65% of the targeted 
OS events for final analysis) and the second interim analysis is planned to occur after observing 
approximately 211 events (83% of targeted OS events needed for final analysis). The stopping 
boundaries at interim and final analyses will be derived based on the number of deaths using 
O’Brien and Fleming α spending function. For example, with 165, 211, and 254 observed events 
in Arm A and Arm C at the first interim, second interim, and final analyses, the respective stopping 
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boundaries would be α=0.011 (two-sided), α=0.025 (two-sided), and α=0.041 (two-sided). If the 
first interim analysis is performed exactly at 165 deaths, it is projected that an observed HR of 
0.673 or less, which corresponds to a 16.0 month or greater improvement in median OS (33 versus 
49 months), would result in a statistically significant improvement in OS for the Arm A versus 
Arm C comparison. At the second interim analysis with 211 deaths, it is projected that an observed 
HR of 0.734 or less, which corresponds to a 12.0 month or greater improvement in median OS (33 
versus 45 months), would result in a statistically significant improvement in OS for the Arm A 
versus Arm C comparison. At the time of final OS analysis when there are 254 deaths, it is 
projected that an observed HR of 0.774 or less, which corresponds to a 9.6 month or greater 
improvement in median OS (33 versus 42.6 months), would result in a statistically significant 
improvement in OS for the Arm A versus Arm C comparison. 
Assuming a constant accrual rate (an average rate of 3 subjects/month in the first 4 months, 
afterwards an average rate of 42 subjects/month), the accrual will take approximately 19 months. 
The final PFS analysis will not occur prior to these conditions being met: 
• at least 8 months minimum follow-up on all randomized subjects; 
• at  least 283 PFS events, which provide at least 90% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C; and  
• at least 149 OS events, which provide 66% power if the observed HR for OS was 0.60. (Note 
that if the analysis of first interim analysis OS takes place with 149 OS events, the alpha 
spending for the OS comparison would be 0.007 with a critical HR=0.643.) 
This expected PFS analysis will occur at approximately 29 months from FPFV. The second interim 
and final analyses of OS are expected to occur approximately 34 months and 40 months from 
FPFV, respectively. Table 5-1 summarizes the results of these calculations. 
Table 5-1: Summary of Sample Size Parameters and Schedule of Analyses 
Primary/Secondary 
Endpoints PFS (Primary) OS (Secondary)
  
Primary analysis population All Randomized Subjects 
Accrual rate per month for all 
randomized population 
3 subjects/month in the first 4 months, afterwards an average rate of 42 
subjects/month  
Power 95% 80%  
Alpha 0.05 2-sided 
0.05 2-sided (0.011 at IA1, 0.025 at IA2, 
0.041 at FA) 
Hypothesized median control 
vs exp (months)  12.4 vs 18.2 33 vs 47.1 
Hypothesized hazard ratio 0.68 0.70 
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Table 5-1: Summary of Sample Size Parameters and Schedule of Analyses 
Primary/Secondary 
Endpoints PFS (Primary) OS (Secondary)
  
Critical hazard ratio (observed 
hazard ratio at which a 
statistically significant 
difference would be observed) / 
Difference in median (months) 
Corresponding to a minimal 
clinically significant effect size 
(FA)  
0.811 / 2.89 0.774 / 9.6 
Critical HR at interim analysis-
1(IA1) /effect size N/A 0.673 / 16.0 
Expected number of event for 
IA1 (percentage of target 
events) 
N/A 165 (65%)  
Timing of IA1 from FPFV 
(months) N/A 29 
Critical HR at interim analysis-
2(IA2) /effect size N/A 0.734 / 12.0 
Expected number of event for 
IA2 (percentage of target 
events) 
N/A 211 (83%)  
Timing of IA2 from FPFV 
(months) N/A 34 
Accrual duration (months) 19 19 
Timing of final analysis (FA) 
from FPFV (months) 29 40 
Sample size 638 638 
Target number of events (Event 
Goal) 350 254 
 
 
6 STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS FOR 
ANALYSES 
6.1 Study Periods 
• Baseline period: 
− Baseline evaluations or events will be defined as evaluations or events that occur before 
the date and time of the first dose of study treatment. Evaluations (laboratory tests, pulse 
oximetry and vital signs) on the same date and time of the first dose of study treatment will 
be considered as baseline evaluations. Events (AEs) on the same date and time of the first 
dose of study treatment will not be considered as pre-treatment events. 
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− In cases where the time (onset time of event or evaluation time and dosing time) is missing 
or not collected, the following definitions will apply: 
♦ Pre-treatment AEs will be defined as AEs with an onset date prior to but not including 
the day of the first dose of study treatment; 
♦ Baseline evaluations (laboratory tests, pulse oximetry and vital signs) will be defined 
as evaluations with a date on or prior to the day of first dose of study treatment. 
− If there are multiple valid assessments on or prior to the first dose of study treatment: 
♦ For laboratory tests, the latest non missing labs value on or before first dose date (and 
time if collected) will be used as the baseline in the analyses.  For 'LIPASE' and 
'GLUCOSE', for treated subjects only, the last predose assessment with non-missing 
toxicity grade will be considered as baseline. If multiple assessments exist with the 
same collection date (and time if collected) and entry date and time, then the first 
observation is used as baseline. 
♦ For PD-L1, among the records prior to or on first dose date (and time if collected), 
identify first those with quantifiable test result. If there are no records with quantifiable 
test result, then select those with indeterminant result (“INDETERMINATE”). If there 
are no records with indeterminant test result, then select those with unavailable result 
(“NOT EVALUABLE). If there are no records with unavailable test result, then select 
those with not reported or not available result (all other records). The latest record will 
be used as the baseline in the analyses. If there is more than one record for the latest 
date, then choose the one with the greatest specimen ID. 
♦ For Anti-Drug Antibody (ADA), the record related to the most recent assessment 
among those records where date (and time if collected) of Nivolumab immunoglobulin 
(IMG) assessment is less than or equal to the date (and time if collected) of the first 
Nivolumab dose date. 
• Post baseline period: 
− On-treatment AEs will be defined as AEs with an onset date and time on or after the date 
and time of the first dose of study treatment (or with an onset date on or after the day of 
first dose of study treatment if time is not collected or is missing). For subjects who are off 
study treatment, AEs will be included if event occurred within a safety window of 30 days 
(or 100 days depending on the analysis) after the last dose of study treatment. No 
“subtracting rule” will be applied when an AE occurs both pre-treatment and post-
treatment with the same preferred term and grade. 
− On-treatment evaluations (laboratory tests, pulse oximetry and vital signs) will be defined 
as evaluations taken after the day (and time, if collected and not missing) of first dose of 
study treatment. For subjects who are off study treatment, evaluations should be within a 
safety window of 30 days (or 100 days depending on the analysis) after the last dose of 
study treatment. 
• Late-emergent drug-related AEs will be defined as drug-related AEs with an onset date greater 
than 100 days after the last dose of study treatment in subjects who are off study treatment. 
6.2 Treatment Regimens 
The treatment group “as randomized” will be retrieved from the IRT system: 
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• Arm A: Experimental arm: nivolumab + cabozantinib 
• Arm B: Experimental arm: nivolumab + ipilimumab + cabozantinib 
• Arm C: Control arm: sunitinib 
The treatment group “as treated” will be the same as the arm as randomized by IRT. However, if 
a subject received the incorrect drug for the entire period of treatment, the subject’s treatment 
group will be defined as the incorrect drug the subject actually received. 
Unless otherwise specified, the safety analysis will be based on the treatment group “as treated”. 
Unless otherwise specified, the efficacy analysis will be based on the treatment group “as 
randomized”. 
6.3 Populations for Analyses 
 
All analyses will be performed using the treatment arm as randomized (intent to treat), with the 
exception of dosing and safety, for which the treatment arm as received will be used. For purposes 
of analysis, the following populations are defined in Table 6.3-1, and all populations for analyses 
given in this table refer to those subjects in Arm A and Arm C. Those subjects who randomized to 
Arm B prior to Revised Protocol 01 will be considered as part of the population of interest for 
descriptive summary of efficacy and safety analyses. 
Table 6.3-1: Populations for Analyses 
Population Description 
All Enrolled Subjects All subjects who sign informed consent and were registered into the IRT. 
All Randomized Subjects  All subjects who were randomized will be used for analyses of demography, 
protocol deviations, baseline characteristics, primary efficacy analysis, 
secondary efficacy analyses, and outcome research analysis which will be 
performed for this population. 
All Treated Subjects All subjects who received at least one dose of any study medication. This is 
the primary population for exposure and safety analyses. 
Intermediate/Poor Risk Subjects All subjects who were randomized with baseline IMDC prognostic score ≥1 at 
the time of randomization (per IRT). This population will be used for subset 
analyses of demography, protocol deviations, baseline characteristics, primary 
efficacy analysis, and secondary efficacy analyses on intermediate/poor risk 
subjects. 
All Intermediate/Poor Risk 
Treated Subjects 
All intermediate/poor risk subjects who received any dose of study therapy. 
This population will be used for subset analyses of exposure and safety 
analyses on intermediate/poor risk subjects. 
Pharmacokinetic Subjects All subjects with available serum time-concentration data from randomized 
subjects dose with nivolumab and cabozantinib. 
Immunogenicity Subjects All subjects with available data from randomized subjects dose with 
nivolumab and cabozantinib. 
PD-L1 Treated Subjects All subjects with a PD-L1 assessment at baseline who received any dose of 
study therapy. 




7 STATISTICAL ANALYSES 
7.1 General Methods 
Unless otherwise noted, discrete variables will be tabulated by the frequency and proportion of 
subjects falling into each category, grouped by treatment. Percentages given in these tables will be 
rounded to the first decimal and, therefore, may not always sum to 100%. Percentages less than 
0.1 will be indicated as ‘< 0.1’. Continuous variables will be summarized by treatment group using 
the mean, standard deviation, median, minimum, and maximum values. 
Time-to-event variables (e.g. time-to resolution) will be analyzed using the Kaplan-Meier 
technique. When specified, the median will be reported along with 95% CI using Brookmeyer and 
Crowley method4F5 (using log-log transformation for constructing the confidence intervals5F6). 
Unless otherwise specified, the stratified log-rank test will be performed to test the comparison 
between time to event distributions. Unless otherwise specified, the stratified hazard ratio between 
2 groups along with CI will be obtained by fitting a stratified Cox model with the group variable 
as a unique covariate. 
Confidence intervals for binomial proportions will be derived using the Clopper-Pearson method.6F7 
The unweighted difference in ORRs between the two treatment arms and corresponding 
asymptotic 95% CI will be estimated using a Newcombe method.7F8 
P-values from sensitivity analyses for efficacy endpoints are for descriptive purpose only and there 
will be no multiplicity adjustment for these analyses. 
The conventions to be used for imputing missing and partial dates for analyses requiring dates are 
described in Section 8. 
Note that, the outputs will present Arm A, Arm B, and Arm C in the following way: 
• All analysis specified in Section 7.3 and 7.4 will present A, B, and C together. 
• For purposes of efficacy analyses, all randomized subjects in Arm A and Arm C will be 
tabulated and presented in the same table. A few seperate efficacy summary tables will be 
generated for those subjects randomized to Arm B, which will be specified in the 
corresponding sections.  
• For purposes of safety analyses, all treated subjects in Arm A and Arm C will be tabulated 
and presented in the same table. A few separate safety summary tables will be generated 
for those subjects treated in Arm B, which will be specified in the corresponding sections. 
• Summaries of outcome research and biomarker data will be tabulated on the Arm A and C 
subjects only. 
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7.1.1 Adverse Events, Serious Adverse Events, Multiple events, Select 
Adverse Events, Other Events of Special Interest and Immune-Mediated 
Adverse Events 
Drug-related AEs are those events with relationship to study drug “Related”, as recorded on the 
CRF. If the relationship to study drug is missing, the AE will be considered as drug-related.  
Serious adverse events consist of AEs deemed serious by the Investigator and flagged accordingly 
in the CRF and clinical database. 
Adverse events leading to study drug discontinuation are AEs with action taken regarding study 
drug(s) = “Drug was discontinued”.  
Adverse events leading to dose delay are AEs with action taken regarding study drug(s) = “Drug 
was delayed”.  
Adverse event that led to dose delay of the oral drug (similarly defined as dose omission or dose 
interruption) will be coded with action “Drug was interrupted”. 
Adverse events leading to dose reduction are AEs with action taken regarding study drug(s) = 
“Dose was reduced”. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
and the most recent version of the dictionary at the time of the database lock will be used. Adverse 
events results will be graded for severity using NCI Common Terminology Criteria for Adverse 
Events (CTCAE) and the most recent version of the criteria at the time of the database lock will 
be used. 
In the AE summary tables, unless otherwise specified, subjects will be counted only once at the 
Preferred Term (PT), only once at the System Organ Class (SOC), and only once at subject level 
for the counting of total number of subjects with an AE. The AE tables will be sorted by the SOCs 
and then PTs. SOC will be ordered by descending frequency overall and then alphabetically. PTs 
will be ordered within SOC by descending frequency overall and then alphabetically. The sorting 
will be done based on the ‘Any Grade’ column of the experimental arm when arms are presented 
side-by-side. 
Unless otherwise specified, the AE summary tables will be restricted to on-treatment events 
regardless of the causality. 
Analyses that take into account the multiple occurrences of a given adverse event will be conducted 
(see Section 7.6.9). To prepare these analyses, the CRF data will be processed according to 
standard BMS algorithms8F9 in order to collapse adverse event records into unique records based on 
the preferred term. These data will be presented as the rate per 100 person-years of exposure. These 
analyses will take into account all on-treatment events (allowing more than 1 event per subject) 
and the total exposure time. The person-year exposure will be computed as the sum over the 
subjects’ exposure expressed in years where the exposure time is defined as  
• (Date of last dose of study treatment - date of first dose of study treatment + 31 days (or  
101 days, depending on the analysis))/365.25, for subject who are off study treatment and were 
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followed for at least 30 days (or 100 days, depending on the analysis) after last dose of study 
treatment. 
• (Last known alive date - date of first dose of study treatment +1)/365.25, for subjects who are 
still on-treatment or who are off study treatment and were followed less than 30 days (or  
100 days depending on the analysis) after last dose of study treatment. 
7.1.1.1 Select Adverse Events (EU/ROW Submissions) 
The select Adverse Events (select AEs) consist of a list of preferred terms grouped by specific 
category (e.g. pulmonary events, gastrointestinal events categories, etc.). AEs that may differ from 
or be more severe than AEs caused by non-immunotherapies and AEs whose early recognition and 
management may mitigate severe toxicity are included as select AEs. Categories of select AEs 
may include subcategories (e.g. adrenal disorders, diabetes, pituitary disorders, and thyroid 
disorders are subcategories of the endocrine event category).  
The list of MedDRA preferred terms used to identify select adverse events is revisited quarterly 
and updated accordingly. The preferred terms used for the selection at the time of the database 
lock will be provided by categories/subcategories. 
In addition to the frequency and worst severity of select AEs, time-to onset, time-to resolution, 
and time-to resolution where immune modulating medication was initiated will be analyzed for 
each specific category/subcategory of drug-related select AEs when applicable. 
Further details on the definitions time-to onset and time-to resolution are described in APPENDIX 
1. 
7.1.1.2 Other Events of Special Interest 
Other events of special interest (OEOSI) consist of a list of preferred terms grouped by specific 
category (e.g. Myositis Event, Myocarditis Event, Demyelination Event, Guillain-Barre 
Syndrome, Pancreatitis Event, Uveitis Event, Encephalitis Event, Myasthenic Syndrome, 
Rhabdomyolysis Event, Graft Versus Host Disease). The list of MedDRA preferred terms used to 
identify OEOSI is revisited quarterly and updated accordingly. The preferred terms used for the 
selection at the time of the database lock by categories will be provided. 
7.1.1.3 Immune-Mediated Adverse Events (US Submission) 
In order to further characterize AEs of special clinical interest, analysis of immune-mediated AEs 
(IMAE) will be conducted. IMAEs are specific events (or groups of PTs describing specific events) 
that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine 
(adrenal insufficiency, hypothyroidism/thyroiditis, hypothyroidism, thyroiditis, hyperthyroidism, 
diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-
mediated events by investigator that meet the definition summarized below:  
• those occurring within 100 days of the last dose,  
• regardless of causality, 
• treated with immune-modulating medication (of note, endocrine AEs such as adrenal 
insufficiency, hypothyroidism/thyroiditis, hypothyroidism, thyroiditis, hyperthyroidism, 
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diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating 
medication use, since endocrine drug reactions are often managed without immune-modulating 
medication). 
• with no clear alternate etiology based on investigator assessment, or with an immune-mediated 
component  
The list of MedDRA preferred terms used to identify IMAEs is revisited quarterly and updated 
accordingly. The preferred terms used for the selection at the time of the database lock by 
categories will be provided. 
7.1.2 Laboratory Tests 
Clinical laboratory parameters (hematology, serum chemistry and electrolytes) will be evaluated. 
Laboratory tests will be graded using the NCI Common Terminology Criteria, and the most recent 
version of the criteria at the time of the database lock will be used. 
Clinical laboratory data will be first analyzed using International System of Units (SI).  
Analyses will be repeated using US conventional units. 
In the laboratory summary tables, unless otherwise specified, subjects will be counted only once 
for each lab parameter according to their worst on treatment CTC grade (worst being the highest 
CTC grade). The laboratory tables and listings will be sorted by laboratory category, laboratory 
subcategory and laboratory test code sequence number. 
7.1.3 Immunogenicity Data 
Blood samples for immunogenicity analysis will be collected from subjects assigned to the 
experimental treatment group(s) according to the protocol schedule. Samples will be evaluated for 
development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) 
immunoassay. 
7.2 Study Conduct 
The following programmable deviations will be considered as relevant protocol deviations and 
summarized by treatment group and overall in all randomized subjects. Non-programmable 
relevant eligibility and on-treatment protocol deviations, as well as significant (both programmable 
and non-programmable) eligibility and on-treatment protocol deviations will be reported through 
ClinSIGHT listings. 
Eligibility: 
• Subjects with baseline KPS < 70% 
• Subjects who received prior systemic anti-cancer treatment in the metastatic setting 
• Subjects without histologically confirmed RCC with a clear-cell component, documented 
advanced or metastatic RCC  
On-study: 
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• Subjects receiving anti-cancer therapy (chemotherapy, hormonal therapy, immunotherapy, 
standard or investigational agents for treatment of cancer) while on study therapy 
• Subjects treated differently than as randomized (subjects who received the wrong treatment, 
excluding the never treated)  
Enrollment by country and site, and enrollment by month will be summarized and listed for all 
enrolled subjects. 
A by-subject listing of batch numbers for all treated subjects will be provided. 
7.3 Study Population 
Analyses in this section will be tabulated for all randomized subjects by treatment group as 
randomized, unless otherwise specified. 
7.3.1 Subject Disposition 
The total number of subjects enrolled (randomized or not randomized) will be presented along 
with the reason for not being randomized. This analysis will be performed on the all enrolled 
subjects population only. 
Number of subjects randomized but not treated along with the reason for not being treated will be 
tabulated by treatment group as randomized.  
Number of subjects who discontinued study treatment along with corresponding reason will be 
tabulated by treatment group as treated. Reason for discontinuation will be derived from subject 
status CRF page. This analysis will be performed only on the all treated subjects population. 
A by-subject listing for all treated subjects will be provided showing the subject’s off treatment 
date and whether the subject continue in the study along with the reason for going off study. A by-
subject listing for all enrolled subjects will also be provided, showing whether the subject was 
randomized along with the reason for not being randomized. 
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, number of subjects 
who discontinued study treatment along with corresponding reason will be tabulated by treatment 
group as treated. 
 
7.3.2 Demographics and Other Baseline Disease Characteristics 
The following demographic and baseline disease characteristics will be summarized and listed by 
treatment group as randomized:  
• Age  
• Age categorization (< 65, ≥ 65 and < 75, ≥ 75 and < 85, ≥ 85, ≥ 75, ≥ 65) 
• Sex (Male, Female) 
• Race (White, Black or African American, Asian, Other) 
• Region (Region (US/Canada/W.Europe/N.Europe vs. ROW) (source: IRT) 
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• Ethnicity (Hispanic/Latino and Not Hispanic/Latino) 
• Karnofsky performance status (70, 80, 90, 100) 
• Baseline IMDC prognostic score (0, 1-2, ≥ 3) (source: IRT) 
• Baseline IMDC prognostic score (0, 1-2, ≥ 3) (source: CRF) 
• Time from initial disease diagnosis to randomization (<1 year, ≥1 year) 
• Baseline LDH level (≤ 1.5 x ULN, >1.5 x ULN) 
• Hemoglobin (<LLN, ≥ LLN) 
• Corrected Calcium (≤ 10 mg/dl, >10mg/dl ) 
• Absolute Neutrophil Count (≤ ULN, > ULN) 
• Platelet Count (≤ ULN, > ULN) 
• Baseline Alkaline phosphatase (< ULN, ≥ ULN) 
• Prior nephrectomy (Yes, No) 
• Prior radiotherapy (Yes, No) 
• Baseline PD-L1+ status based on a 1% cut off (≥ 1% vs. < 1% or indeterminate) 
• Baseline PD-L1+ status based on a 5% cut off (≥ 5% vs. < 5% or indeterminate) 
• Baseline PD-L1+ status based on a 10% cut off (≥ 10% vs. < 10% or indeterminate) 
• Sites of diseases (all lesions) 
• Number of disease sites per subject (1, 2, 3, 4 , >4) 
• Tumor burden: sum of the diameters of target lesions at baseline 
• Most common sites of metastasis (lung, lymph node, bone, liver, adrenal gland) 
• Sarcomatoid features (Yes, No) 
• Stage at the initial diagnosis (Stage IV, non-Stage IV) 
• Pre-treatment events tumor assessment (per Investigator) 
 
Summary table (cross-tabulation) by treatment group for stratification factor (except for region) 
will be provided to show any discrepancies between what was reported through IRT vs. other data 
sources at baseline. This summary will be performed based on all randomized subjects. 
• IMDC Prognostic Score: 0 versus 1-2 versus 3-6 
• Region: US/Canada/W Europe/N Europe versus ROW 
• PD-L1 tumor expression: ≥ 1% versus < 1% or indeterminate 
A listing of randomization scheme presenting randomized treatment group and as treated treatment 
group will be provided for all randomized subjects.  
Note that for all intermediate/poor risk subjects in Arm A and Arm C, demographic and baseline 
disease characteristics will be summarized and listed by treatment group as randomized. 
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7.3.3 Medical History 
A by-subject listing of general medical history for all randomized subjects will be provided.  
7.3.4 Prior Therapy Agents 
Prior adjuvant or neo-adjuvant therapy will be summarized by treatment group and overall. 
Prior systemic cancer therapy will be summarized by treatment group and overall and listed by 
subject.  
Prior radiotherapy and prior surgery related to cancer will be listed by subject. 
 
7.3.5 Physical Examinations 
Subjects with abnormal baseline physical examination will be listed by subject. 
7.3.6 Baseline Physical Measurements 
Baseline physical measurements will be listed by subject. 
7.4 Extent of Exposure 
Listings will include all available exposure data. Analyses will be performed by treatment group 
“as treated” in all treated subjects, unless otherwise specified. 
7.4.1 Administration of Study Therapy  
The following parameters will be summarized (descriptive statistics) by study therapy and 
treatment group: 
• Number of doses received 
• Cumulative dose 
• Relative dose intensity (%) using the following categories: < 50%; 50 - < 70%; 70 - < 90%;  
90 - < 110%; ≥ 110% 
• Average daily dose  
Duration of study therapy will be summarized (descriptive statistics) by treatment group.  
A by-subject listing of dosing of study medication (record of study medication, infusion details, 
and dose changes) will be also provided. 
Note that similar study therapy table will be summarized for all intermediate/poor risk treated 
subjects in Arm A and Arm C. 
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Table 7.4.1-1: Study Therapy Parameter Definitions for Arm A and C 
 Nivolumab Cabozantinib Sunitinib 
Dosing Schedule per 
Protocol 
240 mg every 2 weeks 40 mg PO once daily 
 
50 mg PO once daily 
for 4 weeks followed 
by 2 weeks off. 
 
Dose mg mg mg 
Cumulative Dose mg 
sum of the doses 
administered to a subject 
mg 
sum of the doses 
administered to a subject 
 
mg 
sum of the doses 
administered to a 
subject 
 
Relative Dose Intensity (%) [Cum dose (mg) /( (Last 
dose date– First dose date + 
14) × 240/14)] × 100 
See below See below 
Duration of Treatment Last dose date - Start dose 
date +1 
Last dose date - Start 
dose date + 1 
Last dose date - Start 
dose date +15 
  
 
Additional Parameters -Cabozantinib treatment 
Average daily dose (in mg/day) is defined as: 
Sum of all Cabozantinib doses in mg actually received / duration of treatment in days. 
Since Cabozantinib treatment consists of 40 mg PO daily dose, the planned dose intensity of 
Cabozantinib is 40 mg/day.  
Relative dose intensity for Cabozantinib (%) is defined as: (Average daily dose / 40) x 100. 
Additional Parameters -Sunitinib treatment 
Average daily dose (in mg/day) is defined as: 
Sum of all Sunitinib doses in mg actually received / duration of treatment in days 
Since Sunitinib treatment consists of 50 mg PO daily dose for 4 weeks followed by 2 weeks of 
washout period, the planned dose intensity of Sunitinib is 33.33 mg/day (50 mg x 28 days / 42 
days). 
Relative dose intensity for Sunitinib (%) is defined as: (Average daily dose / 33.33) x 100. 
 
Table 7.4.1-2: Study Therapy Parameter Definitions for Arm B (Cycle 1-4) 
 Nivolumab Ipilimumab Cabozantinib 
Dosing Schedule per 
Protocol 
3 mg/kg every 3 weeks for 4 
doses 
1 mg/kg every 3 weeks for 4 
doses 
40 mg PO once 
daily  
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Table 7.4.1-2: Study Therapy Parameter Definitions for Arm B (Cycle 1-4) 
 Nivolumab Ipilimumab Cabozantinib 
  
Dose Dose (mg/kg) is defined as 
Total Dose administered 
(mg)/Most recent weight 
(kg). Dose administered in 
mg at each dosing date and 
weight are collected on the 
CRF. 
Dose (mg/kg) is defined as 
Total Dose administered 
(mg)/Most recent weight 
(kg). Dose administered in 
mg at each dosing date and 
weight are collected on the 
CRF. 
mg 
Cumulative Dose Cum Dose (mg/kg) is the 
sum of the doses 
administered to a subject. 
Cum Dose (mg/kg) is the sum 




sum of the doses 
administered to a 
subject 
 
Cycle Duration(i) (wk) (Dose date(i+1) - Dose 
date(i))/7 





Dose(i)/Cycle Duration(i) Dose(i)/Cycle Duration(i) N/A 
Relative Cycle Intensity (i) 
(%) 
(Cycle Intensity(i)/intended 
dose per week)(i) * 100 
(Cycle Intensity(i)/intended 
dose per week)(i) * 100 
N/A 
Relative Dose Intensity 
(%) 
Sum of all Relative Cycle 
Intensities divided by N 
Sum of all Relative Cycle 
Intensities divided by N 
(Average daily 
dose / 40) x 100 
Duration of Treatment Last dose date - Start dose 
date +1 
Last dose date - Start dose 
date +1 
Last dose date - 
Start dose date 
+1 
 
Table 7.4.1-3: Study Therapy Parameter Definitions for Arm B (Cycle 5 
Onward) 
 Nivolumab Cabozantinib 
Dosing Schedule per 
Protocol 
240 mg every 2 weeks 40 mg PO once daily 
 
Dose mg mg 
Cumulative Dose mg 
sum of the doses administered to a 
subject 
mg 
sum of the doses administered to a 
subject 
 
Relative Dose Intensity (%) [Cum dose (mg) /( (Last dose date– 
First dose date + 14) × 240/14)] × 100 
(Average daily dose / 40) x 100 
Duration of Treatment Last dose date - Start dose date +1 Last dose date - Start dose date + 1  
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7.4.2 Modifications of Study Therapy 
7.4.2.1 Dose Delays 
Each nivolumab infusion or sunitinib dose may be delayed. A dose will be considered as actually 
delayed if the delay is exceeding 3 days (ie greater than or equal to 4 days from scheduled dosing 
date) for nivolumab. Reason for dose delay will be retrieved from CRF dosing pages. It is worth 
noting that during the two week mandatory washout period for sunitinib, a daily dose of 0 mg will 
be entered in the CRF pages, with corresponding reason for dose modification recorded as “No 
Change”. For cabozantinib, a daily dose of 0 mg entered in the CRF pages will be considered as 
delay. If cabozantinib is given every other day, then a daily dose of 0 mg will be entered in the 
CRF pages, with corresponding reason for dose modification recorded as “No Change”. 
The following parameters will be summarized by treatment group: 
• Number of subjects with at least one dose delayed, the number of dose delays per subject, the 
reason for dose delay and the length of dose delay. 
 
Note that similar dose delay summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects. 
For Arm B, both nivolumab and ipilimumab can be delayed at the same cycle. A dose will be 
considered as actually delayed if the delay is exceeding 3 days (ie greater than or equal to 4 days 
from scheduled dosing date) for nivolumab and ipimumab. Cabozantinib a daily dose of 0 mg 
entered in the CRF pages will be considered as delay. Similar table will be produced for Arm B 
subjects previously randomized to Arm B continue with Arm B treatment and continue with Arm 
B clinical planned events, per protocol. 
7.4.2.2 Infusion Interruptions and Rate Changes 
Each nivolumab or ipilimumab infusion can be interrupted and/or the IV infusion rate can be 
reduced. This information will be retrieved from CRF dosing pages. 
The following parameters will be summarized by treatment group: 
• Number of subjects with at least one dose infusion interruption, the reason for interruption, 
and the number of infusion interruptions per subject. 
• Number of subjects with at least one IV infusion rate reduction, the reason for reduction and 
the number of infusion with IV rate reduction per subject. 
 
Note that similar summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects. 
 
7.4.2.3 Dose Escalations 
Dose escalations are permitted for cabozantinib and sunitinib but not for nivolumab and 
ipilimumab.  
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7.4.2.4 Dose Reductions 
Dose reductions are permitted for cabozantinib and sunitinib but not for nivolumab and 
ipilimumab.  
Dose reduction for subjects treated with sunitinib is defined as at least one day with a non zero 
dose smaller than 50 mg and smaller than previous non zero dose with a CRF reason different from 
“Dosing Error” or “No Change”. 
Dose reduction for subjects treated with cabozantinib is defined as at least one day with a non zero 
dose smaller than 40 mg and smaller than previous non zero dose with a CRF reason “Dosing 
Error” or “No Change”. 
Note that similar dose redcution summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects. 
 
The following summaries will be presented for the cabozantinib component of study treatment:  
i. For dose reductions due to AE     
Categorical summaries for: 
• Subjects with any dose reduction 
• Dose levels received by a subject 
• Lowest non-zero dose level received   
• Last non-zero dose level received  
• Last dose level received (including dose holds)  
Descriptive statistics for: 
• Duration of treatment in months for each dose level (40 mg, 20 mg, 0 mg) 
• Time to second dose level reduction (first receipt of 20mg) (days) 
ii. Summaries for dose holds due to AE (those with 0 mg due to AE):  
• Descriptive statistics for number of dose holds due to an AE 
• Descriptive statistics for duration of dose holds per dose hold and per subject due 
to an AE, calculated as (stop date of hold – start date of hold + 1)  
• Categorical summary for subjects with duration of  holds due to an AE that can be 
classified as any number of days, ≥ 7 days,  ≥ 14 days, ≥ 21  days, and >42 days 
• Descriptive statistics for time to first dose hold, time to first dose hold that  ≥ 7 
days,  ≥ 14 days, ≥ 21  days, and >42 days. The time to dose hold is calculated as 
(start date of the hold – first dose date + 1)   
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• Descriptive statistics for time to second dose hold, time to second dose hold that 
was  ≥ 7 days,  ≥ 14 days, ≥ 21  days, and >42 days. 
iii. Summaries for dose modifications (defined as a reduction or hold) due to AE:  
• Frequency counts and percentages for subjects with any dose modifications 
• Descriptive statistics for number of dose modifications (0-3) 
• Descriptive statistics for time to the first dose modification  
• Descriptive statistics for time to the second dose modification 
7.4.2.5 Dose Omissions 
Dose omissions are not permitted. 
7.4.3 Concomitant Medications 
Concomitant medications, defined as medications other than study medications which are taken at 
any time on-treatment (i.e. on or after the first day of study therapy and within 100 days following 
the last dose of study therapy), will be coded using the UMC WHO Drug Global Dictionary. 
The following summary table will be provided:  
• Concomitant medications (subjects with any concomitant medication, subjects by medication 
class and generic term)  
A by-subject listing will accompany the table. 
7.4.3.1 Immune Modulating Medication  
Immune modulating concomitant medications are medications entered on an immune modulating 
medication form or available from the most current pre-defined list of immune modulating 
medications. The list of anatomic class, therapeutic class and generic name used for the selection 
at the time of the database lock will be provided. 
The percentage of subjects who received immune modulating concomitant medication for 
• management of adverse event  
• premedication  
• other use 
• any use 
• management of drug-related select adverse event (any grade, grade 3-5) by select AE category/ 
subcategory (EU/ROW Submissions) 
• management of IMAEs (any grade, grade 3-5) by IMAE category (US Submission) 
will be reported separately for each treatment group (percentages of treated subjects by medication 
class and generic term). 
For each category/subcategory of drug-related select AEs (any grade, grade 3-5) and IMAEs (any 
grade, grade 3-5), the following will be reported for each treatment group: 
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• The total immune modulating medication treatment duration (excluding overlaps), duration of 
high dose of corticosteroid, initial dose of corticosteroid, and tapering duration (summary 
statistics) 
Duration represents the total duration the subject received the concomitant medication of interest. 
If the subject took the medication periodically, then DURATION in the summation of all use. 
Initial dose represents the dose of the concomitant medication of interest received at the start of 
the event. In the case multiple medications started on the same date, the highest equivalent dose is 
chosen and converted to mg/kg by dividing by the subject’s recent weight. 
These analyses, except the ones related to IMAEs will be conducted using the 30-day safety 
window. The analyses related to IMAEs will be conducted using the 100-day safety window. 
7.4.3.2 Subsequent Cancer Therapy 
Number and percentage of subjects receiving subsequent cancer therapies will be summarized for 
all randomized subjects. Categories include:  
• Subsequent systemic therapy  
• Subsequent surgery for treatment of tumors  
• Subsequent radiotherapy for treatment of tumors 
A by-subject listing of subsequent cancer therapy will also be produced for all randomized 
subjects. 
Note that similar tables will be summarized for all intermediate/poor risk subjects in Arm A and 
Arm C. 
7.5 Efficacy 
Analyses in this section will be tabulated for all randomized subjects in Arm A and Arm C, unless 
otherwise specified. A few seperate efficacy summary tables will be generated for those subjects 
who randomized to Arm B prior to Revised Protocol 01, which is specified in the relevant 
subsections below. 
Principal analyses of progression free survival (PFS) and objective response rate (ORR) will be 
based on the Blinded Independent Central Review (BICR) evaluation, unless noted otherwise.  
Analyses in this section will be tabulated for all randomized subjects by treatment group as 
randomized, unless otherwise specified. 
Unless stated otherwise, whenever a stratified analysis is specified, the following stratifications 
factors (recorded at randomization as per IRT) will be used:  
 
• IMDC Prognostic Score: 0 versus 1-2 versus 3-6 
• Region: US/Canada/W Europe/N Europe versus ROW 
• PD-L1 tumor expression: ≥ 1% versus < 1% or indeterminate 




The key secondary objective Overall Survival among all randomized subjects will be tested after 
conducting the primary objective analyses of PFS on all randomized subjects. For assessing this 
secondary objective of this study, a hierarchical testing procedure9F10 will be used so that the overall 
experiment-wise Type I error rate is two-sided 0.05.  
Confidence intervals (CI) for primary and secondary endpoint analyses included in hierarchy will 
be based on nominal significance level adjusted for primary endpoints and interim analyses to 
preserve overall type one error rate. 
Alpha (𝛼𝛼) for the CI will be the same as nominal significance level for hypothesis testing. CIs for 
other endpoints will be at the two-sided 95% level. All p-values reported will be two-sided. P-
values will be rounded to the fourth decimal place. Point estimates and confidence bounds for 
efficacy variables will be rounded to the second decimal place. 
A by-subject listing of efficacy results will be presented including treatment group, treatment 
duration, BICR progression date, overall survival, death date, etc.  
 
7.5.1 Analysis of Progression-Free Survival 
The primary objective of the study is to compare the PFS per BICR of Arm A to Arm C in 
randomized subjects with previously untreated (first line) advanced or metastatic RCC. All the 
analyses outlined in this section are specified for the all randomized subjects population in Arm A 
and Arm C, unless otherwise specified.  
PFS per BICR will be compared between the treatment groups via stratified log-rank test among 
all randomized subjects at a two-sided α = 0.05 level. The stratification factors will be IMDC 
prognostic risk score (0 vs 1-2 vs 3-6), region (US/Canada/W Europe/N Europe vs ROW)’ and 
PD-L1 status (≥ 1% vs < 1% or indeterminate). 
The primary definition of PFS adjusting for subsequent anticancer therapy will be used in this 
analysis. The two-sided log-rank p-value will be reported. 
The estimate of the PFS hazard ratio between treatment groups will be calculated using a stratified 
Cox proportional hazards model, with treatment as the sole covariate. Ties will be handled using 
the exact method. A two-sided 95% CI for the hazard ratio will also be presented. 
The PFS function for each treatment group will be estimated using the KM product limit method 
and will be displayed graphically. A two-sided 95% CI for median PFS in each treatment group 
will be computed via the log-log transformation method. PFS rates at fixed time points (e.g. 6 
months, depending on the minimum follow-up) will be presented along with their associated 95% 
CIs. These estimates will be derived from the Kaplan Meier estimate and corresponding CIs will 
be derived based on Greenwood10F11 formula for variance derivation and on log-log transformation 
applied on the survivor function11F12. 
Analyses of PFS will also be conducted based on the secondary definition of PFS. These analyses 
will be the same as those specified above. 
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The source of PFS event (progression or death) will be summarized by treatment group. The status 
of subjects who are censored (as per primary definition of PFS) in the PFS KM analysis will be 
tabulated for each treatment group including the following categories: 
• On-study (on-treatment, in follow-up) 
• Off-study (lost to follow-up, withdraw consent, never treated) 
• No baseline tumor assessment 
• No on-study tumor assessment and no death 
• Received subsequent anticancer therapy 
A by-subject listing will be presented including treatment group, PFS duration under the primary 
definition, PFS duration on the ITT definition, whether the subject was censored under the primary 
definition, and if censored, the reason, and whether the subject was censored under the ITT 
definition, and if censored, the reason. 
A by-subject listing of lesion evaluations per BICR will be presented. 
Note that similar tables (KM plot, median PFS with its 95% CI, PFS rates, source of PFS event, 
and status of subjects who are censored) along with by-subject listing will be summarized for all 
intermediate/poor risk subjects in Arm A and Arm C. 
For those subjects who randomized to Arm B prior to Revised Protocol 01, the PFS function will 
be estimated using the KM product limit method and reported seperately for Arm B. A two-sided 
95% CI for median PFS will be computed via the log-log transformation method. A by-subject 
listing will be presented including treatment group, PFS duration under the primary definition, 
PFS duration on the ITT definition, whether the subject was censored under the primary definition, 
and if censored, the reason, and whether the subject was censored under the ITT definition, and if 
censored, the reason. 
 
7.5.2 Supportive Analyses of Progression-Free Survival 
The following sensitivity analyses will be conducted using both the primary and the secondary 
definition of PFS in all randomized subjects: 
1. Delayed effect of immunotherapy interventions may cause a late separation in the PFS KM 
curves and non-proportional hazards. PFS (as determined by BICR) will be compared 
between treatment groups via two-sided 0.05 stratified weighted log-rank test among 
subjects. The primary definition of PFS will be used in this analysis. The two-sided 
stratified weighted log-rank p-value will be reported using G (rho = 0, gamma = 1) weights, 
in the terminology of Fleming and Harrington12F13.  
The Fleming Harrington test can be unstable, so it is possible, though uncommon, that thep-
value for this trial will not be estimable.  
The estimate of the PFS hazard ratio in the period before and following 6 months will be 
calculated using a stratified time-dependent Cox model with effects for treatment and 
period-by-treatment interaction. In this model, period is a binary variable indicating pre- 
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vs. post-6 months. Ties will be handled using the exact method. A two-sided 95% CI for 
the hazard ratio will also be presented. 
2. A multivariate Cox regression model will be used in order to estimate the treatment effect 
after adjustment for possible imbalances in known or potential prognostic factors. The 
factors used in the randomization, which, by definition, will be balanced across treatment 
groups, will still be included in the model as stratification factors. However, all additional 
factors will be incorporated as covariates. The additional factors, which are all measured 
at baseline, will include: 
a. Age categorization (< 65 vs. ≥ 65 - < 75 vs. ≥ 75) 
b. Gender (Male vs. Female)  
c. Race (White, Black or African American, Asian, Other) 
d. Region (US/Canada/W.Europe/N.Europe vs. ROW) 
e. IMDC score (0 vs 1-2 vs 3-6) 
f. Karnofsky performance status (70, 80, 90, 100) 
g. Prior Nephrectomy (Yes, No) 
h. LDH level (≤ 1.5 x ULN , > 1.5 x ULN) 
i. Baseline PD-L1+ status based on a 1% cut off 
j. Number of disease site (1 vs. 2 vs. >2) 
 
The level of the covariate normally associated with the worst prognosis will be coded as 
the reference level. The hazard ratio associated with treatment and with each of the baseline 
covariates will be presented along with associated 95% CIs.  
3. PFS using stratification factors as obtained from the baseline CRF pages (instead of IRT). 
The hazard ratio associated with treatment will be presented along with the associated 
two-sided 95% CIs. This analysis will be performed only if at least one stratification 
variable/factor at randomization (as per IRT) and baseline are not concordant for at least 
10% of the randomized subjects. 
4. PFS using the investigator’s assessment. The hazard ratio associated with treatment and 
median PFS will be presented along with the associated two-sided 95% CIs. 
A cross tabulation of PFS assessment by BICR versus PFS assessment by investigator will 
be presented, by treatment group. Concordance Rate of event will be computed as the 
frequency with which investigator and BICR agree on classification of a subject as event 
versus censored as a proportion of the total number of randomized subjects assessed by 
both the investigator and BICR. 
A by-subject listing of PFS assessment per BICR and investigator will be presented. 
5. PFS using an un-stratified log rank test. The hazard ratio associated with treatment will be 
presented along with the associated two-sided 95% CIs.   
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6. PFS using an un-stratified Cox proportional hazards model, adjusted, using as covariates 
only the stratification factors used in randomization. The hazard ratio associated with 
treatment will be presented along with the associated two-sided 95% CIs. 
7. PFS for subjects with no relevant protocol deviations. This analysis will be conducted only 
if there are more than 10% subjects with relevant protocol deviations. The hazard ratio 
associated with treatment will be presented along with the associated two-sided 95% CIs. 
8. The method of Gail and Simon13F14 will be used to test for a qualitative interaction between 
treatment and strata. This test will be conducted at α= 0.10 level. The p-value reported 
from this specific analysis is for descriptive purposes alone. 
9. To examine the assumption of proportional hazards in the Cox regression model, in 
addition to treatment, a time-dependent variable defined by treatment by time interaction 
will be added into the model. A two-sided Wald Chi-square p-value of less than 0.1 may 
indicate a potential nonconstant treatment effect. In that case, additional exploratory 
analyses may be performed. 
7.5.3 Subset Analyses of Progression-Free Survival 
The influence of baseline and demographic characteristics on the treatment effect among all 
randomized subjects will be explored via exploratory subset analyses. The median PFS based on 
KM product-limit method along with two-sided 95% CIs will be produced for the following 
subgroups: 
• Age  
• Age categorization (< 65, ≥ 65 and < 75, ≥ 75 and < 85, ≥ 85, ≥ 75, ≥ 65) 
• Sex (Male, Female) 
• Race (White, Black or African American, Asian, Other) 
• Region (Region (US/Canada/W.Europe/N.Europe vs. ROW) (source: IRT) 
• Ethnicity (Hispanic/Latino and Not Hispanic/Latino) 
• Karnofsky performance status (100-90, 80-70) 
• Baseline IMDC prognostic score (0, 1-2, ≥ 3) (source: IRT) 
• Baseline IMDC prognostic score (0, 1-2, ≥ 3) (source: CRF) 
• Time from initial disease diagnosis to randomization (<1 year, ≥1 year) 
• Baseline LDH level (≤ 1.5 x ULN, >1.5 x ULN) 
• Hemoglobin (<LLN, ≥ LLN) 
• Corrected Calcium (≤ 10 mg/dl, >10mg/dl ) 
• Absolute Neutrophil Count (≤ ULN, > ULN) 
• Platelet Count (≤ ULN, > ULN) 
• Baseline Alkaline phosphatase (< ULN, ≥ ULN) 
• Prior nephrectomy (Yes, No) 
• Prior radiotherapy (Yes, No) 
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• Bone metastasis (Yes, No) 
• Sarcomatoid features (Yes, No) 
• Stage at the initial diagnosis (Stage IV, non-Stage IV) 
• Baseline PD-L1+ status based on a 1% cut off (≥ 1% vs. < 1% or indeterminate) 
• Baseline PD-L1+ status based on a 5% cut off (≥ 5% vs. < 5% or indeterminate) 
• Baseline PD-L1+ status based on a 10% cut off (≥ 10% vs. < 10% or indeterminate) 
 
A forest plot of the unstratified PFS hazard ratios (along with the 95% CIs) will be produced for 
each level of the subgroups listed above. The analysis comparing treatment (i.e., Hazard Ratio) 
will be conducted if the number of subjects in the subgroup category is more than 10.  
7.5.4 Analysis of Overall Survival 
One of the secondary objectives of the study is to compare the overall survival of Arm A to Arm 
C in all randomized subjects. All the analyses outlined in this section are specified for the all 
randomized subjects population in Arm A and Arm C, unless otherwise specified.  
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure. 
Overall survival will be compared between the treatment groups at the interim and final analyses, 
using stratified log-rank test. The stratification factors will be those used in the analysis of PFS. 
An O’Brien and Fleming α-spending function will be employed to determine the nominal 
significance levels for the interim and final analyses. The stratified hazard ratio between the 
treatment groups will be presented along with 100*(1- α)% CI (adjusted for interim). In addition, 
two-sided p-value will also be reported for the analysis of OS. 
OS will be estimated using the KM techniques. A two-sided 95% CI for median OS in each 
treatment group will be computed via the log-log transformation method. OS rates at fixed time 
points (e.g. 6 months, depending on the minimum follow-up) will be presented along with their 
associated 95% CIs. These estimates will be derived from the Kaplan Meier estimate and 
corresponding CIs will be derived based on Greenwood formula for variance derivation and on 
log-log transformation applied on the survivor function. 
The status of subjects who are censored in the OS KM analysis will be tabulated for each treatment 
group using the following categories: 
• On-study (on-treatment, in follow-up) 
• Off-study (lost to follow-up, withdraw consent, never treated) 
A by-subject listing will be presented including treatment group, first and last dose date, whether 
the subject died, and if censored, the reason, event/censored date and OS duration. 
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Note that similar tables (KM plot, median OS with its 95% CI, OS rates, and status of subjects 
who are censored) along with by-subject listing will be summarized for all intermediate/poor risk 
subjects in Arm A and Arm C. 
The analysis performed for PFS (detailed in section 7.5.1) for those subjects who randomized to 
Arm B prior to Revised Protocol 01 will be repeated for OS. 
7.5.5 Subset Analysis of Overall Survival 
The influence of baseline and demographic characteristics on the treatment effect among all 
randomized subjects will be explored via exploratory subset analyses. The median OS based on 
KM product-limit method along with two-sided 95% CIs will be produced for the same subgroups 
as used for PFS (see Section 7.5.3). 
A forest plot of the unstratified OS hazard ratios (along with the 95% CIs) will be produced for 
each level of the subgroups listed above. 
An analysis will be conducted if the number of subjects in the subgroup category is more than 10. 
7.5.6 Current Status of PFS and OS Follow-up 
The extent of follow-up for survival, defined as the time between randomization date and last 
known alive date (for subjects who are alive) or death date (for subjects who died), will be 
summarized descriptively (median, min, max, etc.) in months for all randomized subjects. 
The currentness of follow-up for survival, defined as the time between last OS contact (i.e., last 
known alive date or death date) and cutoff date (defined by last subject last visit date), will be 
summarized in months for all randomized subjects. Subjects who died and subjects with last known 
alive date on or after data cut-off date will have zero value for currentness of follow-up. 
Minimum follow-up of OS for all randomized subjects, defined as the time from cutoff date to last 
subject’s randomization date, will be summarized in months. 
Time from last evaluable tumor assessment to cutoff date in months will be summarized by 
treatment group and overall for all randomized subjects. Subjects who have a PFS event will be 
considered as current for this analysis. The secondary definition of PFS will be used for this 
summary.  
In addition, time to treatment discontinuation will be summarized and presented by treatment 
group using a Kaplan-Meier curve whereby the last dose date will be the event date for those 
subjects who are off study therapy. Median duration of study therapy and associated 95% CI will 
be provided. Subjects who are still on study therapy will be censored on their last dose date. 
A by-subject listing will also be produced to accompany the subject time from last evaluable tumor 
assessment. 
7.5.7 Interim Analysis of Overall Survival 
An independent statistician external to BMS will perform the analysis. In addition to the formal 
planned interim analyses for OS, the Data Monitoring Committee (DMC) will have access to 
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periodic un-blinded interim reports of efficacy and safety to allow a risk/benefit assessment. 
Details are included in the DMC charter. 
Two interim analyses of OS are planned for this study.  The first interim analysis of OS is planned 
at the time of final PFS analysis and expected after observing 165 deaths (approximately 65% of 
the targeted OS events) have been observed among all randomized subjects in Arm A and Arm C 
based on above accrual rate and the exponential distribution in each arm. These formal 
comparisons of OS will allow for early stopping for superiority, and the boundaries for declaring 
superiority will be derived based on the actual number of deaths using Lan-DeMets spending 
function with O’Brien and Fleming type of boundary in EAST version 6. If the first interim 
analysis is performed exactly at 165 deaths, the boundary in terms of statistical significance for 
declaring superiority would be 0.011 (HR=0.673 with 16 months improvement in median OS for 
the Arm A versus Arm C comparison (33 versus 49 months)). The second interim analysis of OS 
is expected after observing 211 deaths (approximately 83% of the targeted OS events) have been 
observed among all randomized subjects based on above accrual rate and the exponential 
distribution in each arm. The boundary for declaring superiority in terms of statistical significance 
for the second interim analysis after 211 events would be 0.025 (HR=0.734 with 12 months 
improvement in median OS for the doublet versus sunitinib comparison (33 versus 45 months). 
The boundary for declaring superiority in terms of statistical significance for the final analysis 
after 254 events would be 0.041 (HR=0.774 with 9.6 months improvement in median OS for the 
Arm A versus Arm C comparison (33 versus 42.6 months). 
Note that if the analysis of PFS final analysis and first interim analysis OS is trigger with 8-months 
minimum follow-up on all randomized subjects, minimum 283 PFS events and 149 OS events, 
then the details of the first interim analysis of OS will be as follows: 
• If the first interim analysis is performed exactly at 149 deaths, the boundary in terms of 
statistical significance for declaring superiority would be 0.007 (HR=0.643 with 18.3 
months improvement in median OS for the Arm A versus Arm C comparison (33 versus 
51.3 months)). 
The DMC will review the safety and efficacy data from the informal interim analyses, BMS will 
remain blinded to these interim results and and will determine if the study should continue with or 
without changes or if accrual should be stopped. Subject enrollment will continue while waiting 
for the DMC’s decisions. 
The chair of the DMC and the sponsor can call an unscheduled review of the safety data. 
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure. 
At the time of the formal interim analysis for superiority of OS, the DMC may recommend 
continuing or stopping the trial. If the trial continues beyond the formal interim analysis, BMS will 
remain blinded to these interim results and the nominal critical point for the final OS analysis will 
be determined using the recalculated information fraction at the time of the interim analysis, as 
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described above. The final OS hazard ratio and corresponding confidence interval will be reported 
whereby the confidence interval will be adjusted accordingly (i.e. using the recalculated nominal 
α level at the final analysis).  
If the trial is stopped for superiority of OS at the interim, the p-value from the interim stratified 
log-rank test will be considered the final primary analysis result. 
7.5.8 Analysis of Objective Response Rate 
One of the secondary objectives of the study is to evaluate the objective response rate in all 
randomized subjects in Arm A and Arm C. All the analyses outlined in this section are specified 
for the all randomized subjects population in Arm A and Arm C, unless otherwise specified. 
The number and percentage of subjects in each category of BOR per BICR (complete response 
[CR], partial response [PR], stable disease [SD], progressive disease [PD], or unable to determine 
[UTD]) will be presented, by treatment group. Estimates of response rate, along with its exact two-
sided 95% CI by Clopper and Pearson14F15 will be presented, by treatment group. 
Similar analyses will be repeated based on the investigator’s assessment of ORR. A cross 
tabulation of BICR best response versus the investigator best response will be presented, by 
treatment group and by response categories. Concordance Rate of Responders will be computed 
as the frequency with which investigator and BICR agree on classification of a subject as responder 
vs. non responder/UTD as a proportion of the total number of randomized subjects assessed by 
both the investigator and BICR. 
The following subject-level graphics will also be provided: 
• For the responders only, time courses of the following events of interest will be graphically 
displayed: tumor response, progression, last dose received, and death. 
• For response evaluable subjects (randomized subjects with baseline and at least one on-study 
tumor assessment),  
− A bar plot showing the best % reduction from baseline in sum of diameter of target lesions 
based on BICR assessment for each subject will be produced (excluding assessments after 
PD and assessments after start of subsequent anti-cancer therapy). 
− A plot of individual time course of tumor burden change per BICR assessment will be 
produced.  
A by-subject listing of best overall response will be presented including treatment group, best 
overall response per BICR and dates of CR/PR/progression.  
A by-subject listing of per time point tumor response per BICR will be presented.  
Note that similar tables along with by-subject listing will be summarized for all intermediate/poor 
risk subjects in Arm A and Arm C. 
For those subjects who randomized to Arm B prior to Revised Protocol 01, estimates of response 
rate, along with its exact two-sided 95% CI by Clopper-Pearson method, will be computed per 
BICR and investigator. DOR and TTR will also be evaluated per BICR. 
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7.5.9 Subset Analyses of Objective Response 
The influence of baseline and demographic characteristics on the treatment effect will be explored 
via exploratory subset analysis. The subsets wil be same as those analyzed for PFS and will be 
reported based on the BICR assessment of ORR. 
A forest plot of treatment effect on ORR per BICR in the above subgroups will be produced. The 
un-weighted differences in ORR between the two treatment groups and corresponding 95% two-
sided CI using the method of Newcombe will be provided if the number of subjects in the subgroup 
category is more than 10.  
7.5.10 Time to Tumor Response and Duration of Response 
The analyses specified in this section will be conducted for all treatment arms. Duration of 
response (DOR) and time to response (TTR) will also be evaluated for subjects who achieved 
confirmed PR or CR. The DOR for each treatment group will be estimated using the Kaplan-Meier 
(KM) product limit method and will be displayed graphically. A table will be produced presenting 
number of events, number of subjects involved, medians, and 95% CIs for the medians. Median 
values of DOR, along with two-sided 95% CI in each treatment group will be computed based on 
a log-log transformation method.  
The status of subjects who are censored in the DOR KM analysis will be tabulated for each 
treatment group including the following categories: 
• Ongoing follow-up (current [last scan within adequate window vs cutoff date], not current) 
• Off-study (lost to follow-up, withdraw consent, never treated) 
• Received subsequent anticancer therapy. 
TTR, which does not involve censoring, will be summarized by treatment group in all responders 
using descriptive statistics.  
Cumulative Response Rates will be tabulated for Week 8, Month 4, 6, 8, and 12, and overall 
response rate will be provided. 
A by-subject listing will be presented including treatment group, best response, time to response, 
duration of response, whether the subject was censored for duration of response, and, if so, the 
reason.  
7.5.11 PFS2 
One of the exploratory objectives of the study is to compare PFS2 between treatment groups in all 
randomized subjects. 
PFS2 will be analyzed similarly to PFS:   
• Median values based on KM method, along with two-sided 95% CI using Brookmeyer and 
Crowley method will be calculated. The estimate of standard error will be calculated using the 
Greenwood formula; 
• PFS2 will be graphically displayed along with the median and 95% CI.  
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A by-subject listing of PFS and PFS2 will be provided. 
7.6 Safety 
Analyses in this section will be tabulated for all treated subjects by treatment group as treated, 
unless otherwise specified. 
Analyses in this section will be tabulated for all treated subjects in Arm A and Arm C, unless 
otherwise specified. Limited selection of the summary tables will be generated for those subjects 
who randomized to Arm B prior to Revised Protocol 01, which is specified in the relevant 
subsections below.  
7.6.1 Deaths 
Deaths will be summarized by treatment group: 
• All deaths, reasons for death. 
• Deaths within 30 days of last dose received, reasons for death. 
• Deaths within 100 days of last dose received, reasons for death. 
A by-subject listing of deaths will be provided for the all enrolled subjects population. 
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, deaths will be 
summarized by treatment group. 
Similar tables will be presented for those subjects treated in Arm B. 
7.6.2 Serious Adverse Events 
Serious adverse events will be summarized by treatment group: 
• Overall summary of SAEs by worst CTC grade (any grade, grade 3-4, grade 5) presented by 
SOC/PT. 
• Overall summary of drug-related SAEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT. 
All analyses will be conducted using the 30-day safety window.  
A by-subject SAE listing will be provided for the “enrolled subjects” population. 
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, serious adverse 
events will be summarized by treatment group. 
Similar tables will be presented for those subjects treated in Arm B. 
7.6.3 Adverse Events Leading to Discontinuation of Study Therapy 
AEs leading to discontinuation will be summarized by treatment group: 
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• Overall summary of AEs leading to discontinuation by worst CTC grade (any grade, grade  
3-4, grade 5) presented by SOC/PT. 
• Overall summary of drug-related AEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by SOC/PT. 
The analyses will be conducted using the 30-day safety window.  
A by-subject AEs leading to discontinuation listing will be provided. 
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, AEs leading to 
discontinuation will be summarized by treatment group. 
Similar table will be presented for those subjects treated in Arm B. 
Note that  
• for Arm A, AEs leading to discontinuation from cabozantinib only, nivolumab only, and 
both cabozantinib and nivolumab.  
• for Arm B, AEs leading to discontinuation from cabozantinib only, nivolumab and 
ipilimumab only, and from cabozantinib, nivolumab, and ipilumumab  
will be summarized in all the tables specified in this section. 
 
7.6.4 Adverse Events Leading to Dose Modification 
AEs leading to dose delay/reduction will be summarized by treatment group: 
• Overall summary of AEs leading to dose delay/reduction by worst CTC grade (any grade, 
grade 3-4, grade 5) presented by SOC/PT. 
• Overall summary of related AEs leading to dose delay/reduction by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by SOC/PT. 
The analysis will be conducted using the 30-day safety window. 
A by-subject AEs leading to dose delay/reduction listing will be provided. 
7.6.5 Adverse Events 
Adverse events will be summarized by treatment group. 
The following analyses will be conducted using the 30 days safety window only: 
• Overall summary of any AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) presented 
by SOC/PT.  
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• Overall summary of any AEs presented by worst CTC grade (any grade, grade 3-4, grade 5) 
by SOC/PT. This table will be restricted to events with an incidence greater or equal to 5% in 
any treatment group. 
• Overall summary of any non-serious AEs presented by SOC/PT. This table will be restricted 
to events with an incidence greater or equal to 5% in any treatment group. 
• Overall summary of any AEs that required immune modulating medication by worst CTC 
grade (any grade, grade 3-4, grade 5) presented by SOC/PT. 
• Overall summary of drug-related AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) 
presented by SOC/PT.  
The following analyses will be conducted using the 30 days safety window and repeated using the 
100 days safety window: 
• Overall summary of drug-related AEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT. 
A by-subject AE listing will be provided. A by-subject listing of any AE requiring immune 
modulating medications will also be provided. 
For those subjects treated in Arm B and for those intermediate/poor risk treated subjects in 
Arm A and Arm C: 
The following analyses will be conducted using the 30 days safety window only: 
• Overall summary of any AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) presented 
by SOC/PT.  
• Overall summary of any AEs that required immune modulating medication by worst CTC 
grade (any grade, grade 3-4, grade 5) presented by SOC/PT. 
• Overall summary of drug-related AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) 
presented by SOC/PT.  
The following analyses will be conducted using the 30 days safety window and repeated using the 
100 days safety window: 
• Overall summary of drug-related AEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT. 
A by-subject AE listing will be provided. A by-subject listing of any AE requiring immune 
modulating medications will also be provided 
7.6.6 Select Adverse Events (EU/ROW Submissions) 
Unless otherwise specified, analyses will be performed by select AE category. Analyses will also 
be repeated by subcategory of endocrine events. 
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7.6.6.1 Incidence of Select AE 
Select AEs will be summarized by treatment group for each category/subcategory.  
The following analyses will be conducted using the 30-day safety window only: 
• Overall summaries of any select AEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by Category or Subcategory/PT. 
• Overall summaries of any drug-related select AEs by worst CTC grade (any grade, grade 3-4, 
grade 5) presented by Category or Subcategory/PT. 
• Overall summaries of any serious select AEs by worst CTC grade (any grade, grade 3-4, grade 
5) presented by Category or Subcategory /PT. 
• Overall summaries of drug-related serious select AEs by worst CTC grade (any grade, grade  
3-4, grade 5) presented by Category or Subcategory /PT. 
• Overall summaries of any select AEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by Category or Subcategory /PT. 
• Overall summaries of drug-related select AEs leading to discontinuation by worst CTC grade 
(any grade, grade 3-4, grade 5) presented by Category or Subcategory /PT. 
• Summary of frequency of unique select AEs by Category. 
A by-subject select AE listing will be provided. 
7.6.6.2 Time-to Onset of Select AE 
Time-to onset of drug-related select AEs (any grade, grade 3-5) will be summarized for each 
category/subcategory by treatment group. 
Time-to onset analyses are restricted to treated subjects who experienced at least one drug-related 
select AE in the category/subcategory. The analyses will be conducted using the 30-day safety 
window. 
Additional details regarding the time-to onset definition are described in time-to onset definition 
subsection of APPENDIX 1. 
7.6.6.3 Time-to Resolution of Select AE 
Time-to resolution of the following specific events will be summarized separately for each 
category/subcategory. 
• Time-to resolution of drug-related select AE (any grade, grade 3-5) by treatment group 
• Time-to resolution of drug-related select AE (any grade, grade 3-5) where immune modulating 
medication was initiated, by treatment group 
Time-to resolution analyses are restricted to treated subjects who experienced the specific events. 
Time-to resolution where immune modulating medication was initiated analyses are restricted to 
treated subjects who experienced the specific events and who received immune modulating 
medication during the longest select AE.  
The analyses will be conducted using the 30-day safety window. 
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The following summary statistics will be reported: percentage of subjects with resolution of the 
longest select AE, median time-to resolution along with 95% CI (derived from Kaplan-Meier 
estimation) and ranges. 
See time-to resolution definition subsection of APPENDIX 1 for additional details. 
7.6.7 Immune-Mediated Adverse Events (US Submission) 
IMAEs will be summarized by treatment group for each immune-mediated category / PT using the 
100-day safety window: 
• Overall summary of non-endocrine IMAEs by worst CTC grade (any grade, grade 3-4, grade 
5) where immune modulating medication was initiated presented by Category / PT. 
• Overall summary of endocrine IMAEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by Category / PT. 
• Overall summary of non-endocrine IMAEs leading to discontinuation by worst CTC grade 
(any grade, grade 3-4, grade 5) where immune modulating medication was initiated presented 
by Category / PT. 
• Overall summary of endocrine IMAEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by Category / PT. 
• Overall summary of non-endocrine IMAEs leading to dose delay or reduction by worst CTC 
grade (any grade, grade 3-4, grade 5) where immune modulating medication was initiated 
presented by Category / PT 
• Overall summary of endocrine IMAEs leading to dose delay or reduction by worst CTC grade 
(any grade, grade 3-4, grade 5) presented by Category / PT. 
• Summaries of time-to onset and time-to resolution of non-endocrine IMAEs where immune 
modulating medication was initiated presented by Category. 
• Summaries of time-to onset and time-to resolution of endocrine IMAEs presented by Category. 
A by-subject listing of IMAEs will be provided. By-subject listings of time-to resolution for 
longest IMAEs cluster (any grade and grade 3-5 in separate summaries) will also be provided. For 
new studies which collect investigator assessment of potential IMAE data, a by-subject listing of 
AEs considered as immune-mediated events per investigator but not qualified for IMAEs 
definition will also be provided. 
In addition, for all nivolumab treated subjects who experienced at least one IMAE, the following 
data presentation will be provided: 
• Summary of subjects who were re-challenged with nivolumab by IMAE category, with 
extended follow-up  
• Summary of subjects who were re-challenged with nivolumab or ipilimumab by IMAE 
category, with extended follow-up 
For these, re-challenge is considered to have occurred when last nivolumab and/or ipilimumab 
infusion was administered after the onset of an IMAE. 
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7.6.8 Other Events of Special Interest 
OEOSI will be summarized by treatment group for each category. 
The following analyses will be conducted using the 100-day safety window: 
• Overall summary of OEOSI by worst CTC grade (any grade, grade 3-4, grade 5) presented by 
Category / PT 
• Overall summary of drug-related OEOSI by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by Category / PT 
A by-subject listing of OEOSI will be provided. 
7.6.9 Multiple Events 
The following summary tables will be provided: 
• A table showing the total number and rate (exposure adjusted) of occurrences for all AEs.  
• A table showing the total number and rate (exposure adjusted) of occurrences for AEs 
occurring in at least 5% of subjects in any treatment group.  
In addition, the rate (exposure adjusted) and its 95% CI evaluated for different time intervals will 
be displayed graphically for each treatment group. This analysis will be limited to the rate of all 
AEs and all drug-related AEs. The analyses will be conducted using the 30-day safety window. 
A listing displaying the unique instances of all AEs, i.e., after duplicates have been eliminated and 
overlapping and contiguous occurrences of the same event (i.e. same PT) have been collapsed will 
be provided. No formal comparisons will be made between treatment groups. 
7.6.10 Laboratory Parameters 
The analysis population for each laboratory test is restricted to treated subjects who underwent that 
laboratory test. Laboratory tests (in addition to the tests specified below) with CTC criteria 
collected in the specific studies may also be included in the summaries. 
A by-subject listing of differences in categorization of SI and US laboratory test results will be 
provided. 
7.6.10.1 Hematology 
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: hemoglobin (HB), platelets, white blood counts (WBC), absolute neutrophils count (ANC) 
and lymphocyte count (LYMPH).  
The analyses will be conducted using the 30-day safety window. 
A by-subject listing of these laboratory parameters will be provided. 
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7.6.10.2 Serum Chemistry 
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: ALT, AST, alkaline phosphatase (ALP), total bilirubin and creatinine.  
The analyses will be conducted using the 30-day safety window. 
A by-subject listing of these laboratory parameters will be provided. 
7.6.10.3 Electrolytes 
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: sodium (high and low), potassium (high and low), calcium (high and low), magnesium 
(high and low), and Glucose Serum (fasting hyperglycemia and hypoglycemia regardless of fasting 
status). 
The analyses will be conducted using the 30-day safety window. 
A by-subject listing of these laboratory parameters will be provided. 
7.6.10.4 Additional Analyses 
In addition, further analyses on specific laboratory parameters will be performed by treatment 
group: 
Abnormal Hepatic Function Test 
The number of subjects with the following laboratory abnormalities from on-treatment evaluations 
will be summarized by treatment group: 
• ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN 
• Total bilirubin > 2 x ULN 
• ALP > 1.5 x ULN 
• Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN 
• Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN 
• Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN 
• Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN 
The analyses will be conducted using the 30-day safety window. 
A by-subject listing of these specific abnormalities will be provided. 
Abnormal Thyroid Function Test 
The number of subjects with the following laboratory abnormalities from on-treatment evaluations 
will be summarized by treatment group: 
• TSH value > ULN and 
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− with baseline TSH value ≤ ULN 
− with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH 
test 
− with all FT3/FT4 test values ≥  LLN within 2-week window after the abnormal TSH test 
− with FT3/FT4 missing within 2-week window after the abnormal TSH test. 
• TSH < LLN and 
− with baseline TSH value ≥ LLN 
− with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal 
TSH test 
− with all FT3/FT4 test values ≤  ULN within 2-week window after the abnormal TSH test 
− with FT3/FT4 missing within 2-week window after the abnormal TSH test 
The analyses will be conducted using the 30-day safety window. 
A by-subject listing of these specific abnormalities will be provided. 
7.6.11 Vital Signs and Pulse Oximetry 
Vital signs and pulse oximetry (i.e. % oxygen saturation) collected on the CRF will be provided 
in separate listings. 
7.6.12 Physical Measurements 
Physical measurements will be listed by subject. 
7.6.13 Non-Protocol Medical Procedures 
Non-protocol medical procedures will be listed by subject. 
7.6.14  Immunogenicity Analysis 
Further details on immunogenicity background and rationale, definitions, population for analyses 
and endpoints are described in APPENDIX 3.  
Incidence of ADA 
Number (%) of subjects will be reported for the following parameters based on Evaluable Subjects. 
• Baseline ADA-positive 
• ADA-positive 
− Persistent Positive (PP) 
− Not PP-Last Sample Positive 
− Other positive 
− Neutralizing Positive 
• ADA-negative 
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A listing of all ADA assessments will be provided. A separate listing of ADA assessments for 
subjects with neutralizing positive will also be provided. 
A spider plot of nivolumab ADA test result (titers) over time may be provided for nivolumab ADA 
positive subjects. 
Clinical implications  
Clinical implications of nivolumab immunogenicity will be primarily focused on subjects with 
persistent ADA-positive relative to ADA-negative. Subjects with any ADA-positive samples after 
initiation of treatment (relative to baseline) may be used to explore clinical implications. Effect of 
immunogenicity on clearance of nivolumab will be explored by comparison of clearance estimates 
(determined by PPK analysis). Effect of immunogenicity on safety will be explored by examining 
the frequency and type of AEs of special interest such as hypersensitivity/infusion reaction. 
Summary tables for incidence of overall and each of the preferred terms will be provided, if the 
number of subjects is of sufficient size (e.g., at least 10 subjects). Otherwise, individual subject’s 
safety profile will be examined and described based on a listing. Clinical implications on efficacy 
will also be explored similarly. Association between trough concentrations of nivolumab or 
combination drug (e.g., ipilimumab) and ADA assessments may be explored, as needed. 
The following data presentation will be provided: 
• Swimmer plot of occurrence of ADA and NAb Occurrence in Relation to PFS, BOR per 
investigator and OS 
7.6.15 Pregnancy 
A by-subject listing of pregnancy tests results will be provided for randomized female subjects. 
7.6.16 Adverse Events By Subgroup 
Overall summary of any AEs and drug-related AEs by worst CTC grade (any grade, grade 3-4, 
grade 5) presented by SOC/PT and for each treatment group for the following subgroups: 
• Sex (Male vs. Female) 
• Race (White, Black,or African American, Asian, Other 
• Age (< 65 vs. 65 - < 75 vs. 75 - < 85 vs. ≥ 85 vs. ≥ 75 vs. ≥ 65) 
• Region (US/Canada/W.Europe/N.Europe vs. ROW) 
These analyses will be conducted using the 30-day safety window only. 
7.7 Pharmacokinetics 
The nivolumab and cabozantinib concentration data obtained in this study will be combined with 
data from other studies in the clinical development program to develop a population PK model. 
This model will be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of 
nivolumab and cabozantinib. In addition, exposure-response analyses with selected efficacy and 
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safety endpoints will be conducted. Results of population PK and exposure response-analyses will 
be reported separately.  
7.8 Biomarkers 
Analyses for PD-L1 are described below.  
7.8.1 Distribution of PD-L1 Expression 
Descriptive statistics of PD-L1 expression: 
• Listing of all PD-L1 IHC data, all randomized subjects 
• Summary of tumor specimen acquisition and characteristics, all randomized subjects 
• Summary statistics of PD-L1 expression in all randomized subjects with quantifiable PD-L1 
expression 
• Summary of BOR and ORR by baseline PD-L1 expression at 1, 5, and 10% cutoffs in all 
randomized subjects 
• Kaplan-Meier curves for PFS and OS by BICR by baseline expression of PD-L1  < 1%, >= 1 
and < 5, > = 5  and < 10, and >= 10  
• Cumulative distribution plot of baseline PD-L1 expression versus population percentile in all 
randomized subjects with quantifiable PD-L1 expression 
• Box plots of PD-L1 expression at 1, 5, and 10% cutoffs versus Response Status (BICR 
assessment) in all randomized subjects with quantifiable PD-L1 expression 
• Waterfall plot of individual PD-L1 expression in all randomized subjects with quantifiable PD-
L1 expression 
 
7.8.2 Other Exploratory Biomarkers 
The following analyses for other exploratory biomarkers will be provided when the data becomes 
available, which may occur after the CSR is written and therefore a seperate Data Presentation 
Plan (DPP) will be developed: 
 
Descriptive statistics of c-MET expression: 
• Listing of all c-MET IHC data, all randomized subjects 
• Summary of tumor specimen acquisition and characteristics, all randomized subjects. 
• Summary statistics of c-MET expression in all randomized subjects with quantifiable c-MET 
expression 
• Correlation statistics of BOR and ORR by baseline c-MET expression levels 
• Cumulative distribution plot of baseline c-MET expression versus population percentile in all 
randomized subjects with quantifiable c-MET expression 
• Kaplan-Meier curves for PFS and OS by BICR by baseline expression of tertile c-MET 
expression 
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• Box plots of c-MET expression at tertile cutoffs versus Response Status (BICR assessment) in 
all randomized subjects with quantifiable c-MET expression  
• Waterfall plot of individual c-MET expression in all randomized subjects with quantifiable c-
MET expression 
 
Descriptive statistics of MDSC expression at baseline: 
• Listing of all MDSC data, all randomized subjects 
• Summary of tumor specimen acquisition and characteristics, all randomized subjects 
• Summary statistics of MDSC expression in all randomized subjects with quantifiable MDSC 
expression 
• Correlation statistics of BOR and ORR by baseline MDSC expression levels 
• Cumulative distribution plot of baseline MDSC expression versus population percentile in all 
randomized subjects with quantifiable MDSC expression 
• Kaplan-Myer curves for PFS and OS by BICR by baseline expression of tertitle MDSC 
expression 
• Box plots of MDSC expression at tertile cutoffs versus Response Status (BICR assessment) in 
all randomized subjects with quantifiable MDSC expression 
• Waterfall plot of individual MDSC expression in all randomized subjects with quantifiable 
MDSC expression 
 
Descriptive statistics of serum cytokine expressions (only MIG, IP10 and IFN-g) changes in the 
course of treatment: 
• Line plot per arm for each cytokine on X axis and with timeline on Y axis with statistical 
difference from the baseline to be marked 
 
Descriptive statistics for gene expression signature analyses: 
• Published, on-target and mechanism of action related pathway related gene expression 
signatures (e.g. CD8, angiogenesis etc) will be assessed in BOR, ORR, PFS and OS 
relationship 
 
7.9 Clinical Outcomes Assessments 
The analysis of FKSI-19 and EQ-5D-3L will be restricted to randomized subjects in Arm A and C 
who have an assessment at baseline and at least one post-baseline assessment. 
7.9.1 FKSI-19 
Unless otherwise specified, the analysis of FKSI-19 will be performed by treatment group in all 
randomized subjects who have an assessment at baseline and at least one or more post-baseline 
assessments. The following descriptive analyses will be conducted:  
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• Questionnaire completion rate, defined as the proportion of questionnaires actually received 
out of the expected number (i.e., number of subjects on treatment or in follow up), will be 
calculated and summarized for each assessment time point.  
• For the total score and subscales, separately:  
− Mean score and mean change from baseline at each assessment time point will be 
summarized using descriptive statistics (N, mean, SD, median, 25th and 75th percentiles, 
minimum, maximum). 
− A plot summarizing the mean change from baseline will be presented and including 95% 
CI. 
By subject listing of FKSI-19 will be provided. 
7.9.2 EuroQol EQ-5D-3L 
The following descriptive analyses will be conducted:  
• EQ-5D-3L questionnaire completion rate, defined as the proportion of questionnaires actually 
received out of the expected number (i.e. number of subjects on treatment or in follow up), will 
be calculated and summarized for each assessment time point by treatment group.  
• A by-subject listing of the level of problems in each dimension, corresponding to EQ-5D-3L 
health state (i.e., 5-digit vector), EQ-5D-3L utility index score, and EQ-5D-3L VAS score will 
be provided. 
• Proportion of subjects reporting problems for the 5 EQ-5D-3L dimensions at each assessment 
time point will be summarized by level of problem and by treatment group. Percentages will 
be based on number of subjects assessed at assessment time point. 
• For the EQ-5D-3L utility index and VAS scores, separately: 
− Mean score and mean change from baseline at each assessment time point will be 
summarized by treatment group using descriptive statistics (N, mean with SD and 95% CI, 
median, first and third quartiles, minimum, maximum). 
− A line graph summarizing the mean changes from baseline will be produced. 
 
8 CONVENTIONS 
The following conventions may be used for imputing partial dates for analyses requiring dates:  
• For missing and partial adverse event onset dates, imputation will be performed using the 
Adverse Event Domain Requirements Specification15F16 
• For missing and partial adverse event resolution dates, imputation will be performed as follows 
(these conventions may change): 
− If only the day of the month is missing, the last day of the month will be used to replace 
the missing day. If the imputed date is after the death date or the last known alive date, then 
the latest known alive date or death date is considered as the resolution date.  
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− If the day and month are missing or a date is completely missing, it will be considered as 
missing. 
• Missing and partial non-study medication domain dates will be imputed using the derivation 
algorithm described in 4.1.3 of BMS Non-Study Medication Domain Requirements 
Specification16F17. 
• Missing and partial radiotherapy and surgery dates will be imputed using algorithm described 
in APPENDIX 2. 
• For death dates, the following conventions will be used for imputing partial dates: 
− If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. The imputed date will be compared to the last known alive date and the 
maximum will be considered as the death date.  
− If the month or the year is missing, the death date will be imputed as the last known alive 
date.  
− If the date is completely missing but the reason for death is present, the death date will be 
imputed as the last known date alive.  
• For date of progression after start of study therapy, the following conventions will be used for 
imputing partial dates:  
− If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. In case of the date of death is present and complete, the imputed progression 
date will be compared to the date of death. The minimum of the imputed progression date 
and date of death will be considered as the date of progression.  
− If the day and month are missing or a date is completely missing, it will be considered as 
missing.  
• For date of progression to prior therapies, the following conventions will be used for imputing 
partial dates:  
− If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day.  
− If the day and month are missing or a date is completely missing, it will be considered as 
missing.  
• For other partial/missing dates, the following conventions were used:  
− If only the day of the month is missing, the 15th of the month will be used to replace the 
missing day.  
− If both the day and the month are missing, “July 1” will be used to replace the missing 
information.  
− If a date is completely missing, it will be considered as missing.  
The following conversion factors will be used to convert days to months or years:  
1 month = 30.4375 days and 1 year = 365.25 days. 
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Duration (e.g. time-to onset, time-to resolution) will be calculated as follows: 
Duration = (Last date - first date + 1) 
Last known alive date will be defined based on all appropriate dates collected on the CRF. 
All statistical analyses will be carried out using SAS (Statistical Analysis System software, SAS 
Institute, North Carolina, USA) unless otherwise noted. 
 
9 CONTENT OF REPORTS 
All analyses described in this SAP will be included in the Clinical Study Report(s) except where 
otherwise noted. Refer to the Data Presentation Plan for mock-ups of all tables and listings. 
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APPENDIX 1 TIME-TO ONSET AND TIME-TO RESOLUTION DEFINITION AND 
CONVENTIONS FOR SELECT ADVERSE EVENTS, IMMUNE-
MEDIATED ADVERSE EVENTS AND EVENTS OF SPECIAL 
INTEREST 
Time-to onset definition 
Time-to onset of AE (any grade) for a specific category is defined as the time between the day of 
the first dose of study treatment and the onset date of the earliest AE (of any grade) in this category. 
The time-to onset of AE (grade 3-5) for a specific category is defined similarly with an onset date 
corresponding to a grade 3-5 AE. 
Time-to onset of drug-related AE (any grade or grade 3-5) for a specific category is defined 
similarly but restricted to drug-related AE. 
Time-to onset for a specific subcategory is defined similarly but restricted to event of this 
subcategory. 
Time-to resolution definition 
In order to derive the time-to resolution, overlapping or contiguous AEs within a specific category 
or subcategory will be collapsed into what will be termed “clustered” AEs. For example, if a 
subject (without pre-treatment AE) experienced an AE from 1st to 5th January, another AE (with 
different PT but within same category) from 6th to 11th January and same AE from 10th to  
12th January, these will be collapsed into one clustered AE from 1st to 12th January.  
Key derivation steps for each type of clustered AEs is summarized as follows: 
• For any grade AE: Collapse any on-treatment AE from the same category 
• For drug-related any grade AE: Collapse any on-treatment drug-related AE from the same 
category 
• For grade 3-5 AE: Collapse any on-treatment AE from the same category. Resolution will 
be based on the onset date of the earliest grade 3-5 records (if no grade 3-5 record, 
clustered AE is excluded) 
• For drug-related grade 3-5 AE: Collapse any on-treatment drug-related AE from the same 
category. Resolution will be based on the onset date of the earliest grade 3-5 records (if no 
grade 3-5 record, clustered AE is excluded) 
 
Time-to resolution of AE (any grade) for a specific category is defined as the longest time from 
onset to complete resolution or improvement to the grade at baseline among all clustered AEs 
experienced by the subject in this category per adverse event criteria category. Events which 
worsened into grade 5 events (death) or have a resolution date equal to the date of death are 
considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be 
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censored to the last known alive date. Improvement to the grade at baseline implies that all 
different events in the clustered adverse event should at least have improved to the corresponding 
(i.e. with same preferred term) baseline grade. This measure is defined only for subjects who 
experienced at least one AE in the specific category. 
The time-to resolution of AE (grade 3-5) for a specific category is defined similarly with an onset 
date corresponding to a grade 3-5 AE. 
Time-to resolution of drug-related AE (any grade or grade 3-5) for a specific category is defined 
similarly but restricted to drug-related AE. 
The time-to resolution of AE (any grade or grade 3-5, drug-related or all) where immune 
modulating medication was initiated is defined similarly. For data presentation not restricted to 
IMAE, the additional condition that the subject started an immune modulating medication during 
the longest AE resolution period will be applied. 
Time-to resolution for a specific subcategory is defined similarly but restricted to event of this 
subcategory. 
The algorithm for collapsing adverse event records is using the following conventions: 
For each subject and specified category, the corresponding adverse event records will be collapsed 
when: 
1) Multiple adverse event records have the same onset date. 
2) The onset date of an event record is either the same day or 1 day later than the resolution date 
of a preceding event record (contiguous events). 
3) The onset date of an event record is after the onset date and prior to or on the resolution date 
of a preceding event record (overlapping events). 
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APPENDIX 2 MISSING AND PARTIAL RADIOTHERAPY AND SURGERY 
DATES IMPUTATION ALGORITHMS 
Procedures – Imputation Rules.  
If reported procedure start date is a full valid date then set start date equal to the date part of 
procedure start date.  
In case of partial date use imputation rules described below:  
• If only day is missing then  
− If month and year of procedure match month and year of first dose date then impute as date 
of first dose;  
− If month and year of procedure don't match month and year of first dose date then impute 
as first day of that month and year.  
• If both day and month are missing, then impute as maximum between 01JAN of the year and 
date of the first dose;  
• If date is completely missing or invalid then leave missing.  
Note: Imputation is not applicable to data where start date is not collected (for example "PRIOR 
RADIOTHERAPY" CRF). Set start date to missing in this case.  
If reported end date is a full valid date then set end date equal to the date part of the reported end 
date.  
In case of partial date use imputation rules described below:  
• If reported end date is partial then set end date equal to the last possible reported end date based 
on the partial entered reported end date.  
• If reported end date is missing, continuing, unknown or invalid then set end date equal to the 
most recent database extraction date.  
If end date was imputed then compare end date to the death date or last known alive date if subject 
is not dead. If posterior then end date should be imputed to death date (or last known alive date if 
subject not dead).  
Note: Imputation of partial dates only applies to data entered on "RADIOTHERAPY” CRF page. 
For other CRF pages in case of partial dates set end date to missing.   
Surgeries – Imputation Rules.  
If reported surgery date is a full valid date then set start date equal to the date part of surgery date.  
In case of partial date, use one of the two imputation rules described below:  
A. For data collected on "PRIOR SURGERY RELATED TO CANCER" CRF page:  
• If only day is missing then impute as the first day of the month;  
• If both day and month are missing then then impute as 01JAN of the year;  
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• If date is completely missing or invalid then leave missing.  
B. For data collected on other CRF pages (deemed to be on-treatment/subsequent surgeries):  
• If only day is missing then  
− If month and year of surgery match month and year of first dose date then impute the 
missing date as the date of first dose;  
− If month and year of surgery don't match month and year of first dose date then impute as 
first day of that month and year;  
• If both day and month are missing then impute as maximum between 01JAN of the year and 
date of the first dose;  
• If date is completely missing or invalid then leave missing.  
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APPENDIX 3 IMMUNOGENICITY ANALYSIS: BACKGROUND AND 
RATIONALE 
The following summary is from the FDA Guidance for Industry Immunogenicity Assessment for 
Therapeutic Protein Products and White Paper on Assessment and Reporting of the Clinical 
Immunogenicity of Therapeutic Proteins and Peptides – Harmonized Terminology and Tactical 
Recommendations by Shankar et al. The program-level definitions of sample- and subject-level 
ADA status are based on recommendation from the BMS Immunogenicity Council. 
Immune responses to therapeutic protein products may pose problems for both subject safety and 
product efficacy. Immunologically based adverse events, such as anaphylaxis and infusion 
reactions, have caused termination of the development of therapeutic protein products or limited 
the use of otherwise effective therapies. Unwanted immune responses to therapeutic proteins may 
also neutralize the biological activity of therapeutic proteins and may result in adverse events not 
only by inhibiting the efficacy of the therapeutic protein product, but by cross-reacting to an 
endogenous protein counterpart, if present. Because most of the adverse effects resulting from 
elicitation of an immune response to a therapeutic protein product appear to be mediated by 
humoral mechanisms, circulating antibody has been the chief criterion for defining an immune 
response to this class of products. 
ADA is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are 
cross-reactive with the administered biologic drug (baseline ADA). Titer is a quasiquantitative 
expression of the level of ADA in a sample. By employing a serial dilution-based test method, titer 
is defined as the reciprocal of the highest dilution of the sample (e.g., dilution of 1/100 = titer of 
100). The ADA is also tested, via a cell-based biologic assay or a non cell-based competitive 
ligand-binding assay for a subpopulation of ADA known as neutralizing antibodies (NAb), which 
inhibits or reduces the pharmacological activity of the biologic drug molecule regardless of its in 
vivo clinical relevance. Non-neutralizing ADA (non-NAb) is ADA that binds to the biologic drug 
molecule but does not inhibits its pharmacological activity. 
ADA should be tested using sensitive and valid methods and employing an appropriate strategy 
for elucidating immunogenicity. Detection of ADA is typically performed in three tiers (screening, 
confirmatory, and titer) using statistically determined cutpoints and samples testing positive in the 
ADA assay are analyzed for neutralizing activity, especially in late-stage clinical studies. 
“Detection” of ADA implies that drug-specific ADA was confirmed. The ‘drug tolerance” of an 
assay (highest drug concentration that does not interfere in the ADA detection method) is not an 
absolute value and differs between individuals due to the varying avidities of ADA immune 
responses. An ADA sampling strategy of collecting samples at times when the least drug 
concentration is anticipated (trough concentrations) can increase the likelihood of accurate ADA 
detection. 
It is useful to present ADA results from clinical studies as (a) characteristics of the ADA immune 
response, (b) relationship of ADA with pharmacokinetics (PK) and, when relevant, 
pharmacodynamics (PD) biomarkers, and (c) relationship of ADA with clinical safety and 
efficacy. 
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Clinical consequences of ADA can range from no apparent clinical effect to lack of efficacy 
(primary treatment failure), loss of efficacy (secondary treatment failure) or heightened effect due 
to altered exposure to the biologic drug, adverse drug reactions (administration-related systemic 
or site reactions), and severe adverse drug reactions (anaphylaxis and unique clinical problems 
associated with cross-reactivity and neutralization of endogenous molecules). Thus it becomes 
important to examine any associations between ADA or any of its attributes with the various 
clinical sequelae. The presence of ADA may or may not preclude the administration of drug to 
ADA-positive subjects because the outcome is dependent upon the magnitude of the impact of 
ADA on PK and PD. Hence, the relationship of ADA with PK/PD is an important additional 
consideration, but does not necessarily result in a clinically impactful consequence per se. 
Immunogenicity Endpoints 
A fundamental metric that informs clinical immunogenicity interpretation is the incidence of ADA 
in a study or across comparable studies. ADA incidence is defined as the proportion of the study 
population found to have seroconverted or boosted their pre-existing ADA during the study period. 
Terms and Definitions 
Validated ADA test methods enable characterization of samples into ADA-positive vs. ADA-
negative. To classify the ADA status of a subject using data from an in vitro test method, each 
sample from the subject is categorized based on the following definitions: 
Sample ADA Status: 
• Baseline ADA-positive sample: ADA is detected in the last sample before initiation of 
treatment 
• Baseline ADA-negative sample: ADA is not detected in the last sample before initiation of 
treatment 
• ADA-positive sample: After initiation of treatment, (1) an ADA detected (positive 
seroconversion) sample in a subject for whom ADA is not detected at baseline, or (2) an ADA 
detected sample with ADA titer to be at least 4-fold or greater (≥) than baseline positive titer 
• ADA-negative sample: After initiation of treatment, ADA not positive sample relative to 
baseline 
Next, using the sample ADA status, subject ADA status is defined as follows: 
Subject ADA Status: 
• Baseline ADA-positive subject: A subject with baseline ADA-positive sample 
• ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline 
at any time after initiation of treatment 
1) Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where 
the first and last ADA-positive samples are at least 16 weeks apart 
2) Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last 
sampling time point 
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3) Other Positive: Not persistent positive but some ADA-positive samples with the last 
sample being negative 
4) Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies 
detected 
• ADA-negative subject: A subject with no ADA-positive sample after the initiation of 
treatment. 
(Note: 16 weeks was chosen based on a long half-life of IgG4.) 
Population for Analyses 
Analysis of immunogenicity data will be based on ADA evaluable subjects defined as all treated 
subjects with baseline and at least 1 post-baseline immunogenicity assessment. Analysis dataset 
and data listing will include all available ADA samples. However, subject-level ADA status will 
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1 BACKGROUND AND RATIONALE
Although multiple agents are approved as monotherapies for the treatment of subjects with 
metastatic renal cell carcinoma (mRCC), the testing of combination therapies, in particular,
treatment with immune-checkpoint inhibitors in combination with tyrosine kinase inhibitors 
(TKIs) has not been fully explored. While single agent therapies have improved outcomes, ongoing 
drug resistance and disease progression demonstrate an urgent need to find more effective 
therapies for mRCC subjects.. The CA2099ER trial will include previously untreated subjects with 
advanced RCC and uses the well-characterized immune checkpoint inhibitor nivolumab in
combination with cabozantinib, a known standard-of-care in mRCC subjects. Nivolumab 
combined with cabozantinib may be an important step forward in evaluating combination regimens 
which could potentially optimize the management of previously untreated subjects with mRCC.
Cabozantinib was shown to improve PFS and OS compared to everolimus, leading to its regulatory 
approval in a randomized phase 3 trial in subjects with advanced RCC that had progressed after 
anti-VEGFR therapy. Subsequently, a randomized phase 2 trial of cabozantinib vs sunitinib has 
demonstrated an improvement in ORR and PFS in intermediate- and poor-risk subjects with 
previously untreated mRCC (see Section 3.2.1.4 of the protocol). Cabozantinib has also been 
demonstrated to have effects on immune cells. In a study of 24 subjects with advanced urothelial 
carcinoma, cabozantinib treatment resulted in a decrease in circulating Tregs and increased PD-1 
expression on Tregs. Low Tregs at baseline were also predictive of improved response to 
cabozantinib and survival.1
Given the promising clinical activity of cabozantinib in previously untreated mRCC and its 
potential immune effects, combining cabozantinib with nivolumab (in a doublet regimen) is a 
rational strategy to optimize first-line therapy in mRCC. An ongoing phase 1 study is evaluating 
both the doublet and triplet (nivolumab and ipilimumab combined with cabozantinib) regimens in 
subjects with refractory advanced urothelial cancer or other genitourinary tumors, including 
mRCC, and has defined dosing for both regimens that produces acceptable safety and tolerability 
(Section 3.2.1.5 of the protocol). CA209-9ER, 2-arm randomized phase 3 trial, will determine if 
the combination doublet regimen (nivolumab combined with cabozantinib) produces greater 
clinical benefit than sunitinib, a standard of care agent for subjects with previously untreated 
mRCC. In addition, this trial will reveal the adverse event profiles, quality of life measures, as well 
as exploratory biomarkers associated with these different first-line treatment regimens.
Research Hypothesis:
Treatment with nivolumab combined with cabozantinib (doublet regimen) will demonstrate an 
improvement in PFS per BICR compared to sunitinib monotherapy in subjects with previously 
untreated mRCC.
Schedule of Analyses:
This study will be monitored by an independent Data Monitoring Committee (DMC). Details are 
specified in the DMC charter.
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The PFS analysis will occur after approximately 9-10 months minimum follow-up on all 
randomized subjects, which will be triggered by approximately 350 events from Arm A
(nivolumab combined with cabozantinib; doublet regimen) and Arm C (sunitinib).
Two interim analyses of OS are planned. The first interim analysis is planned at the time of final 
PFS analysis and expected after observing 165 deaths among the randomized subjects in Arm A 
and Arm C (65% of the targeted OS events for final analysis). The second interim analysis is 
expected after observing 211 deaths among the randomized subjects in Arm A and Arm C (83% 
of targeted OS events needed for final analysis. The final analysis of OS is expected after observing
211 deaths among the randomized subjects in Arm A and Arm C.
The final PFS analysis will not occur prior to these conditions being met:
 at least 8 months minimum follow-up on all randomized subjects;
 at  least 283 PFS events, which provide at least 90% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C; and 
 at least 149 OS events, which provide 66% power if the observed HR for OS was 0.60.
The expected PFS analysis will occur at approximately 29 months from FPFV. The second interim 
and final analyses of OS are expected to occur approximately 34 months and 40 months from 
FPFV.
Secondary endpoints (including both efficacy endpoints OS and ORR) will be analyzed at the time 
of the final analysis of PFS based on a hierarchical testing strategy. In the event that the interim 
analysis for superiority of overall survival is positive, final (CSR) analyses will be performed prior 
to achieving 254 deaths; additional details can be found in section 7.5.7.
2 STUDY DESCRIPTION
Implementation of CA2099ER Global Revised Protocol 01 stops further randomization into Arm 
B (nivolumab + ipilimumab combined with cabozantinib). Subjects previously randomized to Arm 
B continue with Arm B treatment and continue with Arm B clinical planned events, per protocol.
This is an open label, randomized trial of nivolumab combined with cabozantinib (doublet 
regimen) versus sunitinib in subjects with previously untreated (first line) advanced or metastatic 
RCC. Subjects will be randomized between Arm A and Arm C in a 1:1 ratio with approximately 
638 subjects (319 per arm) capped at approximate 25% to represent the normal frequency of 
favorable risk group in mRCC. The rest of the randomized subjects will provide approximately 
478 intermediate/poor risk randomized subjects (239 per arm). Subjects will be stratified at the 
time of randomization by IMDC prognostic score (0 [favorable risk] versus 1-2 [intermediate risk] 
versus 3-6 [poor risk]), PD-L1 tumor expression ( 1% versus < 1% or indeterminate), and region 
(US/Canada/Western Europe/Northern Europe versus rest of the world [ROW]).
The subject is randomly assigned to 1 of the 2 treatment arms as noted in the study schematic 
below. 
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 Arm A (Doublet): Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
 Nivolumab to be continued until disease progression, unacceptable toxicity, or a maximum 
treatment of 2 years from the first dose in Cycle 1.
 Cabozantinib to be continued until disease progression or unacceptable toxicity.
 Arm C: Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle. Cycles to be 
continued until progression or unacceptable toxicity.
Note - Randomization to Arm B stops with implementation of approved CA2099ER Global 
Revised Protocol 01. Treatment B continues only for subjects randomized to Arm B prior to 
implementation of Global Revised Protocol 01.
 Arm B (Triplet): Nivolumab 3mg/kg IV + Ipilimumab 1 mg/kg IV, both Q3W x 4 doses + 
Cabozantinib 40 mg PO QD
 Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD.
 Nivolumab to be continued until disease progression, unacceptable toxicity, or a 
maximum of 2 years from the first dose in Cycle 1.
 Cabozantinib to be continued until progression or unacceptable toxicity.
Once randomized subjects in Arm A will continue nivolumab until progression, unacceptable 
toxicity, withdrawal of consent, or a maximum of 2 years from the first dose in Cycle 1, whichever 
occurs first. Cabozantinib (Arm A) may be continued until progression, unacceptable toxicity, or 
withdrawal of consent, whichever occurs first, and may extend beyond 2 years from the first dose 
in Cycle 1.
The study design schematic is presented in the figure below.
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Figure 2-1: Study Design Schematic
2.1 Treatment Assignment
After the subject’s initial eligibility is established and informed consent has been obtained, the 
subject must be enrolled into the study by accessing an Interactive Response Technologies web-
based system (IRT) to obtain the subject number. All subjects will be centrally randomized using 
an Interactive Response Technology (IRT). Before the study is initiated, each user will receive log 
in information and directions on how to access the IRT.
Every subject that signs the informed consent form must be assigned a subject number in IRT. The 
investigator or designee will register the subject for enrollment by following the enrollment 
procedures established by BMS. The following information is required for enrollment:
 Date that informed consent was obtained
 Date of birth
 Sex at birth.
Once enrolled in IRT, enrolled subjects that have met all eligibility criteria will be ready to be 
randomized through the IRT. The following information is required for subject randomization:
 Subject number
 Date of birth
 IMDC Prognostic Score (0 versus 1-2 versus 3-6)
 Region (US/Canada/W Europe/N Europe versus ROW)
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 PD-L1 tumor expression ( 1% versus < 1% or indeterminate)
Subjects meeting all eligibility criteria will be randomized in a 1:1 ratio to Arm A (nivolumab 
combined with cabozantinib) or Arm C (sunitinib), stratified by the following factors:
 IMDC Prognostic Score: 0 versus 1-2 versus 3-6
 Region: US/Canada/W Europe/N Europe versus ROW
 PD-L1 tumor expression:  1% versus < 1% or indeterminate
The randomization procedures will be carried out via permuted blocks within each stratum.
2.2 Blinding and Unblinding
This is an open label study. 
2.3 Protocol Amendments
Table 2.3-1: Protocol Amendments
Document Date of Issue Summary of Change
Revised Protocol 02 06-MAY-2019
Major Changes:
 Revised protocol 02 adjusts the timing of the PFS and OS 
interim analyses with modified hypothesized OS hazard 
ratio (HR). The number of randomized subjects is 
increased.
 The interim analysis for ORR is removed, resulting in
revised overall alpha for PFS and OS endpoints.
 No change in eligibility or study procedure.
 Clinical data for nivolumuab + ipilimumab in RCC has 
been updated.
Other changes include more detail on PRO measures and updates 
to align with BMS standards for the nivolumab program.
Revised Protocol 01 18-DEC-2017
Primary revisions: (i) To stop enrollment into Arm B (nivolumab, 
ipilimumab and cabozantinib triplet) and (ii) to include favorable 
risk subjects (capped at 25%) in the primary data analysis.
Secondary items include: (i) to add a Data Monitoring Committee 
review after 30 subjects are treated for 6 weeks, (ii) to adjust, 
clarify and add exclusion criteria, (iii) to add treatment 
restrictions, (iv) to clarify criteria associated with hemorrhage with 
regard to resuming treatment, (v) to specify an additional 
precaution when sunitinib dosing is resumed, and (vi) to apply 
newly updated Sponsor standards for nivolumab clinical protocols.
Tertiary items include (i) incorporation of Administrative Letter 
01 and (ii) correction of typographical and grammatical errors.
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2.4 Data Monitoring Committee
An independent Data Monitoring Committee (DMC) has been established to provide oversight of 
safety and efficacy considerations, study conduct, and risk-benefit ratio. Following review, the 
DMC will recommend continuation, modification, or discontinuation of this study based on 
reported safety and efficacy data. Details of DMC responsibilities and procedures are specified in 
the DMC charter. Representatives of the Sponsor will serve only as coordinators of the committee, 
without having full member responsibilities or privileges. In addition, the Sponsor will 
independently review safety data in a blinded manner during the conduct of this trial to ensure that 
any safety issues are identified and addressed.
The DMC will conduct the first review of the safety data after at least 30 subjects are treated and 
followed for at least 6 weeks. The DMC will conduct its second review of the safety data after at 
least 75 subjects are treated and followed for at least 6 weeks. The DMC will conduct its review 
of the safety data focusing on the initial approximately 12 Japanese subjects (6 per arm) treated 
and followed for at least 4 weeks. The DMC will then review safety and the available efficacy data 
pertaining to primary endpoint to evaluate safety in the context of benefit, every six months 
thereafter. 
The DMC will also review the formal final analysis of PFS (as per BICR) and first interim analysis 
of superiority of OS scheduled at around 29 months from FPFV. A second interim analysis of OS
will be at around 34 months from FPFV. BMS will remain blinded to OS interim analyses unless 
DMC decides to disclose the formal interim analysis to BMS. 
Details of the interim analyses can be found in section 7.5.7.
2.5 Blinded Independet Central Review
A blinded independent central review (BICR) committee has been established to provide an 
independent imaging review of images obtained in subjects participating in this study. Details of
BICR responsibilities and processes may be found in the BICR Charter. The BICR determined 
PFS and ORR endpoints will be utilized as a part of primary and secondary efficacy analyses.
3 OBJECTIVES
3.1 Primary
 To compare PFS per BICR of nivolumab combined with cabozantinib (Arm A: doublet) with 
sunitinib (Arm C) in all randomized subjects.
3.2 Secondary
 To compare overall survival (OS) of Arm A with Arm C in all randomized subjects.
 To evaluate the objective response rate (ORR) of Arm A with Arm C per BICR in all 
randomized subjects.
 To assess overall safety and tolerability in all treated subjects.
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 To explore potential predictive biomarkers of clinical response to nivolumab and cabozantinib 
combination.
 To evaluate health related quality of life (HRQoL).
 To characterize the pharmacokinetics of nivolumab and cabozantinib and explore exposure 
response relationships, if applicable.
 To characterize the immunogenicity of nivolumab.
 To assess PFS after next line of treatment (PFS2) in each arm.
4 ENDPOINTS
4.1 Primary Endpoints
Progression-free survival (PFS) is the primary endpoint. Two definitions are used for the analysis 
of PFS. The primary definition accounts for subsequent therapy by censoring at the last evaluable 
tumor assessment on or prior to the date of subsequent therapy. The secondary definition is 
irrespective of subsequent therapy and does not account for subsequent therapy. 
Clinical deterioration in the absence of unequivocal evidence of progression (per RECIST v1.1 
criteria) is not considered progression for purposes of determining PFS.
PFS rate at time T is defined as the probability that a subject has not progressed and is alive at 
time T following randomization. PFS rates at fixed time points (e.g. 6 months, depending on the 
minimum follow-up) are defined as the probability that a subject has not progressed and is alive at 
time T following randomization.
The first on-study tumor assessment is scheduled to be conducted at 12 weeks ( 1 week) following 
randomization. Subsequent tumor assessments are scheduled every 6 weeks ( 1 week) up to 
week 60, then every 12 weeks ( 2 weeks) until disease progression.
4.1.1 Primary Definition of Progression-Free Survival (Accounting for 
Subsequent Therapy)
The primary definition of PFS (PFS truncated at subsequent therapy, which includes anti-cancer 
therapy, tumor directed radiotherapy, or tumor directed surgery) is defined as the time between the 
date of randomization and the date of first documented tumor progression, based on BICR 
assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. 
Subjects who die without a reported progression will be considered to have progressed on the date 
of their death. The following censoring rules will be applied for the primary definition of PFS:
 Subjects who did not progress or die will be censored on the date of their last evaluable tumor 
assessment.
 Subjects who did not have any on study tumor assessments and did not die will be censored on 
their date of randomization.
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 Subjects who receive subsequent anti-cancer therapy prior to documented progression will be 
censored at the date of the last evaluable tumor assessment conducted on or prior to the date 
of initiation of the subsequent anti-cancer therapy.
 Subjects who did not have a documented progression and received subsequent anti-cancer 
therapy will be censored at the date of the last evaluable tumor assessment conducted on or 
prior to the initiation of the subsequent anti-cancer therapy.
Censoring rules for the primary definition of PFS (PFS truncated at subsequent therapy) are 
presented as follows and in Table 4.1.1-1.
Figure 4.1.1-1: PFS Primary Definition
Table 4.1.1-1: Censoring Scheme Used in Primary Definition of PFS
Situation Date of Progression or Censoring Outcome 
No baseline tumor assessments* Date of randomization Censored 
No on study tumor assessments and 
no death*
Date of randomization Censored
Subsequent anti-cancer therapy 
started without death or progression 
per RECIST v1.1 reported prior or 
on the same day
Date of last evaluable tumor 
assessment prior to or on the date of 
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Table 4.1.1-1: Censoring Scheme Used in Primary Definition of PFS
Situation Date of Progression or Censoring Outcome 
Documented progression per 
RECIST v1.1 and no new anti-
cancer started before
Date of the first documented 
progression per RECIST v1.1 
(excludes clinical progression)
Progressed 
No progression and no death, and 
no new anti-cancer therapy started
Date of last evaluable tumor 
assessment 
Censored 
Death without progression per 
RECIST v1.1 and no new anti-
cancer started before
Date of death Progressed 
* Tumor assessments and death if any, occurring after start of subsequent anti-cancer therapy are not considered.
4.1.2 Secondary Definition of Progression Free Survival (Irrespective of 
Subsequent Therapy)
The secondary definition of PFS (ITT definition) is defined as the time between the date of 
randomization and the date of first documented tumor progression, based on BICR assessments 
(per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. 
Subjects who die without a reported progression will be considered to have progressed on the date 
of their death. The following censoring rules will be applied for the secondary definition of PFS:
 Subjects who did not progress or die will be censored on the date of their last evaluable tumor 
assessment.
 Subjects who did not have any on study tumor assessments and did not die will be censored on 
their date of randomization.
Censoring rules for the secondary definition of PFS (ITT definition) are presented as follows and 
in Table 4.1.1-1.
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Figure 4.1.2-1: PFS Secondary Definition
Table 4.1.2-1: Censoring Scheme for Secondary Definition of PFS
Situation Date of Progression of Censoring Outcome
No baseline tumor assessment Date of randomization Censored
No on-study tumor assessments and 
no death
Date of randomization Censored
Documented progression per 
RECIST v1.1 
Date of first documented 
progression per RECIST v1.1 
criteria (excludes clinical 
progression)
Progressed
No progression and no death Date of last evaluable tumor 
assessment
Censored
Death without progression per 
RECIST v1.1
Date of death Progressed
Note that the secondary definition will only be used as supportive analysis.
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Overall survival (OS) is defined as the time from randomization to the date of death from any 
cause. For subjects that are alive, their survival time will be censored at the date of last contact 
date (or “last known alive date”). Overall survival will be censored at the date of randomization 
for subjects who were randomized but had no follow-up.
Follow-up visit #1 (FU1) should occur 30 days from the last dose and follow-up visit #2 (FU2) 
occurs approximately 100 days from last dose of study drug. After FU2, survival follow-up will 
be conducted every 3 months.
4.2.2 Objective Response Rate
Objective Response Rate (ORR) is defined as the number of randomized subjects who achieve a 
best response of confirmed complete response (CR) or confirmed partial response (PR) based on 
BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized subjects. 
Best Overall Response (BOR) is defined as the best response, as determined by the BICR, recorded 
between the date of randomization and the date of objectively documented progression per 
RECIST v1.1 criteria or the date of subsequent therapy (including tumor-directed radiotherapy and 
tumor-directed surgery), whichever occurs first. For subjects without documented progression or 
subsequent therapy, all available response designations will contribute to the BOR determination. 
Confirmation of response is required at least 4 weeks after the initial response.
4.2.2.1 Time to Response
Time to Response (TTR) is defined as the time from randomization to the date of the first 
confirmed documented response (CR or PR), as assessed by the BICR. TTR will be evaluated for 
responders (confirmed CR or PR) only.
4.2.2.2 Duration of Response
Duration of Response (DOR) is defined as the time between the date of first confirmed documented 
response (CR or PR) to the date of the first documented tumor progression as determined by the 
BICR (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who 
start subsequent therapy without a prior reported progression will be censored at the last evaluable 
tumor assessments prior to initiation of the subsequent anti-cancer therapy. Subjects who die 
without a reported prior progression will be considered to have progressed on the date of their 
death. Subjects who neither progress nor die, DOR will be censored on the date of their last 
evaluable tumor assessment. DOR will be evaluated for responders (confirmed CR or PR) only.
4.3 Safety Endpoints
The assessment of safety will be based on the incidence of adverse events (AEs), serious adverse 
events (SAEs), adverse events leading to discontinuation, adverse events leading to dose 
modification, select adverse events (select AEs) for EU/ROW Submissions, immune-mediated 
AEs (IMAEs) for US Submission, other events of special interest (OEOSI), and deaths. The use 
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of immune modulating concomitant medication will be also summarized. In addition clinical 
laboratory tests, and immunogenicity (i.e. development of anti-drug antibody) will be analyzed.
4.4 Exploratory Endpoints
4.4.1 Biomarkers
Biomarkers potentially associated with clinical endpoints will be measured by analyzing tumor 
and blood samples. Biomarker endpoints include, but are not limited to, single-nucleotide 
polymorphisms (SNPs), proteins in tumor specimens and serum, and immune cell populations. 
4.4.1.1 PD-L1 Expression
PD-L1 expression is defined as the percent of tumor cells membrane staining in a minimum of 100 
evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is 
referred to as quantifiable PD-L1 expression. If the PD-L1 staining could not be quantified, it is 
further classified as:
1) Indeterminate: Tumor cell membrane staining hampered for reasons attributed to the biology 
of the tumor tissue sample and not because of improper sample preparation or handling.
2) Not evaluable: Tumor tissue sample was not optimally collected or prepared and PD-L1 
expression is neither quantifiable nor indeterminate. Not evaluable can be determined from 
H&E process before the tumor biopsy specimen is sent for PD-L1 evaluation or from the H&E 
process during PD-L1 evaluation.
Subjects with missing PD-L1 expression are subjects with no tumor tissue sample available for 
evaluation.
PD-L1 expression will be collected in the IRT as well as in the clinical database. Statistical analysis 
using PD-L1 expression will be solely based on PD-L1 expression data from clinical database.
Efficacy endpoints defined above (PFS and ORR by BICR, OS) will be analyzed by PD-L1 
expression to explore the association of PD-L1 expression on tumor and/or tumor associated 
immune cells (TAIC) with clinical benefit.
4.4.2 Clinical Outcomes Assessments
The FSKI-19 and EQ-5D-3L patient-reported outcomes will be collected and analyzed in this 
study.
4.4.2.1 FKSI-19
The NCCN FKSI-19 is a 19-item scale that measures tumor specific HrQoL in kidney cancer 
subjects. The FKSI-19 uses 5 Likert-type response categories that range from “not at all” to “
very much.” Subjects are asked to circle the response category that best characterizes their 
response over the last 7 days on 19 items that include symptoms such as lack of energy, fatigue, 
appetite, coughing, shortness of breath, pain, nausea, and ability to work.
The instrument yields a total score and four subscale scores: Disease Related Symptoms (DRS), 
Treatment Side Effects (TSE), and Functional Well Being (FWB). 
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FKSI-Disease Related Symptoms Physical (FKSI-DRS-P; 12 items; score range 0-48);
FKSI-Disease Related Symptoms Emotional (FKSI-DRS-E; 1 item; score range 0-4);
FKSI-Treatment Side Effects (FKSI-TSE; 3 items; score range 0-12);
FKSI-Functional Well Being (FKSI-FWB; 3 items; score range 0-12);
FKSI-19 Total Score (FKSI-19; 19 items; score range 0-76).
In addition, a score for the FKSI-DRS, a 9-item subscale, can also be calculated.
A higher score indicates fewer symptoms. The recall period is 7 days. Each item is rated on a five-
point Likert scale ranging from 0 = “not at all” to 4 = “very much.”
If there are missing items, subscale scores can be prorated according to the standard FACT 
(Functional Assessment of Cancer Therapy) scoring methodology. This can be done using the 
following formula:
                        =
[                  ]   [                      ]
[                   ]
When there are missing data, prorating by subscale in this way is acceptable as long as more than
50% of the items were answered.  The total score is then calculated as the sum of the un-weighted 
subscale scores.
Table 4.4.2.1-1: Time Windows for FKSI-19 and EQ-5D-3L Assessments
Nominal Time-Point (Cycle) Time Window
Nivolumab+Cabozantinib (Arm A) treatment group
Baseline (Cycle 1) Prior to first dose on Day 1
Week 3 (Cycle 2) Nominal Day 15 (Day 2 thru Day 22,)
Every 2 weeks thereafter (Cycles 3+) Nominal Days 29+ (+7 days/-6 days, inclusive)
Nivolumab+Ipilimumab+Cabozantinib (Arm B) treatment group
Baseline (Cycle 1) Prior to first dose on Day 1
Week 4 (Cycle 2) Nominal Day 22 (Day 2 thru Day 32, inclusive)
Every 3 weeks up to Week 10 (Cycles 3-4) Nominal Days 43 and 64 (+10 days/-10 days, 
inclusive)
Week 13 (Cycle 5) Nominal Day 85 (+7 days/-10 days, inclusive)
Every 2 weeks thereafter (Cycles 6+) Nominal Days 99+ (+7 days/-6 days, inclusive)
Sunitinib (Arm C) treatment group
Baseline (Cycle 1) Prior to first dose on Day 1
Week 7 (Cycle 2) Nominal Day 43 (Day 2 thru Day 64, inclusive)
Every 6 weeks thereafter (Cycles 3+) Nominal Days 85+ (+21 days/-20 days, inclusive)
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Table 4.4.2.1-1: Time Windows for FKSI-19 and EQ-5D-3L Assessments
Nominal Time-Point (Cycle) Time Window
For all treatment groups
Follow Up:
Follow-Up 1 30 days from the last dose (7 days) or coincide with 
the date of discontinuation (7 days) if date of 
discontinuation is greater than 42 days after last dose. 
Follow-Up 2 100 days (7 days) from last dose of study treatment. 
Subjects must be followed for at least 100 days after 
last dose of study treatment.
Survival Follow-Up i a
(i = 1, 2, 3, 4, ...)
3 months (± 14 Days) after Follow-up Visit 2, and 
subsequent survival follow-up visits every 3 months (± 
14 days). 
a Survival Follow-Up is only relevant for EQ-5D, not FKSI-19 assesments.
4.4.2.2 EuroQoL EQ-5D-3L
Subjects’ reports of general health status will be assessed using the EuroQoL Group’s EQ-5D-3L. 
EQ-5D-3L essentially has 2 components: the descriptive system and the visual analogue scale 
(VAS).
The instrument’s descriptive system consists of 5 dimensions:  mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. Each dimension has 3 levels, reflecting "no health 
problems," "moderate health problems," and "extreme health problems." A dimension for which 
there are no problems is said to be at level 1, while a dimension for which there are extreme 
problems is said to be at level 3. Thus, the vectors 11111 and 33333 represent the best health state 
and the worst health state, respectively, described by the EQ-5D-3L. Altogether, the instrument 
describes 35 = 243 health states. Empirically derived weights can be applied to an individual’s 
responses to the EQ-5D-3L descriptive system to generate an index measuring the value to society 
of his or her current health. Such preference-weighting systems have been developed for the UK, 
US, Spain, Germany, and numerous other populations. For this study, EQ-5D-3L utility index 
values will be computed using a scoring algorithm based on the United Kingdom Time-Trade-Off 
(UK TTO) value set2
In addition, the EQ-5D-3L includes a VAS, which allows respondents to rate their own current 
health on a 101-point scale ranging from 0=”worst imaginable” health to 100=“best imaginable” 
health state 3.
A change from baseline of 0.08 for the EQ-5D-3L utility index score and of 7 for the EQ-5D-3L 
VAS are considered minimally important differences for the EQ-5D-3L4.
All questionnaires completed at baseline and on-study will be assigned to a time-point according 
to the windowing criteria in Table 4.4.2.1-1 and included in the analysis. In case a subject has two 
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on-study assessments within the same window, the assessment closest to the time-point will be 
used. And, in the case of two assessments at a similar distance to the time-point, the latest one will 
be chosen. In the event where the subject has no assessment at all in a specific window, the 
observation will be treated as missing for that time-point.
4.4.3 Pharmacokinetics
PK will be measured by the serum concentration of nivolumab and/or ipilimumab and/or 
cabozantinib. Samples will be collected to characterize pharmacokinetics of nivolumab and to 
explore exposure-safety and exposure-efficacy relationships. 
4.4.4 Immunogenicity
Serum samples collected will be analyzed by a validated immunogenicity assay. Selected serum 
samples may be analyzed by an exploratory orthogonal method that measures anti-nivolumab.
In addition, ad hoc serum samples designated for pharmacokinetic or biomarker assessments may 
also be used for immunogenicity analysis if required (e.g., insufficient volume for complete 
immunogenicity assessment or to follow up on suspected immunogenicity related AE).
Further details on immunogenicity background and rationale, definitions, population for analyses 
and endpoints are described in APPENDIX 3.
4.4.5 PFS2
PFS on next-line therapy (PFS2) is defined as the time from randomization to objectively 
documented progression, per investigator assessment, after the next line of therapy or to death 
from any cause, whichever occurs first. Subjects who were alive and without progression after the 
next line of therapy will be censored at last known alive date. 
The following censoring rules will be applied for PFS2:
 Subjects who did not receive subsequent anti-cancer therapy (i.e. second-line therapy):
 Subjects who died, the death date is the event date;
 Else the subject’s PFS2 is censored at the last known alive date.
 Subjects who received subsequent anti-cancer therapy (i.e. second-line therapy):
 Subjects who had a disease progression after the start of subsequent anti-cancer therapy, 
this disease progression date is the event date;
 Else if a subject died or start of second next line therapy, the date of min (death, start date 
of second next line therapy) is the event date;
 Else the subject’s PFS2 is censored at the last known alive date.
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Figure 4.4.5-1: PFS2 Definition
5 SAMPLE SIZE AND POWER
The sample size calculations of this study summarized below are based on the target randomized 
subjects in Arm A and Arm C only. That is, the total randomized subjects will be higher than the 
target randomized subjects due to randomized subjects into Arm B prior to implementation of 
CA2099ER Global Revised Protocol 01, which stopped further randomization into Arm B.
The sample size of this study accounts for the primary endpoint of progression-free survival (PFS) 
per BICR in all randomized subjects. Assuming a 25% screen failure rate, it is expected that 
approximately 850 subjects will need to be enrolled in order to randomize 638 subjects (319 per 
arm) in a 1:1 ratio. To represent the normal frequency of the favorable risk group in mRCC, the
favorable risk subjects are capped at approximate 25%; thus, at most 212 favorable risk subjects 
(106 per arm) will be enrolled to randomize 160 favorable risk subjects in a 1:1 ratio. The rest of 
the enrolled participants will provide approximately 478 intermediate/poor risk randomized 
subjects (239 per each arm).
The overall alpha for this study is 0.05 (two-sided). PFS will be evaluated for treatment effect at 
an alpha of 0.05 (two-sided), with at least 95% power. No interim analysis of PFS is planned. OS 
will be evaluated for treatment effect at an alpha level of 0.05 (two-sided) with 80% power, 
accounting for two formal interim analyses to assess efficacy.
Sample Size Justification for Primary PFS Endpoint
The primary endpoint of PFS per BICR of Arm A versus Arm C analysis conducted on all 
randomized subjects. The PFS analysis will occur after approximately 9-10 months minimum 
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follow-up on all randomized subjects, which will be triggered by approximately 350 events from 
Arm A and Arm C. The 350 PFS events provide at least 95% power to detect a HR of 0.68 for PFS 
of Arm A versus Arm C with a type I error of 0.05 (two-sided). The HR of 0.68 corresponds to a 
47% increase in the median PFS, assuming a median PFS of 18.2 months for Arm A and 
12.4 months for Arm C. It is projected that an observed HR of 0.811 or less, which corresponds to 
a 2.89 month or greater improvement in median PFS (12.4 versus 15.3 months), would result in a 
statistically significant improvement in PFS for the Arm A versus Arm C comparison.
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure. If the formal analysis of OS (interim or final, whichever occurs first) among all 
randomized subjects is statistically significant, then formal analysis of ORR among all randomized 
subjects will be tested, as per hierarchical testing procedure. The formal ORR analyses specified 
in the SAP supersede those specified in the protocol.
Sample Size Computation for Secondary OS Endpoint
The secondary endpoint of OS in all randomized subjects specifies the comparison of Arm A 
versus Arm C. Among all randomized subjects, approximately 254 events (ie, deaths) in Arm A 
and Arm C provides at least 80% power to detect a HR of 0.70 for OS of Arm A and Arm C with 
an overall type 1 error of 0.05 (two-sided) for each test. The HR of 0.70 corresponds to a 43% 
increase in the median OS, assuming a median OS of 47.1 months for Arm A and 33 months for 
Arm C.
Two formal interim analyses of OS are planned for this study. The first interim analysis is planned 
at the time of final PFS analysis and it is expected to observe 165 OS events (65% of the targeted 
OS events for final analysis) and the second interim analysis is planned to occur after observing 
approximately 211 events (83% of targeted OS events needed for final analysis). The stopping 
boundaries at interim and final analyses will be derived based on the number of deaths using 
O’Brien and Fleming  spending function. For example, with 165, 211, and 254 observed events 
in Arm A and Arm C at the first interim, second interim, and final analyses, the respective stopping 
boundaries would be =0.011 (two-sided), =0.025 (two-sided), and α=0.041 (two-sided). If the 
first interim analysis is performed exactly at 165 deaths, it is projected that an observed HR of 
0.673 or less, which corresponds to a 16.0 month or greater improvement in median OS (33 versus 
49 months), would result in a statistically significant improvement in OS for the Arm A versus 
Arm C comparison. At the second interim analysis with 211 deaths, it is projected that an observed 
HR of 0.734 or less, which corresponds to a 12.0 month or greater improvement in median OS 
(33 versus 45 months), would result in a statistically significant improvement in OS for the Arm 
A versus Arm C comparison. At the time of final OS analysis when there are 254 deaths, it is 
projected that an observed HR of 0.774 or less, which corresponds to a 9.6 month or greater 
improvement in median OS (33 versus 42.6 months), would result in a statistically significant 
improvement in OS for the Arm A versus Arm C comparison.
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Assuming a constant accrual rate (an average rate of 3 subjects/month in the first 4 months, 
afterwards an average rate of 42 subjects/month), the accrual will take approximately 19 months. 
The final PFS analysis will not occur prior to these conditions being met:
 at least 8 months minimum follow-up on all randomized subjects;
 at  least 283 PFS events, which provide at least 90% power to detect a HR of 0.68 for PFS of 
Arm A versus Arm C; and 
 at least 149 OS events, which provide 66% power if the observed HR for OS was 0.60.
(Note that if the analysis of first interim analysis OS takes place with 149 OS events, the alpha 
spending for the OS comparison would be 0.007 with a critical HR=0.643.)
This expected PFS analysis will occur at approximately 29 months from FPFV. The second interim 
and final analyses of OS are expected to occur approximately 34 months and 40 months from 
FPFV, respectively. Table 5-1 summarizes the results of these calculations.
Table 5-1: Summary of Sample Size Parameters and Schedule of Analyses
Primary/Secondary Endpoints PFS (Primary) OS (Secondary)
Primary analysis population All Randomized Subjects
Accrual rate per month for all randomized population
3 subjects/month in the first 4 months, afterwards an 




0.05 2-sided (0.011 at IA1, 
0.025 at IA2, 0.041 at FA)
Hypothesized median control vs exp (months) 12.4 vs 18.2 33 vs 47.1
Hypothesized hazard ratio 0.68 0.70
Critical hazard ratio (observed hazard ratio at which a 
statistically significant difference would be observed) 
/ Difference in median (months) Corresponding to a 
minimal clinically significant effect size (FA)
0.811 / 2.89 0.774 / 9.6
Critical HR at interim analysis-1(IA1) /effect size N/A 0.673 / 16.0
Expected number of event for IA1 (percentage of 
target events)
N/A 165 (65%) 
Timing of IA1 from FPFV (months) N/A 29
Critical HR at interim analysis-2(IA2) /effect size N/A 0.734 / 12.0
Expected number of event for IA2 (percentage of 
target events)
N/A 211 (83%) 
Timing of IA2 from FPFV (months) N/A 34
Accrual duration (months) 19 19
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Table 5-1: Summary of Sample Size Parameters and Schedule of Analyses
Primary/Secondary Endpoints PFS (Primary) OS (Secondary)
Timing of final analysis (FA) from FPFV (months) 29 40
Sample size 638 638
Target number of events (Event Goal) 350 254




 Baseline evaluations or events will be defined as evaluations or events that occur before 
the date and time of the first dose of study treatment. Evaluations (laboratory tests, pulse 
oximetry and vital signs) on the same date and time of the first dose of study treatment will 
be considered as baseline evaluations. Events (AEs) on the same date and time of the first 
dose of study treatment will not be considered as pre-treatment events.
 In cases where the time (onset time of event or evaluation time and dosing time) is missing 
or not collected, the following definitions will apply:
 Pre-treatment AEs will be defined as AEs with an onset date prior to but not including 
the day of the first dose of study treatment;
 Baseline evaluations (laboratory tests, pulse oximetry and vital signs) will be defined 
as evaluations with a date on or prior to the day of first dose of study treatment.
 If there are multiple valid assessments on or prior to the first dose of study treatment:
 For laboratory tests, the latest non missing labs value on or before first dose date (and 
time if collected) will be used as the baseline in the analyses. For 'LIPASE' and 
'GLUCOSE', for treated subjects only, the last predose assessment with non-missing 
toxicity grade will be considered as baseline. If multiple assessments exist with the 
same collection date (and time if collected) and entry date and time, then the first 
observation is used as baseline.
 For PD-L1, among the records prior to or on first dose date (and time if collected), 
identify first those with quantifiable test result. If there are no records with quantifiable 
test result, then select those with indeterminant result (“INDETERMINATE”). If there 
are no records with indeterminant test result, then select those with unavailable result 
(“NOT EVALUABLE). If there are no records with unavailable test result, then select 
those with not reported or not available result (all other records). The latest record will 
be used as the baseline in the analyses. If there is more than one record for the latest 
date, then choose the one with the greatest specimen ID.
 For Anti-Drug Antibody (ADA), the record related to the most recent assessment 
among those records where date (and time if collected) of Nivolumab immunoglobulin 
(IMG) assessment is less than or equal to the date (and time if collected) of the first 
Nivolumab dose date.
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 Post baseline period:
 On-treatment AEs will be defined as AEs with an onset date and time on or after the date 
and time of the first dose of study treatment (or with an onset date on or after the day of 
first dose of study treatment if time is not collected or is missing). For subjects who are off 
study treatment, AEs will be included if event occurred within a safety window of 30 days 
(or 100 days depending on the analysis) after the last dose of study treatment. No 
“subtracting rule” will be applied when an AE occurs both pre-treatment and post-
treatment with the same preferred term and grade.
 On-treatment evaluations (laboratory tests, pulse oximetry and vital signs) will be defined 
as evaluations taken after the day (and time, if collected and not missing) of first dose of 
study treatment. For subjects who are off study treatment, evaluations should be within a 
safety window of 30 days (or 100 days depending on the analysis) after the last dose of 
study treatment.
 Late-emergent drug-related AEs will be defined as drug-related AEs with an onset date greater 
than 100 days after the last dose of study treatment in subjects who are off study treatment.
6.2 Treatment Regimens
The treatment group “as randomized” will be retrieved from the IRT system:
 Arm A: Experimental arm: nivolumab + cabozantinib
 Arm B: Experimental arm: nivolumab + ipilimumab + cabozantinib
 Arm C: Control arm: sunitinib
The treatment group “as treated” will be the same as the arm as randomized by IRT. However, if 
a subject received the incorrect drug for the entire period of treatment, the subject’s treatment 
group will be defined as the incorrect drug the subject actually received.
Unless otherwise specified, the safety analysis will be based on the treatment group “as treated”.
Unless otherwise specified, the efficacy analysis will be based on the treatment group “as 
randomized”.
6.3 Populations for Analyses
All analyses will be performed using the treatment arm as randomized (intent to treat), with the 
exception of dosing and safety, for which the treatment arm as received will be used. For purposes
of analysis, the following populations are defined in Table 6.3-1, and all populations for analyses
given in this table refer to those subjects in Arm A and Arm C. Those subjects who randomized to 
Arm B prior to Revised Protocol 01 will be considered as part of the population of interest for 
descriptive summary of efficacy and safety analyses.
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Table 6.3-1: Populations for Analyses
Population Description
All Enrolled Subjects All subjects who sign informed consent and were registered into the IRT.
All Randomized Subjects All subjects who were randomized will be used for analyses of demography, 
protocol deviations, baseline characteristics, primary efficacy analysis,
secondary efficacy analyses, and outcome research analysis which will be 
performed for this population.
All Treated Subjects All subjects who received at least one dose of any study medication. This is 
the primary population for exposure and safety analyses.
Intermediate/Poor Risk Subjects All subjects who were randomized with baseline IMDC prognostic score 1 at 
the time of randomization (per IRT). This population will be used for subset 
analyses of demography, protocol deviations, baseline characteristics, primary 
efficacy analysis, and secondary efficacy analyses on intermediate/poor risk 
subjects.
All Intermediate/Poor Risk 
Treated Subjects
All intermediate/poor risk subjects who received any dose of study therapy.
This population will be used for subset analyses of exposure and safety
analyses on intermediate/poor risk subjects.
Pharmacokinetic Subjects All subjects with available serum time-concentration data from randomized 
subjects dose with nivolumab and cabozantinib.
Immunogenicity Subjects All subjects with available data from randomized subjects dose with 
nivolumab and cabozantinib.




Unless otherwise noted, discrete variables will be tabulated by the frequency and proportion of 
subjects falling into each category, grouped by treatment. Percentages given in these tables will be 
rounded to the first decimal and, therefore, may not always sum to 100%. Percentages less than 
0.1 will be indicated as ‘< 0.1’. Continuous variables will be summarized by treatment group using 
the mean, standard deviation, median, minimum, and maximum values.
Time-to-event variables (e.g. time-to resolution) will be analyzed using the Kaplan-Meier 
technique. When specified, the median will be reported along with 95% CI using Brookmeyer and 
Crowley method5 (using log-log transformation for constructing the confidence intervals6).
Unless otherwise specified, the stratified log-rank test will be performed to test the comparison
between time to event distributions. Unless otherwise specified, the stratified hazard ratio between 
2 groups along with CI will be obtained by fitting a stratified Cox model with the group variable 
as a unique covariate.
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Confidence intervals for binomial proportions will be derived using the Clopper-Pearson method.7
The unweighted difference in ORRs between the two treatment arms and corresponding 
asymptotic 95% CI will be estimated using a Newcombe method.8
P-values from sensitivity analyses for efficacy endpoints are for descriptive purpose only and there 
will be no multiplicity adjustment for these analyses.
The conventions to be used for imputing missing and partial dates for analyses requiring dates are 
described in Section 8.
Note that, the outputs will present Arm A, Arm B, and Arm C in the following way:
 All analysis specified in Section 7.3 and 7.4 will present A, B, and C together.
 For purposes of efficacy analyses, all randomized subjects in Arm A and Arm C will be 
tabulated and presented in the same table. A few seperate efficacy summary tables will be 
generated for those subjects randomized to Arm B, which will be specified in the 
corresponding sections. 
 For purposes of safety analyses, all treated subjects in Arm A and Arm C will be tabulated and 
presented in the same table. A few separate safety summary tables will be generated for those 
subjects treated in Arm B, which will be specified in the corresponding sections.
 Summaries of outcome research and biomarker data will be tabulated on the Arm A and C 
subjects only.
7.1.1 Adverse Events, Serious Adverse Events, Multiple events, Select 
Adverse Events, Other Events of Special Interest and Immune-Mediated 
Adverse Events
Drug-related AEs are those events with relationship to study drug “Related”, as recorded on the 
CRF. If the relationship to study drug is missing, the AE will be considered as drug-related. 
Serious adverse events consist of AEs deemed serious by the Investigator and flagged accordingly 
in the CRF and clinical database.
Adverse events leading to study drug discontinuation are AEs with action taken regarding study 
drug(s) = “Drug was discontinued”. 
Adverse events leading to dose delay are AEs with action taken regarding study drug(s) = “Drug
was delayed”.
Adverse event that led to dose delay of the oral drug (similarly defined as dose omission or dose 
interruption) will be coded with action “Drug was interrupted”.
Adverse events leading to dose reduction are AEs with action taken regarding study drug(s) = 
“Dose was reduced”.
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
and the most recent version of the dictionary at the time of the database lock will be used. Adverse 
events results will be graded for severity using NCI Common Terminology Criteria for Adverse 
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Events (CTCAE) and the most recent version of the criteria at the time of the database lock will 
be used.
In the AE summary tables, unless otherwise specified, subjects will be counted only once at the 
Preferred Term (PT), only once at the System Organ Class (SOC), and only once at subject level 
for the counting of total number of subjects with an AE. The AE tables will be sorted by the SOCs 
and then PTs. SOC will be ordered by descending frequency overall and then alphabetically. PTs 
will be ordered within SOC by descending frequency overall and then alphabetically. The sorting 
will be done based on the ‘Any Grade’ column of the experimental arm when arms are presented 
side-by-side.
Unless otherwise specified, the AE summary tables will be restricted to on-treatment events 
regardless of the causality.
Analyses that take into account the multiple occurrences of a given adverse event will be conducted
(see Section 7.6.9). To prepare these analyses, the CRF data will be processed according to 
standard BMS algorithms9 in order to collapse adverse event records into unique records based on 
the preferred term. These data will be presented as the rate per 100 person-years of exposure. These 
analyses will take into account all on-treatment events (allowing more than 1 event per subject) 
and the total exposure time. The person-year exposure will be computed as the sum over the 
subjects’ exposure expressed in years where the exposure time is defined as 
 (Date of last dose of study treatment - date of first dose of study treatment + 31 days 
(or 101 days, depending on the analysis))/365.25, for subject who are off study treatment and 
were followed for at least 30 days (or 100 days, depending on the analysis) after last dose of 
study treatment.
 (Last known alive date - date of first dose of study treatment +1)/365.25, for subjects who are 
still on-treatment or who are off study treatment and were followed less than 30 days 
(or 100 days depending on the analysis) after last dose of study treatment.
7.1.1.1 Select Adverse Events (EU/ROW Submissions)
The select Adverse Events (select AEs) consist of a list of preferred terms grouped by specific 
category (e.g. pulmonary events, gastrointestinal events categories, etc.). AEs that may differ from 
or be more severe than AEs caused by non-immunotherapies and AEs whose early recognition and 
management may mitigate severe toxicity are included as select AEs. Categories of select AEs 
may include subcategories (e.g. adrenal disorders, diabetes, pituitary disorders, and thyroid 
disorders are subcategories of the endocrine event category). 
The list of MedDRA preferred terms used to identify select adverse events is revisited quarterly 
and updated accordingly. The preferred terms used for the selection at the time of the database 
lock will be provided by categories/subcategories.
In addition to the frequency and worst severity of select AEs, time-to onset, time-to resolution, 
and time-to resolution where immune modulating medication was initiated will be analyzed for 
each specific category/subcategory of drug-related select AEs when applicable.
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Further details on the definitions time-to onset and time-to resolution are described in APPENDIX 
1.
7.1.1.2 Other Events of Special Interest
Other events of special interest (OEOSI) consist of a list of preferred terms grouped by specific 
category (e.g. Myositis Event, Myocarditis Event, Demyelination Event, Guillain-Barre 
Syndrome, Pancreatitis Event, Uveitis Event, Encephalitis Event, Myasthenic Syndrome, 
Rhabdomyolysis Event, Graft Versus Host Disease). The list of MedDRA preferred terms used to 
identify OEOSI is revisited quarterly and updated accordingly. The preferred terms used for the 
selection at the time of the database lock by categories will be provided.
7.1.1.3 Immune-Mediated Adverse Events (US Submission)
In order to further characterize AEs of special clinical interest, analysis of immune-mediated AEs 
(IMAE) will be conducted. IMAEs are specific events (or groups of PTs describing specific events) 
that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine 
(adrenal insufficiency, hypothyroidism/thyroiditis, hypothyroidism, thyroiditis, hyperthyroidism, 
diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-
mediated events by investigator that meet the definition summarized below: 
 those occurring within 100 days of the last dose, 
 regardless of causality,
 treated with immune-modulating medication (of note, endocrine AEs such as adrenal 
insufficiency, hypothyroidism/thyroiditis, hypothyroidism, thyroiditis, hyperthyroidism, 
diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating 
medication use, since endocrine drug reactions are often managed without immune-modulating 
medication).
 with no clear alternate etiology based on investigator assessment, or with an immune-mediated 
component 
The list of MedDRA preferred terms used to identify IMAEs is revisited quarterly and updated 
accordingly. The preferred terms used for the selection at the time of the database lock by 
categories will be provided.
7.1.2 Laboratory Tests
Clinical laboratory parameters (hematology, serum chemistry and electrolytes) will be evaluated.
Laboratory tests will be graded using the NCI Common Terminology Criteria, and the most recent 
version of the criteria at the time of the database lock will be used.
Clinical laboratory data will be first analyzed using International System of Units (SI). 
Analyses will be repeated using US conventional units.
In the laboratory summary tables, unless otherwise specified, subjects will be counted only once 
for each lab parameter according to their worst on treatment CTC grade (worst being the highest 
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CTC grade). The laboratory tables and listings will be sorted by laboratory category, laboratory 
subcategory and laboratory test code sequence number.
7.1.3 Immunogenicity Data
Blood samples for immunogenicity analysis will be collected from subjects assigned to the 
experimental treatment group(s) according to the protocol schedule. Samples will be evaluated for 
development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) 
immunoassay.
7.2 Study Conduct
The following programmable deviations will be considered as relevant protocol deviations and 
summarized by treatment group and overall in all randomized subjects. Non-programmable 
relevant eligibility and on-treatment protocol deviations, as well as significant (both programmable 
and non-programmable) eligibility and on-treatment protocol deviations will be reported through 
ClinSIGHT listings.
Eligibility:
 Subjects with baseline KPS < 70%
 Subjects who received prior systemic anti-cancer treatment in the metastatic setting
 Subjects without histologically confirmed RCC with a clear-cell component, documented 
advanced or metastatic RCC 
On-study:
 Subjects receiving anti-cancer therapy (chemotherapy, hormonal therapy, immunotherapy, 
standard or investigational agents for treatment of cancer) while on study therapy
 Subjects treated differently than as randomized (subjects who received the wrong treatment, 
excluding the never treated)
Enrollment by country and site, and enrollment by month will be summarized and listed for all 
enrolled subjects.
A by-subject listing of batch numbers for all treated subjects will be provided.
7.3 Study Population
Analyses in this section will be tabulated for all randomized subjects by treatment group as 
randomized, unless otherwise specified.
7.3.1 Subject Disposition
The total number of subjects enrolled (randomized or not randomized) will be presented along 
with the reason for not being randomized. This analysis will be performed on the all enrolled 
subjects population only.
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Number of subjects randomized but not treated along with the reason for not being treated will be 
tabulated by treatment group as randomized. 
Number of subjects who discontinued study treatment along with corresponding reason will be 
tabulated by treatment group as treated. Reason for discontinuation will be derived from subject 
status CRF page. This analysis will be performed only on the all treated subjects population.
A by-subject listing for all treated subjects will be provided showing the subject’s off treatment 
date and whether the subject continue in the study along with the reason for going off study. A by-
subject listing for all enrolled subjects will also be provided, showing whether the subject was 
randomized along with the reason for not being randomized.
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, number of subjects 
who discontinued study treatment along with corresponding reason will be tabulated by treatment 
group as treated.
7.3.2 Demographics and Other Baseline Disease Characteristics
The following demographic and baseline disease characteristics will be summarized and listed by 
treatment group as randomized:
 Age 
 Age categorization (< 65,  65 and < 75,  75 and < 85,  85,  75,  65)
 Sex (Male, Female)
 Race
 Region (Region (US/Canada/W.Europe/N.Europe vs. ROW) (source: IRT)
 Ethnicity (Hispanic/Latino and Not Hispanic/Latino)
 Karnofsky performance status (70, 80, 90, 100)
 Baseline IMDC prognostic score (0, 1-2,  3) (source: IRT)
 Baseline IMDC prognostic score (0, 1-2,  3) (source: CRF)
 Time from initial disease diagnosis to randomization (<1 year, ≥1 year)
 Baseline LDH level ( 1.5 x ULN, >1.5 x ULN)
 Hemoglobin (<LLN,  LLN)
 Corrected Calcium ( 10 mg/dl, >10mg/dl )
 Absolute Neutrophil Count ( ULN, > ULN)
 Platelet Count ( ULN, > ULN)
 Baseline Alkaline phosphatase (< ULN,  ULN)
 Prior nephrectomy (Yes, No)
 Prior radiotherapy (Yes, No)
 Baseline PD-L1+ status based on a 1% cut off ( 1% vs. < 1% or indeterminate)
 Baseline PD-L1+ status based on a 5% cut off ( 5% vs. < 5% or indeterminate)
 Baseline PD-L1+ status based on a 10% cut off ( 10% vs. < 10% or indeterminate)
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 Number of disease sites per subject (1, 2, 3, 4 , >4)
 Tumor burden: sum of the diameters of target lesions at baseline
 Most common sites of metastasis
 Sarcomatoid features (Yes, No)
 Stage at the initial diagnosis (Stage IV, non-Stage IV)
 Pre-treatment events tumor assessment (per Investigator)
Summary table (cross-tabulation) by treatment group for stratification factor (except for region) 
will be provided to show any discrepancies between what was reported through IRT vs. CRF at 
baseline. This summary will be performed based on all randomized subjects.
 IMDC Prognostic Score: 0 versus 1-2 versus 3-6
 Region: US/Canada/W Europe/N Europe versus ROW
 PD-L1 tumor expression:  1% versus < 1% or indeterminate
A listing of randomization scheme presenting randomized treatment group and as treated treatment 
group will be provided for all randomized subjects.
Note that for all intermediate/poor risk subjects in Arm A and Arm C, demographic and baseline 
disease characteristics will be summarized and listed by treatment group as randomized.
7.3.3 Medical History
A by-subject listing of general medical history for all randomized subjects will be provided.
7.3.4 Prior Therapy Agents
Prior adjuvant or neo-adjuvant therapy will be summarized by treatment group and overall.
Prior systemic cancer therapy will be summarized by treatment group and overall and listed by 
subject.
Prior radiotherapy and prior surgery related to cancer will be listed by subject.
7.3.5 Physical Examinations
Subjects with abnormal baseline physical examination will be listed by subject.
7.3.6 Baseline Physical Measurements
Baseline physical measurements will be listed by subject.
7.4 Extent of Exposure
Listings will include all available exposure data. Analyses will be performed by treatment group 
“as treated” in all treated subjects, unless otherwise specified.
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7.4.1 Administration of Study Therapy 
The following parameters will be summarized (descriptive statistics) by study therapy and 
treatment group:
 Number of doses received
 Cumulative dose
 Relative dose intensity (%) using the following categories: < 50%; 50 - < 70%; 70 - < 90%; 
90 - < 110%;  110%
 Average daily dose
Duration of study therapy will be summarized (descriptive statistics) by treatment group. 
A by-subject listing of dosing of study medication (record of study medication, infusion details, 
and dose changes) will be also provided.
Note that similar study therapy table will be summarized for all intermediate/poor risk treated 
subjects in Arm A and Arm C.
Table 7.4.1-1: Study Therapy Parameter Definitions for Arm A and C
Nivolumab Cabozantinib Sunitinib
Dosing Schedule per 
Protocol
240 mg every 2 weeks 40 mg PO once daily 50 mg PO once daily 
for 4 weeks followed 
by 2 weeks off.
Dose mg mg mg
Cumulative Dose mg
sum of the doses 
administered to a subject
mg
sum of the doses 
administered to a subject
mg
sum of the doses 
administered to a 
subject
Relative Dose Intensity (%) [Cum dose (mg) /( (Last 
dose date– First dose date + 
14) × 240/14)] × 100
See below See below
Duration of Treatment Last dose date - Start dose 
date +1
Last dose date - Start 
dose date + 1
Last dose date - Start 
dose date +15
Additional Parameters -Cabozantinib treatment
Average daily dose (in mg/day) is defined as:
Sum of all Cabozantinib doses in mg actually received / duration of treatment in days.
Since Cabozantinib treatment consists of 40 mg PO daily dose, the planned dose intensity of 
Cabozantinib is 40 mg/day.
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Relative dose intensity for Cabozantinib (%) is defined as: (Average daily dose / 40) x 100.
Additional Parameters -Sunitinib treatment
Average daily dose (in mg/day) is defined as:
Sum of all Sunitinib doses in mg actually received / duration of treatment in days
Since Sunitinib treatment consists of 50 mg PO daily dose for 4 weeks followed by 2 weeks of 
washout period, the planned dose intensity of Sunitinib is 33.33 mg/day (50 mg x 28 days / 42 
days).
Relative dose intensity for Sunitinib (%) is defined as: (Average daily dose / 33.33) x 100.
Table 7.4.1-2: Study Therapy Parameter Definitions for Arm B (Cycle 1-4)
Nivolumab Ipilimumab Cabozantinib
Dosing Schedule per 
Protocol
3 mg/kg every 3 weeks for 4 
doses
1 mg/kg every 3 weeks for 4 
doses
40 mg PO once 
daily 
Dose Dose (mg/kg) is defined as 
Total Dose administered 
(mg)/Most recent weight
(kg). Dose administered in 
mg at each dosing date and 
weight are collected on the 
CRF.
Dose (mg/kg) is defined as 
Total Dose administered 
(mg)/Most recent weight
(kg). Dose administered in 
mg at each dosing date and 
weight are collected on the 
CRF.
mg
Cumulative Dose Cum Dose (mg/kg) is the 
sum of the doses 
administered to a subject.
Cum Dose (mg/kg) is the sum 
of the doses administered to a 
subject.
mg
sum of the doses 
administered to a 
subject
Cycle Duration(i) (wk) (Dose date(i+1) - Dose 
date(i))/7





Dose(i)/Cycle Duration(i) Dose(i)/Cycle Duration(i) N/A
Relative Cycle Intensity (i)
(%)
(Cycle Intensity(i)/intended 
dose per week)(i) * 100
(Cycle Intensity(i)/intended 
dose per week)(i) * 100
N/A
Relative Dose Intensity 
(%)
Sum of all Relative Cycle 
Intensities divided by N
Sum of all Relative Cycle 
Intensities divided by N
(Average daily 
dose / 40) x 100
Duration of Treatment Last dose date - Start dose 
date +1
Last dose date - Start dose 
date +1
Last dose date -
Start dose date 
+1
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Table 7.4.1-3: Study Therapy Parameter Definitions for Arm B (Cycle 5 
Onward)
Nivolumab Cabozantinib
Dosing Schedule per 
Protocol
240 mg every 2 weeks 40 mg PO once daily
Dose mg mg
Cumulative Dose mg
sum of the doses administered to a 
subject
mg
sum of the doses administered to a 
subject
Relative Dose Intensity (%) [Cum dose (mg) /( (Last dose date–
First dose date + 14) × 240/14)] × 100
(Average daily dose / 40) x 100
Duration of Treatment Last dose date - Start dose date +1 Last dose date - Start dose date + 1
7.4.2 Modifications of Study Therapy
7.4.2.1 Dose Delays
Each nivolumab infusion or sunitinib dose may be delayed. A dose will be considered as actually 
delayed if the delay is exceeding 3 days (ie greater than or equal to 4 days from scheduled dosing 
date) for nivolumab. Reason for dose delay will be retrieved from CRF dosing pages. It is worth 
noting that during the two week mandatory washout period for sunitinib, a daily dose of 0 mg will 
be entered in the CRF pages, with corresponding reason for dose modification recorded as “No 
Change”.
If cabozantinib is given daily, a daily dose of 0 mg entered in the CRF pages will be considered as 
delay. If cabozantinib is given every other day, then a daily dose of 0 mg will be entered every 
other day in the CRF pages, with corresponding reason for dose modification recorded as “No 
Change”. If there are more than one 0 mg daily dose entered consecutively, then this will be 
considered as delay.
The following parameters will be summarized by treatment group:
 Number of subjects with at least one dose delayed, the number of dose delays per subject, the 
reason for dose delay and the length of dose delay.
Note that similar dose delay summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects.
For Arm B, both nivolumab and ipilimumab can be delayed at the same cycle. A dose will be 
considered as actually delayed if the delay is exceeding 3 days (ie greater than or equal to 4 days 
from scheduled dosing date) for nivolumab and ipimumab. Cabozantinib a daily dose of 0 mg 
entered in the CRF pages will be considered as delay. Similar table will be produced for Arm B 
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subjects previously randomized to Arm B continue with Arm B treatment and continue with Arm 
B clinical planned events, per protocol.
7.4.2.2 Infusion Interruptions and Rate Changes
Each nivolumab or ipilimumab infusion can be interrupted and/or the IV infusion rate can be 
reduced. This information will be retrieved from CRF dosing pages.
The following parameters will be summarized by treatment group:
 Number of subjects with at least one dose infusion interruption, the reason for interruption, 
and the number of infusion interruptions per subject.
 Number of subjects with at least one IV infusion rate reduction, the reason for reduction and 
the number of infusion with IV rate reduction per subject.
Note that similar summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects.
7.4.2.3 Dose Escalations
Dose escalations are permitted for cabozantinib and sunitinib but not for nivolumab and 
ipilimumab.
7.4.2.4 Dose Reductions
Dose reductions are permitted for cabozantinib and sunitinib but not for nivolumab and 
ipilimumab.
Dose reduction for subjects treated with sunitinib is defined as at least one day with a non zero 
dose smaller than 50 mg and smaller than previous non zero dose with a CRF reason different from 
“Dosing Error” or “No Change”.
Dose reduction for subjects treated with cabozantinib is defined as at least one day with 20 mg or 
20 mg every other day with a CRF reason different from “Dosing Error” or “No Change”.
Note that similar dose redcution summary table for Arm A and Arm C will be summarized for all 
intermediate/poor risk treated subjects.
The following summaries will be presented for the cabozantinib component of study treatment: 
i) For dose reductions due to AE    
Categorical summaries for:
 Subjects with any dose reduction
 Dose levels received by a subject
 Lowest non-zero dose level received  
 Last non-zero dose level received 
 Last dose level received (including dose holds) 
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 Duration of treatment in months for each dose level (40 mg, 20 mg, 0 mg)
 Time to second dose level reduction (first receipt of 20mg) (days)
ii) Summaries for dose holds due to AE (those with 0 mg due to AE): 
 Descriptive statistics for number of dose holds due to an AE
 Descriptive statistics for duration of dose holds per dose hold and per subject due 
to an AE, calculated as (stop date of hold – start date of hold + 1) 
 Categorical summary for subjects with duration of  holds due to an AE that can be 
classified as any number of days,  7 days,   14 days,  21 days, and >42 days
 Descriptive statistics for time to first dose hold, time to first dose hold that  7 days, 
 14 days,  21  days, and >42 days. The time to dose hold is calculated as (start 
date of the hold – first dose date + 1)  
 Descriptive statistics for time to second dose hold, time to second dose hold that 
was  7 days,  14 days,  21 days, and >42 days.
iii) Summaries for dose modifications (defined as a reduction or hold) due to AE: 
 Frequency counts and percentages for subjects with any dose modifications
 Descriptive statistics for number of dose modifications (0-3)
 Descriptive statistics for time to the first dose modification 
 Descriptive statistics for time to the second dose modification
7.4.2.5 Dose Omissions
Dose omissions are not permitted.
7.4.3 Concomitant Medications
Concomitant medications, defined as medications other than study medications which are taken at 
any time on-treatment (i.e. on or after the first day of study therapy and within 100 days following 
the last dose of study therapy), will be coded using the UMC WHO Drug Global Dictionary.
The following summary table will be provided:
 Concomitant medications (subjects with any concomitant medication, subjects by medication 
class and generic term) 
A by-subject listing will accompany the table.
7.4.3.1 Immune Modulating Medication 
Immune modulating concomitant medications are medications entered on an immune modulating 
medication form or available from the most current pre-defined list of immune modulating 
medications. The list of anatomic class, therapeutic class and generic name used for the selection 
at the time of the database lock will be provided.
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The percentage of subjects who received immune modulating concomitant medication for




 management of drug-related select adverse event (any grade, grade 3-5) by select AE category/ 
subcategory (EU/ROW Submissions)
 management of IMAEs (any grade, grade 3-5) by IMAE category (US Submission) will be 
reported separately for each treatment group (percentages of treated subjects by medication 
class and generic term).
For each category/subcategory of drug-related select AEs (any grade, grade 3-5) and IMAEs (any 
grade, grade 3-5), the following will be reported for each treatment group:
 The total immune modulating medication treatment duration (excluding overlaps), duration of 
high dose of corticosteroid, initial dose of corticosteroid, and tapering duration (summary 
statistics)
Duration represents the total duration the subject received the concomitant medication of interest. 
If the subject took the medication periodically, then DURATION in the summation of all use. 
Initial dose represents the dose of the concomitant medication of interest received at the start of 
the event. In the case multiple medications started on the same date, the highest equivalent dose is 
chosen and converted to mg/kg by dividing by the subject’s recent weight.
These analyses, except the ones related to IMAEs will be conducted using the 30-day safety 
window. The analyses related to IMAEs will be conducted using the 100-day safety window.
7.4.3.2 Subsequent Cancer Therapy
Number and percentage of subjects receiving subsequent cancer therapies will be summarized for 
all randomized subjects. Categories include: 
 Subsequent systemic therapy 
 Subsequent surgery for treatment of tumors 
 Subsequent radiotherapy for treatment of tumors
A by-subject listing of subsequent cancer therapy will also be produced for all randomized 
subjects.
Note that similar tables will be summarized for all intermediate/poor risk subjects in Arm A and 
Arm C.
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Analyses in this section will be tabulated for all randomized subjects in Arm A and Arm C, unless 
otherwise specified. A few seperate efficacy summary tables will be generated for those subjects 
who randomized to Arm B prior to Revised Protocol 01, which is specified in the relevant 
subsections below.
Principal analyses of progression free survival (PFS) and objective response rate (ORR) will be 
based on the Blinded Independent Central Review (BICR) evaluation, unless noted otherwise. 
Analyses in this section will be tabulated for all randomized subjects by treatment group as 
randomized, unless otherwise specified.
Unless stated otherwise, whenever a stratified analysis is specified, the following stratifications 
factors (recorded at randomization as per IRT) will be used:
 IMDC Prognostic Score: 0 versus 1-2 versus 3-6
 Region: US/Canada/W Europe/N Europe versus ROW
 PD-L1 tumor expression:  1% versus < 1% or indeterminate
The key secondary objective Overall Survival among all randomized subjects will be tested after 
conducting the primary objective analyses of PFS on all randomized subjects. For assessing this 
secondary objective of this study, a hierarchical testing procedure10 will be used so that the overall 
experiment-wise Type I error rate is two-sided 0.05. 
The secondary objective of ORR among all randomized subjects will be tested after conducting 
the key secondary objective analyses of OS on all randomized subjects, per a hierarchical testing 
procedure so that the overall experiment-wise Type I error rate is two-sided 0.05. Note that the 
formal ORR analysis specified in the SAP supersede those specified in the protocol.
Confidence intervals (CI) for primary and secondary endpoint analyses included in hierarchy will 
be based on nominal significance level adjusted for primary endpoints and interim analyses to 
preserve overall type one error rate.
Alpha ( ) for the CI will be the same as nominal significance level for hypothesis testing. CIs for 
other endpoints will be at the two-sided 95% level. All p-values reported will be two-sided. P-
values will be rounded to the fourth decimal place. Point estimates and confidence bounds for 
efficacy variables will be rounded to the second decimal place.
A by-subject listing of efficacy results will be presented including treatment group, treatment 
duration, BICR progression date, overall survival, death date, etc. 
7.5.1 Analysis of Progression-Free Survival
The primary objective of the study is to compare the PFS per BICR of Arm A to Arm C in 
randomized subjects with previously untreated (first line) advanced or metastatic RCC. All the 
analyses outlined in this section are specified for the all randomized subjects population in Arm A 
and Arm C, unless otherwise specified. 
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PFS per BICR will be compared between the treatment groups via stratified log-rank test among 
all randomized subjects at a two-sided  = 0.05 level. The stratification factors will be IMDC 
prognostic risk score (0 vs 1-2 vs 3-6), region (US/Canada/W Europe/N Europe vs ROW)’ and 
PD-L1 status ( 1% vs < 1% or indeterminate).
The primary definition of PFS adjusting for subsequent anticancer therapy will be used in this 
analysis. The two-sided log-rank p-value will be reported.
The estimate of the PFS hazard ratio between treatment groups will be calculated using a stratified 
Cox proportional hazards model, with treatment as the sole covariate. Ties will be handled using 
the exact method. A two-sided 95% CI for the hazard ratio will also be presented.
The PFS function for each treatment group will be estimated using the KM product limit method 
and will be displayed graphically. A two-sided 95% CI for median PFS in each treatment group 
will be computed via the log-log transformation method. PFS rates at fixed time points (e.g. 
6 months, depending on the minimum follow-up) will be presented along with their associated 
95% CIs. These estimates will be derived from the Kaplan Meier estimate and corresponding CIs 
will be derived based on Greenwood11 formula for variance derivation and on log-log 
transformation applied on the survivor function12.
Analyses of PFS will also be conducted based on the secondary definition of PFS. These analyses 
will be the same as those specified above.
The source of PFS event (progression or death) will be summarized by treatment group. The status 
of subjects who are censored (as per primary definition of PFS) in the PFS KM analysis will be 
tabulated for each treatment group including the following categories:
 On-study (on-treatment, in follow-up)
 Off-study (lost to follow-up, withdraw consent, never treated)
 No baseline tumor assessment
 No on-study tumor assessment and no death
 Received subsequent anticancer therapy
A by-subject listing will be presented including treatment group, PFS duration under the primary 
definition, PFS duration on the ITT definition, whether the subject was censored under the primary 
definition, and if censored, the reason, and whether the subject was censored under the ITT 
definition, and if censored, the reason.
A by-subject listing of lesion evaluations per BICR will be presented.
Note that similar tables (KM plot, median PFS with its 95% CI, PFS rates, source of PFS event,
and status of subjects who are censored) along with by-subject listing will be summarized for all 
intermediate/poor risk subjects in Arm A and Arm C.
For those subjects who randomized to Arm B prior to Revised Protocol 01, the PFS function will 
be estimated using the KM product limit method and reported seperately for Arm B. A two-sided 
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95% CI for median PFS will be computed via the log-log transformation method. A by-subject 
listing will be presented including treatment group, PFS duration under the primary definition, 
PFS duration on the ITT definition, whether the subject was censored under the primary definition, 
and if censored, the reason, and whether the subject was censored under the ITT definition, and if 
censored, the reason.
7.5.2 Supportive Analyses of Progression-Free Survival
The following sensitivity analyses will be conducted using both the primary and the secondary 
definition of PFS in all randomized subjects:
1) Delayed effect of immunotherapy interventions may cause a late separation in the PFS KM 
curves and non-proportional hazards. PFS (as determined by BICR) will be compared between 
treatment groups via two-sided 0.05 stratified weighted log-rank test among subjects. The 
primary definition of PFS will be used in this analysis. The two-sided stratified weighted log-
rank p-value will be reported using G (rho = 0, gamma = 1) weights, in the terminology of 
Fleming and Harrington13. 
a) The Fleming Harrington test can be unstable, so it is possible, though uncommon, that thep-
value for this trial will not be estimable. 
b) The estimate of the PFS hazard ratio in the period before and following 6 months will be 
calculated using a stratified time-dependent Cox model with effects for treatment and 
period-by-treatment interaction. In this model, period is a binary variable indicating pre-
vs. post-6 months. Ties will be handled using the exact method. A two-sided 95% CI for 
the hazard ratio will also be presented.
2) A multivariate Cox regression model will be used in order to estimate the treatment effect after 
adjustment for possible imbalances in known or potential prognostic factors. The factors used 
in the randomization, which, by definition, will be balanced across treatment groups, will still 
be included in the model as stratification factors. However, all additional factors will be 
incorporated as covariates. The additional factors, which are all measured at baseline, will 
include:
a) Age categorization (< 65 vs.  65)
b) Gender (Male vs. Female) 
c) Race
d) Region (US/Canada/W.Europe/N.Europe vs. ROW)
e) IMDC score (0 vs 1-2 vs 3-6)
f) Karnofsky performance status (100-90, <90)
g) Prior Nephrectomy (Yes, No)
h) LDH level ( 1.5 x ULN , > 1.5 x ULN)
i) Baseline PD-L1+ status based on a 1% cut off
j) Number of organ with metastasis (1 vs. 2)
The level of the covariate normally associated with the worst prognosis will be coded as 
the reference level. The hazard ratio associated with treatment and with each of the 
baseline covariates will be presented along with associated 95% CIs. 
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3) PFS using stratification factors as obtained from the baseline CRF pages (instead of IRT). The 
hazard ratio associated with treatment will be presented along with the associated two-sided 
95% CIs. This analysis will be performed only if at least one stratification variable/factor at 
randomization (as per IRT) and baseline are not concordant for at least 10% of the randomized 
subjects.
4) PFS using the investigator’s assessment. The hazard ratio associated with treatment and 
median PFS will be presented along with the associated two-sided 95% CIs.
A cross tabulation of PFS assessment by BICR versus PFS assessment by investigator will be 
presented, by treatment group. Concordance Rate of event will be computed as the frequency 
with which investigator and BICR agree on classification of a subject as event versus censored 
as a proportion of the total number of randomized subjects assessed by both the investigator 
and BICR.
A by-subject listing of PFS assessment per BICR and investigator will be presented.
5) PFS using an un-stratified log rank test. The hazard ratio associated with treatment will be 
presented along with the associated two-sided 95% CIs.  
6) PFS using an un-stratified Cox proportional hazards model, adjusted, using as covariates only 
the stratification factors used in randomization. The hazard ratio associated with treatment will 
be presented along with the associated two-sided 95% CIs.
7) PFS for subjects with no relevant protocol deviations. This analysis will be conducted only if 
there are more than 10% subjects with relevant protocol deviations. The hazard ratio associated 
with treatment will be presented along with the associated two-sided 95% CIs.
8) The method of Gail and Simon14 will be used to test for a qualitative interaction between 
treatment and strata. This test will be conducted at = 0.10 level. The p-value reported from 
this specific analysis is for descriptive purposes alone.
9) To examine the assumption of proportional hazards in the Cox regression model, in addition 
to treatment, a time-dependent variable defined by treatment by time interaction will be added 
into the model. A two-sided Wald Chi-square p-value of less than 0.1 may indicate a potential 
nonconstant treatment effect. In that case, additional exploratory analyses may be performed.
10) PFS using censoring for 2 missing TA 
7.5.3 Subset Analyses of Progression-Free Survival
The influence of baseline and demographic characteristics on the treatment effect among all 
randomized subjects will be explored via exploratory subset analyses. The median PFS based on 
KM product-limit method along with two-sided 95% CIs will be produced for the following 
subgroups:
 Age 
 Age categorization (< 65,  65 and < 75,  75 and < 85,  85,  75,  65)
 Sex (Male, Female)
 Race
 Region (Region (US/Canada/W.Europe/N.Europe vs. ROW) (source: IRT)
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 Ethnicity (Hispanic/Latino and Not Hispanic/Latino)
 Karnofsky performance status (100-90, <90)
 Baseline IMDC prognostic score (0, 1-2,  3) (source: IRT)
 Baseline IMDC prognostic score (0, 1-2,  3) (source: CRF)
 Time from initial disease diagnosis to randomization (<1 year, ≥1 year)
 Baseline LDH level ( 1.5 x ULN, >1.5 x ULN)
 Hemoglobin (<LLN,  LLN)
 Corrected Calcium ( 10 mg/dl, >10mg/dl )
 Absolute Neutrophil Count ( ULN, > ULN)
 Platelet Count ( ULN, > ULN)
 Baseline Alkaline phosphatase (< ULN,  ULN)
 Prior nephrectomy (Yes, No)
 Prior radiotherapy (Yes, No)
 Bone metastasis (Yes, No)
 Sarcomatoid features (Yes, No)
 Stage at the initial diagnosis (Stage IV, non-Stage IV)
 Baseline PD-L1+ status based on a 1% cut off 
 Baseline PD-L1+ status based on a 5% cut off 
 Baseline PD-L1+ status based on a 10% cut off 
A forest plot of the unstratified PFS hazard ratios (along with the 95% CIs) will be produced for 
each level of the subgroups listed above. The analysis comparing treatment (i.e., Hazard Ratio)
will be conducted if the number of subjects in the subgroup category is more than 10. 
7.5.4 Analysis of Overall Survival
One of the secondary objectives of the study is to compare the overall survival of Arm A to Arm 
C in all randomized subjects. All the analyses outlined in this section are specified for the all 
randomized subjects population in Arm A and Arm C, unless otherwise specified.
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure.
Overall survival will be compared between the treatment groups at the interim and final analyses, 
using stratified log-rank test. The stratification factors will be those used in the analysis of PFS. 
An O’Brien and Fleming α-spending function will be employed to determine the nominal 
significance levels for the interim and final analyses. The stratified hazard ratio between the 
treatment groups will be presented along with 100*(1- α)% CI (adjusted for interim). In addition, 
two-sided p-value will also be reported for the analysis of OS.
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OS will be estimated using the KM techniques. A two-sided 95% CI for median OS in each 
treatment group will be computed via the log-log transformation method. OS rates at fixed time 
points (e.g. 6 months, depending on the minimum follow-up) will be presented along with their 
associated 95% CIs. These estimates will be derived from the Kaplan Meier estimate and 
corresponding CIs will be derived based on Greenwood formula for variance derivation and on 
log-log transformation applied on the survivor function.
The status of subjects who are censored in the OS KM analysis will be tabulated for each treatment 
group using the following categories:
 On-study (on-treatment, in follow-up)
 Off-study (lost to follow-up, withdraw consent, never treated)
A by-subject listing will be presented including treatment group, first and last dose date, whether 
the subject died, and if censored, the reason, event/censored date and OS duration.
Note that similar tables (KM plot, median OS with its 95% CI, OS rates, and status of subjects 
who are censored) along with by-subject listing will be summarized for all intermediate/poor risk 
subjects in Arm A and Arm C.
The analysis performed for PFS (detailed in section 7.5.8) for those subjects who randomized to 
Arm B prior to Revised Protocol 01 will be repeated for OS.
7.5.5 Subset Analysis of Overall Survival
The influence of baseline and demographic characteristics on the treatment effect among all 
randomized subjects will be explored via exploratory subset analyses. The median OS based on 
KM product-limit method along with two-sided 95% CIs will be produced for the same subgroups 
as used for PFS (see Section APPENDIX 1).
A forest plot of the unstratified OS hazard ratios (along with the 95% CIs) will be produced for 
each level of the subgroups listed above.
An analysis will be conducted if the number of subjects in the subgroup category is more than 10.
7.5.6 Current Status of PFS and OS Follow-up
The extent of follow-up for survival, defined as the time between randomization date and last 
known alive date (for subjects who are alive) or death date (for subjects who died), will be 
summarized descriptively (median, min, max, etc.) in months for all randomized subjects.
The currentness of follow-up for survival, defined as the time between last OS contact (i.e., last 
known alive date or death date) and cutoff date (defined by last subject last visit date), will be
summarized in months for all randomized subjects. Subjects who died and subjects with last known 
alive date on or after data cut-off date will have zero value for currentness of follow-up.
Minimum follow-up of OS for all randomized subjects, defined as the time from cutoff date to last 
subject’s randomization date, will be summarized in months.
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Time from last evaluable tumor assessment to cutoff date in months will be summarized by 
treatment group and overall for all randomized subjects. Subjects who have a PFS event will be 
considered as current for this analysis. The secondary definition of PFS will be used for this 
summary. 
In addition, time to treatment discontinuation will be summarized and presented by treatment 
group using a Kaplan-Meier curve whereby the last dose date will be the event date for those 
subjects who are off study therapy. Median duration of study therapy and associated 95% CI will 
be provided. Subjects who are still on study therapy will be censored on their last dose date.
A by-subject listing will also be produced to accompany the subject time from last evaluable tumor 
assessment.
7.5.7 Interim Analysis of Overall Survival
An independent statistician external to BMS will perform the analysis. In addition to the formal 
planned interim analyses for OS, the Data Monitoring Committee (DMC) will have access to 
periodic un-blinded interim reports of efficacy and safety to allow a risk/benefit assessment. 
Details are included in the DMC charter.
Two interim analyses of OS are planned for this study.  The first interim analysis of OS is planned 
at the time of final PFS analysis and expected after observing 165 deaths (approximately 65% of 
the targeted OS events) have been observed among all randomized subjects in Arm A and Arm C 
based on above accrual rate and the exponential distribution in each arm. These formal 
comparisons of OS will allow for early stopping for superiority, and the boundaries for declaring 
superiority will be derived based on the actual number of deaths using Lan-DeMets spending 
function with O’Brien and Fleming type of boundary in EAST version 6. If the first interim 
analysis is performed exactly at 165 deaths, the boundary in terms of statistical significance for 
declaring superiority would be 0.011 (HR=0.673 with 16 months improvement in median OS for 
the Arm A versus Arm C comparison (33 versus 49 months)). The second interim analysis of OS 
is expected after observing 211 deaths (approximately 83% of the targeted OS events) have been 
observed among all randomized subjects based on above accrual rate and the exponential 
distribution in each arm. The boundary for declaring superiority in terms of statistical significance 
for the second interim analysis after 211 events would be 0.025 (HR=0.734 with 12 months 
improvement in median OS for the doublet versus sunitinib comparison (33 versus 45 months).
The boundary for declaring superiority in terms of statistical significance for the final analysis 
after 254 events would be 0.041 (HR=0.774 with 9.6 months improvement in median OS for the 
Arm A versus Arm C comparison (33 versus 42.6 months).
Note that if the analysis of PFS final analysis and first interim analysis OS is trigger with 8-months 
minimum follow-up on all randomized subjects, minimum 283 PFS events and 149 OS events, 
then the details of the first interim analysis of OS will be as follows:
 If the first interim analysis is performed exactly at 149 deaths, the boundary in terms of 
statistical significance for declaring superiority would be 0.007 (HR=0.643 with 18.3 months 
improvement in median OS for the Arm A versus Arm C comparison (33 versus 51.3 months)).
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The DMC will review the safety and efficacy data from the informal interim analyses, BMS will 
remain blinded to these interim results and and will determine if the study should continue with or 
without changes or if accrual should be stopped. Subject enrollment will continue while waiting 
for the DMC’s decisions.
The chair of the DMC and the sponsor can call an unscheduled review of the safety data.
If the formal analysis of PFS among all randomized subjects is statistically significant, the formal 
interim analysis of OS among all randomized subjects will be tested, as per hierarchical testing 
procedure.
At the time of the formal interim analysis for superiority of OS, the DMC may recommend 
continuing or stopping the trial. If the trial continues beyond the formal interim analysis, BMS will 
remain blinded to these interim results and the nominal critical point for the final OS analysis will 
be determined using the recalculated information fraction at the time of the interim analysis, as 
described above. The final OS hazard ratio and corresponding confidence interval will be reported 
whereby the confidence interval will be adjusted accordingly (i.e. using the recalculated nominal 
level at the final analysis). 
If the trial is stopped for superiority of OS at the interim, the p-value from the interim stratified 
log-rank test will be considered the final primary analysis result.
7.5.8 Analysis of Objective Response Rate
One of the secondary objectives of the study is to evaluate the objective response rate in all 
randomized subjects in Arm A and Arm C. All the analyses outlined in this section are specified 
for the all randomized subjects population in Arm A and Arm C, unless otherwise specified. If the 
formal analysis of OS among all randomized subjects is statistically significant, the formal analysis 
of ORR among all randomized subjects will be tested, as per hierarchical testing procedure. Note 
that the formal ORR analysis specified in the SAP supersede those specified in the protocol.
The number and percentage of subjects in each category of BOR per BICR (complete response 
[CR], partial response [PR], stable disease [SD], progressive disease [PD], or unable to determine 
[UTD]) will be presented, by treatment group. Estimates of response rate, along with its exact two-
sided 95% CI by Clopper and Pearson15 will be presented, by treatment group.
Similar analyses will be repeated based on the investigator’s assessment of ORR. A cross 
tabulation of BICR best response versus the investigator best response will be presented, by 
treatment group and by response categories. Concordance Rate of Responders will be computed 
as the frequency with which investigator and BICR agree on classification of a subject as responder 
vs. non responder/UTD as a proportion of the total number of randomized subjects assessed by 
both the investigator and BICR.
The following subject-level graphics will also be provided:
 For the responders only, time courses of the following events of interest will be graphically 
displayed: tumor response, progression, last dose received, and death.
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 For response evaluable subjects (randomized subjects with baseline and at least one on-study 
tumor assessment), 
 A bar plot showing the best % reduction from baseline in sum of diameter of target lesions 
based on BICR assessment for each subject will be produced (excluding assessments after 
PD and assessments after start of subsequent anti-cancer therapy).
 A plot of individual time course of tumor burden change per BICR assessment will be 
produced. 
A by-subject listing of best overall response will be presented including treatment group, best 
overall response per BICR and dates of CR/PR/progression. 
A by-subject listing of per time point tumor response per BICR will be presented. 
Note that similar tables along with by-subject listing will be summarized for all intermediate/poor 
risk subjects in Arm A and Arm C.
For those subjects who randomized to Arm B prior to Revised Protocol 01, estimates of response 
rate, along with its exact two-sided 95% CI by Clopper-Pearson method, will be computed per 
BICR and investigator. DOR and TTR will also be evaluated per BICR.
7.5.9 Subset Analyses of Objective Response
The influence of baseline and demographic characteristics on the treatment effect will be explored 
via exploratory subset analysis. The subsets wil be same as those analyzed for PFS and will be 
reported based on the BICR assessment of ORR.
A forest plot of treatment effect on ORR per BICR in the above subgroups will be produced. The 
un-weighted differences in ORR between the two treatment groups and corresponding 95% two-
sided CI using the method of Newcombe will be provided if the number of subjects in the subgroup 
category is more than 10. 
7.5.10 Time to Tumor Response and Duration of Response
The analyses specified in this section will be conducted for all treatment arms. Duration of 
response (DOR) and time to response (TTR) will also be evaluated for subjects who achieved 
confirmed PR or CR. The DOR for each treatment group will be estimated using the Kaplan-Meier 
(KM) product limit method and will be displayed graphically. A table will be produced presenting 
number of events, number of subjects involved, medians, and 95% CIs for the medians. Median 
values of DOR, along with two-sided 95% CI in each treatment group will be computed based on 
a log-log transformation method.
The status of subjects who are censored in the DOR KM analysis will be tabulated for each
treatment group including the following categories:
 Ongoing follow-up (current [last scan within adequate window vs cutoff date], not current)
 Off-study (lost to follow-up, withdraw consent, never treated)
 Received subsequent anticancer therapy.
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TTR, which does not involve censoring, will be summarized by treatment group in all responders 
using descriptive statistics. 
Cumulative Response Rates will be tabulated for Week 8, Month 4, 6, 8, and 12, and overall 
response rate will be provided.
A by-subject listing will be presented including treatment group, best response, time to response, 
duration of response, whether the subject was censored for duration of response, and, if so, the 
reason. 
7.5.11 PFS2
One of the exploratory objectives of the study is to compare PFS2 between treatment groups in all 
randomized subjects.
PFS2 will be analyzed similarly to PFS:  
 Median values based on KM method, along with two-sided 95% CI using Brookmeyer and 
Crowley method will be calculated. The estimate of standard error will be calculated using the 
Greenwood formula;
 PFS2 will be graphically displayed along with the median and 95% CI. 
A by-subject listing of PFS and PFS2 will be provided.
7.6 Safety
Analyses in this section will be tabulated for all treated subjects by treatment group as treated, 
unless otherwise specified.
Analyses in this section will be tabulated for all treated subjects in Arm A and Arm C, unless 
otherwise specified. Limited selection of the summary tables will be generated for those subjects 
who randomized to Arm B prior to Revised Protocol 01, which is specified in the relevant 
subsections below.
7.6.1 Deaths
Deaths will be summarized by treatment group:
 All deaths, reasons for death.
 Deaths within 30 days of last dose received, reasons for death.
 Deaths within 100 days of last dose received, reasons for death.
A by-subject listing of deaths will be provided for the all enrolled subjects population.
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, deaths will be 
summarized by treatment group.
Similar tables will be presented for those subjects treated in Arm B.
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7.6.2 Serious Adverse Events
Serious adverse events will be summarized by treatment group:
 Overall summary of SAEs by worst CTC grade (any grade, grade 3-4, grade 5) presented by 
SOC/PT.
 Overall summary of drug-related SAEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT.
All analyses will be conducted using the 30-day safety window. 
A by-subject SAE listing will be provided for the “enrolled subjects” population.
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, serious adverse 
events will be summarized by treatment group.
Similar tables will be presented for those subjects treated in Arm B.
7.6.3 Adverse Events Leading to Discontinuation of Study Therapy
AEs leading to discontinuation will be summarized by treatment group:
 Overall summary of AEs leading to discontinuation by worst CTC grade (any grade, grade 
3-4, grade 5) presented by SOC/PT.
 Overall summary of drug-related AEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by SOC/PT.
The analyses will be conducted using the 30-day safety window.
A by-subject AEs leading to discontinuation listing will be provided.
Note that for all intermediate/poor risk treated subjects in Arm A and Arm C, AEs leading to 
discontinuation will be summarized by treatment group.
Similar table will be presented for those subjects treated in Arm B.
Note that 
 for Arm A, AEs leading to discontinuation from cabozantinib only, nivolumab only, and both 
cabozantinib and nivolumab. 
 for Arm B, AEs leading to discontinuation from cabozantinib only, nivolumab and ipilimumab 
only, and from cabozantinib, nivolumab, and ipilumumab will be summarized in all the tables 
specified in this section.
7.6.4 Adverse Events Leading to Dose Modification
AEs leading to dose delay/reduction will be summarized by treatment group:
 Overall summary of AEs leading to dose delay/reduction by worst CTC grade (any grade, 
grade 3-4, grade 5) presented by SOC/PT.
2.0Approved 9301407052.0v
STATISTICAL ANALYSIS PLAN CA2099ER
BMS-936558 nivolumab
51
 Overall summary of related AEs leading to dose delay/reduction by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by SOC/PT.
The analysis will be conducted using the 30-day safety window.
A by-subject AEs leading to dose delay/reduction listing will be provided.
7.6.5 Adverse Events
Adverse events will be summarized by treatment group.
The following analyses will be conducted using the 30 days safety window only:
 Overall summary of any AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) presented 
by SOC/PT.
 Overall summary of any AEs presented by worst CTC grade (any grade, grade 3-4, grade 5) 
by SOC/PT. This table will be restricted to events with an incidence greater or equal to 5% in 
any treatment group.
 Overall summary of any non-serious AEs presented by SOC/PT. This table will be restricted 
to events with an incidence greater or equal to 5% in any treatment group.
 Overall summary of any AEs that required immune modulating medication by worst CTC 
grade (any grade, grade 3-4, grade 5) presented by SOC/PT.
 Overall summary of drug-related AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) 
presented by SOC/PT. 
The following analyses will be conducted using the 30 days safety window and repeated using the 
100 days safety window:
 Overall summary of drug-related AEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT.
A by-subject AE listing will be provided. A by-subject listing of any AE requiring immune 
modulating medications will also be provided.
For those subjects treated in Arm B and for those intermediate/poor risk treated subjects in 
Arm A and Arm C:
The following analyses will be conducted using the 30 days safety window only:
 Overall summary of any AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) presented 
by SOC/PT. 
 Overall summary of any AEs that required immune modulating medication by worst CTC 
grade (any grade, grade 3-4, grade 5) presented by SOC/PT.
 Overall summary of drug-related AEs by worst CTC grade (1, 2, 3, 4, 5, not reported, total) 
presented by SOC/PT. 
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The following analyses will be conducted using the 30 days safety window and repeated using the 
100 days safety window:
 Overall summary of drug-related AEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by SOC/PT.
A by-subject AE listing will be provided. A by-subject listing of any AE requiring immune 
modulating medications will also be provided
7.6.6 Select Adverse Events (EU/ROW Submissions)
Unless otherwise specified, analyses will be performed by select AE category. Analyses will also 
be repeated by subcategory of endocrine events.
7.6.6.1 Incidence of Select AE
Select AEs will be summarized by treatment group for each category/subcategory. 
The following analyses will be conducted using the 30-day safety window only:
 Overall summaries of any select AEs by worst CTC grade (any grade, grade 3-4, grade 5)
presented by Category or Subcategory/PT.
 Overall summaries of any drug-related select AEs by worst CTC grade (any grade, grade 3-4, 
grade 5) presented by Category or Subcategory/PT.
 Overall summaries of any serious select AEs by worst CTC grade (any grade, grade 3-4, grade 
5) presented by Category or Subcategory /PT.
 Overall summaries of drug-related serious select AEs by worst CTC grade (any grade, grade 
3-4, grade 5) presented by Category or Subcategory /PT.
 Overall summaries of any select AEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by Category or Subcategory /PT.
 Overall summaries of drug-related select AEs leading to discontinuation by worst CTC grade
(any grade, grade 3-4, grade 5) presented by Category or Subcategory /PT.
 Summary of frequency of unique select AEs by Category.
A by-subject select AE listing will be provided.
7.6.6.2 Time-to Onset of Select AE
Time-to onset of drug-related select AEs (any grade, grade 3-5) will be summarized for each 
category/subcategory by treatment group.
Time-to onset analyses are restricted to treated subjects who experienced at least one drug-related 
select AE in the category/subcategory. The analyses will be conducted using the 30-day safety 
window.
Additional details regarding the time-to onset definition are described in time-to onset definition 
subsection of APPENDIX 1.
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7.6.6.3 Time-to Resolution of Select AE
Time-to resolution of the following specific events will be summarized separately for each 
category/subcategory.
 Time-to resolution of drug-related select AE (any grade, grade 3-5) by treatment group
 Time-to resolution of drug-related select AE (any grade, grade 3-5) where immune modulating 
medication was initiated, by treatment group
Time-to resolution analyses are restricted to treated subjects who experienced the specific events. 
Time-to resolution where immune modulating medication was initiated analyses are restricted to 
treated subjects who experienced the specific events and who received immune modulating 
medication during the longest select AE.
The analyses will be conducted using the 30-day safety window.
The following summary statistics will be reported: percentage of subjects with resolution of the 
longest select AE, median time-to resolution along with 95% CI (derived from Kaplan-Meier 
estimation) and ranges.
See time-to resolution definition subsection of APPENDIX 1 for additional details.
7.6.7 Immune-Mediated Adverse Events (US Submission)
IMAEs will be summarized by treatment group for each immune-mediated category / PT using the 
100-day safety window:
 Overall summary of non-endocrine IMAEs by worst CTC grade (any grade, grade 3-4, grade 
5) where immune modulating medication was initiated presented by Category / PT.
 Overall summary of endocrine IMAEs by worst CTC grade (any grade, grade 3-4, grade 5) 
presented by Category / PT.
 Overall summary of non-endocrine IMAEs leading to discontinuation by worst CTC grade 
(any grade, grade 3-4, grade 5) where immune modulating medication was initiated presented 
by Category / PT.
 Overall summary of endocrine IMAEs leading to discontinuation by worst CTC grade (any 
grade, grade 3-4, grade 5) presented by Category / PT.
 Overall summary of non-endocrine IMAEs leading to dose delay or reduction by worst CTC 
grade (any grade, grade 3-4, grade 5) where immune modulating medication was initiated 
presented by Category / PT
 Overall summary of endocrine IMAEs leading to dose delay or reduction by worst CTC grade 
(any grade, grade 3-4, grade 5) presented by Category / PT.
 Summaries of time-to onset and time-to resolution of non-endocrine IMAEs where immune 
modulating medication was initiated presented by Category.
 Summaries of time-to onset and time-to resolution of endocrine IMAEs presented by Category.
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A by-subject listing of IMAEs will be provided. By-subject listings of time-to resolution for 
longest IMAEs cluster (any grade and grade 3-5 in separate summaries) will also be provided. For 
new studies which collect investigator assessment of potential IMAE data, a by-subject listing of 
AEs considered as immune-mediated events per investigator but not qualified for IMAEs 
definition will also be provided.
In addition, for all nivolumab treated subjects who experienced at least one IMAE, the following 
data presentation will be provided:
 Summary of subjects who were re-challenged with nivolumab by IMAE category, with 
extended follow-up 
 Summary of subjects who were re-challenged with nivolumab or ipilimumab by IMAE 
category, with extended follow-up
For these, re-challenge is considered to have occurred when last nivolumab and/or ipilimumab 
infusion was administered after the onset of an IMAE.
7.6.8 Other Events of Special Interest
OEOSI will be summarized by treatment group for each category.
The following analyses will be conducted using the 100-day safety window:
 Overall summary of OEOSI by worst CTC grade (any grade, grade 3-4, grade 5) presented by 
Category / PT
 Overall summary of drug-related OEOSI by worst CTC grade (any grade, grade 3-4, grade 5)
presented by Category / PT
A by-subject listing of OEOSI will be provided.
7.6.9 Multiple Events
The following summary tables will be provided:
 A table showing the total number and rate (exposure adjusted) of occurrences for all AEs. 
 A table showing the total number and rate (exposure adjusted) of occurrences for AEs 
occurring in at least 5% of subjects in any treatment group. 
In addition, the rate (exposure adjusted) and its 95% CI evaluated for different time intervals will 
be displayed graphically for each treatment group. This analysis will be limited to the rate of all 
AEs and all drug-related AEs. The analyses will be conducted using the 30-day safety window.
A listing displaying the unique instances of all AEs, i.e., after duplicates have been eliminated and 
overlapping and contiguous occurrences of the same event (i.e. same PT) have been collapsed will 
be provided. No formal comparisons will be made between treatment groups.
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The analysis population for each laboratory test is restricted to treated subjects who underwent that 
laboratory test. Laboratory tests (in addition to the tests specified below) with CTC criteria
collected in the specific studies may also be included in the summaries.
A by-subject listing of differences in categorization of SI and US laboratory test results will be 
provided.
7.6.10.1 Hematology
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: hemoglobin (HB), platelets, white blood counts (WBC), absolute neutrophils count (ANC) 
and lymphocyte count (LYMPH). 
The analyses will be conducted using the 30-day safety window.
A by-subject listing of these laboratory parameters will be provided.
7.6.10.2 Serum Chemistry
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: ALT, AST, alkaline phosphatase (ALP), total bilirubin and creatinine. 
The analyses will be conducted using the 30-day safety window.
A by-subject listing of these laboratory parameters will be provided.
7.6.10.3 Electrolytes
The following will be summarized by treatment group as worst CTC grade on-treatment per 
subject and as shift table of worst on-treatment CTC grade compared to baseline CTC grade per 
subject: sodium (high and low), potassium (high and low), calcium (high and low), magnesium 
(high and low), and Glucose Serum (fasting hyperglycemia and hypoglycemia regardless of fasting 
status).
The analyses will be conducted using the 30-day safety window.
A by-subject listing of these laboratory parameters will be provided.
7.6.10.4 Additional Analyses
In addition, further analyses on specific laboratory parameters will be performed by treatment 
group:
Abnormal Hepatic Function Test
The number of subjects with the following laboratory abnormalities from on-treatment evaluations 
will be summarized by treatment group:
 ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN
 Total bilirubin > 2 x ULN
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 ALP > 1.5 x ULN
 Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN
 Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN
 Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
 Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
The analyses will be conducted using the 30-day safety window.
A by-subject listing of these specific abnormalities will be provided.
Abnormal Thyroid Function Test
The number of subjects with the following laboratory abnormalities from on-treatment evaluations 
will be summarized by treatment group:
 TSH value > ULN and
 with baseline TSH value  ULN
 with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH 
test
 with all FT3/FT4 test values  LLNwithin 2-week window after the abnormal TSH test
 with FT3/FT4 missing within 2-week window after the abnormal TSH test.
 TSH < LLN and
 with baseline TSH value  LLN
 with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal 
TSH test
 with all FT3/FT4 test values  ULNwithin 2-week window after the abnormal TSH test
 with FT3/FT4 missing within 2-week window after the abnormal TSH test
The analyses will be conducted using the 30-day safety window.
A by-subject listing of these specific abnormalities will be provided.
7.6.11 Vital Signs and Pulse Oximetry
Vital signs and pulse oximetry (i.e. % oxygen saturation) collected on the CRF will be provided 
in separate listings.
7.6.12 Physical Measurements
Physical measurements will be listed by subject.
7.6.13 Non-Protocol Medical Procedures
Non-protocol medical procedures will be listed by subject.
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Further details on immunogenicity background and rationale, definitions, population for analyses 
and endpoints are described in APPENDIX 3. 
Incidence of ADA
Number (%) of subjects will be reported for the following parameters based on Evaluable Subjects.
 Baseline ADA-positive
 ADA-positive
 Persistent Positive (PP)




A listing of all ADA assessments will be provided. A separate listing of ADA assessments for 
subjects with neutralizing positive will also be provided.
A spider plot of nivolumab ADA test result (titers) over time may be provided for nivolumab ADA 
positive subjects.
Clinical implications 
Clinical implications of nivolumab immunogenicity will be primarily focused on subjects with 
persistent ADA-positive relative to ADA-negative. Subjects with any ADA-positive samples after 
initiation of treatment (relative to baseline) may be used to explore clinical implications. Effect of 
immunogenicity on clearance of nivolumab will be explored by comparison of clearance estimates 
(determined by PPK analysis). Effect of immunogenicity on safety will be explored by examining 
the frequency and type of AEs of special interest such as hypersensitivity/infusion reaction. 
Summary tables for incidence of overall and each of the preferred terms will be provided, if the 
number of subjects is of sufficient size (e.g., at least 10 subjects). Otherwise, individual subject’s 
safety profile will be examined and described based on a listing. Clinical implications on efficacy 
will also be explored similarly. Association between trough concentrations of nivolumab or 
combination drug (e.g., ipilimumab) and ADA assessments may be explored, as needed.
The following data presentation will be provided:
 Swimmer plot of occurrence of ADA and NAb Occurrence in Relation to PFS, BOR per 
investigator and OS
7.6.15 Pregnancy
A by-subject listing of pregnancy tests results will be provided for randomized female subjects.
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7.6.16 Adverse Events By Subgroup
Overall summary of any AEs and drug-related AEs by worst CTC grade (any grade, grade 3-4, 
grade 5) presented by SOC/PT and for each treatment group for the following subgroups:
 Sex (Male vs. Female)
 Race
 Age (< 65 vs. 65 - < 75 vs. 75 - < 85 vs.  85 vs.  75 vs.  65)
 Region (US/Canada/W.Europe/N.Europe vs. ROW)
These analyses will be conducted using the 30-day safety window only.
7.7 Pharmacokinetics
The nivolumab and cabozantinib concentration data obtained in this study will be combined with 
data from other studies in the clinical development program to develop a population PK model. 
This model will be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of 
nivolumab and cabozantinib. In addition, exposure-response analyses with selected efficacy and 
safety endpoints will be conducted. Results of population PK and exposure response-analyses will 
be reported separately. 
7.8 Biomarkers
Analyses for PD-L1 are described below.
7.8.1 Distribution of PD-L1 Expression
Descriptive statistics of PD-L1 expression:
 Listing of all PD-L1 IHC data, all randomized subjects
 Summary of tumor specimen acquisition and characteristics, all randomized subjects
 Summary statistics of PD-L1 expression in all randomized subjects with quantifiable PD-L1 
expression
 Summary of BOR and ORR by baseline PD-L1 expression at 1, 5, and 10% cutoffs in all 
randomized subjects
 Kaplan-Meier curves for PFS and OS by BICR by baseline expression of PD-L1  < 1%, >= 1 
and < 5, > = 5  and < 10, and >= 10 
 Cumulative distribution plot of baseline PD-L1 expression versus population percentile in all 
randomized subjects with quantifiable PD-L1 expression
 Box plots of PD-L1 expression at 1, 5, and 10% cutoffs versus Response Status (BICR
assessment) in all randomized subjects with quantifiable PD-L1 expression
 Waterfall plot of individual PD-L1 expression in all randomized subjects with quantifiable PD-
L1 expression
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7.8.2 Other Exploratory Biomarkers
The following analyses for other exploratory biomarkers will be provided when the data becomes 
available, which may occur after the CSR is written and therefore a seperate Data Presentation 
Plan (DPP) will be developed:
Descriptive statistics of MDSC expression at baseline:
 Listing of all MDSC data, all randomized subjects
 Summary statistics of MDSC expression in all randomized subjects with quantifiable MDSC
expression
 Correlation statistics of BOR and ORR by baseline MDSC expression levels
 Cumulative distribution plot of baseline MDSC expression versus population percentile in all 
randomized subjects with quantifiable MDSC expression
 Kaplan-Meier curves for PFS and OS by BICR by baseline expression of tertitle MDSC
expression
 Box plots of MDSC expression at tertile cutoffs versus Response Status (BICR assessment) in 
all randomized subjects with quantifiable MDSC expression
Descriptive statistics of c-MET expression at baseline:
Summary statistics of c-MET expression in all randomized subjects will be reported.
Descriptive statistics of serum cytokine expressions (only MIG, IP10 and IFN-g) changes in the 
course of treatment:
 Line plot per arm for each cytokine on X axis and with timeline on Y axis with statistical 
difference from the baseline to be marked
Descriptive statistics for gene expression signature analyses:
 Published, on-target and mechanism of action related pathway related gene expression 
signatures (e.g. CD8, angiogenesis etc) will be assessed in BOR, ORR, PFS and OS 
relationship
7.9 Clinical Outcomes Assessments
The analysis of FKSI-19 and EQ-5D-3L will be restricted to randomized subjects in Arm A and C
who have an assessment at baseline and at least one post-baseline assessment.
7.9.1 FKSI-19
Unless otherwise specified, the analysis of FKSI-19 will be performed by treatment group in all 
randomized subjects who have an assessment at baseline and at least one or more post-baseline 
assessments. The following descriptive analyses will be conducted: 
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 Questionnaire completion rate, defined as the proportion of questionnaires actually received 
out of the expected number (i.e., number of subjects on treatment or in follow up), will be 
calculated and summarized for each assessment time point. 
 For the total score and subscales, separately: 
 Mean score and mean change from baseline at each assessment time point will be 
summarized using descriptive statistics (N, mean, SD, median, 25th and 75th percentiles, 
minimum, maximum).
 A plot summarizing the mean change from baseline will be presented and including 95% 
CI.
By subject listing of FKSI-19 will be provided.
7.9.2 EuroQol EQ-5D-3L
The following descriptive analyses will be conducted: 
 EQ-5D-3L questionnaire completion rate, defined as the proportion of questionnaires actually 
received out of the expected number (i.e. number of subjects on treatment or in follow up), will 
be calculated and summarized for each assessment time point by treatment group. 
 A by-subject listing of the level of problems in each dimension, corresponding to EQ-5D-3L 
health state (i.e., 5-digit vector), EQ-5D-3L utility index score, and EQ-5D-3L VAS score will 
be provided.
 Proportion of subjects reporting problems for the 5 EQ-5D-3L dimensions at each assessment 
time point will be summarized by level of problem and by treatment group. Percentages will 
be based on number of subjects assessed at assessment time point.
 For the EQ-5D-3L utility index and VAS scores, separately:
 Mean score and mean change from baseline at each assessment time point will be 
summarized by treatment group using descriptive statistics (N, mean with SD and 95% CI, 
median, first and third quartiles, minimum, maximum).
 A line graph summarizing the mean changes from baseline will be produced.
8 CONVENTIONS
The following conventions may be used for imputing partial dates for analyses requiring dates: 
 For missing and partial adverse event onset dates, imputation will be performed using the 
Adverse Event Domain Requirements Specification16
 For missing and partial adverse event resolution dates, imputation will be performed as follows 
(these conventions may change):
 If only the day of the month is missing, the last day of the month will be used to replace 
the missing day. If the imputed date is after the death date or the last known alive date, then 
the latest known alive date or death date is considered as the resolution date. 
 If the day and month are missing or a date is completely missing, it will be considered as 
missing.
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 Missing and partial non-study medication domain dates will be imputed using the derivation 
algorithm described in 4.1.3 of BMS Non-Study Medication Domain Requirements 
Specification17.
 Missing and partial radiotherapy and surgery dates will be imputed using algorithm described 
in APPENDIX 2.
 For death dates, the following conventions will be used for imputing partial dates:
 If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. The imputed date will be compared to the last known alive date and the 
maximum will be considered as the death date. 
 If the month or the year is missing, the death date will be imputed as the last known alive 
date. 
 If the date is completely missing but the reason for death is present, the death date will be 
imputed as the last known date alive. 
 For date of progression after start of study therapy, the following conventions will be used for 
imputing partial dates: 
 If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. In case of the date of death is present and complete, the imputed progression 
date will be compared to the date of death. The minimum of the imputed progression date 
and date of death will be considered as the date of progression. 
 If the day and month are missing or a date is completely missing, it will be considered as 
missing. 
 For date of progression to prior therapies, the following conventions will be used for imputing 
partial dates: 
 If only the day of the month is missing, the 1st of the month will be used to replace the 
missing day. 
 If the day and month are missing or a date is completely missing, it will be considered as 
missing. 
 For other partial/missing dates, the following conventions were used: 
 If only the day of the month is missing, the 15th of the month will be used to replace the 
missing day. 
 If both the day and the month are missing, “July 1” will be used to replace the missing 
information. 
 If a date is completely missing, it will be considered as missing. 
The following conversion factors will be used to convert days to months or years: 
1 month = 30.4375 days and 1 year = 365.25 days.
Duration (e.g. time-to onset, time-to resolution) will be calculated as follows:
Duration = (Last date - first date + 1)
Last known alive date will be defined based on all appropriate dates collected on the CRF.
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All statistical analyses will be carried out using SAS (Statistical Analysis System software, SAS 
Institute, North Carolina, USA) unless otherwise noted.
9 CONTENT OF REPORTS
All analyses described in this SAP will be included in the Clinical Study Report(s) except where 
otherwise noted. Refer to the Data Presentation Plan for mock-ups of all tables and listings.
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1 Burcin Simsek Original issue
2 Burcin Simsek Employ hierarchical strategy to ORR after PFS and OS. 
Biomarker and QoL sections are updated slightly. Wording of 
cabozantinib dose delay and dose reductions are cleaned.
APPENDIX 1 TIME-TO ONSET AND TIME-TO RESOLUTION DEFINITION AND 
CONVENTIONS FOR SELECT ADVERSE EVENTS, IMMUNE-
MEDIATED ADVERSE EVENTS AND EVENTS OF SPECIAL 
INTEREST
Time-to onset definition
Time-to onset of AE (any grade) for a specific category is defined as the time between the day of 
the first dose of study treatment and the onset date of the earliest AE (of any grade) in this category.
The time-to onset of AE (grade 3-5) for a specific category is defined similarly with an onset date 
corresponding to a grade 3-5 AE.
Time-to onset of drug-related AE (any grade or grade 3-5) for a specific category is defined 
similarly but restricted to drug-related AE.
Time-to onset for a specific subcategory is defined similarly but restricted to event of this 
subcategory.
Time-to resolution definition
In order to derive the time-to resolution, overlapping or contiguous AEs within a specific category
or subcategory will be collapsed into what will be termed “clustered” AEs. For example, if a 
subject (without pre-treatment AE) experienced an AE from 1st to 5th January, another AE (with 
different PT but within same category) from 6th to 11th January and same AE from 10th to 
12th January, these will be collapsed into one clustered AE from 1st to 12th January. 
Key derivation steps for each type of clustered AEs is summarized as follows:
 For any grade AE: Collapse any on-treatment AE from the same category
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 For drug-related any grade AE: Collapse any on-treatment drug-related AE from the same 
category
 For grade 3-5 AE: Collapse any on-treatment AE from the same category. Resolution will be 
based on the onset date of the earliest grade 3-5 records (if no grade 3-5 record, clustered AE 
is excluded)
 For drug-related grade 3-5 AE: Collapse any on-treatment drug-related AE from the same 
category. Resolution will be based on the onset date of the earliest grade 3-5 records (if no 
grade 3-5 record, clustered AE is excluded)
Time-to resolution of AE (any grade) for a specific category is defined as the longest time from 
onset to complete resolution or improvement to the grade at baseline among all clustered AEs
experienced by the subject in this category per adverse event criteria category. Events which 
worsened into grade 5 events (death) or have a resolution date equal to the date of death are 
considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be 
censored to the last known alive date. Improvement to the grade at baseline implies that all 
different events in the clustered adverse event should at least have improved to the corresponding 
(i.e. with same preferred term) baseline grade. This measure is defined only for subjects who 
experienced at least one AE in the specific category.
The time-to resolution of AE (grade 3-5) for a specific category is defined similarly with an onset 
date corresponding to a grade 3-5 AE.
Time-to resolution of drug-related AE (any grade or grade 3-5) for a specific category is defined 
similarly but restricted to drug-related AE.
The time-to resolution of AE (any grade or grade 3-5, drug-related or all) where immune 
modulating medication was initiated is defined similarly. For data presentation not restricted to 
IMAE, the additional condition that the subject started an immune modulating medication during 
the longest AE resolution period will be applied.
Time-to resolution for a specific subcategory is defined similarly but restricted to event of this 
subcategory.
The algorithm for collapsing adverse event records is using the following conventions:
For each subject and specified category, the corresponding adverse event records will be collapsed 
when:
1) Multiple adverse event records have the same onset date.
2) The onset date of an event record is either the same day or 1 day later than the resolution date 
of a preceding event record (contiguous events).
3) The onset date of an event record is after the onset date and prior to or on the resolution date 
of a preceding event record (overlapping events).
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APPENDIX 2 MISSING AND PARTIAL RADIOTHERAPY AND SURGERY 
DATES IMPUTATION ALGORITHMS
Procedures – Imputation Rules. 
If reported procedure start date is a full valid date then set start date equal to the date part of 
procedure start date. 
In case of partial date use imputation rules described below: 
 If only day is missing then 
 If month and year of procedure match month and year of first dose date then impute as date 
of first dose; 
 If month and year of procedure don't match month and year of first dose date then impute 
as first day of that month and year. 
 If both day and month are missing, then impute as maximum between 01JAN of the year and 
date of the first dose; 
 If date is completely missing or invalid then leave missing. 
Note: Imputation is not applicable to data where start date is not collected (for example "PRIOR 
RADIOTHERAPY" CRF). Set start date to missing in this case. 
If reported end date is a full valid date then set end date equal to the date part of the reported end 
date. 
In case of partial date use imputation rules described below: 
 If reported end date is partial then set end date equal to the last possible reported end date based 
on the partial entered reported end date. 
 If reported end date is missing, continuing, unknown or invalid then set end date equal to the 
most recent database extraction date. 
If end date was imputed then compare end date to the death date or last known alive date if subject 
is not dead. If posterior then end date should be imputed to death date (or last known alive date if 
subject not dead). 
Note: Imputation of partial dates only applies to data entered on "RADIOTHERAPY” CRF page. 
For other CRF pages in case of partial dates set end date to missing.  
Surgeries – Imputation Rules. 
If reported surgery date is a full valid date then set start date equal to the date part of surgery date. 
In case of partial date, use one of the two imputation rules described below: 
A. For data collected on "PRIOR SURGERY RELATED TO CANCER" CRF page: 
 If only day is missing then impute as the first day of the month; 
 If both day and month are missing then then impute as 01JAN of the year; 
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 If date is completely missing or invalid then leave missing. 
B. For data collected on other CRF pages (deemed to be on-treatment/subsequent surgeries): 
 If only day is missing then 
 If month and year of surgery match month and year of first dose date then impute the 
missing date as the date of first dose; 
 If month and year of surgery don't match month and year of first dose date then impute as 
first day of that month and year; 
 If both day and month are missing then impute as maximum between 01JAN of the year and 
date of the first dose; 
 If date is completely missing or invalid then leave missing. 
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APPENDIX 3 IMMUNOGENICITY ANALYSIS: BACKGROUND AND 
RATIONALE
The following summary is from the FDA Guidance for Industry Immunogenicity Assessment for 
Therapeutic Protein Products and White Paper on Assessment and Reporting of the Clinical 
Immunogenicity of Therapeutic Proteins and Peptides – Harmonized Terminology and Tactical 
Recommendations by Shankar et al. The program-level definitions of sample- and subject-level
ADA status are based on recommendation from the BMS Immunogenicity Council.
Immune responses to therapeutic protein products may pose problems for both subject safety and
product efficacy. Immunologically based adverse events, such as anaphylaxis and infusion
reactions, have caused termination of the development of therapeutic protein products or limited
the use of otherwise effective therapies. Unwanted immune responses to therapeutic proteins may 
also neutralize the biological activity of therapeutic proteins and may result in adverse events not 
only by inhibiting the efficacy of the therapeutic protein product, but by cross-reacting to an 
endogenous protein counterpart, if present. Because most of the adverse effects resulting from 
elicitation of an immune response to a therapeutic protein product appear to be mediated by
humoral mechanisms, circulating antibody has been the chief criterion for defining an immune
response to this class of products.
ADA is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are 
cross-reactive with the administered biologic drug (baseline ADA). Titer is a quasiquantitative 
expression of the level of ADA in a sample. By employing a serial dilution-based test method, titer 
is defined as the reciprocal of the highest dilution of the sample (e.g., dilution of 1/100 = titer of 
100). The ADA is also tested, via a cell-based biologic assay or a non cell-based competitive 
ligand-binding assay for a subpopulation of ADA known as neutralizing antibodies (NAb), which 
inhibits or reduces the pharmacological activity of the biologic drug molecule regardless of its in 
vivo clinical relevance. Non-neutralizing ADA (non-NAb) is ADA that binds to the biologic drug 
molecule but does not inhibits its pharmacological activity.
ADA should be tested using sensitive and valid methods and employing an appropriate strategy
for elucidating immunogenicity. Detection of ADA is typically performed in three tiers (screening, 
confirmatory, and titer) using statistically determined cutpoints and samples testing positive in the 
ADA assay are analyzed for neutralizing activity, especially in late-stage clinical studies. 
“Detection” of ADA implies that drug-specific ADA was confirmed. The ‘drug tolerance” of an 
assay (highest drug concentration that does not interfere in the ADA detection method) is not an 
absolute value and differs between individuals due to the varying avidities of ADA immune 
responses. An ADA sampling strategy of collecting samples at times when the least drug 
concentration is anticipated (trough concentrations) can increase the likelihood of accurate ADA 
detection.
It is useful to present ADA results from clinical studies as (a) characteristics of the ADA immune
response, (b) relationship of ADA with pharmacokinetics (PK) and, when relevant,
pharmacodynamics (PD) biomarkers, and (c) relationship of ADA with clinical safety and
efficacy.
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Clinical consequences of ADA can range from no apparent clinical effect to lack of efficacy
(primary treatment failure), loss of efficacy (secondary treatment failure) or heightened effect due 
to altered exposure to the biologic drug, adverse drug reactions (administration-related systemic 
or site reactions), and severe adverse drug reactions (anaphylaxis and unique clinical problems 
associated with cross-reactivity and neutralization of endogenous molecules). Thus it becomes 
important to examine any associations between ADA or any of its attributes with the various 
clinical sequelae. The presence of ADA may or may not preclude the administration of drug to 
ADA-positive subjects because the outcome is dependent upon the magnitude of the impact of 
ADA on PK and PD. Hence, the relationship of ADA with PK/PD is an important additional 
consideration, but does not necessarily result in a clinically impactful consequence per se.
Immunogenicity Endpoints
A fundamental metric that informs clinical immunogenicity interpretation is the incidence of ADA 
in a study or across comparable studies. ADA incidence is defined as the proportion of the study 
population found to have seroconverted or boosted their pre-existing ADA during the study period.
Terms and Definitions
Validated ADA test methods enable characterization of samples into ADA-positive vs. ADA-
negative. To classify the ADA status of a subject using data from an in vitro test method, each 
sample from the subject is categorized based on the following definitions:
Sample ADA Status:
 Baseline ADA-positive sample: ADA is detected in the last sample before initiation of
treatment
 Baseline ADA-negative sample: ADA is not detected in the last sample before initiation of 
treatment
 ADA-positive sample: After initiation of treatment, (1) an ADA detected (positive 
seroconversion) sample in a subject for whom ADA is not detected at baseline, or (2) an ADA 
detected sample with ADA titer to be at least 4-fold or greater () than baseline positive titer
 ADA-negative sample: After initiation of treatment, ADA not positive sample relative to
baseline
Next, using the sample ADA status, subject ADA status is defined as follows:
Subject ADA Status:
 Baseline ADA-positive subject: A subject with baseline ADA-positive sample
 ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline 
at any time after initiation of treatment
1) Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where 
the first and last ADA-positive samples are at least 16 weeks apart
2) Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last 
sampling time point
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11) Other Positive: Not persistent positive but some ADA-positive samples with the last
sample being negative
12) Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies 
detected
 ADA-negative subject: A subject with no ADA-positive sample after the initiation of 
treatment.
(Note: 16 weeks was chosen based on a long half-life of IgG4.)
Population for Analyses
Analysis of immunogenicity data will be based on ADA evaluable subjects defined as all treated
subjects with baseline and at least 1 post-baseline immunogenicity assessment. Analysis dataset
and data listing will include all available ADA samples. However, subject-level ADA status will
be defined based on only adequate samples (e.g., excluding 1-hour post-infusion samples when
clearly indicated).
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